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Chapter 1  
Introduction 
1.1 Public Health Importance of Selected Chronic Diseases 
Chronic diseases, such as hypertension, type 2 diabetes, and heart disease affect 109 
million Americans (DeVol, et al, 2007), or more than 1 in every 3 Americans. These 
diseases are estimated to cost the U.S. $1.3 trillion annually through both direct 
healthcare spending on treating the diseases and their consequences and indirect costs 
through lost wages and productivity. Between 1980 and 2007, type 2 diabetes incidence 
rates have increased from 3.5% to 7.8% (National Center for Health Statistics), and a 
similar, if less dramatic, rise has been reported in hypertension (Tu, et al, 2008). Heart 
disease prevalence has increased from 8% of the adult US population in 1981 (Collins, 
1986) to 11% of the adult US population in 2006 (Pleis, et al, 2007), and remains the 
single greatest cause of death among US adults (Rosamond, et al, 2008). The increase in 
obesity among children and young adults may mean that the rates of these common 
chronic diseases will continue to rise (Lee, 2008). 
 
By their nature, chronic diseases have long-term cost impacts, and while they can be 
controlled they cannot be cured. The most cost-effective way to deal with these diseases 
is to focus on preventing or delaying their onset and, in individuals who have already 
developed a chronic disease, to prevent the development of complications (Russell, 
2009). These preventive efforts, however, will be most cost-effective, and may even be 
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cost-saving, if targeted at those individuals at highest risk. The identification if 
individuals at increased risk for developing a chronic disease or at higher risk of a 
complication from a chronic disease, however, is not routinely done in clinical practice 
(Emery, et al, 2001). For many chronic diseases, in fact, there are no widely used 
methods to estimate an individual’s risk. An important exception, described in detail 
below, is the Framingham Coronary Heart Disease (CHD) risk score. 
 
The promise of genomic medicine has been that information about an individual’s 
genome could be used to identify the diseases they are at increased risk for and give 
insight into how to treat the diseases they have. As the “omics” revolution has progressed 
it has become possible to measure all of the genes being expressed in a sample of cells 
from an individual, identify the most abundant proteins in those cells, profile all of the 
metabolites in those cell, and genotype nearly a million single nucleotide polymorphisms 
(SNPs). This has provided great hope that risk prediction methods can be developed that 
integrate “omics” information to improve prediction accuracy as well as allow for the 
early identification of individuals at increased risk of developing a disease. However, one 
of the key stumbling blocks on the path toward genomic medicine is the lack of 
translational studies on how genetic information can be used to better predict, diagnose, 
and treat diseases. Most complex diseases, like hypertension, diabetes, and heart disease, 
have multifactorial genetic and environmental etiologies and will need complex, or at 
least multivariable risk prediction methods to make clinically useful predictions. 
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This dissertation develops, tests, and applies a risk prediction method designed to predict 
susceptibility to chronic disease. In order to do so, first the characteristics that make risk 
prediction methods suited for use in clinical practice, namely analytical validity, clinical 
utility, and clinical validity (Holtzman, et al, 1997), are examined in Section 1.2. In 
Section 1.3 a short survey of different types of risk prediction methods and their 
characteristics is outlined, focusing on methods that exclusively use data easily measured 
in a clinical setting, methods that exclusively use “omics” data that is collected in a high-
throughput manner but is typically not collected in clinical practice, and methods which 
integrate clinical and high-throughput “omics” data together. In Section 1.4, genetic risk 
scores, a class of risk prediction methods that use information about SNPs to make 
predictions about an individual’s risk of disease, are reviewed to identify ways that this 
class of methods can be improved using the insights about risk prediction methods from 
Section 1.3. Finally, Section 1.5 provides an overview of the risk prediction method that 
is developed and of the structure of the remainder of this dissertation. 
 
When assessing or developing any risk prediction method there are a number of decisions 
that must be made and issues that must be considered. Figure 1-1 gives a graphical 
overview of these. Before a risk prediction method can be used there are three categories 
of issues that must be examined, data issues, modeling building issues, and model 
assessment issues. To address the data issues, the outcome being examined, the types of 
variables being used as input, and any transformations or modifications that must be done 
to those variables needs to be chosen. To address model building issues, the way the risk 
prediction method models the available variables as a function of the outcome, the way 
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variables are selected, and the way the parameters are estimated must be chosen. Lastly, 
to address model assessment issues, the way the predictive accuracy of the method will 
be estimated and how to interpret the model must be decided. Chapter 2 describes in 
detail the choices that have been made for the risk prediction method that forms the core 
of this dissertation. Section 1.2 discusses the features that are relevant to clinical risk 
prediction specifically.  
 
 
Figure 1-1 Considerations for Risk Prediction Methods 
 
1.2 Features of Clinical Risk Prediction Methods 
Creating a system that can make clinical predictions requires more than simply predictive 
accuracy. There are three important features that these systems must exhibit to come into 
broad clinical use, and any attempt at creating such a system must be guided by three 
principles: analytical validity, clinical validity and clinical utility (Haddow, et al, 2004).  
Figure 1-2 shows the relationship between these elements and the features of risk 




Figure 1-2 Relationship of Analytical Validity, Clinical Utility, and Clinical Validity 
with Risk Prediction Methods 
 
1.2.1 Analytical Validity 
Any algorithm that will be used by physicians must also offer an assessment of its 
analytical validity, or how well it identifies and classifies at-risk individuals in the 
population (Haddow, et al, 2004). Minimally, it should provide an estimate of how well it 
has performed in the past and how well it can be expected to perform in the future. There 
are numerous ways to assess this, but the most standard is an estimate of prediction 
accuracy (what proportion of predictions were correct) or of prediction error (what 
proportion of predictions were incorrect). Typically, a cross-validation scheme is used to 
measure the algorithm’s performance. This allows for a reliable assessment of 
performance without the added requirement of a second, fully independent test 
population. It is important to remember, however, that the performance estimate is valid 
only for individuals similar to those used to build the predictor. Applying a predictor that 
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was created using people older than sixty with hypertension to, for example, a population 
of forty-year olds with normal blood pressure will produce a performance estimate that is 
unlikely to be valid. 
 
1.2.2 Clinical Utility 
Next, the prediction that comes out of the system must have clinical utility, which means 
that a physician must be able to make a treatment decision based on the prediction made 
(Haddow, et al, 2004). It is unrealistic to expect that in every case any algorithm is 
capable of extracting enough information to make a useful prediction, but at least one of 
the potential predictions should offer clinicians information that can be used to tailor a 
diagnosis or treatment plan. For example, if a given type of cancer has a known, rare 
subset that responds extremely well to a particular type of treatment, an algorithm that 
can distinguish that subtype would be of clinical utility even though it says nothing about 
the majority of patients that the prediction algorithm is applied to. Conversely, an 
algorithm that can distinguish between two common molecular sub-types of a cancer, 
whose treatments, therapy responses, and prognoses are essentially identical, would not 
be of real clinical utility, even though it makes a very accurate prediction about the 
majority of patients with respect to sub-type.  
 
Clinical utility can be assessed by examining a risk prediction method’s impact in four 
areas: how it affects a physician’s understanding of the diagnosis of a patient, how it 
affects a physician’s choice of treatments for a patient, how the use of the information 
from this risk prediction method affects the clinical outcome of a patient (either in terms 
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of mortality or in terms of quality of life), and how the use of the information from this 
risk prediction method has a societal benefit (such as improved cost-effectiveness in 
treating a particular disease (Tatsioni, et al, 2005). While the assessment of a risk 
prediction method’s impact on patient’s outcomes or cost-effectiveness would require 
separate studies, Grosse suggests that this is not always necessary, and that impact on a 
doctor’s diagnostic thinking or therapeutic choice could be sufficient to determine a risk 
prediction method’s clinical utility even if health outcomes and cost-effectiveness data do 
not exist (Grosse, et al, 2006). 
 
1.2.3 Clinical Validity 
Finally, any prediction system that is intended for wide-spread clinical use should also 
provide evidence of clinical validity, or how well the system performs when applied to a 
clinical population (Holtzman, et al, 1997). Clinical validity is assessed using a several 
criteria: 1) clinical sensitivity, or the probability that a person who develops the disease 
was identified as high risk, 2) clinical specificity, the probability that a person who does 
not develop the disease was identified as low risk, 3) positive predictive value, the 
probability a person who has been predicted as being high risk will develop the disease, 
and 4) negative predictive value, the probability that a person who has been predicted as 
low risk will not develop the disease (Holtzman, et al, 1997). Clinical validation of risk 
prediction methods is an important step; however, it most often accomplished through the 
collection of a secondary validation set after the method is used in clinical practice. For 
example, Aaronson, et al. (Aaronson, et al, 1997) describe the heart failure survival score 
(HFSS), which will be discussed in detail below as an example of clinical nomogram-
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based risk prediction method. The study, however, was conducted prior to the wide-
spread use of "-blocker treatment in heart failure. In order to test if the HFSS was valid in 
patients treated with "-blockers, Koelling, et al. (Koelling, et al, 2004) undertook a 
follow-up study which found that HFSS strata was a significant predictor of survival in 
both "-blocker treated and untreated groups, and that the area under the receiver operator 
characteristics (ROC) curve (AUC), a measure of the predictive accuracy of a model, for 
the HFSS was similar in both "-blocker treated and untreated patients. Because of 
prospective nature of clinical validation studies, however, a discussion of the clinical 
validity of the risk index described is beyond the scope of this dissertation. 
 
1.3 Risk Prediction Methods 
Risk prediction methods have been a topic of much research for more than two decades. 
As medical and epidemiological research has advanced and the risk factors underlying 
chronic diseases and other adverse events have been identified, ways of assessing a 
patient’s risk have followed. One of the most famous risk prediction methods is the 
Framingham CHD risk score (Wilson, et al, 1998). This is a simple algorithm that assigns 
a numerical score to the values of several easily obtained clinical variables and translates 
the patient’s final score into their risk of developing CHD within ten years. The 
Framingham CHD risk score sheet is shown in Figure 1-3. Other risk prediction methods 
can predict a patient’s risk of disease recurrence (Stephenson, et al, 2005), their 
likelihood of responding to a drug (Thuerigen, et al, 2006), or how aggressive their 
cancer is (Spurgeon, et al, 2006). These prediction methods run the gamut from simple to 
complex, and their discriminatory power and predictive utilities vary widely. This review 
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of risk prediction methods focuses on three main groups: 1) prediction methods that use 
exclusively clinical measurements, 2) methods that use gene expression or proteomic 
signatures, and 3) methods that integrate clinical and gene expression measurements.  
 
Figure 1-3 The Framingham CHD Risk Score Worksheet 
 
1.3.1 Clinical Nomograms 
The oldest and most heavily researched type of risk prediction method is the clinical 
nomogram. This class of methods combines demographic and clinical measurements, 
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such as age, gender, cholesterol, and blood pressure that are reasonably easily obtained 
by a physician and make a prediction about a person’s risk of a disease or complication. 
The Framingham CHD risk score is a well known example, and the score sheet 
distributed to physicians is shown in Figure 1-3. To use this nomogram, a physician 
needs a patient’s age, LDL or total cholesterol level, HDL level, systolic and diastolic 
blood pressure, current smoking status, and diabetes status. Using this information the 
doctor adds up a patient’s points from the risk score sheet (each risk table has two sets of 
point values; the LDL points column is used if the doctor has the patient’s LDL 
cholesterol level and the cholesterol points are used if the doctor has the patient’s total 
cholesterol level. Once points have been assigned for each of these variables they can be 
added up and an estimate of 10-year CHD risk can be obtained from the table. Lastly, the 
doctor can then compare the individual’s 10-year CHD risk to the average 10-year CHD 
risk for an individual in the same age group. 
 
The Framingham CHD risk score discussed above is one example, but others exists for 
predicting whether or not a patient’s cancer is likely to be malignant (Lu, et al, 2003), 
how long a patient will survive after transplant (Thuluvath, et al, 2003), and nearly any 
other clinically important outcome or event. These predictions are typically based on 
fairly simple statistical methods, such as logistic regression (Thuluvath, et al, 2003), 
proportional hazards modeling (Aaronson, et al, 1997,Wilson, et al, 1998), and 
classification and regression trees (CART) (Spurgeon, et al, 2006). Outcomes that have 
proven resistant to prediction with traditional statistical methods are modeled using more 
advanced statistical methods, such as support vector machines (SVM) (Lu, et al, 2003) 
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and random forests (RF) (Ward, et al, 2006).  This section briefly reviews each of these 
clinical nomograms to illustrate the type of modeling and predictions that are the standard 
in the field. 
 
Wilson, et al. (1998) used Cox proportional hazards modeling to define the Framingham 
CHD risk score. This score is simple for physicians to calculate and apply to individual 
patients, provides a quantitative measure of risk, and had been validated in a number of 
external studies (Milne, et al, 2003,Ramachandran, et al, 2000,McEwan, et al, 2004). 
Physicians can then tailor interventions to reduce 10-year CHD risk for patients at very 
high risk. However, it is not clear how well patients understand and can use absolute 
measures of risk like those that are provided by this score, meaning that the impact of this 
risk score on patient’s medical decision making is unclear. Additionally, the score’s 
applicability and reliability is poorly understood for African Americans and Asians.  
 
Thuluvath, et al. (2003) developed a logistic regression model to predict survival one 
month, one year, and five years after organ transplant based on pre-transplant clinical 
characteristics. This method is extremely straightforward for physicians to understand 
and implement, and, in the test sample, the proportion of survival at each time point is 
concordant with the prediction of the models. No assessment of the predictive accuracy is 
provided, however, and so, while the method is effective at estimating the proportion of 
individuals that survive it is not clear that the method  is effective at predicting the 
survival of particular individuals. 
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Spurgeon, et al. (2006) classified prostate cancer samples into high and low 
aggressiveness groups using classification trees built with both demographic information 
and results from prostate ultrasounds. This method is simple to create and interpret and 
has excellent sensitivity, identifying 91% of truly aggressive tumors. However, its 
specificity and positive predictive values are quite low, meaning it has difficulty 
identifying less aggressive tumors.  
 
Aaronson, et al. (1997) used Cox modeling to develop a heart failure survival score 
(HFSS) which is used to stratify patients with end-stage heart failure by high, medium, 
and low risk of death. This is easy for a physician to implement and interpret and is very 
easily applied to new patients. Log-rank tests show good separation between high, 
medium, and low risk.  This study was performed in a sample collected between 1993 
and 1995, at a time before the wide-spread use of "-blocker to treat heart failure patients. 
A validation study described in detail above (Koelling, et al, 2004), however, confirmed 
the HFSS’s applicability in patients using "-blockers. 
 
Ward, et al. (2006) developed a risk prediction model using Random Forests to predict 
short-term mortality from lupus erythematosus. The model’s overall misclassification is 
11-13%, which is quite good, but the model was difficult to develop, very sensitive to 
changes in the modeling parameters, such as the number of variables considered at each 
split and the number of trees constructed, and not validated by any external sample. Lu, et 
al. (Lu, et al, 2003) describe an even more complex model, developed using a Support 
Vector Machine (SVM) with a radial basis function as its kernel. It predicts ovarian 
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cancer mortality using clinical, histological, and ultrasound variables. The model’s 
performance is good and well-balanced, with a sensitivity of 85% and a specificity of 
84%, but the method is extremely complex to develop and train, or calibrate to making 
predictions about a given population, and the resulting model is nearly impossible for 
physicians to interpret. An overview of these six risk prediction methods based on 
clinical data is given in Table 1-1 to illustrate the breadth of modeling approaches and 
highlight their advantages or disadvantages. 
 
Overall, clinical nomograms have a number of advantages that make them attractive 
choices for risk prediction. They base their prediction on variables that are commonly 
used in clinical practice and are fairly straightforward to obtain. Using these variables has 
the additional advantage of giving the predictive models some amount of interpretability. 
This might offer a physician insight into how to treat the disease or what preventative 
steps to take. Also, most clinical nomograms are fairly straightforward to calculate. Since 
they typically depend on a small number of variables, it is simple to develop either score 
sheets (e.g., the Framingham CHD risk score, Figure 1-3) or even web-based applications 
(National Cancer Institute) that physicians can easily enter information into and derive a 
risk estimate. Even more complex clinical nomograms using more sophisticated 
statistical modeling can be easily converted to computer programs that are relatively 





Table 1-1 Brief Overview of Selected Clinical Nomograms (Alphabetic by First 
Author) 





Uses proportional hazards 
modeling to stratify patients 
with end-stage congestive heart 
failure into high and low risk of 
death. Log rank tests indicate 
that the model does a good job 




to calculate and 
interpret for a 
physician. 
Quickly 









Uses Support Vector Machines 
with a Radial Basis Function 
kernel to identify malignant 
ovarian tumors using clinical, 
histological and ultrasound 
measurements. In a validation 
set the model gives a sensitivity 
of 85%, a specificity of 84%, 





support for the 
results. 
Extremely complicated 
to create and train. 
Complete black box 









information with data from 
prostate ultrasound to assess 
prostate cancer aggressiveness. 
In a validation sample the 
model gives a sensitivity of 
91%, a specificity of 33.5%, 
and a positive predictive value 
(PPV) of 12.7%. 
Very sensitive, 
easy to calculate, 
and simple for 
physician to 
interpret. 






Uses logistic regression 
modeling that includes clinical 
characteristics prior to 
transplant to predict survival at 
one month, one year, and five 
years. The proportion of 
survival observed at each time 
point is concordant with the 
prediction. 
Simple to create. 
Authors provide no 
realistic assessment of 
predictive accuracy. 
Despite extremely large 
sample size, only use a 
single validation as 
opposed to cross-
validation. Modeling 
approach does not 
accurately reflect the 






Predicts short-term mortality in 
patients with systemic lupus 
erythematosus using Random 
Forests with 47 clinical and 
demographic variables. The 




Impossible to determine 
the relationships 
between the variables. 
Difficult to train and 
tune. Lacks validation 
to determine broad 
applicability. 
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Uses Cox proportional hazards 
modeling from a large cohort 
(~6000) using 10-year 
incidence of CHD to develop a 
risk score. The area under the 
ROC Curve ranges from 0.69-
0.77, indicating that the model 
predicts CHD risk well. 




Applicability to any 
group other than 
Caucasians unclear. 
Overestimates older 
patients' risk of CHD. 
 
Clinical nomograms also have disadvantages. Because they are typically developed using 
a small number of variables and relatively simple statistical techniques, they are not 
always well suited to predicting extremely complex outcomes, such as which individuals 
will require adjuvant chemotherapy. The development  and validation of these risk 
prediction methods typically requires very large samples and a large amount of time for 
follow-up of outcomes, but their broad applicability is uncertain. Even the Framingham 
CHD score, which has been validated in a number of studies, is not necessarily applicable 
to groups other than Caucasians between 30 and 74 years of age, and it also overestimates 
CHD risk in older individuals. 
 
1.3.2 Molecular Signatures 
Molecular signature detection methods are one of the newest classes of risk prediction 
methods, and they have gained increasing popularity as gene expression arrays have 
dropped in cost and improved in quality. Simply, these methods attempt to identify a 
subset of gene expression values that allows samples to be classified into risk groups 
(e.g., low, medium, and high risk) or disease subgroups (e.g., histological subtypes of 
cancer with known differences in treatment or survival outcomes). The algorithms used 
to identify the signature and classify the samples vary in their complexity. The most 
straightforward algorithms use fairly simple methods such as hierarchical clustering or 
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linear discriminant analysis to group the samples and identify genes that are differentially 
expressed between the groups to define the signature (Pawitan, et al, 2005). More 
complex methods can involve using Support Vector Machines (Thuerigen, et al, 2006) or 
Random Forests (Hoffmann, et al, 2006) to identify the signature and classify the 
samples. Some molecular signature risk prediction methods may also offer new ways of 
thinking about the mechanism for the disease or outcome. While the identification of a 
gene in a molecular signature is not hard evidence of a causal role, the signature genes 
offer a starting place for deeper mechanistic investigation that cannot be achieved with 
clinical variables alone.  
 
Briefly, Thuerigen, et al. (2006) developed a Support Vector Machine based method to 
predict whether a patient will respond to a course of chemotherapy. Using a technique 
called recursive feature elimination they identify a 512 gene signature that provided 78% 
sensitivity and 90% specificity in a validation set. The complexity of the method makes 
interpretation difficult, and the only way to measure the signature is to run a full gene 
expression array – something not typical in clinical practice. Pawitan, et al. (2005) used 
Linear Discriminant Analysis to identify a 64 gene signature that stratifies a group of 
breast cancer patients into high, medium, and low risk of distant relapse or death to 
identify those patients with the greatest need for adjuvant chemotherapy. The model does 
well at identifying patients who do well without therapy and who do poorly despite 
therapy, but it does not identify those who would respond well to treatment or those who 
would do poorly without treatment, which are more clinically useful classifications. 
Hoffman, et al. (2006) used Random Forests to identify subgroups of patients in a small 
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set of childhood acute lymphocytic leukemia patients. While the predictive accuracy is 
high, little can be said about the resulting model, both because it is difficult to interpret 
and because the sample used to generate it was so small. Table 1-2 presents an overview 
of these three molecular signature based risk prediction schemes to illustrate the breadth 
of modeling approaches used to create molecular signatures and the types of predictions 
these methods make. While this section focused on gene expression-based molecular 
signatures, these issues extend to proteomic-based biomarker detection, metabolomic-
based metabolite profiles, and genome-wide SNP genotypes. 
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Table 1-2 Brief Overview of Selected Molecular Signatures (Alphabetic by First 
Author) 





Uses Random Forests to find 
a small set of genes for 
subgroup distinction in 
childhood ALL. Cross-
validation showed a 
prediction accuracy of 98%. 
High accuracy. 
Not enough predictive 
performance metrics 
given to assess how 






Using Linear Discriminant 
Analysis, identified 64 genes 
to determine which breast 
cancer patients need adjuvant 
chemotherapy in addition to 
surgery. Log rank tests show 
good separation between 




who do well 
without treatment 




people who would do 
well with treatment and 
those who would do 
poorly without 
treatment (need clinical 






Using Support Vector 
Machines and Recursive 
Feature Elimination, found a 
512 gene signature that they 
used to predict whether or 
not a patient will have a 
complete response to a 
specific course of 
chemotherapy. In a 
validation set the signature 
gave a sensitivity of 78%, a 
specificity of 90%, and a 










No simple way to 
measure the signature; 
have to run a 
microarray. Only 
predicts whether the 
person has a complete 
response, not whether 
they survive. 
 
Molecular signatures developed with traditional statistical methods (e.g., Pawitan, et al. 
2005) are potentially useful because they are straightforward to construct and can be 
interpreted. This makes them easy for physicians to use and easy to develop into a score 
sheet or application. However, the scale and complexity of the data being examined 
means that these methods are not well suited for complex outcomes like chronic disease 
risk, where the causes are not only multifactorial, but there are likely numerous pathways 
leading to the outcome. 
 
 19 
Molecular signatures using more sophisticated machine learning algorithms have the 
advantage of being able to predict more complex outcomes, as well as deal effectively 
with large numbers of weak predictors, or variables which explain only a small fraction 
of the variability in the outcome. They often use sophisticated variable selection 
procedures which help tune the models very precisely, giving high predictive accuracy, 
sensitivity, and specificity. The complexity of the methods, though, makes it difficult if 
not impossible for physicians to interpret the results. While tuning can provide excellent 
performance in one dataset, it can also lead to over-fitting, which reduces the model’s 
applicability to other populations. Additionally, while the molecular signature methods 
discussed above have been assessed with external validation sets, no further validation 
has been published, and none of the methods are near real-world use in clinical practice. 
 
1.3.3 Integrative Approaches 
Most risk prediction methods focus on one type of data, such as clinical data or high-
throughput “omics” data. Recently, however, more integrative approaches to risk 
prediction that combine information from high-throughput biological assays with clinical 
data have been attempted. These approaches are important, because they attempt to more 
accurately reflect the complexity of the underlying conditions and to utilize the full range 
of data that is available for prediction. Attempting to predict a person’s risk of a disease, 
then, by only considering gene expression misses an important source of information that 
may be provided by clinical measurements. At the same time, clinical variables are not 
uniformly accurate predictors, and a specific clinical phenotype may have different 
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meanings depending on the genetic background of the individual. Ignoring information 
about genetics, then, misses a potentially important tool for stratifying disease risk.  
 
Integrative methods are, for the time being, fairly uncommon, but they mark the 
beginning of a trend towards risk prediction methods that are respectful of the complexity 
of the outcome being predicted. They range in complexity from logistic regression 
(Stephenson, et al, 2005) and Cox proportional hazards modeling (Pittman, et al, 2004) to 
advanced statistical techniques such as partial-sliced inverse regression (Li, 2006).  
 
Three examples of this type of integrative methods are reviewed in Table 1-3. 
Stephenson, et al. (Stephenson, et al, 2005) develop a logistic regression model to predict 
prostate cancer recurrence. When prediction was made using only gene expression data, 
the accuracy was only 53%, but when a clinical nomogram was added to the gene 
expression data the accuracy rose to 89%. The clinical nomogram + gene expression data 
improved the accuracy of predictions for those people that the clinical nomogram alone 
classified as indeterminate, but for those that were well predicted by the nomogram the 
gene expression data did not offer any additional benefit. Pittman, et al. (Pittman, et al, 
2004) describe a “clinico-genomic model” that uses Cox proportional hazards modeling 
with both clinical data and gene expression data to predict breast cancer recurrence. 
Combining the data provides better performance than either the clinical data or the gene 
expression data alone. However, the clinical data seems to underperform in this case, 
raising some questions about the broad applicability of these results. Li, et al. (Li, 2006) 
combine clinical data and 40 principal components based on gene expression data using 
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partial-slice inverse regression to predict recurrence in a dataset of diffuse large B-cell 
lymphoma. The combined clinical and gene expression data provided better separation 
between the medium- and low-risk strata than the clinical data alone. However, the 
method is extremely complex and the use of 40 principal components means that there is 
no way to interpret the results. 
 
Table 1-3 Overview of Selected Integrative Approaches (Alphabetic by First 
Author) 
Author Year Description Pros Cons 





Uses partial-sliced inverse 
regression to predict survival 
in DLBCL (diffuse large B-
cell lymphoma). The first 40 
principal components are used 
for the inverse regression. 
Combined model shows good 
separation by the log rank test 
between the low and medium 
risk groups. 







medium and low 
risk groups. 
Because principal 
components are used, 
the results have no 
scientific 
interpretation. The 
method is complicated 
to perform. 




Incorporates clinical info and 
gene expression to predict 
breast cancer recurrence with 
proportional hazards 
modeling. The combined data 
gives 90% sensitivity and 
90% specificity. The gene 
expression only model and 
the clinical only model can 
only reach 70-75% sensitivity 
to achieve 90% specificity. 
Combining clinical 




Clinical predictors do 
not perform as well as 




the clinical data only 
model and the clinical 






Uses logistic regression to 
predict prostate cancer 
recurrence with two models: 
exclusively gene expression, 
and gene expression + clinical 
nomogram. Assessed using 
leave-one-out cross-validation 
and compared to the clinical 
nomogram alone. The clinical 
+ gene expression model has 
an accuracy of 89% vs. 53% 










For patients whom the 
nomogram predicts 
well, this method does 
not add any value. 
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The primary advantage of these integrative approaches is an increase in predictive 
accuracy. It is often the case that while a simple risk prediction method does a fairly good 
job at predicting most of the individuals, they often do a poor job classifying those 
individuals that are at an intermediate level of risk. The integrated systems, however, 
perform quite well for those individuals predicted at intermediate risk using these more 
simple approaches approach. The extra information that results from using both types of 
data yields a prediction method that is superior to ones built from either of the data types 
alone for those individuals initially assessed as having intermediate risk. However, these 
risk prediction methods produce models that are often not as easily interpretable to 
physicians as clinical nomograms, because the introduction of gene expression levels 
requires a detailed understanding of cellular molecular biology and genetics not typically 
found among physicians. Despite these disadvantages, integrative risk prediction systems 
offer significant promise for risk prediction and are likely to become more common as 
“omics” technologies move into clinical practice. One of the goals of this dissertation is 
to develop and refine a risk prediction method that integrates clinical data and single 
nucleotide polymorphism (SNP) genotypes to increase high predictive accuracy for 
individuals at intermediate risk.  
 
1.4 Genetic Risk Scores 
Since the goal of this dissertation is to utilize emerging genetic technologies to improve 
risk prediction, a more detailed examination of genetic risk scores follows. “Genetic risk 
score” is the name used to describe a class of risk prediction methods that work by 
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summing an individual’s risk alleles and using the final score as a basis for risk 
prediction. It is well established that chronic diseases have a strong genetic component, 
with heritability estimates for hypertension of 30% (Agarwal, et al, 2005), for diabetes 
from 72-78% (Permutt, et al, 2005), and for coronary heart disease from 49-51%(Fischer, 
et al, 2005), and polymorphisms have been identified which are known to influence an 
individual’s risk of developing these particular chronic diseases (See Table 1-4). These 
well-validated associations are important to understanding the etiology of chronic 
diseases, but they are of limited value by themselves. They represent either a significant 
risk to a very small number of people (an example of this would be the BRCA1/2 
mutations, which greatly increase lifetime risk of breast and ovarian cancer , but affect 
only a small number of women (Antoniou, et al, 2003)), or, more commonly, a small to 
moderate risk which is modified by other polymorphisms, environmental factors, and 
health behaviors (Cho, 2009,Burke, et al, 2007). Rather than focus on single 
polymorphisms, genetic risk scores combine information from a number of 
polymorphisms with the explicit purpose of making a prediction about an individual’s 
risk. 
 
Table 1-4 Examples of Selected Genetic Associations with Chronic Diseases 
Chronic Disease Type of Study Reference Association Notes 
Candidate Gene 
(Rice, et al, 
2000,Rigat, et al, 







polymorphism in the ACE gene is 
one of the most widely validated 
genetic contributors to 
hypertension risk.  
Hypertension 
Genome Wide 
(Wang, et al, 




Recent studies have identified 
STK39 as a hypertension 
susceptibility locus in Amish & 
other Caucasian samples (Wang) 
and CDH13 as a hypertension 
susceptibility locus in two 
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 European samples (Org). 
Candidate Gene (Grant, et al, 2006) TCF7L2 
Polymorphisms in TCF7L2 has 
been associated with diabetes risk 
in a number of studies. 
Diabetes 
Genome Wide 
(Scott, et al, 
2007,Zeggini, et al, 
2007,Diabetes 
Genetics Initiative of 
Broad Institute of 
Harvard and MIT, 
Lund University, and 
Novartis Institutes of 
BioMedical 




Working together, large consortia 
have identified polymorphisms in 
three genes which contribute to 
diabetes risk in several 
independent samples. 
Candidate Gene (Klerk, et al, 2002) MTHFR 
A meta-analysis found that a 
polymorphism in MTHFR 
increased heart disease risk in 
Europeans, but not in North 
Americans. The authors suggest 
this may be due to an interaction 




(McPherson, et al, 
2007,Helgadottir, et 
al, 2007,Schunkert, et 
al, 2008) 
9p21 
Polymorphisms from 9p21 have 
been associated with heart disease 
risk independent of hypertension 
or diabetes in a number of studies.  
 
The risk index method developed and tested in this dissertation draws from the idea of a 
genetic risk score and the risk index method utilized by Beer, et al (Beer, et al, 2002). 
Genetic risk scores (GRS) are particularly appealing because they allow for the compiling 
of a large amount of potential risk information in a straightforward manner. Ideally, they 
also allow for a semi-quantitative comparison of the disease risk for two individuals (i.e., 
while the overall scale of the risk score may differ between populations, the difference in 
risk score between two individuals from the same population should provide information 
about one individual’s risk relative to the other). Looking closely at a few examples of 
GRS methods offers insight into their best characteristics and how to leverage these while 
minimizing the drawbacks of the methods. 
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1.4.1 A Simple Example of a Genetic Risk Score 
Morrison, et al. (2007) propose a straight-forward approach to developing a GRS, 
focusing on the impact of polymorphisms on a survival phenotype. Using time to 
developing coronary heart disease as their outcome, the authors use the Atherosclerosis 
Risk in Communities (ARIC) cohort to develop a GRS using 116 polymorphisms. 
Working separately in whites and blacks, the authors begin by using each polymorphism 
as the explanatory variable in a Cox proportional hazards regression, and excluding all 
polymorphisms with a p-value > 0.10. They identified 11 polymorphisms which passed 
this criteria in whites and 11 which passed this criteria in blacks. These n polymorphisms 
are then summed for each individual j, giving 
! 
GRS j = SNPij
i=1
n
" , with each SNP genotype 
coded as 1 for the risk-conferring homozygote, 0 for the heterozygote, and -1 for the risk-
lowering homozygote. This set of GRS values for the sample being investigated was then 
used as an explanatory variable in a Cox proportional Hazards model, and the authors 
found it to be significantly associated with the time to developing CHD in both whites 
and blacks. 
 
The authors then take an important next step, and assess the predictive ability of the GRS 
above and beyond already existing measurements of CHD risk. They added the GRS to 
the Atherosclerosis Risk in Communities (ARIC) Score (ARCS), a nomogram developed 
using the ARIC study to assess an individual’s risk of developing CHD, and assessed the 
area under the receiver operating characteristics curve (AUC) for the Cox model 
containing only the ARCS and for the Cox model containing both the ACRS and the 
GRS. The authors found that in whites including the GRS in addition to the ARCS 
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proved to be only marginally statistically significant, while in blacks the AUC for the 
ARCS + GRS proved to be statistically significantly larger than the AUC for the ARCS 
alone. Finally, the authors investigated whether the predictive ability of the GRS was 
equal over the entire range of the ARCS. When the ARCS values were split into tertiles, 
Cox modeling in each tertile showed the GRS to be a significant predictor in each tertile. 
Additionally, Cox modeling showed that there was no significant interaction between the 
GRS and the ARCS tertiles, indicating the impact of the GRS on predictive ability is 
consistent across the range of ARCS values and not confined to improving prediction in 
individuals with extreme ARCS values. 
 
The GRS approach described by Morrison, et al. has a number of advantages. It is simple 
to implement, deals easily with a potentially large number of polymorphisms, and can be 
used in conjunction with pre-existing risk assessment methods. However, the method 
assumes an approximately equivalent effect of each polymorphism, while polymorphisms 
may in fact have a broad range of effects (Knudsen, et al, 2001). Also, as with the method 
described by Horne, at al. (2005), there is no model selection procedure in place, which, 
if there are multiple polymorphisms capturing the same genetic variation, could lead to an 
over- or under-estimate of risk.  Lastly, this method as described assumes complete data 
is available for each individual. The Morrison, et al. (2007) approach is explicitly 
described as a proof-of-concept to show the utility of aggregating genetic information to 
predict risk of incident chronic disease in a longitudinal study. Only a fairly small 
number of polymorphisms were considered, but the early success from this method 
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suggests that a GRS can be of substantial utility in identifying individuals at risk of 
developing CHD. 
 
1.4.2 A More Complex Approach to a Genetic Risk Score 
The goal of the GRS described by Horne, et al. (2005) is to predict clinically relevant 
chronic disease endpoints using features of the underlying biology. Specifically, because 
of the complexity of the biology of common chronic disease endpoints, the authors work 
under the assumption that it will be easier to connect genetic polymorphisms with 
measurable intermediate phenotypes known to influence the outcome of interest. The 
authors choose this set of intermediate biological phenotypes and then collect a set of 
genetic polymorphisms thought to influence the intermediate phenotypes. 
 
Each polymorphism is modeled as the explanatory variable in a linear regression of the 
intermediate phenotype, and polymorphisms that achieve univariate significance are 
retained. For each retained polymorphism s influencing intermediate phenotype i there is 
a beta coefficient !is estimated from the linear modeling. Each of the intermediate 
phenotypes is then used as the explanatory variable in a univariate logistic regression of 
the outcome, and for each intermediate phenotype i there is a beta coefficient !i. Then, if 
n is the number of intermediate phenotypes examined and pi is the number of 
polymorphisms retained for intermediate phenotype i, then these can be added, giving the 









# , where !max is given 
by max{|!1|,…,|!n|} and genotypeisj is the genotype for the sth polymorphism for the ith 
intermediate phenotype in person j. The genetic risk score variable is then used as the 
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explanatory variable in a logistic regression of the clinical endpoint and its performance 
assessed. When used with large numbers of polymorphisms the GRS will approximate a 
continuous variable, but when used with a small number only a limited number of values 
will be possible. In this case, the authors suggest dividing the GRS into several groups 
and using the resulting categorical variable as the independent variable in the predictive 
model. 
 
Horne, et al. (2005) illustrate their GRS method using the clinical endpoint of coronary 
artery disease (CAD), with three intermediate phenotypes, low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides 
(TG). One SNP was genotyped in each of three genes – CETP, ABCA1, and HL. None of 
these three SNPs significantly predicted CAD in a logistic regression model, even after 
adjustment for age, sex, hypertension, diabetes, hyperlipidemia, family history of early 
CAD, tobacco use, and C-reactive protein levels. For the GRS, none of the three SNPs 
were associated with differences in LDL-C or TG. On the other hand, HDL-C variation 
was significantly associated with all three SNPs. The resulting GRStot distribution ranged 
discontinuously from -2.09 to 0, and there were few predictors, so the authors stratified 
the sample into five groups based on their GRStot value. When that strata was used as the 
explanatory variable in a logistic regression (using strata 4, the largest group, as the 
reference group) the authors found that groups 1, 2, and 3, which had lower mean values 
of GRStot had significantly beneficial odds ratios compared to group 4. When this 
stratification was collapsed into two group (with groups 1, 2, and 3 forming the “low 
risk” strata and groups 4 and 5 comprising the “high risk” strata) the significance 
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remained, with the low risk strata having an odds ratio of 0.77.  Although this example is 
quite small in scale, it offers evidence that polymorphisms not directly associated with a 
clinical outcome can be used to stratify risk using intermediate phenotypes. 
 
This approach to combining genetic information to make predictions about clinical 
endpoints offers some advantages. Beginning with clinically relevant endpoints ensures 
that the prediction that will be made has a direct relationship to disease. Moving from the 
clinical endpoints to intermediate phenotypes reduces the potential search space to a more 
manageable level and adds an element of interpretability to the eventual results. The 
polymorphisms considered for building the predictive model are chosen from genes with 
prior evidence of involvement with one of the intermediate phenotypes. The resulting 
predictive model is then grounded in functional knowledge, so even if the precise 
mechanism by which the polymorphisms act is unknown, as is often the case (Rebbeck, 
et al, 2004), there is still a body of evidence connecting the polymorphism to the clinical 
endpoint. At the same time, by restraining the search space in this way, many potentially 
predictive polymorphisms are excluded either because they lack a priori evidence 
associating them with an intermediate phenotype known to influence the clinical endpoint 
or because they are linked with an intermediate phenotype whose role in affecting the 
clinical endpoint is either not recognized or poorly understood. Additionally, because 
there is no selection method implemented beyond simple univariate significance, the 
presence of multiple polymorphisms marking the same genetic information might lead to 
an over-estimate of the amount of risk being conferred. Although this is not the case in 
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the example discussed by the authors, which focuses on only three polymorphisms, if a 
larger number of polymorphisms were examined this could quickly become an issue. 
 
1.4.3 An Application of the Genetic Risk Score Concept to Other Data Types 
Beer, et al. (2002) describe a risk classification method they term a “risk index” that sums 
information about risk from a number of different variables and uses that sum to make a 
qualitative predction about an individual’s risk. This approach deals with gene expression 
values, and so is not strictly a genetic risk score, but it shares many features with other 
genetic risk scores. This method focuses on classifying lung cancer patients as at high or 
low risk of death based on gene expression profiling. Using gene expression levels as 
quantified by Affymetrix oligonucletide expression arrays as predictor variables instead 
of SNP genotypes, Beer, et al. define a risk index, a linear combination of the 50 most 
significant predictors of survival as assessed by univariate Cox proportional hazards 
modeling weighted by their beta coefficients from the Cox model. The final number of 
predictors used, 50, resulted from empirical testing of models comprised of the top 10, 
20, 50, and 75 genes. Fifty was chosen because this model had the highest association 
with the survival outcome. This risk index is given  by the equation 
! 




where RIj is the risk index for the jth person, "i is the Cox proportional hazards model for 
the ith most significant gene expression variable, and Eij is the value of ith most significant 
gene expression variable for person j. A value for the risk index is then calculated for a 
new individual, and they are classified as high or low risk depending on whether their 
risk index value is above or below the 60th percentile value among the sample initially 
used to generate the risk index.  
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The rationale for this risk index approach is simple: when dealing with a small dataset 
with a large number of potential features to examine (p >> n), it is impossible to estimate 
them all simultaneously. So, to take into consideration the greatest amount of 
information, the features were treated as independent predictors and used univariately to 
make predictions. Beer, et al. (2002) found that this procedure stratified their sample of 
67 stage I tumors into groups with significantly different survival, with a log rank test p-
value of 0.0006 for the comparison between the high and low risk classes. The risk index 
developed with the original sample was also able to stratify an independent sample of 84 
tumors into high- and low-risk groups with significantly different survival times 
(P=0.003). 
 
The risk index has several advantages in its design. It is straightforward to implement, but 
examines multiple models to determine which performs best. In the example given it also 
performs well, and the list of gene expression values used to build the risk index offers 
some measure of interpretability. This method, however, has a very simple variable 
selection procedure, considers only a fairly small number of variables, and does not 
provide a comprehensive assessment of its predictive performance at the group and 
individual level. The risk index can be improved as a risk prediction tool by expanding 
the variables being examined to include common clinical variables in addition to genetic 
polymorphisms, implementing a more sophisticated variable selection procedure, and 
adding measures of analytical validity. 
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1.5 Developing, Testing, and Applying the Risk Index to Chronic Disease Risk 
Prediction 
Examining the current GRS methodologies offers several lessons for developing new 
approaches. First, begin with a clinically relevant endpoint And focus on providing a 
qualitative assessment of risk (e.g., high risk / low risk), and this type of prediction is 
most useful in a clinical setting. Second, create methods that can be integrated with other 
risk assessments both to demonstrate the usefulness of the assessment above and beyond 
other methods and also to improve overall predictive performance. Third, integrate 
weightings of genetic effects into GRS methods, in contrast to the uniform weighting 
found in Morrison, et al. (2007). The weights allow for an assessment of the relative 
importance of particular polymorphisms or gene expression levels, and account for 
differences when not all variables have an equivalent impact (Ryall, et al, 1992).  Last, it 
is important to have provisions to deal with missing variable values. It will often be the 
case in real-world data that an individual will be missing one or more variable values, 
particularly when a large number have been investigated. Careful consideration of this 
eventuality can prevent potential biases that may unintentionally arise when individuals 
with missing variable values have differential contributions to a risk index formed by 
many variables and end up being systematically assigned higher or lower risk values 
because of their missing values. 
 
Using existing genetic risk score methodologies for inspiration, this dissertation develops, 
extends, and tests a risk prediction system based on the risk index methodology described 
by Beer et al. (2002). This system will make predictions about an individual’s level of 
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risk for developing a particular outcome (e.g., developing diabetes) based on both clinical 
data and genetic factors. Chapter 2 will describe in detail the development of this 
statistical methodology. Chapter 3 will describe a simulation study that was used to 
investigate the method’s performance with different scales of data. Lastly, chapter 4 will 
discuss the application of this method to a dataset from the Framingham Heart Study’s 
Offspring Cohort and it’s ability to predict risk of three different chronic disease 
outcomes: ten-year incident hypertension, ten-year incident diabetes, and prevalent 
hypertension. 
 
By extending and rigorously testing the genetic risk score methodology, the risk index 
method developed in this dissertation will provide insight into the potential applications 
that genetic risk score methods are well suited to. If the risk index methodology is shown 
to be a prediction method that performs well then it will offer a practical way for 
clinicians to classify an individual’s risk of developing a given chronic disease as high or 
low. This method could then be deployed using a particular clinic’s existing population 
and used to assess risk in any new individuals entering the clinic, and would allow 
physicians to assess its performance and determine the appropriateness of the predictions 
for the population being examined. To assess the performance of the clinical + genetics 
model developed by the risk index, it’s predictive performance will be compared both to 
a Random Forests model built using the clinical and genomic model and to a risk index 
model developed using only the available clinical data. 
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Chapter 2  
The Development of a Risk Index Prediction Method 
The purpose of this dissertation is to develop and evaluate the performance of a risk 
prediction method called the risk index. The risk index is composed of the linear 
combination of the values of a set of covariates weighted by their regression coefficients 
estimated from univariate models of the covariates predicting the particular outcome of 
interest. Using a particular risk index model, a risk index value can be calculated for each 
individual in a dataset. In addition, the risk index can then be used to make predictions 
about a new individual’s risk of developing the outcome (e.g., in an independent testing 
set). Figure 2-1 shows a graphical overview of the risk index procedure, and the 
mathematical details are laid out in section 2.1. Choice of performance criteria and 
assessment methods are laid out in section 2.2, SNP selection methodology is described 
in section 2.3, and section 2.4 describes the comparison between the risk index 
methodology and Random Forests (RF), a widely-used machine-learning algorithm that 
has been used for risk prediction with high-dimensional data. 
 
2.1 The Risk Index 
The risk index method requires a sample of n individuals with a vector of outcomes Y, 
where yj represents the outcome of the jth individual. The implementation of the risk 
index method used for this project requires a dichotomous outcome (coded as 0 for “no” 
and 1 for “yes”), although it is straightforward to extended the procedure to consider 
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either continuous or survival outcomes. The risk index method also requires two matrices 
of covariates, Xcov and XSNP, with Xcov representing a set of typical clinical covariates 
(e.g., demographic and anthropometric measurements, biochemical measurements, past 
medical history) and XSNP representing a set of genotypes, from either a candidate gene 
study or from a genome-wide association study. Xcov is an n x vcov matrix where vcov is the 
number of variables in the set of typical clinical covariates and xcov kj is the value of the kth 
variable from the set of typical clinical covariates for the jth person. Similarly, XSNP is an 
n x vSNP matrix where vSNP is the number of variables in the set of genotype variables and 
xSNP kj is the value of the kth variable from the set of genotype variables for the jth person. 
 
Risk index models will be built for each of the two sets of variables, clinical covariates 
and genotype variables. The risk index model for the set of genotypes variables begins 
with the risk index model that has been created for the set of clinical covariates. The risk 
index model for the clinical covariates takes the form of 
! 





, and the 
risk index model for the genotype variables takes the form 
! 
RISNP|cov j = "cov l * xcov lj
l=1
lcov
# + "SNP l * xSNP lj
l=1
lSNP
# . For these models, j is the individual that the 
risk index value is being calculated for, lcov and lSNP are the number of variables in the 
risk index model for the clinical covariates and the genotype variables respectively. !covl 
and !SNPl are the beta coefficient for the lth variable in clinical covariates and the 
genotype variables respectively, and xcov lj and xSNP lj is the value of the lth variable in 
clinical covariates and the genotype variables respectively for the jth person. The final 
risk index models are denoted RIcov and RISNP|cov, where RIcov represents the model built 
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using Xcov, and RISNP|cov representing the models built with XSNP given RIcov. For 
mathematical precision, in this chapter the risk index models will be referred to as RIcov 
and RISNP|cov,. In Chapters 3, 4, and 5 these models will be reffered to as the Clinical and 
Clinical + Genotype risk index models, respectively. 
 
Figure 2-1 A Visual Overview of the Risk Index Method 
 
2.1.1 Logistic Regression 
As it is currently implemented, the risk index methodology begins the model building 
procedure by estimating logistic regression models of the dichotomous outcome being 
examined with each individual clinical covariate and genotype variable as an explanatory 
variable. Logistic regression is a form of the generalized linear model (GLM) that is 
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based on the logit function, 
! 












represents the odds of the outcome variable being equal to one (ie, the probability that the 
outcome is equal to one divided by the probability that the outcome is equal to zero). The 
logit function is then modeled as a linear function of the explanatory variable, 
! 





. Estimates of # 
and " are made by maximizing the likelihood function 
! 
l(") = # (x j )
j=1
n
$ , where 
! 
" (x j ) = p
y j (1# p)1#y j , which takes the value of p when yj equals 1 and (1-p) when yj 
equals 0.  
 
For categorical explanatory variables, one category is chosen as the reference group and 
the term 
! 
e" l is interpreted as the odds ratio of the two groups (the odds of a person in that 
category having the outcome divided by the odds of a person in the reference category 
having the outcome). For continuous explanatory variables, the reference group can be 
thought of as a person who has a value of zero for the variable, and a person’s odds of 
developing the outcome given the variable is the beta coefficient multiplied by the 
person’s value for that variable, 
! 
e" l xlj . 
 
2.1.2 Dividing the Data 
Developing and applying the risk index requires the ability to reliably track the 
performance of risk index models during the model building process and to estimate the 
final model’s performance on a real-world dataset. To accomplish this, the original 
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sample of n individuals will be split into two parts, as shown in part A of Figure 2-1. One 
part will consist of a random twenty-five percent of the sample that is set aside as an 
“independent test set”. This data will be used after the final steps of model building to 
assess the performance of the risk index models. The remaining seventy-five percent of 
the data will comprise the “optimization set” and be used to construct the risk index 
models. This portion of the data will be further subdivided into four equal parts for four-
fold cross-validation. A visual representation of this is given in part B of Figure 2-1. 
Division into cross-validation sets will be repeated ten times to account for random 
fluctuations in performance due to the stochastic process of data division (Molinaro, et al, 
2005). Each part will be used as a “testing set” once, while the remaining three parts will 
be used as the “training set”. The training set will be used to estimate the logistic 
regression coefficients, and a prediction will be made about whether each person in the 
testing set will develop the outcome or not. These predictions will then be used to 
calculate sensitivity, specificity, and other performance characteristics by comparing 
them to the actual individual outcomes that were observed, as described below.  
 
2.1.3 Building the Risk Index 
Building the risk index begins with the set of typical clinical covariates, Xcov. Part F of 
Figure 2-1 displays the model building procedure described here in a graphical manner. 
Each variable xcov k is used as the explanatory variable in a univariate logistic regression 
on Y, and regression coefficients are estimated using the training set. These coefficient 
estimates are stored and will be used throughout the building of the risk index model for 
Xcov. Each of the vcov coefficients are then used to form a one-variable risk index model, 
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! 
RIcov j = "cov k * xcov kj , with the associated covariate and calculate the risk index values for 
people in the training set and testing set. The single best performing (as described in 
Section 2.2) of the vcov one-variable models is selected, and that variable (denoted 
variable “1”), is fixed into the risk index model. A new set of vcov-1 risk index models are 
then constructed using variable “1” and one of the remaining variables: 
! 
RIcov j = "cov1 * xcov1 j + "cov k * xcov kj . The best performing is chosen, the new variable, “2”, 
is fixed into the model, and the process is repeated until either all variables of the 
covariate set Xcov have been incorporated into the model or some maximum limit (e.g., 
ten variables) has been reached. This yields a set of successively nested models, with 
each risk index model containing one more variable than the previous risk index model. 
The best performing (again, as described in Section 2.2) of these nested models is then 
selected, giving 
! 
RIcov j = "cov l * xcov lj
l=1
lcov
# ,, where each variable xcov l is in the final, best-
performing model, and lcov is the total number of variables in that model. The risk index 
building procedure is then repeated with the set of covariates XSNP, using the risk index 
model developed for covariate set Xcov as a base and successively adding the variable that 
improves the performance of the model by the greatest amount. This yields 
! 
RISNP j = "cov l * xcov lj
l=1
lcov
# + "SNP l * xSNP lj
l=1
lSNP
# .  
 
2.1.4 Accounting for Missing Values 
To account for the fact that some individuals may be missing values for covariates that 
are used in risk index models, an additional term is used to adjust individual risk index 
values by the amount of available covariate variables. For Xcov, the value RIcov j for the jth 
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person is divided by ncov j, the number of clinical covariates for which person j has non-
missing values, and for XSNP the value RISNP j for the jth person is divided by nSNP j, the 
number of genotype variables for which person j has non-missing values,. This makes the 
risk index model for clinical covariates 
! 
RIcov j =






















2.1.5 Making Predictions 
The purpose of the risk index methodology is to make predictions about the disease risk 
of individuals. In order to turn the risk index values into a discrete (yes/no) prediction, a 
cut-point is selected during the model building procedure (shown in part F of Figure 2-1) 
using the following algorithm: 
1) One of the ten cross-validation iterations is selected 
2) For one of the four training set / testing set pairs in that iteration is selected 
3) For a given risk index model, risk index values are calculated for each person in the 
training and testing set 
4) The value at the pth percentile of the training set risk index values distribution, c*, is 
obtained 
5) All individuals in the testing set with an risk index value less than c* are assigned a 
prediction of 0 or “low risk of developing the outcome” 
6) All individuals in the testing set with an risk index value greater than c* are assigned 
a prediction of 1 or “high risk of developing the outcome” 
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7) Steps 3-6 are performed for the remaining three training set / testing set pairs in the 
selected cross-validation iteration 
8) The performance of the predictions made on the individuals in the testing sets is 
assessed (as described in Section 2.2)  
9) Steps 1-8 are performed for the remaining nine iterations of cross-validation samples 
10)  Performance of the ten iterations are averaged 
11) Steps 1-10 are performed for a range of values of p 
12) The percentile with the highest performance (as described in section 2.2) is chosen as 
the cutpoint 
This process is encapsulated in part F of Figure 2-1 as “Choosing the ‘Best’ Performing 
Model”. 
 
2.1.6 Ensemble Prediction 
The predictive performance of the risk index building procedure described above depends 
heavily on the optimization set’s split into cross-validation sets. To provide a more stable 
prediction an additional step inspired by ensemble prediction methods will be performed 
(Optiz and Maclin, 1999). To begin, a bootstrap sample S of the optimization set will be 
generated. The risk index procedure will be used to generate a risk index model using the 
clinical covariates and a risk index model using both the clinical covariates and genotype 
variables. These models will be used to make a high risk/low risk prediction about the 
individuals in the independent test set that was set aside . The bootstrap procedure will be 
repeated W times, and each person in the independent testing set will be assigned a final 
high risk prediction if more than (W/2)+1 of the models predicted the individual to be 
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high risk. If more than (W/2)+1 of the models predicted the individual to be low risk that 
person will be assigned a final prediction of low risk. 
 
2.2 Assessing Performance 
Once predictions have been made about individuals in the testing set, they can be 
compared to the observed values of the outcome for each individual. Table 1 shows the 
appropriate way to classify individual predictions. From these predictions, performance 
metrics can be calculated as shown in Table 2. 
Table 2-1 Description of a 2x2 Table 
 True “Yes” True “No” 
Predicted “Yes” True Positive False Positive 
Predicted “No” False Negative True Negative 
 
Table 2-2 Calculation of Performance Metrics 
Name Abbrev. Formula 
Sensitivity Sen TP/(TP + FN) 
Specificity Spe. TN/(TN + FP) 
Accuracy Acc. (TP + TN)/(TP + TN + FP + FN) 
Positive Predictive Value PPV TP/(TP + FP) 
 
These performance metrics will be calculated once for each of the ten four-fold  cross-
validations. The four-fold cross-validation will yield one prediction for each individual, 
and the values for all individuals will be used to calculate sensitivity, specificity, 
misclassification, and positive predictive value. These performance metrics will then be 
averaged across all ten iterations of four-fold cross-validation. Next, sensitivity, 
specificity, misclassification, and positive predictive value will be calculated for the 
 43 
independent testing set. Finally a receiver operating characteristics (ROC) curve will be 
generated and the area under the ROC curve (AUC) will be estimated. 
 
2.2.1 Model Building Optimization Function 
Part F of Figure 2-1 provides a visual overview of the model building procedure and 
indicates that an optimal or “best” new variable is chosen during the actual model 
building, and an optimal submodel is chosen as the final step in the model building 
procedure. An additional metric is needed to make these comparisons between sets of 
predictive models during the model building procedure. Although a number of potential 
scores have been developed for this purpose, no single score is appropriate for all 
contexts. The risk index as it will be applied in this context will focus on future disease-
state prediction, and so an appropriate performance metric should compare the predicted 
disease probabilities that are assigned to each person to their eventual outcome. The Brier 
score, or quadratic score, is a model score that does this and will be used for model 
comparison and optimization. The Brier score begins with maximum time in which to 
have the outcome, t*, an indicator function 
! 
I(Ti < t*) , and an individual’s predicted 
probability of developing that outcome, 
! 
ˆ " (t* | ˜ X ) . The indicator function I(Ti<t*) takes 
the value of 0 if individual i’s time to th outcome (Ti) is greater than t* and takes the 
value of 1 if individual i’s time to develop the outcome is less than t*. 
! 
ˆ " (t* | ˜ X )  is 
referred to at the “strata-specific outcome probability”, which is the probability that a any 
person in the given risk strata (high or low) that individual i is assigned to will develop 
the outcome by t* . This is calculated for a given risk strata by adding the number of 
individuals individual in the strata who develop the event by t* and dividing by the total 
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number of individuals in that strata. The score itself is given by 
! 
Brier Score = 1
n




$  and is the average of the squared difference 
between an individual’s outcome status and the probability of a person in the same risk 
strata developing the outcome by t*. 
 
2.2.2 Calculating Strata-Specific Outcome Probabilities 
An important component of the Brier score is the strata-specific outcome probabilities. 
For the model building process, performed in the optimization set, the Brier score will be 
estimated on the testing sets of a given cross-validation iteration and the averaged across 
all ten iterations. For a particular testing set in a given cross-validation iteration, the 
strata-specific outcome probabilities will be estimated in the associated training set. This 
process is illustrated in Figure 2-2. For the cutpoint being investigated, each individual in 
the training set will be assigned to either the high or low risk strata. For each of the strata, 
then, the number of individuals who develop the outcome by t* will be divided by the 
total number of individuals assigned to that strata. This proportion will be the probability 
of a person in that risk strata developing the outcome by t*. For the final model 
assessment process, performed in the independent test set, the strata-specific outcome 





Figure 2-2 An Overview of the Assignment of Strata-Specific Probabilities for Use in 
the Brier Score 
 
2.2.3 Estimating Individual Predicted Probabilities of Disease 
The bootstrapping procedure used to generate the final predictions for each individual 
provides a simple measure of that individual’s predicted probability of disease. The final 
prediction for an individual is taken to be the prediction which was most often given by 
the ensemble procedure. Analogously, the predicted probability of disease for the 
individual is simply the number of bootstrap samples which predicted an individuals 
would develop the disease being examined divided by the total number of bootstrap 
samples. Using the binomial distribution a 95% confidence interval we might be able to 
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construct an estimate of the predicted probability of disease with the Wilson score 
interval (Wilson, 1927). This interval, given by 
! 
95% CI =














ˆ p is the predicted probability of 
disease and n is the number of bootstrap samples, might be useful physicians to gauge the 
prediction. We should note that the n bootstraps are not independent as this equation 
assumes. 
 
2.2.4 Bootstrap Estimate of Model Performance 
Beyond individual prediction confidence, it is also important to be able to compare the 
performance of two different risk index models created with the same data. The 
performance of the two risk index models is estimated on the independent test set; 
however, this point estimate is based on a random division of the data, and a bootstrap 
procedure will provide a confidence interval that can be used for comparisons. To begin, 





* . Both the risk index models Rcov and RSNP will then be applied to each of 
the 1000 bootstrapped independent test samples, and sensitivity, specificity, 
misclassification, positive predictive value, and model score will be calculated. For each 
risk index model the 1000 values for each of these measurements will be sorted, and the 
lower bound of the 95% confidence interval will be the value at the 2.5th percentile and 
the upper bound will be the value at the 97.5th percentile.  
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For each of these performance measures (sensitivity, specificity, misclassification, and 
positive predictive value), the standard error and the bias can be estimated. For each ni, 
there will be 1000 estimates of each of the performance measures. The standard error of 











, where B is the total number of bootstrap 
samples generated (1000 in this case), 
! 
s B  is the value of a particular performance 
measure averaged over all of the B bootstraps, and sb is the particular performance 
measure from the bth bootstrap of the independent test set. The bias, or average deviation 
of the performance measure in a bootstrap sample from the estimate in the independent 








, where s is a particular performance estimate for the 
independent test set, sb is the estimate for the same performance measure for the bth 
bootstrap sample of the independent test set, and B is the total number of bootstrap 
samples generated.  
 
2.3 SNP Selection 
The search through the set of SNPs is exhaustive, and if no limit is placed on the number 
of SNPs that may be fixed into the risk index model, for g SNPs, the risk index procedure 
must evaluate 
! 
g " (h "1)
h=1
g
#  models, which can be alternatively expressed 
! 
g2 " g(g "1)
2
. If 
the number of SNPs that may be added to the risk index model is limited to some smaller 
number, q, then the risk index model building procedure must evaluate 
! 




models. For a set of 500,000 SNPs and a limit of at most twenty SNPs allowed into the 




, or 9,999,810 models to be examined 
by the risk index model building procedure. In order to keep the number of models to be 
examined reasonable, two different SNP selection approaches will be tested. First, each 
available SNP will be tested for association with the outcome of interest in the entire 
optimization set. The 1% of SNPs most highly associated with the outcome, as measured 
by p-value, will be then be used for the risk index procedure because these SNPs are most 
likely to be strong predictors of the outcome. Second, a principal components analysis 
(PCA) approach will be used to reduce the dimensionality of the entire set of genotype 
data.  
 
2.3.1 Principal Components Analysis 
Principal Components Analysis (PCA) is a dimensionality reduction tool that is 
commonly used in many fields of study (Jackson, 2003). PCA computes the eigenvectors 
and eigenvalues of a p x p covariance or correlation matrix where p is the number of 
variables being examined.  Each of the principal components is orthogonal to all others 
(i.e., there is no overlap in the variance they explain) and explains a proportion of the 
total variance of the sample. In this dissertation the PCA will be performed exclusively 
on SNP genotypes. This means that “variance” here refers to population level genomic 
variability in the DNA sequence. Principal components are ordered, with the first 
component explaining the most variance and each successive component explaining 
successively less of the variance. Because of these features, new variables (i.e., the 
principal components) can be constructed such that a significant portion of the variance 
 49 
can be explained with relatively small number of variables, as opposed to the potentially 
tens or hundreds of thousands of variables used to construct the set of principal 
components, and each of the new variables explains a discrete subset of the variance in 
the sample. PCA has been used to correct for population structure in genome-wide 
association studies with programs such as SMARTPCA (part of EIGENSTRAT) 
(Patterson, et al, 2006), to precisely determine an individual’s population of origin (Price, 
et al, 2008) and to identify the relationships between subpopulations (Seldin, et al, 2006). 
The same benefits that make PCA well-suited to population structure analysis, 
particularly its ability to reduce the number of variables being examined while 
representing a significant amount of the genetic variation contained in the original set of 
genotypes, also make PCA a good choice for reducing the dimensionality of SNP data in 
this project. 
 
The principal components procedure begins with an n x p set of data, where n is the 
number of individuals in the dataset and p is the number of variables. A covariance 
matrix S is then calculated, where sij is the covariance of the ith and jth variable if i $ j and 
the variance of the ith if i = j (Jackson, 2003). The set of p eigenvalues, %, for the matrix S 
are found by taking the determinant det(S - %I), where I is the identity matrix, and 
solving the resulting pth order polynomial. The eigenvectors ui are calculated by solving 





. The set of eigenvalues and eigenvectors 
is then used to create a new set of uncorrelated variables, the principal components. This 
is done for each of the n subjects by multiplying each of the p eigenvectors by the 
standardized value of each variable, 
! 
zi = " u i[x # x ]. These new variables, or some subset 
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of them, can then be used in place of the original variables. For this project, the complete 
set of SNP genotypes have been decomposed into its principal components (PCs). The 
PCs that account for 90% of the variation in the sample are then used as the genotype 
variables for the risk index procedure. Additionally, the set of SNPs most highly 
associated with the outcome being investigated have been decomposed into its PCs, and 
the PCs that account for 90% of the variation in the sample are used as the genotype 
variables for the risk index procedure. 
 
2.4 Performance Comparison 
The development of a novel risk prediction algorithm requires a standard against which 
to judge its performance.  An appropriate comparison method must have three essential 
characteristics: 1) the goals and underlying assumptions of the methods are similar, 2) the 
methods are capable of dealing with the same types of data, and 3) the performance 
metrics produced are comparable.  This project will compare the performance of the risk 
index methodology to that of random forests (RF). Developed by Leo Brieman, one of 
the developers of the classification and regression trees (CART) methodology (Breiman, 
et al, 1984), RF is a modification of a decision tree algorithm that is capable of dealing 
with very high-dimensional data (Breiman, 1996). 
 
2.4.1 Classification and Regression Trees 
CART is a specific implementation of a decision tree algorithm. Given a dataset of 
samples with class labels, CART creates a binary tree by splitting the samples at each 
node in such a way that makes the two new nodes as pure as possible (i.e., they contain as 
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close to exactly one class as possible) (Breiman, et al, 1984). Once the specified stopping 
criterion has been reached, class labels can be assigned to each of the terminal nodes 
based on the classes of the samples in the node. New samples, with unknown class labels, 
can be placed in the tree, and by following the splitting rules, these samples can be 
assigned the class label associated with the terminal node they reach. In the following 
sections the statistical and analytical strategies underlying CART are outlined in detail 
using the same nomenclature and terminology as is used in Brieman, et al. (1984). 
 
2.4.2 Splitting Nodes 
Four things are needed to create the tree: a set of binary questions used to split the nodes, 
a measure to assess the goodness of a specific split, a stop-splitting rule, and a method to 
assign class labels to the terminal nodes (Breiman, et al, 1984). The most straight-forward 
of these requirements is the set of binary questions with which to split the nodes. 
Breiman, et al. propose a set of standard questions that encompasses all possible splits of 
a node using a single variable (Breiman, et al, 1984). For each continuous variable x, the 
questions are of the form “Is x ! c ?” for all c ranging over (-","), and for each 
categorical variable x that takes class labels (c1, …,cn), the questions are of the form “Is x 
& S ?”, as S ranges over all subsets of (c1, …,cn).  
 
2.4.3 Measurement of Impurity 
The goal of tree growing is to create a tree in which the terminal nodes hold samples of 
exactly one class. Due to limitations in CART implementations this result is not always 
achievable in practice, however it suggests a logical choice for a measure of the goodness 
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of a split s of node t: the impurity of the resulting left and right nodes tL and tR, 
respectively (Breiman, et al, 1984). A good measure of impurity i(t) should be maximal 
when each class is equally represented in a single node and equal to zero when exactly 
one class is represented. The optimal split s derived from the set of questions described 
above is the split that maximizes the decrease in impurity, 
! 
"i(s,t) = i(t) # pLi(tL ) # pRi(tR ), where pL is the proportion of people in node t that are in 
node tL and pR is the proportion of people in node t that are in node tR. Breiman, et al. 
(1984) suggest two possible impurity measures, the Gini criterion and the Twoing 
criterion. The Gini criterion is straightforward, and defines impurity as 
! 
i(t) = p( j | t)p(i | t)
j" i
# . In the case of a two class problem, this reduces to 
! 
i(t) = p(1 | t)p(2 | t), which the authors describe as the appropriate impurity function for 
two class problems. The Twoing criterion is more complex and begins with grouping all 
class labels C = (1,…,J) into two super classes C1 = (j1,…,jn) and C2 = C – C1. Splitting 
then proceeds as if it were a two class problem. The optimal split, then, depends on the 
choice of C1 and C2, and so all groupings of C1 and C2 and all potential splits s within 
those groupings are considered. This is a much more computationally intensive intense 
procedure than the Gini criterion; however, it has the advantage of grouping similar class 
labels together. The final tree does not depend heavily on the choice of criteria, but the 
Gini criterion is the preferred method due to better performance in some instances. 
 
2.4.4 Stop Splitting Criteria 
Choosing when to stop growing the tree has proven to be a difficult problem. Although 
common sense suggests growing the tree until the decrease in impurity falls below some 
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threshold, in practice that threshold is often either too high, resulting in trees which are 
too small, or too low, resulting in very large trees that have poor predictive ability 
(Breiman, et al, 1984). Minimizing the misclassification error rate is one potential 
solution; however, this measure continually decreases as tree size increases and leads to 
over-estimation of a large tree’s predictive ability. A procedure for both finding the 
optimal size of a tree and for giving an accurate estimate of the real-world 
misclassification rate is therefore necessary. Breiman, et al. propose pruning as the best 
way for reducing tree size and using the estimated misclassification error rate as the 
criterion for choosing the optimally sized tree. Pruning proceeds recursively, beginning 
with the largest tree (i.e., the tree that was grown to completion) and identifying a 
weakest-link subtree that, for some cost penalty #, has a cost-complexity 
! 






 is the number of terminal nodes in the tree and R(TT) is 
the misclassification error rate) that is equal for the subtree and its root node. The 
appropriate # is found by finding the node that minimizes 
! 
g1(t) =




, t # T1
~


















 is the number of terminal 
nodes in subtree t. Once the weakest-link subtree has been removed, the procedure is 
repeated until only the root node of tree T remains. This yields a nested set of subtrees 
ranging from a single root node to the full tree created during the growing phase. An 
estimate of the true misclassification error can then be used to identify the optimal pruned 
tree. This estimate can be obtained either through the use of a test sample (if the original 
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sample size is sufficiently large) or by cross-validation. For the test sample method, some 
proportion of the original samples is left out, a tree is constructed and pruned, and classes 
in the test sample are obtained with each of the trees. Misclassification rates can then be 
calculated for each of the trees, and the tree with the lowest rate is selected as the optimal 
tree. Cross-validation is more complex but also more commonly used, owing to sample 
size constraints. Briefly, the whole sample is divided into n approximately evenly sized 
groups. As the tree is grown with the full sample, n auxiliary trees are grown with each of 
the possible sets of n-1 groups (so each group is used to construct n-1 trees and is left out 
of 1 tree). Each of the auxiliary trees are pruned using the # that was used for the full 
tree, and the misclassification error can be estimated by putting each of the n groups 
down the auxiliary tree that it was not used to create. If n is sufficiently large, this 
approximates the misclassification error obtained by putting an independent test set down 
the full tree, and because there is a misclassification error estimate associated with each 
of the pruned subtrees, it can be used to identify the optimal subtree. 
 
2.4.5 Assigning Class Labels 
There are multiple approaches for assigning class labels to each of the terminal nodes of 
the tree. The approach preferred by Brieman et al. is to have each sample in a terminal 
node “vote” on the class label, with the class that is most highly represented being set as 
the label for that node(Breiman, et al, 1984). If two or more classes are equally 
represented in a terminal node, they suggest choosing a class label at random from among 
the most represented classes.  
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CART has become a very widely used classification method because it flexible, 
computationally efficient, and creates a tree that is easily interpretable. CART performs 
well in cases where linear methods such as logistic regression do poorly (Brieman, et al. 
1984). However, large numbers of variables can cause a significant increase in the time 
required to create the tree. For this reason, CART is best suited to data types with fewer 
variables, such as demographic, clinical, environmental and social, and biochemical 
variables, or to data types where feature selection has been applied, reducing the number 
of variables to be considered. 
 
2.4.6 Random Forests 
Random Forests (RF), however, an ensemble learning algorithm based on CART, is not 
limited by the number of variables contained in the dataset. In its most basic form, a large 
number of trees are grown (e.g.,100 or 1000). Each tree is grown with a bootstrap sample 
from the original data (i.e., a sample of the same size as the original is chosen, with 
replacement, from the original sample) and the best split at each node is chosen from 
among some number of randomly selected input variables. An unknown sample can then 
be run down each of the trees, and the class label that is selected by the most classifiers 
can be applied (Breiman, 1996). 
 
With the RF method, trees are grown as in CART but are not pruned. Breiman states that 
the ensemble nature of the classifier places a limiting value on the generalization error 
(i.e., the error expected when the classifier is presented with a novel set of samples), 
removing the need for tree pruning (Breiman, 1996). At each node, some number F of 
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input variables are selected, and the best possible split among those variables is chosen. 
Breiman describes two different values for F, 
! 
F =1 and 
! 
F = floor(log2(M +1)) (where 
M is the total number of input variables available), but the performance of the algorithm 
does not heavily depend on F. Error estimation, a problem that is solved only with cross-
validation or an independent test set in CART, can be performed using an “out-of-bag” 
method. When each bootstrap sample is created, approximately one-third of the cases are 
held out. Then, once all of the trees have been constructed, each case can be run down the 
one-third of trees it was not used to create. The proportion of incorrect classifications can 
then be averaged over all cases, giving an estimate of the misclassification error rate. 
Because only one-third of all trees were used for the classification, this is actually an 
overestimate of the misclassification error rate, but it is unbiased; thus, it will approach 
the true misclassification error rate as sample size increases. Unlike CART, RF does not 
lend itself to simple interpretation. In its raw form it is a “black box”, but assessing 
variable importance can allow insight into the relationships that the RF is modeling. To 
measure importance, trees are constructed as described above. Then, for all out-of-bag 
samples for a given tree, the nth variable is permuted. Misclassification error is estimated, 
and the percent difference between the misclassification error rate estimated with and 
without the permutation of the nth variable is that variable’s measure of importance for 
that tree. Importance measurements for each variable can then be averaged across all 
trees, and by standardizing with the standard error of the importance, a z-score for the 




Figure 2-3 An Example of a Random Forest and Its Prediction About a New 
Individual 
 
RF excels at classification in situations in which a large number of variables and a large 
number of cases are available (Breiman, 1996). Its performance is excellent even when 
all available variables have very weak predictive power, a condition that is common 
when considering genomic features such as SNP genotypes but that prevents other 
classification algorithms from performing well.  
 
2.4.7 Comparison Methodology 
RF’s ability to deal with a large number of variables makes it an excellent choice for 
comparison to the risk index, although the comparison procedure must be done so as to 
ensure that the comparison is as valid as possible. First, the optimization set used in the 
construction of the risk index will be used to build a forest of 500 trees. An optimization 
procedure will be used to identify the number of variables to be examined at each split, k.  
Initially the forest will be generated with 
! 
k = v , where v is the total number of variables 
in the dataset, and the out-of-bag (OOB) error will be estimated. Then k will be increased 
from this initial value by factors of 2 until the OOB improves by less than 5%. Finally, k 
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will be decreased from its initial value by factors of 2 until the OOB no longer improves 
by 5% or more. The value of k which provides the lowest OOB will be used.  
 
The true comparison of the methods is their predictive performance on the independent 
test set and, as with the risk index, a bootstrapping procedure will be used to provide a 
confidence interval for the forest’s performance. As before, 1000 bootstrap samples of 
the independent test set will be taken, and the forest will be applied to each. 
 
As a default, the final prediction from the random forest is given by a simple voting 
procedure. If a majority of trees predict an individual is at high risk, then that individual 
is assigned a prediction of “high risk”. If not, the individual is assigned a prediction of 
“low risk”. To fully examine the potential performance of the random forests, predictions 
will be made using a number of voting cutoffs. To begin, all individual for whom 5% or 
more of the trees in the forest predict to be at high risk will be assigned a prediction of 
“high risk”, and this cutoff will be increased until only individuals who 95% or more of 
trees in the forest predict as high risk will be assigned a prediction of “high risk”. 
 
Once predictions have been made for each individual, the sensitivity, specificity, 
misclassification rate, and positive predictive value will be calculated for each of the 
bootstrap samples. These values will then be sorted and the 95% confidence interval for 
each of these measurements will be the values at the 2.5th percentile and the 97.5th 
percentile. The bootstrapped performance estimates of the two techniques will then be 
compared. 
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Chapter 3  
Simulation Study to Characterize the Performance of the Risk Index 
While the final assessment of the utility of any risk prediction algorithm should be rooted 
in its ability to accurately make predictions about real datasets, the use of simulation 
datasets is an important step in the characterization of performance. Datasets obtained 
from real-world studies have complex structures that make it impossible to say 
definitively that a particular variable is or is not related to the outcome being studied. In a 
simulation study, however, the correlation structure of the data can be directly specified, 
giving a dataset where the relationship between each variable and the outcome is known. 
 
Applying the risk index methodology to simulated datasets allows for the systematic 
investigation of its functioning and performance. By having fine-grained control over the 
precise structure of the dataset being tested, it is possible to address important questions 
about the risk index methodology’s sensitivity to noise variables, ability to account for 
correlation among predictor variables, and performance with varying numbers of 
predictors. The simulation study carried out here examines two different scenarios that 
the risk index might be expected to handle. First, a small-scale study was simulated 
consisting of one thousand people with a small number of standard covariates (eight) and 
a moderate number of polymorphisms (five hundred). This small-scale simulation is 
patterned after a candidate gene study, where the polymorphisms investigated are not 
evenly spread throughout the genome, but rather in selected regions thought to be 
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involved in the disease process being studied. Second, a large-scale study was simulated, 
with ten thousand individuals, thirty covariates, and approximately forty thousand 
polymorphisms. This large-scale simulation is patterned after a genome-wide association 
study, with polymorphisms chosen to reflect the frequencies observed on Chromosome 
one in the Affymetrix 500K genome-wide genotyping system. 
 
3.1 Small-scale Simulation Study Methodology 
The small-scale simulation study consists of one thousand people, eight covariates, and 
five hundred polymorphisms. The outcome is a dichotomous variable with a 30% 
prevalence and is simulated as a continuously distributed normal random variable with a 
mean of 120 and a standard deviation of 40. Approximately 30% of the individuals will 
have values for the outcome of >140, and this cutoff is used to convert the continuous 
outcome into the dichotomous outcome. 
 
The covariate and outcome simulation are generated with a multivariate normal random 
number generator. The correlation matrix between the covariates and the continuous 
outcome is specified, with the first variable having a 0.56 correlation with the outcome, 
the second a 0.41 correlation with the outcome, the third a 0.50 correlation with the 
outcome and an 0.80 correlation with variable one, and the fourth a 0.28 correlation with 
the outcome. The remaining four variables will be noise variables, with no correlation 
with the outcome or any of the explanatory variables. Though this simulation is 
simplistic, it allows the examination of the behavior of the risk index procedure in the 
presence of highly correlated explanatory variables. In particular, by including correlation 
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between the first and third variable, it is possible to see the effect of that correlation on 
the variable selection procedure.  
 
Genotype simulation was performed using the genomeSIMLA program (Edwards, et al, 
2008). Genotypes for five hundred SNPs were generated for each individual in the 
simulation dataset. All of the SNPs were considered independent from every other SNP 
and had no pairwise linkage disequilibrium. Four polymorphisms were set as associated 
with the outcome, each with a beta coefficient of between 0.4 and 0.8, corresponding to 
an odds ratio for a given locus of between 1.5 and 2.2. Genotypes were coded additively, 
with a value of 0 representing an individual homozygous for the major allele, a value of 1 
representing a heterozygous individual, and a value of 2 representing an individual 
homozygous for the minor allele. 
 
3.2 Small-scale Simulation Study Complete SNP Set Results 
3.2.1 Variable Selection 
Using the methodology outlined above, 100 small-scale simulation datasets were 
generated, each with 1000 individuals, eight covariates, and 500 polymorphisms. The risk 
index procedure was then applied to each of the 100 simulation datasets. The datasets 
were divided into an independent testing set of 250 individuals and an optimization set of 
750 individuals. One hundred bootstrap samples of the optimization set were generated, 
and the risk index procedure was used to generate Clinical and Clinical + Genotype risk 
index models for each of the bootstrap samples. Each of these models was then used to 
make a prediction (high risk or low risk for developing hypertension) about each of the 
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250 individuals in the independent testing set. For both the Clinical risk index model and 
the Clinical + Genotype risk index model the predictions from each of the 100 bootstrap 
samples were used as votes, and the prediction most frequently assigned was designated 
as the consensus prediction. For each of the 250 individuals in the independent testing set 
there was one prediction for Clinical risk index model and one prediction for the Clinical 
+ Genotype prediction. 
 
Table 3-1 shows the summary of the variable selection procedure from the Clinical risk 
index model averaged across the 100 simulation datasets. Variables one, two, and four 
are most frequently selected; on average, they each appear in more than half of the 100 
trimmed Clinical risk index models (a “trimmed model” here refers to a risk index model 
that has been grown to its maximum size and had the optimal submodel chosen). Variable 
three, because of its high correlation with variable one, is typically chosen as one of the 
last variables (on average, variable three is chosen as the sixth, seventh, or eighth variable 
in 71.05 of the 100 untrimmed Clinical risk index models for a given simulation dataset). 
However, each trimmed Clinical risk index models contained, on average, 3.83 variables, 
so variable 3, because it is typically selected into position six, seven, or eight, appears in 
only an average of 26.58 of the 100 trimmed Clinical risk index models.  
 
Table 3-2 shows the summary of the variable selection procedure from the Clinical + 
Genotype risk index model averaged across the 100 simulation datasets. No SNP was in 
more than 5.76 out of 100 Clinical + Genotype risk index models on average. The SNPs 
most commonly observed in trimmed Clinical + Genotype risk index models were SNP 
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180 (5.76 out of 100 trimmed Clinical + Genotype risk index models, on average),  SNP 
168 (5.28 out of 100 trimmed Clinical + Genotype risk index models, on average), SNP 
425 (5.27 out of 100 trimmed Clinical + Genotype risk index models, on average), SNP 
411 (5.06 out of 100 trimmed Clinical Genotype risk index models, on average), and SNP 
73 (5.05 out of 100 trimmed Clinical + Genotype risk index models, on average. The 
genotype simulation specified 4 SNPs as being associated with the outcome, (i.e., SNP 1, 
SNP 10, SNP 50, and SNP 100). Although these polymorphisms were, when selected, 
often chosen as the first variable in the Clinical + Genotype risk index model, the Small-
scale Simulation only included these variables in trimmed Clinical + Genotype risk index 
models in between 1.25 and 1.76 out of 100 times, on average. 
 
Table 3-1 Summary of the Number of Times Each Variable is Selected into a 
Specific Model Position for the Small-scale Simulation Clinical Risk Index Models 
  Variable Position 
Variable 1 2 3 4 5 6 7 8 
Total # of Times 
in Trimmed 
Model 
v1 42.59 6.17 2.6 3.11 3.35 6.28 14.76 21.14 56.15 
v2 8.51 39 9.64 4.24 7.79 16.08 4.41 10.33 62.7 
v3 12.75 3.76 3.18 3.92 5.34 11.57 22.66 36.82 26.58 
v4 1.57 11.35 28.89 11.33 23.18 10.13 7.52 6.03 54.05 
v5 8.88 9.12 13.67 20.34 15.24 13.48 12.8 6.47 45.48 
v6 8.76 9.79 14.32 19.44 15.12 14.41 12.48 5.68 46.82 
v7 8.61 10.43 13.64 18.98 15.3 14.26 12.41 6.37 46.1 




Table 3-2 Summary of the Number of Times Selected Genotype Variables are Selected into a Specific Model Position for the 
Small-scale Simulation Clinical + Genotype Risk Index Models  
  Variable Position 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 








s39 0.27 0.23 0.3 0.4 0.28 0.37 0.32 0.35 0.35 0.3 0.29 0.28 0.31 0.36 0.36 0.3 0.27 0.29 0.34 0.21 6.18 4.91 
s51 0.19 0.21 0.3 0.3 0.34 0.22 0.24 0.22 0.4 0.3 0.33 0.25 0.27 0.29 0.29 0.25 0.29 0.32 0.27 0.24 5.52 4.6 
s73 0.13 0.44 0.3 0.31 0.35 0.42 0.41 0.29 0.24 0.35 0.46 0.2 0.3 0.29 0.27 0.25 0.47 0.36 0.33 0.32 6.49 5.05 
s135 0.16 0.25 0.36 0.3 0.28 0.3 0.22 0.27 0.33 0.31 0.22 0.32 0.28 0.25 0.35 0.31 0.33 0.31 0.22 0.42 5.79 4.55 
s168 0.18 0.23 0.34 0.4 0.37 0.43 0.37 0.38 0.37 0.28 0.33 0.32 0.25 0.4 0.35 0.32 0.37 0.23 0.33 0.36 6.61 5.28 
s180 0.25 0.29 0.41 0.29 0.33 0.45 0.3 0.43 0.36 0.43 0.52 0.39 0.36 0.32 0.35 0.33 0.26 0.34 0.27 0.33 7.01 5.76 
s240 0.2 0.36 0.17 0.33 0.33 0.42 0.23 0.36 0.3 0.32 0.34 0.27 0.21 0.24 0.35 0.38 0.35 0.3 0.28 0.38 6.12 4.81 
s273 0.16 0.27 0.34 0.34 0.29 0.35 0.28 0.27 0.27 0.28 0.25 0.28 0.34 0.31 0.28 0.32 0.21 0.35 0.24 0.37 5.8 4.6 
s288 0.16 0.23 0.29 0.35 0.26 0.32 0.42 0.23 0.29 0.32 0.28 0.28 0.27 0.28 0.36 0.34 0.26 0.26 0.39 0.34 5.93 4.64 
s302 0.12 0.24 0.38 0.41 0.26 0.35 0.23 0.28 0.32 0.4 0.4 0.26 0.34 0.29 0.27 0.25 0.29 0.26 0.33 0.27 5.95 4.79 
s329 0.17 0.34 0.32 0.38 0.2 0.4 0.39 0.2 0.25 0.33 0.27 0.29 0.29 0.28 0.29 0.36 0.41 0.32 0.24 0.24 5.97 4.72 
s387 0.12 0.27 0.31 0.19 0.33 0.34 0.37 0.26 0.37 0.34 0.24 0.24 0.28 0.33 0.35 0.27 0.3 0.28 0.31 0.33 5.83 4.57 
s411 0.15 0.22 0.35 0.33 0.36 0.38 0.24 0.49 0.32 0.41 0.32 0.29 0.29 0.38 0.23 0.38 0.31 0.32 0.26 0.35 6.38 5.06 
s413 0.2 0.24 0.31 0.35 0.33 0.34 0.25 0.36 0.24 0.32 0.38 0.33 0.4 0.29 0.24 0.34 0.33 0.38 0.29 0.32 6.24 4.96 
s417 0.29 0.38 0.24 0.31 0.22 0.33 0.21 0.42 0.19 0.29 0.38 0.28 0.27 0.22 0.28 0.36 0.24 0.29 0.27 0.26 5.73 4.6 
s425 0.17 0.35 0.39 0.28 0.37 0.18 0.37 0.38 0.4 0.41 0.31 0.37 0.33 0.41 0.35 0.3 0.34 0.39 0.4 0.45 6.95 5.27 
s462 0.26 0.18 0.25 0.29 0.28 0.24 0.34 0.4 0.27 0.38 0.27 0.34 0.3 0.32 0.18 0.2 0.27 0.35 0.34 0.34 5.8 4.57 
s477 0.15 0.32 0.3 0.28 0.26 0.31 0.32 0.31 0.38 0.33 0.29 0.34 0.31 0.21 0.28 0.31 0.3 0.38 0.21 0.29 5.88 4.61 
s486 0.16 0.21 0.31 0.46 0.34 0.34 0.38 0.34 0.26 0.23 0.37 0.39 0.3 0.35 0.24 0.33 0.36 0.19 0.38 0.37 6.31 4.81 
s494 0.17 0.21 0.25 0.35 0.35 0.38 0.29 0.42 0.34 0.24 0.41 0.48 0.25 0.3 0.27 0.36 0.27 0.33 0.37 0.18 6.22 4.93 
s1 0.46 0.14 0.05 0.11 0.05 0.03 0.04 0.04 0.02 0.05 0.02 0.04 0.08 0.05 0.03 0.02 0.03 0.01 0.03 0.06 1.36 1.25 
s10 0.3 0.14 0.08 0.11 0.12 0.1 0.12 0.11 0.17 0.06 0.11 0.04 0.05 0.08 0.11 0.06 0.06 0.07 0.1 0.05 2.04 1.76 
s50 0.44 0.33 0.14 0.06 0.07 0.05 0.06 0.04 0.05 0.03 0.08 0.08 0.01 0.05 0.04 0.04 0.07 0.08 0.05 0.05 1.82 1.68 
s100 0.43 0.2 0.1 0.1 0.1 0.11 0.1 0.05 0.07 0.05 0.05 0.06 0.02 0.07 0.03 0.06 0.05 0.08 0.12 0.04 1.89 1.7 
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3.2.2 Models 
Once the variable selection procedure is finished each of the 100 small-scale simulation 
datasets have 100 trimmed Clinical and Clinical + Genotype risk index models. Tables 3-
3, 3-4, and 3-5 each show five trimmed Clinical risk index models randomly selected 
from one of three randomly chosen small-scale simulation datasets (datasets #5, #12, and 
#25). Figures 3-1, 3-2, and 3-3 show the full distribution of risk index values in the 
optimization set for a randomly selected trimmed Clinical risk index model from each of 
the three small-scale simulation datasets. Figures 3-4, 3-5, and 3-6 show the full 
distribution of risk index values in the independent testing set for a randomly selected 
trimmed Clinical risk index model from each of the three small-scale simulation datasets. 
In all six of these figures a red line indicates the cut-off point. All individuals with a risk 
index value greater than or equal to this cut-off point are predicted as “high risk” and all 
individuals with a value less than this cut-off point are predicted as “low risk”. Tables 3-
6, 3-7, and 3-8 show the risk index values and predictions from the same set of five 
Clinical risk index models from the same three small-scale simulation datasets for a set of 
25 individuals randomly selected from the optimization set.  
 
Table 3-3 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Small-scale Simulation Dataset #5 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
2 0.1601*v1 + 0.3749*v2 + 0.1046*v4 
5 0.1596*v1 + 0.3284*v2 + 0.0047*v6 + 0.0239*v8  
44 0.143*v1 + 0.3871*v2 + 0.0864*v4  
83 0.1539*v1 + 0.3756*v2 + 0.0766*v3 + 0.055*v4 + 0.0531*v5 + 0.1189*v8  
85 0.1472*v1 + 0.417*v2 - 0.2374*v5 + 0.0189*v8 
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Table 3-4 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Small-scale Simulation Dataset #12 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
24 0.3645*v2 + 0.0979*v3 + 0.0945*v4 - 0.2109*v8  
27 -0.0133*v5  
37 -0.2249*v5 + 0.0167*v6 + 0.0116*v7 + 0.0195*v8  
49 0.1481*v1 + 0.4174*v2 + 0.0845*v3 + 0.0918*v4 - 0.0016*v6 
83 0.1352*v1 + 0.3632*v2 + 0.0904*v3 + 0.0856*v4 + 0.1224*v5 + 0.0173*v6 - 0.0492*v8 
 
Table 3-5 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Small-scale Simulation Dataset #15 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
25 0.1271*v1 + 0.3612*v2 + 0.0798*v3 + 0.0501*v6 
76 0.3139*v2 - 0.5463*v5 - 0.0426*v8 
79 0.1516*v1 + 0.0964*v3 + 0.0909*v4 + 0.0158*v6 - 6e-04*v7 + 0.1363*v8 
88 0.1149*v5 + 0.0023*v7 




Figure 3-1 Clinical Risk Index Value Distribution in the Optimization Set for Small-
scale Dataset #5, Bootstrap Sample #2 
 
Figure 3-2 Clinical Risk Index Value Distribution in the Optimization Set for Small-
scale Dataset #12, Bootstrap Sample #24 
 68 
 
Figure 3-3 Clinical Risk Index Value Distribution in the Optimization Set for Small-
scale Dataset #15, Bootstrap Sample #25 
 
 
Figure 3-4 Clinical Risk Index Value Distribution in the Independent Testing Set for 
Small-scale Dataset #5, Bootstrap Sample #2 
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Figure 3-5 Clinical Risk Index Value Distribution in the Independent Testing Set for 
Small-scale Dataset #12, Bootstrap Sample #24 
 
 
Figure 3-6 Clinical Risk Index Value Distribution in the Independent Testing Set for 
Small-scale Dataset #15, Bootstrap Sample #25
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Table 3-6 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Small-scale Simulation Dataset #5 
    Bootstrap Sample #2 Bootstrap Sample #5 Bootstrap Sample #44 Bootstrap Sample #83 Bootstrap Sample #85 












1 1 5.371 1 3.245 1 4.933 1 3.906 1 2.674 1 
2 1 4.422 0 2.392 0 3.984 0 2.881 0 1.789 0 
3 0 4.650 0 2.735 0 4.335 0 3.060 0 2.265 0 
4 0 4.541 0 2.444 0 4.102 0 3.123 0 1.851 0 
5 0 3.817 0 2.197 0 3.453 0 2.806 0 1.556 0 
6 0 4.879 0 2.713 0 4.434 0 3.282 0 2.126 0 
7 0 4.330 0 2.597 0 3.976 0 3.002 0 2.055 0 
8 0 4.976 0 3.021 0 4.573 0 3.381 0 2.445 0 
9 0 5.104 1 3.049 0 4.648 0 3.634 0 2.432 0 
10 1 4.747 0 2.816 0 4.352 0 3.347 0 2.235 0 
11 1 5.214 1 3.302 1 4.760 0 3.786 1 2.682 1 
12 1 5.183 1 3.251 1 4.701 0 3.757 1 2.555 1 
13 0 4.280 0 2.454 0 3.896 0 3.204 0 1.884 0 
14 0 4.282 0 2.539 0 3.946 0 3.047 0 2.003 0 
15 1 6.074 1 3.694 1 5.559 1 4.125 1 3.115 1 
16 0 4.537 0 2.972 0 4.182 0 3.490 0 2.399 0 
17 1 5.526 1 3.219 1 5.082 1 3.501 0 2.647 1 
18 0 4.225 0 2.668 0 3.855 0 3.145 0 2.044 0 
19 1 6.463 1 3.838 1 5.911 1 4.497 1 3.281 1 
20 0 5.295 1 2.944 0 4.821 0 3.650 0 2.420 0 
21 0 4.835 0 2.825 0 4.448 0 3.190 0 2.322 0 
22 0 4.586 0 2.347 0 4.209 0 3.035 0 1.860 0 
23 0 4.517 0 2.567 0 4.089 0 3.128 0 1.927 0 
24 0 4.250 0 2.414 0 3.883 0 2.928 0 1.838 0 
25 1 5.715 1 3.522 1 5.255 1 3.993 1 2.939 1 
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Table 3-7 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Small-scale Simulation Dataset #12 
    Bootstrap Sample #24 Bootstrap Sample #27 Bootstrap Sample #37 Bootstrap Sample #49 Bootstrap Sample #83 












1 1 3.302 1 -0.131 1 -0.233 1 4.837 1 3.464 1 
2 0 2.483 0 -0.141 0 -0.268 0 3.637 0 2.622 0 
3 0 2.721 0 -0.142 0 -0.328 0 4.099 0 2.994 0 
4 1 3.168 1 -0.129 1 -0.261 0 4.216 0 3.022 0 
5 0 2.464 0 -0.129 1 -0.240 1 3.996 0 2.894 0 
6 0 2.457 0 -0.134 0 -0.281 0 3.803 0 2.717 0 
7 0 3.198 1 -0.135 0 -0.266 0 4.353 1 3.128 0 
8 0 2.862 0 -0.127 1 -0.210 1 3.988 0 2.852 0 
9 1 2.678 0 -0.131 1 -0.249 1 3.906 0 2.802 0 
10 1 3.096 1 -0.132 0 -0.226 1 4.253 1 3.113 0 
11 0 2.938 0 -0.132 0 -0.287 0 4.441 1 3.186 0 
12 0 2.598 0 -0.131 1 -0.214 1 4.031 0 2.911 0 
13 1 1.978 0 -0.131 1 -0.232 1 2.821 0 2.115 0 
14 1 3.388 1 -0.135 0 -0.231 1 4.647 1 3.358 1 
15 0 2.590 0 -0.135 0 -0.234 1 3.791 0 2.761 0 
16 0 1.937 0 -0.128 1 -0.261 0 3.257 0 2.363 0 
17 0 2.400 0 -0.129 1 -0.267 0 3.526 0 2.539 0 
18 0 3.305 1 -0.134 0 -0.261 0 4.070 0 2.921 0 
19 1 3.143 1 -0.129 1 -0.267 0 4.621 1 3.337 1 
20 1 2.989 0 -0.131 1 -0.254 1 4.568 1 3.277 0 
21 0 2.767 0 -0.131 0 -0.228 1 3.759 0 2.744 0 
22 1 3.439 1 -0.138 0 -0.329 0 4.849 1 3.403 1 
23 0 2.300 0 -0.138 0 -0.290 0 3.427 0 2.483 0 
24 1 3.291 1 -0.128 1 -0.292 0 4.662 1 3.310 1 
25 0 2.725 0 -0.134 0 -0.292 0 3.634 0 2.644 0 
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Table 3-8 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Small-scale Simulation Dataset #15 
   Bootstrap Sample #25 Bootstrap Sample #76 Bootstrap Sample #79 Bootstrap Sample #88 Bootstrap Sample #92 












1 0 3.839 0 -1.095 0 3.038 0 0.621 0 2.752 0 
2 0 4.035 0 -1.265 0 3.126 0 0.621 0 3.120 0 
3 1 5.608 1 -1.005 0 4.310 1 0.673 1 4.646 1 
4 0 3.363 0 -1.107 0 2.713 0 0.642 0 2.340 0 
5 1 4.982 1 -1.337 0 4.121 1 0.637 0 3.928 1 
6 0 3.799 0 -1.016 0 2.911 0 0.635 0 2.898 0 
7 0 4.076 0 -0.964 0 3.242 0 0.630 0 3.119 0 
8 0 3.729 0 -1.059 0 2.844 0 0.613 0 2.676 0 
9 1 4.375 0 -1.166 0 3.590 1 0.621 0 3.357 1 
10 0 4.545 0 -0.827 1 3.325 0 0.603 0 3.465 1 
11 0 3.866 0 -0.696 1 2.794 0 0.612 0 2.730 0 
12 0 3.336 0 -1.029 0 2.531 0 0.642 0 2.370 0 
13 1 4.476 0 -0.930 0 3.431 0 0.645 1 3.485 1 
14 0 2.972 0 -0.753 1 2.108 0 0.614 0 1.921 0 
15 0 2.329 0 -1.043 0 1.816 0 0.651 1 1.407 0 
16 0 3.994 0 -0.948 0 2.921 0 0.626 0 2.964 0 
17 1 4.645 0 -0.708 1 3.427 0 0.618 0 3.434 1 
18 0 4.291 0 -0.730 1 3.120 0 0.620 0 3.137 0 
19 1 4.553 0 -0.949 0 3.376 0 0.646 1 3.445 1 
20 1 4.296 0 -0.912 0 3.186 0 0.610 0 3.196 0 
21 1 5.095 1 -0.637 1 3.820 1 0.640 0 3.982 1 
22 0 3.506 0 -1.229 0 2.766 0 0.634 0 2.576 0 
23 1 5.052 1 -0.538 1 3.657 1 0.641 0 3.917 1 
24 1 4.552 0 -0.748 1 3.082 0 0.644 1 3.393 1 
25 0 4.038 0 -0.874 0 3.003 0 0.622 0 3.010 0 
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Tables 3-9, 3-10, and 3-11 each show the five trimmed Clinical + Genotype risk index 
models corresponding with the models shown in Tables 3-3, 3-4, and 3-5. Tables 3-12, 3-
13, and 3-14 show the risk index values and predictions from the same set of five Clinical 
+ Genotype risk index models. Figures 3-7, 3-8, and 3-9 show the full distribution of risk 
index values in the optimization set for a randomly selected trimmed Clinical + Genotype 
risk index model from each of the three small-scale simulation datasets described above. 
Figures 3-10, 3-11, and 3-12 show the full distribution of risk index values in the 
independent testing set for a randomly selected trimmed Clinical + Genotype risk index 
model from each of the three small-scale simulation datasets. As in the previous set of 
figures, in all six of these figures a red line indicates the cut-off point. All individuals 
with a risk index value greater than or equal to this cut-off point are predicted as “high 




Table 3-9 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Small-scale Simulation Dataset #5 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
2 
0.1601*v1 + 0.3749*v2 + 0.1046*v4 + 0.0011*s16 - 0.0074*s138 + 0.0488*s166 - 
0.0444*s172 + 0.0488*s181 - 0.0088*s186 + 0.0268*s204 - 0.0241*s252 - 0.0691*s295 - 
0.0267*s348 + 0.2672*s356 
5 
0.1596*v1 + 0.3284*v2 + 0.0047*v6 + 0.0239*v8 - 0.0142*s110 + 0.1455*s127 - 
0.0438*s134 + 0.0473*s152 - 0.0685*s220 + 0.0281*s267 - 0.048*s273 + 0.0209*s326 - 
0.0131*s385 - 0.0665*s417 
44 0.143*v1 + 0.3871*v2 + 0.0864*v4 - 0.0517*s22 + 0.0501*s58 - 0.0154*s203 + 0.0276*s231 - 0.017*s341 + 0.2082*s396 
83 
0.1539*v1 + 0.3756*v2 + 0.0766*v3 + 0.055*v4 + 0.0531*v5 + 0.1189*v8 + 0.0076*s58 - 
0.0746*s66 - 0.1219*s74 - 0.048*s136 - 0.0812*s192 - 0.0173*s216 - 0.0506*s229 + 
0.0561*s236 + 0.1519*s245 - 0.0691*s256 - 0.0374*s264 - 0.0397*s272 - 0.0056*s294 + 
0.0758*s315 - 0.0796*s325 + 0.2099*s443 + 0.0547*s479 
85 
0.1472*v1 + 0.417*v2 - 0.2374*v5 + 0.0189*v8 + 0.0379*s3 - 0.0563*s22 + 0.0814*s137 
- 0.0868*s207 + 0.0149*s208 + 0.1528*s230 + 0.0863*s273 - 0.0042*s322 - 0.1984*s361 
- 0.3127*s370 - 0.0524*s402 + 0.0735*s411 + 0.0042*s430 
 
Table 3-10 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Small-scale Simulation Dataset #12 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
24 0.3645*v2 + 0.0979*v3 + 0.0945*v4 - 0.2109*v8 + 0.0228*s141 + 0.2769*s175 - 0.047*s208 + 0.0244*s237 - 0.0554*s262 + 0.0216*s380 + 0.2255*s482 
27 
-0.0133*v5 + 0.0094*s5 + 0.012*s28 - 0.0264*s51 + 0.0161*s61 - 0.0541*s125 - 
0.0602*s136 - 0.0169*s137 - 0.0381*s167 - 0.0375*s176 - 0.0464*s231 - 0.0178*s314 + 
1e-04*s321 + 0.0251*s324 - 0.0459*s328 - 0.0078*s356 - 0.0711*s357 - 0.0019*s378 + 
0.0201*s408 
37 
-0.2249*v5 + 0.0167*v6 + 0.0116*v7 + 0.0195*v8 + 0.0201*s37 + 0.0418*s52 - 
0.0061*s67 - 0.0491*s108 + 0.0699*s112 + 0.0688*s125 + 8e-04*s161 + 0.1483*s201 - 
0.0363*s208 + 4e-04*s218 + 0.0133*s241 - 0.0445*s276 - 0.0223*s295 - 0.0644*s296 + 
0.1699*s328 + 0.044*s365 + 0.0515*s389 + 0.0466*s398 + 0.0049*s452 
49 
0.1481*v1 + 0.4174*v2 + 0.0845*v3 + 0.0918*v4 - 0.0016*v6 + 0.0303*s42 + 0.0316*s80 
+ 0.0064*s87 - 0.0536*s133 - 0.0201*s139 + 0.1096*s150 + 0.0791*s197 + 0.0791*s259 - 
0.1046*s349 - 0.1563*s369 + 0.1707*s373 + 0.0667*s375 + 0.1017*s406 + 0.0174*s416 + 
0.4357*s459 - 0.0326*s465 
83 
0.1352*v1 + 0.3632*v2 + 0.0904*v3 + 0.0856*v4 + 0.1224*v5 + 0.0173*v6 - 0.0492*v8 + 




Table 3-11 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Small-scale Simulation Dataset #15 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
25 
0.1271*v1 + 0.3612*v2 + 0.0798*v3 + 0.0501*v6 - 0.0156*s14 + 0.0383*s22 + 
0.0094*s49 - 0.0231*s82 + 0.0235*s101 + 0.0356*s113 - 0.0424*s119 + 0.04*s168 - 
0.0988*s201 - 0.2504*s255 - 0.0315*s273 - 0.0067*s375 + 0.0185*s385 + 0.0288*s420 - 
0.0376*s424 - 0.0148*s458 + 0.0167*s479 + 0.0043*s491 + 0.2736*s496 
76 
0.3139*v2 - 0.5463*v5 - 0.0426*v8 + 0.4962*s12 + 0.0094*s18 + 0.0132*s56 + 
0.0368*s65 + 0.0054*s106 - 0.0112*s124 - 0.0961*s141 - 0.0199*s143 - 0.0262*s214 - 
0.1017*s218 - 0.0064*s240 + 0.1556*s257 - 0.0235*s289 + 0.0977*s310 + 0.0272*s311 + 
0.1166*s405 + 0.0248*s436 + 0.0533*s485 
79 
0.1516*v1 + 0.0964*v3 + 0.0909*v4 + 0.0158*v6 - 6e-04*v7 + 0.1363*v8 - 0.1052*s46 - 
0.0304*s86 + 0.1201*s158 - 0.096*s162 + 0.0155*s173 + 0.0827*s254 - 0.1274*s265 + 
0.4236*s329 - 0.0118*s336 - 0.0026*s337 + 0.0312*s359 - 0.1349*s377 + 0.0325*s405 - 
0.1539*s426 + 0.0686*s439 - 0.0048*s444 - 0.0332*s469 
88 
0.1149*v5 + 0.0023*v7 + 0.0135*s59 - 0.122*s166 - 7e-04*s179 + 0.0221*s195 + 
0.0075*s251 - 0.0147*s265 - 0.0067*s352 - 0.0137*s360 + 0.0162*s374 - 0.0627*s384 + 
0.0103*s388 - 0.0242*s391 + 0.0109*s406 - 0.0854*s413 + 0.0619*s440 + 0.0079*s448 + 
0.0531*s461 + 0.0122*s464 + 0.0347*s495 
92 
0.1537*v1 + 0.2992*v2 + 0.0974*v3 + 0.0072*v6 - 0.1636*v8 + 0.0106*s51 - 0.2487*s75 
- 0.0166*s84 - 0.1151*s90 + 0.0016*s123 - 0.0618*s133 - 0.0326*s136 + 0.0098*s166 - 
0.0228*s186 - 0.0633*s193 + 0.0691*s207 + 0.0473*s212 + 0.0169*s215 + 0.0756*s269 + 
0.1881*s275 + 0.0381*s366 - 0.0177*s422 + 0.0664*s435 + 0.1145*s475 
 
 
Figure 3-7 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Small-scale Dataset #5, Bootstrap Sample #2 
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Figure 3-8 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Small-scale Dataset #12, Bootstrap Sample #24 
 
Figure 3-9 Clinical + Genotype Risk Index Value Distribution in the Optimization 




Figure 3-10 Clinical + Genotype Risk Index Value Distribution in the Independent 
Testing Set for Small-scale Dataset #5, Bootstrap Sample #2 
 
Figure 3-11 Clinical + Genotype Risk Index Value Distribution in the Independent 
Testing Set for Small-scale Dataset #12, Bootstrap Sample #24 
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Figure 3-12 Clinical + Genotype Risk Index Value Distribution in the Independent 
Testing Set for Small-scale Dataset #15, Bootstrap Sample #25
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Table 3-12 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Small-scale Simulation Dataset #5 
   Bootstrap Sample #2 Bootstrap Sample #5 Bootstrap Sample #44 Bootstrap Sample #83 Bootstrap Sample #85 












1 1 5.396 1 3.270 1 4.990 1 3.902 1 2.672 1 
2 1 4.448 0 2.409 0 3.984 0 2.885 0 1.811 0 
3 0 4.652 0 2.753 0 4.337 0 3.070 0 2.250 0 
4 0 4.559 0 2.448 0 4.100 0 3.116 0 1.809 0 
5 0 3.843 0 2.237 0 3.528 0 2.806 0 1.549 0 
6 0 4.909 0 2.697 0 4.436 0 3.278 0 2.098 0 
7 0 4.359 0 2.609 0 3.969 0 3.006 0 2.057 0 
8 0 4.967 0 3.020 0 4.570 0 3.388 0 2.440 0 
9 0 5.107 1 3.045 0 4.646 0 3.647 0 2.450 0 
10 1 4.772 0 2.827 0 4.352 0 3.370 0 2.196 0 
11 1 5.211 1 3.321 1 4.823 0 3.797 1 2.686 1 
12 1 5.211 1 3.250 1 4.733 0 3.740 1 2.495 0 
13 0 4.318 0 2.465 0 3.896 0 3.197 0 1.902 0 
14 0 4.317 0 2.542 0 3.943 0 3.034 0 1.981 0 
15 1 6.095 1 3.717 1 5.545 1 4.112 1 3.065 1 
16 0 4.566 0 2.988 0 4.249 0 3.481 0 2.359 0 
17 1 5.531 1 3.230 1 5.118 1 3.508 0 2.669 1 
18 0 4.248 0 2.671 0 3.879 0 3.147 0 2.051 0 
19 1 6.489 1 3.837 1 5.905 1 4.486 1 3.290 1 
20 0 5.282 1 2.958 0 4.846 0 3.653 0 2.416 0 
21 0 4.833 0 2.841 0 4.474 0 3.181 0 2.337 0 
22 0 4.643 0 2.351 0 4.235 0 3.036 0 1.842 0 
23 0 4.520 0 2.565 0 4.124 0 3.133 0 1.900 0 
24 0 4.267 0 2.439 0 3.946 0 2.907 0 1.825 0 
25 1 5.718 1 3.532 1 5.274 1 3.985 1 2.952 1 
 
80 
Table 3-13 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Small-scale Simulation Dataset #12 
   Bootstrap Sample #24 Bootstrap Sample #27 Bootstrap Sample #37 Bootstrap Sample #49 Bootstrap Sample #83 












1 1 3.403 1 -0.142 0 -0.230 1 4.838 1 3.483 1 
2 0 2.558 0 -0.145 0 -0.257 0 3.667 0 2.671 0 
3 0 2.748 0 -0.144 0 -0.320 0 4.080 0 2.985 0 
4 1 3.204 1 -0.138 1 -0.249 0 4.201 0 3.040 0 
5 0 2.459 0 -0.143 0 -0.211 1 4.019 0 2.899 0 
6 0 2.491 0 -0.143 0 -0.270 0 3.815 0 2.749 0 
7 0 3.292 1 -0.145 0 -0.243 0 4.361 1 3.138 0 
8 0 2.901 0 -0.141 0 -0.189 1 3.987 0 2.874 0 
9 1 2.716 0 -0.142 0 -0.233 0 3.920 0 2.833 0 
10 1 3.163 1 -0.136 1 -0.210 1 4.251 1 3.109 0 
11 0 3.038 0 -0.133 1 -0.275 0 4.468 1 3.209 0 
12 0 2.626 0 -0.137 1 -0.211 1 4.036 0 2.925 0 
13 1 2.046 0 -0.142 0 -0.204 1 2.828 0 2.109 0 
14 1 3.423 1 -0.149 0 -0.204 1 4.680 1 3.421 1 
15 0 2.625 0 -0.152 0 -0.220 1 3.819 0 2.773 0 
16 0 2.083 0 -0.137 1 -0.246 0 3.248 0 2.389 0 
17 0 2.467 0 -0.133 1 -0.250 0 3.547 0 2.547 0 
18 0 3.344 1 -0.141 0 -0.241 0 4.072 0 2.971 0 
19 1 3.210 1 -0.144 0 -0.246 0 4.639 1 3.350 1 
20 1 3.046 0 -0.134 1 -0.256 0 4.563 1 3.321 1 
21 0 2.885 0 -0.132 1 -0.223 1 3.779 0 2.790 0 
22 1 3.531 1 -0.147 0 -0.298 0 4.893 1 3.421 1 
23 0 2.356 0 -0.146 0 -0.273 0 3.431 0 2.531 0 
24 1 3.358 1 -0.132 1 -0.281 0 4.668 1 3.362 1 
25 0 2.765 0 -0.142 0 -0.266 0 3.622 0 2.681 0 
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Table 3-14 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Small-scale Simulation Dataset #15 
   Bootstrap Sample #25 Bootstrap Sample #7 Bootstrap Sample #79 Bootstrap Sample #88 Bootstrap Sample #92 












1 0 3.854 0 -1.068 0 3.016 0 0.617 0 2.777 0 
2 0 4.035 0 -1.191 0 3.106 0 0.617 0 3.139 0 
3 1 5.596 1 -0.997 0 4.289 1 0.676 1 4.644 1 
4 0 3.358 0 -1.067 0 2.689 0 0.645 0 2.363 0 
5 1 4.989 1 -1.313 0 4.125 1 0.641 0 3.960 1 
6 0 3.798 0 -0.997 0 2.882 0 0.635 0 2.894 0 
7 0 4.088 0 -0.935 0 3.221 0 0.640 0 3.136 0 
8 0 3.727 0 -1.048 0 2.827 0 0.611 0 2.687 0 
9 1 4.351 0 -1.129 0 3.573 0 0.621 0 3.370 1 
10 0 4.540 0 -0.798 1 3.291 0 0.617 0 3.481 1 
11 0 3.882 0 -0.647 1 2.805 0 0.603 0 2.716 0 
12 0 3.335 0 -0.992 0 2.547 0 0.636 0 2.378 0 
13 1 4.494 0 -0.888 0 3.438 0 0.651 1 3.480 1 
14 0 2.963 0 -0.680 1 2.087 0 0.610 0 1.927 0 
15 0 2.346 0 -0.976 0 1.817 0 0.657 1 1.412 0 
16 0 4.022 0 -0.863 0 2.903 0 0.627 0 2.952 0 
17 1 4.637 0 -0.676 1 3.429 0 0.622 0 3.458 1 
18 0 4.269 0 -0.667 1 3.154 0 0.625 0 3.186 0 
19 1 4.569 0 -0.934 0 3.388 0 0.657 1 3.446 1 
20 1 4.319 0 -0.904 0 3.185 0 0.606 0 3.202 0 
21 1 5.080 1 -0.566 1 3.797 1 0.633 0 4.004 1 
22 0 3.491 0 -1.202 0 2.768 0 0.643 0 2.587 0 
23 1 5.075 1 -0.488 1 3.655 1 0.643 0 3.930 1 
24 1 4.554 0 -0.671 1 3.087 0 0.647 1 3.405 1 
25 0 4.048 0 -0.857 0 3.008 0 0.631 0 3.001 0 
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3.2.3 Predictive Performance 
After the variable selection procedure is completed and the models are applied to each 
individual in the independent testing set then the sensitivity, specificity, misclassification, 
and positive predictive value are estimated for both the Clinical and Clinical + Genotype 
risk index models for each of the 100 small-scale simulation datasets. Table 3-15 shows 
the means and standard deviations of these measurements. To provide a 95% confidence 
for these measurements of sensitivity, specificity, misclassification, and positive 
predictive value for each independent testing set, 1000 bootstrap samples were generated. 
By making predictions about each individual in these bootstrap samples and calculating 
the sensitivity, specificity, misclassification, and positive predictive value for each 
bootstrap sample, 95% confidence intervals were estimated for these measurements in 
each of the 100 small-scale simulation datasets. The mean and standard deviation of the 
spread (i.e., range) of these confidence intervals for both the Clinical and Clinical + 
Genotype risk index model is shown in Table 3-16. This provides a view to the variability 
of the sensitivity, specificity, misclassification, and positive predictive value 
estimates.Table 3-17 shows the predictive performance and confidence intervals for the 
three small-scale simulation datasets discussed in Section 3.2.2. 
 
Table 3-15 Means and Standard Deviations of Predictive Performance Estimates for 




































Table 3-16 Means and Standard Deviations of Predictive Performance 95% 
Confidence Intervals for the 100 Small-scale Simulation Datasets 
 Mean Range of 95% Confidence Interval (SD) 
Model Sensitivity  Specificity  Misclassification  PPV  
Clinical 0.219 (0.017) 0.093 (0.013) 0.099 (0.006) 0.220 (0.021) 
Clinical + Genotype 0.0220 (0.016) 0.090 (0.013) 0.098 (0.006) 0.223 (0.023) 
 
Table 3-17 Predictive Performance Estimates for Three Small-scale Simulation 
Datasets 


















































Using the number of models predicting an individual in the independent testing set as 
“high risk”, receiver operating characteristic (ROC) curves were generated for the 
Clinical and Clinical + Genotype risk index model for each of the 100 small-scale 
simulation datasets, and the area under the ROC curve (AUC) was estimated. The 
average AUC of the Clinical risk index models was 0.832 (SD = 0.027), and the average 
AUC of the Clinical + Genotype risk index models was 0.846 (SD = 0.024). Figure 3-13, 
3-14, and 3-15 show the ROC curves for the Clinical risk index model the three small-
scale simulation datasets discussed in sections 3.2.2, and Figure 3-16, 3-17, and 3-18 
show the ROC curve for the Clinical + Genotype risk index model from those three 




Figure 3-13 ROC Curve of the Clinical Risk Index Model for Small-scale Simulation 
Dataset #5 
 





Figure 3-15 ROC Curve of the Clinical Risk Index Model for Small-scale Simulation 
Dataset #15 
 
Figure 3-16 ROC Curve of the Clinical + Genotype Risk Index Model for Small-




Figure 3-17 ROC Curve of the Clinical + Genotype Risk Index Model for Small-
scale Simulation Dataset #12 
 
Figure 3-18 ROC Curve of the Clinical + Genotype Risk Index Model for Small-




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. It is currently thought 
that the proportion of models that predict that an individual as high risk, then, represents 
the predicted probability of an individual developing the outcome. More theoretical work 
would be needed to determine this relationship. Using the binomial distribution a 95% 
confidence interval can be constructed for this estimated probability with the Wilson 
score interval (Wilson, 1927). Physicians can then use this interval, given by 
! 
95% CI =












, to gauge the prediction. As an example, 
one individual in the independent testing set for the 5th small-scale simulation dataset has 
a predicted probability of developing the outcome of 0.14. The lower bound for this 






























3.2.4 Random Forest Comparison 
For each of the 100 small-scale simulation datasets a random forest was generated using 
the optimization set created by the risk index procedure. Each forest had 500 individual 
trees, and a tuning procedure was used to find the number of variables k considered at 
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each split that provided the lowest out-of-bag error estimate. Beginning with , 
where v is the total number of predictor variables, the forest was grown and out-of-bag 
error was measured. Then, the number of variables considered at each split was 
progressively increased by a factor of two (i.e., ) until the out-
of-bag error decreased by less than 5% from the out-of-bag error for the previous value of 
k. Next, returning to , the number of variables considered at each split was 
progressively decreased by a factor of two (i.e., ) until the out-
of-bag error decreased by less than 5% from the out-of-bag error for the previous value of 
k. 
 
For each of the random forests an ROC curve was generated and the AUC was estimated. 
The mean AUC of the random forest models was 0.987 (SD = 0.006). Figures 3-19, 3-20, 
and 3-21 show the ROC curve for the random forest generated from the three small-scale 
simulation datasets described in Section 3.2.2. When working with a dataset that has two 
possible classes, the standard procedure for a random forest is to assign a prediction to an 
individual based on a simple majority of votes. When the prevalence of the outcome is 
less than 50% changing the proportion of votes needed to classify an individual can 
significantly impact the estimates of performance. To fully examine the performance of 
the random forest, predictions were made about each individual in the independent 
testing set using a range of proportions. First, an individual was assigned a prediction of 
“high risk” if 5% or more of the trees in the forest predicted the individual to be “high 
risk”. This was then repeated in increments of 5% until individuals were assigned a 
prediction of “high risk” only if 95% or more of the trees in the forest predicted the 
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individual to be “high risk”. Table 3-28 shows the mean and standard deviation of the 
sensitivity, specificity, misclassification, and PPV for a range of different proportions. 
 
Figure 3-19 ROC Curve of the Random Forest Generated for Small-scale 




Figure 3-20 ROC Curve of the Random Forest Generated for Small-scale 
Simulation Dataset #12 
 
 
Figure 3-21 ROC Curve of the Random Forest Generated for Small-scale 
Simulation Dataset #15 
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Table 3-18 Means and Standard Deviations of Performance Estimates of the 
Random Forest Models Generated from the 100 Small-scale Simulation Datasets 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 1 (0.002) 0.184 (0.079) 0.565 (0.057) 0.353 (0.037) 
0.1 0.998 (0.005) 0.499 (0.069) 0.347 (0.048) 0.47 (0.045) 
0.15 0.992 (0.011) 0.705 (0.05) 0.207 (0.034) 0.6 (0.049) 
0.2 0.983 (0.015) 0.82 (0.035) 0.13 (0.024) 0.708 (0.047) 
0.25 0.972 (0.018) 0.888 (0.028) 0.086 (0.019) 0.794 (0.046) 
0.3 0.954 (0.025) 0.922 (0.022) 0.068 (0.015) 0.844 (0.042) 
0.35 0.933 (0.029) 0.941 (0.017) 0.061 (0.014) 0.876 (0.037) 
0.4 0.915 (0.032) 0.958 (0.015) 0.055 (0.012) 0.905 (0.033) 
0.45 0.893 (0.036) 0.969 (0.013) 0.054 (0.013) 0.928 (0.03) 
0.5 0.868 (0.041) 0.979 (0.011) 0.055 (0.014) 0.949 (0.027) 
0.55 0.839 (0.046) 0.987 (0.01) 0.058 (0.015) 0.966 (0.024) 
0.6 0.81 (0.048) 0.993 (0.007) 0.063 (0.015) 0.981 (0.019) 
0.65 0.781 (0.049) 0.996 (0.006) 0.07 (0.016) 0.989 (0.015) 
0.7 0.717 (0.055) 0.998 (0.003) 0.088 (0.018) 0.994 (0.01) 
0.75 0.593 (0.06) 0.999 (0.002) 0.125 (0.021) 0.998 (0.007) 
0.8 0.419 (0.074) 1 (0.001) 0.178 (0.026) 0.999 (0.005) 
0.85 0.209 (0.069) 1 (0) 0.242 (0.029) 1 (0) 
0.9 0.049 (0.043) 1 (0) 0.292 (0.031) 1 (0) 
0.95 0.001 (0.003) 1 (0) 0.307 (0.03) 1 (0) 
 
3.2.5 Conclusion 
In the small-scale simulation study the risk index procedure quite often identified and 
selected the covariates that were associated with the outcome. However, the SNPs that 
were designated as being associated with the outcome were not selected by the risk index 
procedure more frequently than those SNPs that were designated as having no association 
with the outcome. Although the “true positive” SNPs have logistic regression coefficients 
similar to, or even higher than, the “true positive” covariates, as shown in Table 3-29, the 
median p-values for the “true positive” SNPs are markedly higher than the median p-
values for the “true positive” covariates (Table 3-29). This suggests that the standard 
errors of the logistic regression coefficients are larger for the SNPs than for the 
covariates, which would lead the SNPs to have a smaller impact on predicting the 
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outcome. When a risk index was built using only the variables that were simulated to be 
associated with the outcome (i.e., v1, v2, v3, v4, s1, s10, s50, s100), the performance is 
slightly better than the best model built using the standard risk index model (Table 3-19) 
 
Table 3-19 Performance Characteristics of the Risk Index Models Including Only 
Variables Associated with the Outcome  
Model Sensitivity (SD) Specificity (SD) Misclassification (SD) PPV (SD) 
Clinical 0.627 (0.119) 0.853 (0.063) 0.216 (0.025) 0.763 (0.005) 
Clinical + Genotypes 0.610 (0.123) 0.862 (0.064) 0.216 (0.026) 0.767 (0.028) 
 
 
Table 3-20 Mean Logistic Regression Coefficients and Median Logistic Regression 
Coefficient P-values for “True Positive” Variables 
Variable Mean Logistic Regression Coefficient 
Median Logistic Regression 
Coefficient P-value 
v1 0.145 1.21E-34 
v2 0.38 4.42E-21 
v3 0.082 2.08E-29 
v4 0.082 7.78E-12 
s1 -0.32 3.03E-03 
s10 -0.218 6.36E-02 
s50 -0.335 9.91E-04 
s100 -0.278 1.16E-02 
 
 
Although the predictive performance of the risk index procedure is quite good, with a 
mean AUC of the Clinical + Genotype risk index models that is significantly greater than 
the mean AUC of the Clinical risk index models (p=0.0002), the random forest models 
had a mean AUC of 0.987 (SD = 0.006), which is significantly greater than the mean 
AUC of the Clinical + Genotype risk index models (p<2.2e-16). Tuning the class 
assignment procedure for the risk index can produce sensitivity, specificity, and positive 
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predictive values greater than 0.9, much greater than the predictive performance 
estimates of the risk index models.  
 
3.3 Small-scale Simulation Study Top Principal Components Results 
3.3.1 Variable Selection 
Using the same procedure as in Section 3.2.1, Clinical and Clinical + Genotype risk index 
models were constructed for each of the 100 small-scale simulation datasets. In place of 
the 500 SNPs, a principal components analysis was performed using SMARTPCA 
(Patterson, et al, 2006), and the principal components that accounted for 90% of the 
variance among the SNPs were used to build the risk index models. On average, 310 
principal components were needed to account for 90% of the variance. 
 
Table 3-20 shows the summary of the variable selection procedure from the Clinical risk 
index model averaged across the 100 simulation datasets. V1, v2, and v4 are most 
frequently selected; on average, they each appear in more than half of the 100 trimmed 
Clinical risk index models. V3, because of its high correlation with v1, is typically 
chosen as one of the last variables (on average, variable three is chosen as the sixth, 
seventh, or eighth variable in 70.93 of the 100 untrimmed Clinical risk index models for a 
given simulation dataset).  
 
Table 3-21 shows the summary of the variable selection procedure from the Clinical + 
Genotype risk index model averaged across the 100 simulation datasets. No principal 
component was in more than 5.92 out of 100 Clinical + Genotype risk index models on 
 
 94 
average. The principal components most commonly observed in trimmed Clinical + 
Genotype risk index models were PC 93 (5.92 out of 100 trimmed Clinical + Genotype 
risk index models, on average), PC 110 (5.89 out of 100 trimmed Clinical + Genotype 
risk index models, on average), PC 10 (5.85 out of 100 trimmed Clinical + Genotype risk 
index models, on average), PC 138 (5.8 out of 100 trimmed Clinical Genotype risk index 
models, on average), and PC 188 (5.75 out of 100 trimmed Clinical + Genotype risk 
index models, on average.  
 
Table 3-21 Summary of the Number of Times Each Variable is Selected into a 
Specific Model Position for the Small-scale Simulation Clinical Risk Index Models 
  Variable Position 
Variable 1 2 3 4 5 6 7 8 
Total # of Times 
in Trimmed 
Model 
v1 43.96 5.62 3.04 2.98 3.66 6.52 13.74 20.48 57.3 
v2 7.57 39.66 10.01 4.24 7.99 15.89 4.34 10.3 62.91 
v3 12.66 3.77 2.76 4.03 5.85 11.16 21.89 37.88 25.98 
v4 1.83 11.92 29.85 10.55 22.9 9.85 7.39 5.71 55.09 
v5 8.44 9.85 13.38 20.18 14.52 13.55 13.57 6.51 46.21 
v6 8.47 9.89 13.98 19.64 14.95 14.73 12.11 6.23 46.64 
v7 8.49 9.71 13.47 19.46 14.79 14.23 13.4 6.45 45.37 




Table 3-22 Summary of the Number of Times Selected Principal Component Variable is Selected into a Specific Model 
Position for the Small-scale Simulation Clinical + Genotype Risk Index Models 
  Variable Position 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 








PC93 0.35 0.33 0.39 0.39 0.49 0.41 0.36 0.42 0.31 0.37 0.26 0.34 0.33 0.41 0.26 0.3 0.38 0.36 0.41 0.32 7.19 5.92 
PC110 0.31 0.33 0.36 0.3 0.37 0.38 0.31 0.42 0.37 0.41 0.32 0.36 0.39 0.44 0.35 0.35 0.36 0.46 0.4 0.33 7.32 5.89 
PC10 0.35 0.34 0.4 0.31 0.3 0.38 0.34 0.3 0.31 0.34 0.36 0.32 0.44 0.34 0.31 0.4 0.5 0.38 0.3 0.35 7.07 5.85 
PC138 0.31 0.37 0.49 0.35 0.39 0.37 0.33 0.44 0.38 0.36 0.43 0.33 0.31 0.26 0.33 0.29 0.34 0.37 0.29 0.27 7.01 5.8 
PC188 0.35 0.26 0.35 0.49 0.35 0.29 0.36 0.38 0.38 0.38 0.35 0.38 0.39 0.3 0.32 0.38 0.36 0.39 0.45 0.31 7.22 5.75 
PC223 0.33 0.41 0.33 0.34 0.34 0.34 0.36 0.37 0.36 0.3 0.3 0.39 0.41 0.4 0.23 0.38 0.36 0.34 0.47 0.38 7.14 5.75 
PC296 0.4 0.33 0.41 0.28 0.32 0.4 0.35 0.47 0.28 0.3 0.37 0.34 0.28 0.34 0.42 0.33 0.31 0.35 0.28 0.31 6.87 5.74 
PC211 0.29 0.34 0.42 0.37 0.29 0.38 0.28 0.3 0.41 0.39 0.38 0.38 0.28 0.28 0.24 0.36 0.44 0.37 0.37 0.25 6.82 5.74 
PC268 0.41 0.33 0.33 0.3 0.36 0.41 0.3 0.42 0.33 0.32 0.27 0.3 0.34 0.31 0.42 0.33 0.38 0.37 0.35 0.45 7.03 5.71 
PC290 0.33 0.29 0.37 0.42 0.34 0.41 0.29 0.42 0.47 0.28 0.34 0.38 0.4 0.33 0.27 0.31 0.31 0.31 0.43 0.3 7 5.69 
PC170 0.44 0.29 0.31 0.4 0.43 0.36 0.38 0.3 0.45 0.29 0.41 0.32 0.38 0.35 0.34 0.31 0.36 0.31 0.34 0.37 7.14 5.68 
PC237 0.29 0.49 0.32 0.44 0.27 0.35 0.37 0.31 0.34 0.44 0.36 0.24 0.36 0.25 0.27 0.38 0.23 0.34 0.42 0.29 6.76 5.66 
PC102 0.42 0.42 0.32 0.37 0.36 0.3 0.49 0.4 0.27 0.33 0.4 0.31 0.25 0.3 0.32 0.31 0.33 0.23 0.22 0.38 6.73 5.64 
PC74 0.43 0.31 0.37 0.28 0.25 0.49 0.42 0.29 0.36 0.35 0.29 0.29 0.37 0.34 0.35 0.37 0.27 0.4 0.4 0.39 7.02 5.63 
PC32 0.32 0.34 0.41 0.25 0.29 0.33 0.27 0.33 0.33 0.39 0.41 0.29 0.44 0.25 0.4 0.33 0.49 0.35 0.29 0.39 6.9 5.61 
PC291 0.42 0.33 0.33 0.35 0.38 0.28 0.45 0.39 0.42 0.37 0.25 0.16 0.37 0.32 0.4 0.35 0.3 0.38 0.37 0.34 6.96 5.59 
PC248 0.35 0.31 0.29 0.42 0.4 0.27 0.29 0.35 0.39 0.36 0.32 0.33 0.23 0.38 0.42 0.38 0.36 0.31 0.29 0.36 6.81 5.59 
PC227 0.35 0.37 0.37 0.41 0.43 0.49 0.34 0.18 0.34 0.31 0.42 0.32 0.32 0.36 0.36 0.34 0.3 0.31 0.24 0.31 6.87 5.58 
PC39 0.3 0.23 0.38 0.4 0.43 0.31 0.19 0.28 0.44 0.31 0.46 0.34 0.35 0.41 0.44 0.3 0.32 0.28 0.37 0.26 6.8 5.58 
PC295 0.35 0.41 0.25 0.3 0.39 0.33 0.47 0.36 0.4 0.29 0.3 0.32 0.32 0.4 0.36 0.32 0.27 0.48 0.2 0.39 6.91 5.56 
PC244 0.27 0.37 0.35 0.37 0.33 0.37 0.35 0.27 0.31 0.35 0.3 0.34 0.44 0.41 0.32 0.32 0.19 0.35 0.3 0.3 6.61 5.56 
PC65 0.43 0.43 0.35 0.29 0.3 0.33 0.36 0.26 0.32 0.42 0.37 0.33 0.26 0.34 0.44 0.35 0.29 0.43 0.28 0.36 6.94 5.55 
PC280 0.37 0.49 0.31 0.34 0.32 0.37 0.33 0.31 0.35 0.31 0.31 0.45 0.34 0.33 0.33 0.26 0.3 0.35 0.33 0.29 6.79 5.55 




Once the variable selection procedure is finished each of the 100 small-scale simulation 
datasets have 100 trimmed Clinical and Clinical + Genotype risk index models. Tables 3-
22, 3-23, and 3-24 each show five trimmed Clinical risk index models randomly selected 
from one of three randomly chosen small-scale simulation datasets (datasets #5, #12, and 
#15). These Clinical risk index models are directly comparable to those described in 
Section 3.2.2 (Tables 3-3, 3-4, and 3-5). Although we will not directly compare these sets 
of models here they represent another entire set of results for the Clinical risk index 
models. Figures 3-22, 3-23, and 3-24 show the full distribution of risk index values in the 
optimization set for a randomly selected trimmed Clinical risk index models from each of 
the three small-scale simulation datasets. Figures 3-25, 3-26, and 3-27 show the full 
distribution of risk index values in the independent testing set for a randomly selected 
trimmed Clinical risk index model from each of the three small-scale simulation datasets. 
In all six of these figures a red line indicates the cut-off point. All individuals with a risk 
index value greater than or equal to this cut-off point are predicted as “high risk” and all 
individuals with a value less than this cut-off point are predicted as “low risk”. Tables 3-
25, 3-26, and 3-27 show the risk index values and predictions from the same set of five 
Clinical risk index models from the same three small-scale simulation datasets for a set of 




Table 3-23 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Small-scale Simulation Dataset #5 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
2 0.004*v6 
5 0.1644*v1 + 0.3554*v2 
44 0.14*v1 + 0.2395*v5 - 0.0079*v6 - 0.0236*v7 
83 0.1366*v1 + 0.3025*v2 + 0.1001*v4 - 0.0116*v6 - 0.0382*v7 - 0.0838*v8 
85 -0.079*v5 
 
Table 3-24 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Small-scale Simulation Dataset #12 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
24 0.156*v1 + 0.3719*v2 + 0.1017*v4 + 0.1242*v5 - 0.006*v7 - 0.0213*v8 
27 0.1348*v1 + 0.4034*v2 + 0.8165*v5 + 3e-04*v7 
37 -0.0194*v8 
49 0.1114*v1 + 0.3982*v2 + 0.0657*v3 + 0.0895*v4 - 0.3266*v5 + 0.0495*v6 + 0.0056*v7 - 0.0054*v8 
83 0.1531*v1 + 0.2988*v2 + 0.0804*v4 + 0.0115*v7 
 
Table 3-25 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Small-scale Simulation Dataset #15 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
25 0.1571*v1 + 0.405*v2 + 0.0867*v3 + 0.0806*v4 + 0.0141*v6 - 0.0154*v7 + 0.0629*v8 
76 0.1696*v1 + 0.2453*v2 + 0.0816*v4 + 0.0044*v6 + 0.0502*v8 
79 0.1418*v1 + 0.4494*v2 + 0.0165*v6 - 0.2143*v8 
88 0.0115*v6 - 0.0408*v8 





Figure 3-22 Clinical Risk Index Value Distribution in the Optimization Set for 
Small-scale Dataset #5, Bootstrap Sample #2 
 
Figure 3-23 Clinical Risk Index Value Distribution in the Optimization Set for 




Figure 3-24 Clinical Risk Index Value Distribution in the Optimization Set for 
Small-scale Dataset #15, Bootstrap Sample #25 
 
 
Figure 3-25 Clinical Risk Index Value Distribution in the Independent Testing Set 




Figure 3-26 Clinical Risk Index Value Distribution in the Independent Testing Set 
for Small-scale Dataset #12, Bootstrap Sample #24 
 
 
Figure 3-27 Clinical Risk Index Value Distribution in the Independent Testing Set 




Table 3-26 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Small-scale Simulation Dataset #5 
   Bootstrap Sample #2 Bootstrap Sample #5 Bootstrap Sample #44 Bootstrap Sample #83 Bootstrap Sample #85 

















1 1 0.081 0 6.614 1 2.553 1 1.882 1 -0.782 0 
2 1 0.141 1 6.229 1 2.440 1 1.830 1 -0.783 0 
3 1 0.120 1 5.652 0 1.965 0 1.490 0 -0.767 1 
4 0 0.131 1 5.033 0 1.867 0 1.544 0 -0.785 0 
5 0 0.118 1 5.872 0 1.880 0 1.629 0 -0.795 0 
6 0 0.082 0 4.882 0 1.640 0 1.245 0 -0.812 0 
7 1 0.109 0 7.009 1 2.111 0 1.929 1 -0.748 1 
8 1 0.118 1 5.809 0 1.868 0 1.795 1 -0.835 0 
9 0 0.110 0 5.714 0 1.942 0 1.625 0 -0.729 1 
10 0 0.088 0 5.434 0 1.972 0 1.624 0 -0.772 0 
11 0 0.098 0 5.967 0 1.740 0 1.583 0 -0.803 0 
12 1 0.084 0 6.573 1 2.312 1 1.854 1 -0.813 0 
13 1 0.118 1 6.255 1 2.339 1 1.784 1 -0.809 0 
14 0 0.102 0 5.977 0 2.111 0 1.596 0 -0.813 0 
15 1 0.153 1 7.404 1 2.182 0 2.182 1 -0.791 0 
16 0 0.105 0 5.502 0 2.080 0 1.360 0 -0.813 0 
17 0 0.084 0 5.762 0 2.084 0 1.779 1 -0.823 0 
18 0 0.120 1 4.583 0 1.813 0 1.220 0 -0.837 0 
19 1 0.062 0 7.008 1 2.383 1 1.879 1 -0.769 1 
20 1 0.079 0 6.963 1 2.271 1 1.879 1 -0.791 0 
21 0 0.099 0 6.347 1 2.028 0 1.672 0 -0.814 0 
22 1 0.121 1 6.243 1 2.112 0 1.651 0 -0.775 0 
23 1 0.135 1 6.932 1 2.447 1 1.946 1 -0.766 1 
24 0 0.104 0 5.435 0 1.882 0 1.586 0 -0.797 0 




Table 3-27 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Small-scale Simulation Dataset #12 
   Bootstrap Sample #24 Bootstrap Sample #27 Bootstrap Sample #37 Bootstrap Sample #49 Bootstrap Sample #83 

















1 0 2.505 0 4.747 0 -0.274 0 1.924 0 3.364 0 
2 1 2.836 1 4.999 0 -0.221 1 2.182 1 3.744 1 
3 0 2.525 0 4.619 0 -0.213 1 1.927 0 3.323 0 
4 0 2.306 0 4.572 0 -0.213 1 1.741 0 3.091 0 
5 1 2.691 1 4.717 0 -0.223 1 1.999 0 3.591 0 
6 1 2.815 1 5.211 1 -0.256 0 2.277 1 3.763 1 
7 0 2.642 0 4.935 0 -0.269 0 1.976 0 3.487 0 
8 1 2.894 1 5.076 1 -0.250 0 2.239 1 3.909 1 
9 1 2.857 1 5.201 1 -0.200 1 2.212 1 3.821 1 
10 1 2.897 1 5.201 1 -0.246 0 2.249 1 3.861 1 
11 0 2.251 0 4.232 0 -0.243 0 1.633 0 2.982 0 
12 0 2.200 0 4.240 0 -0.233 0 1.589 0 2.928 0 
13 1 3.149 1 5.635 1 -0.268 0 2.288 1 4.094 1 
14 0 2.315 0 4.267 0 -0.229 0 1.719 0 3.055 0 
15 1 2.859 1 5.183 1 -0.207 1 2.183 1 3.871 1 
16 0 2.487 0 4.481 0 -0.211 1 1.874 0 3.271 0 
17 0 2.487 0 4.810 0 -0.238 0 1.858 0 3.426 0 
18 0 2.506 0 4.716 0 -0.203 1 1.978 0 3.356 0 
19 0 2.691 1 5.049 0 -0.249 0 2.021 0 3.667 0 
20 1 2.270 0 4.404 0 -0.229 0 1.567 0 2.932 0 
21 0 2.070 0 3.858 0 -0.282 0 1.556 0 2.742 0 
22 1 2.949 1 5.260 1 -0.243 0 2.363 1 3.957 1 
23 1 2.849 1 5.204 1 -0.244 0 2.244 1 3.810 1 
24 0 2.797 1 4.813 0 -0.246 0 2.218 1 3.739 0 




Table 3-28 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Small-scale Simulation Dataset #15 
   Bootstrap Sample #25 Bootstrap Sample #76 Bootstrap Sample #79 Bootstrap Sample #88 Bootstrap Sample #92 

















1 1 3.180 1 3.072 1 2.574 1 -0.057 1 3.116 1 
2 1 3.314 1 2.972 1 2.784 1 -0.073 0 2.958 1 
3 1 2.956 0 2.742 0 2.352 0 -0.074 0 3.054 1 
4 1 3.350 1 3.213 1 2.660 1 -0.146 0 3.042 1 
5 1 3.305 1 2.982 1 2.815 1 -0.095 0 3.197 1 
6 0 2.524 0 2.348 0 2.040 0 -0.083 0 2.470 0 
7 1 3.472 1 3.194 1 2.661 1 -0.120 0 3.326 1 
8 0 2.784 0 2.687 0 2.240 0 -0.144 0 2.571 0 
9 1 3.651 1 3.283 1 3.119 1 -0.068 0 3.441 1 
10 0 3.021 0 2.800 0 1.990 0 -0.062 1 2.799 0 
11 1 2.992 0 2.992 1 2.477 0 -0.056 1 3.299 1 
12 0 2.924 0 2.631 0 2.104 0 -0.066 1 2.488 0 
13 0 3.082 0 2.704 0 2.491 0 0.012 1 2.746 0 
14 1 3.338 1 3.226 1 2.412 0 -0.158 0 2.991 1 
15 1 3.703 1 3.546 1 2.930 1 -0.115 0 3.417 1 
16 1 3.562 1 3.213 1 2.779 1 -0.135 0 3.225 1 
17 1 3.300 1 3.161 1 2.831 1 -0.105 0 3.292 1 
18 1 3.367 1 3.215 1 2.705 1 -0.148 0 3.144 1 
19 0 2.628 0 2.368 0 1.974 0 -0.039 1 2.177 0 
20 0 3.008 0 2.802 0 2.188 0 -0.155 0 2.725 0 
21 0 2.498 0 2.375 0 1.955 0 -0.030 1 2.329 0 
22 1 3.578 1 3.285 1 3.000 1 -0.159 0 3.425 1 
23 1 3.321 1 3.063 1 2.503 1 -0.020 1 3.207 1 
24 1 3.411 1 3.141 1 2.570 1 -0.041 1 3.104 1 




Tables 3-28, 3-29, and 3-30 each show five trimmed Clinical + Genotype risk index 
models corresponding to the Clinical risk index models shown in Tables 3-22, 3-23, and 
3-24. Tables 3-31, 3-32, and 3-33 show the risk index values and predictions from the 
same set of five Clinical + Genotype risk index models from the same three small-scale 
simulation datasets for a set of 25 individuals randomly selected from the optimization 
set. Figures 3-28, 3-29, and 3-30 show the full distribution of risk index values in the 
optimization set for a randomly selected trimmed Clinical + Genotype risk index model 
from each of the three small-scale simulation datasets. Figures 3-31, 3-32, and 3-33 show 
the full distribution of risk index values in the independent testing set for a randomly 
selected trimmed Clinical + Genotype risk index model from each of the three small-
scale simulation datasets. As in the previous set of figures, in all six of these figures a red 
line indicates the cut-off point. All individuals with a risk index value greater than or 
equal to this cut-off point are predicted as “high risk” and all individuals with a value less 




Table 3-29 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Small-scale Simulation Dataset #5 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
2 
0.004*v6 + 0.0336*PC7 + 0.0337*PC23 - 0.0028*PC30 + 0.0507*PC58 + 0.0357*PC66 - 
0.0138*PC89 + 0.0299*PC94 + 0.0282*PC100 - 0.0062*PC106 - 0.016*PC113 + 
0.0046*PC134 + 0.03*PC145 - 0.0269*PC198 - 0.0356*PC211 - 0.0345*PC226 - 
0.0495*PC244 + 0.0469*PC258 + 0.0558*PC262 - 0.0123*PC274 + 0.0613*PC302 
5 
0.1644*v1 + 0.3554*v2 + 0.0146*PC34 + 0.0335*PC45 + 0.0491*PC49 - 0.0321*PC62 - 
0.0484*PC77 - 0.0078*PC98 - 0.2477*PC143 - 0.0485*PC144 - 0.3438*PC169 - 
0.0411*PC204 + 0.082*PC220 + 0.0639*PC228 - 0.0958*PC235 + 0.2721*PC261 
44 
0.14*v1 + 0.2395*v5 - 0.0079*v6 - 0.0236*v7 - 0.0163*PC16 + 0.0154*PC21 + 
0.0104*PC33 + 0.0654*PC81 - 0.0028*PC99 - 6e-04*PC118 - 0.0194*PC119 + 
0.1481*PC125 + 0.0388*PC163 + 0.1901*PC188 - 0.0313*PC217 + 0.0369*PC223 - 
0.0824*PC232 + 0.0326*PC258 - 0.0472*PC265 + 0.3294*PC271 - 0.028*PC278 - 
0.1468*PC289 - 0.0032*PC296 + 0.1262*PC301 
83 
0.1366*v1 + 0.3025*v2 + 0.1001*v4 - 0.0116*v6 - 0.0382*v7 - 0.0838*v8 + 0.009*PC25 
+ 0.3087*PC55 - 0.2883*PC80 + 0.1097*PC133 - 0.1625*PC172 - 0.2277*PC238 + 
0.1097*PC260 + 0.1392*PC279 
85 
 -0.079*v5 + 0.0414*PC1 + 0.0456*PC36 - 0.0147*PC48 - 0.0249*PC74 - 0.0231*PC81 + 
0.0097*PC110 + 0.0211*PC118 + 0.0284*PC119 - 0.0349*PC159 + 0.014*PC167 + 
0.0091*PC179 - 0.017*PC232 + 0.0437*PC234 + 0.044*PC260 + 0.0137*PC262 + 





Table 3-30 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Small-scale Simulation Dataset #12 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
24 
0.156*v1 + 0.3719*v2 + 0.1017*v4 + 0.1242*v5 - 0.006*v7 - 0.0213*v8 - 0.05*PC20 + 
0.0208*PC31 + 0.0604*PC70 + 0.309*PC74 + 0.0226*PC90 - 0.0657*PC91 - 
0.1191*PC92 - 0.0217*PC107 + 0.1019*PC152 + 0.0944*PC161 + 0.0321*PC177 - 
0.055*PC215 + 0.0841*PC231 + 0.0799*PC240 + 0.0115*PC249 - 0.0425*PC262 + 
0.018*PC272 - 0.2959*PC297 
27 
0.1348*v1 + 0.4034*v2 + 0.8165*v5 + 3e-04*v7 + 0.028*PC50 + 0.0627*PC57 - 
0.0183*PC62 - 0.0188*PC111 - 0.1222*PC117 - 0.0167*PC157 - 0.0525*PC163 + 
0.0596*PC181 + 0.1473*PC195 - 0.0069*PC210 + 0.1309*PC227 + 0.0691*PC233 + 
0.0142*PC235 + 0.3777*PC288 + 0.0419*PC292 - 0.5166*PC298 + 0.0255*PC302 + 
0.1219*PC304 
37 
 -0.0194*v8 + 0.033*PC45 + 0.0713*PC93 + 0.1551*PC102 - 0.0501*PC104 + 
0.036*PC122 - 0.0147*PC144 + 0.009*PC145 + 0.0787*PC159 - 0.0742*PC170 + 
0.009*PC190 + 0.0354*PC193 - 0.0657*PC198 - 0.0797*PC215 + 0.0165*PC223 - 
0.0071*PC260 + 0.0564*PC263 
49 
0.1114*v1 + 0.3982*v2 + 0.0657*v3 + 0.0895*v4 - 0.3266*v5 + 0.0495*v6 + 0.0056*v7 - 
0.0054*v8 - 0.1036*PC26 + 0.1341*PC52 - 0.0534*PC75 - 0.0626*PC107 - 0.304*PC121 
- 0.0061*PC128 - 0.1893*PC150 + 0.0491*PC151 - 0.0646*PC159 - 0.185*PC183 + 
0.0439*PC191 - 0.4759*PC200 + 0.0296*PC217 + 0.1851*PC224 + 0.0286*PC231 + 
0.2401*PC274 + 0.0341*PC304 + 0.0939*PC308 
83 
0.1531*v1 + 0.2988*v2 + 0.0804*v4 + 0.0115*v7 + 0.0084*PC7 - 0.0779*PC25 - 
0.0164*PC31 - 0.0246*PC63 - 0.0237*PC67 + 0.0642*PC125 - 0.0172*PC148 + 
0.1322*PC151 + 0.1042*PC157 + 0.0662*PC176 + 0.0523*PC177 - 0.2565*PC178 + 






Table 3-31 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Small-scale Simulation Dataset #15 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
25 
0.1271*v1 + 0.3612*v2 + 0.0798*v3 + 0.0501*v6 - 0.0156*s14 + 0.0383*s22 + 
0.0094*s49 - 0.0231*s82 + 0.0235*s101 + 0.0356*s113 - 0.0424*s119 + 0.04*s168 - 
0.0988*s201 - 0.2504*s255 - 0.0315*s273 - 0.0067*s375 + 0.0185*s385 + 0.0288*s420 - 
0.0376*s424 - 0.0148*s458 + 0.0167*s479 + 0.0043*s491 + 0.2736*s496 
76 
0.3139*v2 - 0.5463*v5 - 0.0426*v8 + 0.4962*s12 + 0.0094*s18 + 0.0132*s56 + 
0.0368*s65 + 0.0054*s106 - 0.0112*s124 - 0.0961*s141 - 0.0199*s143 - 0.0262*s214 - 
0.1017*s218 - 0.0064*s240 + 0.1556*s257 - 0.0235*s289 + 0.0977*s310 + 0.0272*s311 + 
0.1166*s405 + 0.0248*s436 + 0.0533*s485 
79 
0.1516*v1 + 0.0964*v3 + 0.0909*v4 + 0.0158*v6 - 6e-04*v7 + 0.1363*v8 - 0.1052*s46 - 
0.0304*s86 + 0.1201*s158 - 0.096*s162 + 0.0155*s173 + 0.0827*s254 - 0.1274*s265 + 
0.4236*s329 - 0.0118*s336 - 0.0026*s337 + 0.0312*s359 - 0.1349*s377 + 0.0325*s405 - 
0.1539*s426 + 0.0686*s439 - 0.0048*s444 - 0.0332*s469 
88 
0.1149*v5 + 0.0023*v7 + 0.0135*s59 - 0.122*s166 - 7e-04*s179 + 0.0221*s195 + 
0.0075*s251 - 0.0147*s265 - 0.0067*s352 - 0.0137*s360 + 0.0162*s374 - 0.0627*s384 + 
0.0103*s388 - 0.0242*s391 + 0.0109*s406 - 0.0854*s413 + 0.0619*s440 + 0.0079*s448 + 
0.0531*s461 + 0.0122*s464 + 0.0347*s495 
92 
0.1537*v1 + 0.2992*v2 + 0.0974*v3 + 0.0072*v6 - 0.1636*v8 + 0.0106*s51 - 0.2487*s75 
- 0.0166*s84 - 0.1151*s90 + 0.0016*s123 - 0.0618*s133 - 0.0326*s136 + 0.0098*s166 - 
0.0228*s186 - 0.0633*s193 + 0.0691*s207 + 0.0473*s212 + 0.0169*s215 + 0.0756*s269 + 





Figure 3-28 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Small-scale Dataset #5, Bootstrap Sample #2 
 
Figure 3-29 Clinical + Genotype Risk Index Value Distribution in the Optimization 




Figure 3-30 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Small-scale Dataset #15, Bootstrap Sample #25 
 
 
Figure 3-31 Clinical + Genotype Risk Index Value Distribution in the Independent 




Figure 3-32 Clinical + Genotype Risk Index Value Distribution in the Independent 
Testing Set for Small-scale Dataset #12, Bootstrap Sample #24 
 
Figure 3-33 Clinical + Genotype Risk Index Value Distribution in the Independent 




Table 3-32 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Small-scale Simulation Dataset #5 
   Bootstrap Sample #2 Bootstrap Sample #5 Bootstrap Sample #44 Bootstrap Sample #83 Bootstrap Sample #85 

















1 1 0.083 0 6.621 1 2.577 1 1.974 1 -0.792 0 
2 1 0.155 1 6.230 1 2.445 1 1.872 1 -0.786 0 
3 1 0.137 1 5.594 0 1.986 0 1.506 0 -0.771 1 
4 0 0.141 1 5.027 0 1.888 0 1.534 0 -0.781 1 
5 0 0.135 1 5.898 0 1.896 0 1.624 0 -0.816 0 
6 0 0.091 0 4.876 0 1.655 0 1.244 0 -0.814 0 
7 1 0.125 1 7.053 1 2.135 0 1.928 1 -0.741 1 
8 1 0.125 1 5.823 0 1.885 0 1.917 1 -0.839 0 
9 0 0.120 1 5.733 0 1.946 0 1.639 0 -0.735 1 
10 0 0.093 0 5.426 0 1.983 0 1.602 0 -0.783 1 
11 0 0.103 0 5.976 0 1.754 0 1.598 0 -0.815 0 
12 1 0.086 0 6.563 1 2.295 1 1.852 1 -0.821 0 
13 1 0.134 1 6.304 1 2.355 1 1.775 1 -0.810 0 
14 0 0.114 0 5.962 0 2.133 0 1.663 0 -0.821 0 
15 1 0.160 1 7.427 1 2.196 0 2.177 1 -0.795 0 
16 0 0.110 0 5.490 0 2.093 0 1.404 0 -0.818 0 
17 0 0.095 0 5.767 0 2.082 0 1.768 1 -0.814 0 
18 0 0.141 1 4.540 0 1.808 0 1.256 0 -0.844 0 
19 1 0.066 0 7.020 1 2.419 1 1.880 1 -0.767 1 
20 1 0.077 0 6.980 1 2.268 1 1.933 1 -0.796 0 
21 0 0.113 0 6.344 1 2.036 0 1.749 1 -0.823 0 
22 1 0.126 1 6.254 1 2.127 0 1.664 0 -0.785 1 
23 1 0.150 1 6.946 1 2.470 1 1.958 1 -0.765 1 
24 0 0.117 0 5.452 0 1.889 0 1.628 0 -0.792 0 




Table 3-33 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Small-scale Simulation Dataset #12 
   Bootstrap Sample #24 Bootstrap Sample #27 Bootstrap Sample #37 Bootstrap Sample #49 Bootstrap Sample #83 

















1 0 2.510 0 4.750 0 -0.258 0 1.890 0 3.370 0 
2 1 2.828 1 4.972 0 -0.220 0 2.123 1 3.726 0 
3 0 2.551 0 4.572 0 -0.195 1 1.896 0 3.339 0 
4 0 2.345 0 4.589 0 -0.192 1 1.672 0 3.076 0 
5 1 2.699 1 4.705 0 -0.217 0 1.980 0 3.622 0 
6 1 2.838 1 5.199 1 -0.257 0 2.212 1 3.779 1 
7 0 2.713 1 4.910 0 -0.249 0 1.946 0 3.479 0 
8 1 2.927 1 5.059 1 -0.238 0 2.175 1 3.900 1 
9 1 2.853 1 5.206 1 -0.202 1 2.150 1 3.834 1 
10 1 2.912 1 5.206 1 -0.235 0 2.205 1 3.890 1 
11 0 2.300 0 4.243 0 -0.228 0 1.599 0 2.999 0 
12 0 2.239 0 4.200 0 -0.222 0 1.463 0 2.941 0 
13 1 3.166 1 5.641 1 -0.257 0 2.233 1 4.090 1 
14 0 2.388 0 4.252 0 -0.214 1 1.649 0 3.036 0 
15 1 2.882 1 5.219 1 -0.187 1 2.156 1 3.875 1 
16 0 2.509 0 4.479 0 -0.216 1 1.812 0 3.258 0 
17 0 2.528 0 4.851 0 -0.227 0 1.761 0 3.415 0 
18 0 2.526 0 4.672 0 -0.195 1 1.920 0 3.329 0 
19 0 2.690 1 5.033 0 -0.245 0 1.940 0 3.688 0 
20 1 2.283 0 4.392 0 -0.225 0 1.500 0 2.939 0 
21 0 2.083 0 3.829 0 -0.258 0 1.547 0 2.743 0 
22 1 2.985 1 5.247 1 -0.249 0 2.322 1 3.985 1 
23 1 2.894 1 5.206 1 -0.240 0 2.237 1 3.826 1 
24 0 2.812 1 4.807 0 -0.252 0 2.138 1 3.751 1 




Table 3-34 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 




#245 Bootstrap Sample #76 Bootstrap Sample #79 Bootstrap Sample #88 Bootstrap Sample #92 

















1 1 3.178 1 2.832 1 2.541 1 -0.059 1 3.174 1 
2 1 3.305 1 2.771 0 2.702 1 -0.084 1 2.929 1 
3 1 2.940 0 2.667 0 2.325 0 -0.083 1 3.022 1 
4 1 3.302 1 3.045 1 2.679 1 -0.159 0 3.002 1 
5 1 3.301 1 2.844 1 2.784 1 -0.109 0 3.218 1 
6 0 2.467 0 2.263 0 2.020 0 -0.091 1 2.488 0 
7 1 3.429 1 3.066 1 2.620 1 -0.122 0 3.306 1 
8 0 2.722 0 2.574 0 2.219 0 -0.154 0 2.541 0 
9 1 3.617 1 3.279 1 3.072 1 -0.070 1 3.411 1 
10 0 3.042 0 2.742 0 1.961 0 -0.066 1 2.893 0 
11 1 2.924 0 2.865 1 2.458 0 -0.070 1 3.278 1 
12 0 2.910 0 2.432 0 2.076 0 -0.073 1 2.477 0 
13 0 3.057 0 2.531 0 2.481 1 -0.001 1 2.677 0 
14 1 3.289 1 3.170 1 2.362 0 -0.172 0 3.004 1 
15 1 3.690 1 3.511 1 2.893 1 -0.124 0 3.419 1 
16 1 3.533 1 3.162 1 2.758 1 -0.148 0 3.194 1 
17 1 3.309 1 3.037 1 2.820 1 -0.109 0 3.235 1 
18 1 3.340 1 3.144 1 2.684 1 -0.156 0 3.072 1 
19 0 2.566 0 2.171 0 1.924 0 -0.053 1 2.238 0 
20 0 3.022 0 2.565 0 2.172 0 -0.167 0 2.704 0 
21 0 2.445 0 2.248 0 1.919 0 -0.035 1 2.300 0 
22 1 3.570 1 3.204 1 2.954 1 -0.167 0 3.403 1 
23 1 3.324 1 2.938 1 2.457 0 -0.033 1 3.214 1 
24 1 3.402 1 3.086 1 2.514 1 -0.050 1 3.109 1 
25 0 3.196 1 2.951 1 2.287 0 -0.181 0 2.898 0 
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3.3.3 Predictive Performance 
After the variable selection procedure is completed and the models are applied to each 
individual in the independent testing set then the sensitivity, specificity, misclassification, 
and positive predictive value are estimated for both the Clinical and Clinical + Genotype 
risk index models for each of the 100 small-scale simulation datasets. Table 3-34 shows 
the means and standard deviations of these measurements. To provide a 95% confidence 
for these measurements of sensitivity, specificity, misclassification, and positive 
predictive value for each independent testing set, 1000 bootstrap samples were generated. 
By making predictions about each individual in these bootstrap samples and calculating 
the sensitivity, specificity, misclassification, and positive predictive value for each 
bootstrap sample, 95% confidence intervals were estimated for these measurements in 
each of the 100 small-scale simulation datasets. The mean and standard deviation of the 
spread (i.e., range) of these confidence intervals for both the Clinical and Clinical + 
Genotype risk index model is shown in Table 3-35. This provides a view into the 
variability of the sensitivity, specificity, misclassification, and positive predictive value 
estimates. Table 3-36 shows the predictive performance and confidence intervals for the 
three small-scale simulation datasets discussed in Section 3.2.2. 
 
Table 3-35 Means and Standard Deviations of Predictive Performance Estimates for 




































Table 3-36 Means and Standard Deviations of Predictive Performance 95% 
Confidence Intervals for the 100 Small-scale Simulation Datasets 
 Mean Range of the 95% Confidence Interval (SD) 
Model Sensitivity  Specificity  Misclassification  PPV  
Clinical 0.218 (0.017) 0.094 (0.013) 0.098 (0.007) 0.220 (0.022) 
Clinical + Genotype 0.220 (0.016) 0.091 (0.013) 0.099 (0.006) 0.222 (0.022) 
 
Table 3-37 Predictive Performance Estimates for Three Small-scale Simulation 
Datasets 


















































Using the number of models predicting an individual in the independent testing set as 
“high risk”, receiver operator characteristic (ROC) curves were generated for the Clinical 
and Clinical + Genotype risk index model for each of the 100 small-scale simulation 
datasets, and the AUC for the ROC curve was estimated. The average AUC of the 
Clinical risk index models was 0.826 (SD = 0.033), and the average AUC of the Clinical 
+ Genotype risk index models was 0.839 (SD = 0.032). Figure 3-32, 3-33, and 3-34 show 
the ROC curves of the Clinical risk index model the three small-scale simulation datasets 
discussed in sections 3.2.2, and Figure 3-35, 3-36, and 3-37 show the ROC curve for the 





Figure 3-34 ROC Curve of the Clinical Risk Index Model for Small-scale Simulation 
Dataset #5 
 





Figure 3-36 ROC Curve of the Clinical Risk Index Model for Small-scale Simulation 
Dataset #15 
 
Figure 3-37 ROC Curve of the Clinical + Genotype Risk Index Model for Small-




Figure 3-38 ROC Curve of the Clinical + Genotype Risk Index Model for Small-
scale Simulation Dataset #12 
 
Figure 3-39 ROC Curve of the Clinical + Genotype Risk Index Model for Small-




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual as high risk, then, represents the predicted 
probability of an individual developing the outcome. For each individual a 95% 
confidence interval can be constructed as described in Section 3.2.3 
 
3.3.4 Random Forest Comparison 
For each of the 100 small-scale simulation datasets a random forest was generated using 
the optimization set created by the risk index procedure. The forests were generated using 
the methodology given in Section 3.2.4. For each of the random forests an ROC curve 
was generated and the AUC was estimated. The mean AUC of the random forest models 
was 0.821 (SD = 0.031). Figures 3-40, 3-41, and 3-42 show the ROC curve of the random 
forest generated from the three small-scale simulation datasets described in Section 3.2.2. 
When working with a dataset that has two possible classes, the standard procedure for a 
random forest is to assign a prediction to an individual based on a simple majority of 
votes. When the prevalence of the outcome is less than 50% changing the proportion of 
votes needed to classify an individual can significantly impact the estimates of 
performance. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set using a range of proportions. 
First, an individual was assigned a prediction of “high risk” if 5% or more of the trees in 
the forest predicted the individual to be “high risk”. This was then repeated in increments 
of 5% until individuals were assigned a prediction of “high risk” only if 95% or more of 
the trees in the forest predicted the individual to be “high risk”. Table 3-37 shows the 
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mean and standard deviation of the sensitivity, specificity, misclassification, and PPV for 
a range of different proportions. 
 
Figure 3-40 ROC Curve of the Random Forest Generated for Small-scale 




Figure 3-41 ROC Curve of the Random Forest Generated for Small-scale 
Simulation Dataset #12 
 
 
Figure 3-42 ROC Curve of the Random Forest Generated for Small-scale 
Simulation Dataset #15 
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Table 3-38 Means and Standard Deviations of Performance Estimates of the 
Random Forest Models Generated from the 100 Small-scale Simulation Datasets 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 0.991 (0.014) 0.098 (0.073) 0.629 (0.056) 0.327 (0.038) 
0.1 0.963 (0.027) 0.264 (0.1) 0.522 (0.069) 0.368 (0.046) 
0.15 0.921 (0.039) 0.433 (0.086) 0.417 (0.058) 0.42 (0.051) 
0.2 0.859 (0.047) 0.577 (0.064) 0.337 (0.043) 0.474 (0.053) 
0.25 0.792 (0.053) 0.693 (0.053) 0.276 (0.035) 0.535 (0.059) 
0.3 0.716 (0.064) 0.768 (0.049) 0.247 (0.031) 0.579 (0.064) 
0.35 0.631 (0.076) 0.832 (0.045) 0.229 (0.028) 0.627 (0.069) 
0.4 0.534 (0.088) 0.884 (0.043) 0.223 (0.027) 0.678 (0.083) 
0.45 0.447 (0.097) 0.923 (0.034) 0.223 (0.026) 0.729 (0.086) 
0.5 0.345 (0.101) 0.953 (0.027) 0.233 (0.029) 0.779 (0.092) 
0.55 0.238 (0.095) 0.975 (0.019) 0.251 (0.033) 0.82 (0.095) 
0.6 0.134 (0.081) 0.99 (0.013) 0.273 (0.035) 0.869 (0.12) 
0.65 0.048 (0.053) 0.997 (0.007) 0.294 (0.035) 0.903 (0.185) 
0.7 0.011 (0.025) 0.999 (0.002) 0.304 (0.034) 0.879 (0.184) 
 
3.3.5 Conclusion 
The performance of the small-scale simulation tests using principal components that 
explain 90% of the variance performed comparably to the small-scale tests using the full 
set of 100 SNPs. This is not surprising, as the principal components analysis was 
performed using the set of 500 SNPs examined earlier, and so the principal components 
are just effectively a compression of the information contained in the SNPs into a smaller 
number of uncorrelated variables. The specification of no linkage disequilibrium between 
the simulated SNPs also helps explain why a fairly large number of components are 
needed to reach 90% of the variance. The performance of the random forests, however, is 
reduced when using the top principal components. This is likely because the tree-based 
nature of the random forest method helps identify context-dependent relationships among 
variables that can be used for classification. Because the principal components are 
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uncorrelated with each other, however, a random forest is not as effective as in a dataset 
with significant correlation among variables. 
 
The predictive performance of the risk index procedure is quite good, with a mean AUC 
of the Clinical + Genotype risk index models that is significantly greater than the mean 
AUC of the Clinical risk index model (p=0.008). Unlike the small-scale simulation tests 
using the full set of SNPs, the random forest models had a mean AUC that was 
significantly lower than that of the Clinical + Genotype risk index models (p=8.4e-5), and 
tuning the class assignment procedure can produce sensitivity, specificity, and positive 
predictive value that is comparable to the risk index methods but does not exceed it.  
 
3.4 Large-scale Simulation Study Methodology 
The large-scale simulation study is made up of ten thousand individuals, twenty-nine 
covariates, and 38,835 polymorphisms. The outcome is generated in the same manner as 
the small-scale simulation study, and as before a multivariate normal random number 
generator is used. For the large-scale simulation study, however, rather than specifying 
the precise correlation matrix for the variables, they were split into blocks, with each 
block having a range of possible correlations with the outcome and with the other 
variables. The precise correlation between each variable and the outcome was modeled as 
a uniformly distributed random variable that takes a value within the range specified for 
the particular variable. The first and second variables have between a 0.45 and 0.65 
correlation with the outcome, the third through fifth variables have a correlation with the 
outcome of between 0.40 and 0.25, the sixth through sixteenth variables have between a 
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0.10 and 0.25 correlation with the outcome, and variables seventeen through twenty-nine 
have between a 0.01 and 0.09 correlation with the outcome. The correlation between 
variables is simulated as a normal random variable with a mean of 0, and a standard 
deviation of 0.2, which gives a 99% probability the correlations will be between -0.52 
and 0.52, and a 99.9999% probability that the correlation will be between -1.0 and 1.0. 
 
Genotype variable simulation was performed using genomeSIMLA (Edwards, et al, 
2008) as with the small-scale simulation study. Using configuration files provided by the 
authors of genomeSIMLA, 38,835 genotypes were generated so that the final dataset is 
similar to data that would be obtained from Chromosome one using the Affymetrix 500K 
Genome-wide genotyping assay (Affymetrix, 2007). Six SNPs were selected as 
associated with the outcome, with beta coefficients ranging from 0.4 to 0.8, 
corresponding to an odds ratio at a given locus of between 1.5 and 2.2. As with the small-
scale simulation genotypes were encoded additively. 
 
3.5 Large-scale Simulation Study Top 500 SNPs Results 
3.5.1 Variable Selection 
Using the same procedure as in Section 3.2.1, Clinical and Clinical + Genotype risk index 
models were constructed for each of the 25 large-scale simulation datasets. The 
association between the dichotomous outcome and each of the 38,835 SNPs was 
estimated, and the 500 SNPs with the smallest p-values from this logistic regression 




Table 3-38 shows the summary of the variable selection procedure from the Clinical risk 
index model averaged across the 25 simulation datasets. Variables v1 through v5 are 
most frequently selected; on average, they each appear in more than half of the 50 
trimmed Clinical risk index models. Variables v12, v15, and v16 are also frequently 
selected, appearing in 17.7, 17.1, and 16.7 trimmed Clinical risk index models on 
average. Table 3-39 shows the summary of the variable selection procedure from the 
Clinical + Genotype risk index model averaged across the 25 simulation datasets. No 




Table 3-39 Summary of the Number of Times Each Variable is Selected into a 
Specific Model Position for the Large-scale Simulation Clinical Risk Index Models 
  Variable Position 
Variable 1 2 3 4 5 6 7 8 
Total # of Times 
in Trimmed 
Model 
v1 31.286 0.429 0.286 0.000 0.286 0.000 0.000 0.000 32.429 
v2 0.143 8.000 5.571 3.571 3.714 2.714 2.714 1.571 29.286 
v3 0.286 7.286 3.857 3.286 2.714 2.000 1.143 0.857 22.143 
v4 0.286 7.000 9.857 3.571 1.857 1.714 2.143 1.714 30.000 
v5 0.143 7.286 5.857 7.143 2.571 1.714 1.429 1.143 29.000 
v6 0.143 0.714 1.571 2.571 2.714 3.000 2.000 1.571 16.429 
v7 0.000 0.286 1.000 0.429 1.571 2.000 1.143 1.857 12.857 
v8 0.000 0.286 1.000 1.429 2.857 2.143 1.286 1.286 13.429 
v9 0.000 0.571 0.143 1.286 2.571 1.429 2.714 2.857 16.571 
v10 0.000 0.143 0.143 0.571 1.000 1.286 0.571 2.429 9.286 
v11 0.143 0.286 0.143 0.857 1.000 1.571 1.714 1.429 10.571 
v12 0.000 0.286 0.714 2.429 2.714 3.857 3.571 2.429 17.714 
v13 0.714 0.143 1.571 1.571 1.429 1.286 1.000 1.000 8.714 
v14 0.000 0.143 0.143 0.429 0.429 1.429 1.000 1.429 9.143 
v15 0.000 0.000 0.714 1.714 1.286 2.714 3.286 3.286 17.143 
v16 0.000 0.000 0.143 1.286 2.000 2.143 3.286 3.143 16.714 
v17 2.286 1.857 2.143 1.286 2.143 2.143 1.286 1.286 6.714 
v18 0.571 1.143 0.429 1.143 2.143 1.429 2.000 2.000 5.000 
v19 0.714 1.143 1.571 2.429 2.857 1.571 1.286 1.857 6.571 
v20 1.143 1.429 1.000 1.286 1.571 1.857 2.286 1.714 5.000 
v21 1.143 1.286 1.000 1.429 0.429 1.857 1.571 1.857 6.714 
v22 1.857 1.571 1.429 1.286 1.857 1.143 1.429 0.714 5.286 
v23 1.286 1.429 1.000 1.857 1.286 0.857 1.429 1.000 4.857 
v24 2.143 2.286 1.286 1.429 1.143 1.286 1.571 2.143 6.286 
v25 1.286 0.714 0.714 0.714 1.714 0.714 1.857 1.714 5.143 
v26 1.000 0.571 2.000 1.000 1.000 0.857 1.571 1.286 5.714 
v27 2.000 2.571 1.857 1.286 1.143 1.429 1.571 1.571 6.857 
v28 0.857 0.571 1.429 1.429 1.000 2.143 1.857 2.857 6.429 




Table 3-40 Summary of the Number of Times Selected Genotype Variables are Selected into a Specific Model Position for the 
Large-scale Simulation Clinical + Genotype Risk Index Models 
  Variable Position 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 








rs1552124 0.00 1.00 0.14 0.57 0.57 1.00 1.29 0.86 0.71 0.43 0.43 1.14 0.57 0.86 0.71 0.43 0.14 0.29 0.14 0.29 11.57 7.29 
rs942904 0.14 0.43 0.57 1.14 0.29 0.29 0.57 0.29 0.57 1.00 0.86 0.86 0.43 0.57 0.71 0.57 0.43 0.43 0.43 0.29 10.86 7.00 
rs10788668 0.14 0.43 0.43 0.43 0.86 0.29 0.86 0.71 0.57 0.57 0.14 0.71 0.57 0.43 0.29 0.43 0.71 0.86 0.29 0.14 9.86 6.14 
rs12141159 0.00 0.14 0.29 0.29 0.43 1.29 0.57 1.00 0.29 0.86 1.00 0.57 0.57 1.00 0.57 0.86 0.57 0.29 0.14 0.43 11.14 5.57 
rs3795479 0.14 0.14 0.14 0.71 0.29 0.71 0.57 0.57 0.71 0.86 0.57 1.29 0.43 0.86 0.43 0.43 0.71 0.00 0.43 0.57 10.57 5.57 
rs2241863 0.00 0.57 0.43 0.71 0.43 0.71 1.00 0.29 0.43 0.14 0.14 0.14 0.71 0.29 0.14 0.43 0.43 0.29 0.29 0.00 7.57 5.29 
rs2157381 0.00 0.29 0.29 0.43 0.29 0.29 0.14 0.14 0.43 0.86 0.86 0.57 0.14 0.71 0.43 0.71 0.71 0.43 0.71 0.43 8.86 4.86 
rs2566753 0.14 0.29 0.29 0.14 0.57 0.43 1.00 0.57 0.00 0.43 0.57 0.14 0.71 0.43 0.57 0.14 0.29 0.29 0.43 0.43 7.86 4.71 
rs1373259 0.00 0.00 0.57 0.29 0.29 0.29 0.43 0.57 0.71 0.71 0.57 0.57 0.86 0.43 0.86 0.43 0.71 0.29 0.43 0.71 9.71 4.43 
rs7514435 0.14 0.86 0.43 0.14 0.71 0.57 0.29 0.14 0.14 0.29 0.71 0.43 0.14 0.43 0.14 0.29 0.00 0.57 0.00 0.43 6.86 4.43 
rs10157886 0.00 0.00 0.00 0.29 0.57 0.57 0.29 0.29 0.29 0.86 0.14 0.43 0.29 0.86 0.43 0.43 1.14 0.00 0.57 0.29 7.71 4.29 
rs12141268 0.00 0.00 0.71 0.29 0.43 0.43 0.29 0.29 0.43 0.29 0.29 0.57 0.43 0.29 0.57 0.14 0.14 0.29 0.14 0.29 6.29 4.00 
rs2494454 0.29 0.14 0.57 0.14 0.43 0.00 0.14 0.00 0.71 0.29 0.14 0.00 0.57 0.57 0.14 0.29 0.29 0.29 0.14 0.29 5.43 4.00 
rs4916041 0.00 0.29 0.29 0.14 0.29 0.43 0.29 0.43 0.43 0.43 0.14 0.86 0.00 0.43 0.14 0.14 0.14 0.71 0.14 0.14 5.86 4.00 
rs6682150 0.29 0.43 0.29 0.29 0.00 0.14 0.29 0.14 0.14 0.14 0.00 0.43 0.14 0.29 0.57 0.29 0.43 0.00 0.43 0.29 5.00 3.57 
rs10913043 0.14 0.00 0.14 0.43 0.00 0.29 0.29 0.43 1.14 0.29 0.57 0.29 0.57 0.86 0.00 0.29 0.14 0.14 0.57 0.43 7.00 3.57 
rs3009947 0.14 0.29 0.14 0.29 0.14 0.14 0.00 0.14 0.43 0.29 0.43 0.29 0.00 0.29 0.29 0.14 0.14 0.14 0.71 0.43 4.86 3.43 
rs1797052 0.00 0.00 0.29 0.29 0.14 0.43 0.14 0.71 0.14 0.14 0.29 0.29 0.29 0.14 0.14 0.14 0.43 0.14 0.00 0.43 4.57 3.43 
rs12047608 0.00 0.14 0.14 0.14 0.29 0.00 0.29 0.14 0.43 0.14 0.57 0.29 0.29 0.86 0.57 0.29 0.00 0.71 1.00 0.29 6.57 3.14 
rs6427160 0.00 0.14 1.00 0.14 0.00 0.43 0.14 0.14 0.29 0.00 0.29 0.14 0.14 0.29 0.00 0.14 0.43 0.14 0.00 0.14 4.00 3.14 




Once the variable selection procedure is finished each of the 25 large-scale simulation 
datasets have 50 trimmed Clinical and Clinical + Genotype risk index models. Tables 3-
40, 3-41, and 3-42 each show five trimmed Clinical risk index models randomly selected 
from one of three randomly chosen large-scale simulation datasets (datasets #9, #22, and 
#25). Figures 3-43, 3-44, and 3-45 show the full distribution of risk index values in the 
optimization set for a randomly selected trimmed Clinical risk index models from each of 
the three large-scale simulation datasets. Figures 3-46, 3-47, and 3-48 show the full 
distribution of risk index values in the independent testing set for a randomly selected 
trimmed Clinical risk index model from each of the three large-scale simulation datasets. 
In all six of these figures a red line indicates the cut-off point. All individuals with a risk 
index value greater than or equal to this cut-off point are predicted as “high risk” and all 
individuals with a value less than this cut-off point are predicted as “low risk”. Tables 3-
43, 3-44, and 3-45 show the risk index values and predictions from the same set of five 
Clinical risk index models from the same three large-scale simulation datasets for a set of 




Table 3-41 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Large-scale Simulation Dataset #9 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
5 0.0285*v1 + 0.0289*v2 + 0.0133*v4 + 0.0042*v5 + 0.0025*v6 - 0.03*v8 + 0.0029*v12 + 0.0025*v16 + 0.0347*v26 + 0.001*v27 
12 0.0299*v1 + 0.0254*v2 + 0.0122*v4 + 0.0045*v5 + 0.0026*v6 - 0.0313*v8 + 0.0035*v11 + 0.0027*v12 + 0.0021*v16 + 0.0011*v27 
14 0.0291*v1 + 0.0279*v2 + 0.023*v3 + 0.0129*v4 + 0.0041*v5 + 0.0025*v6 - 0.0265*v8 + 0.0058*v9 + 0.0029*v11 + 0.0032*v12 
20 0.0292*v1 + 0.0294*v2 + 0.0136*v4 + 0.0038*v5 + 0.0024*v6 + 0.0038*v7 - 0.0292*v8 + 0.0056*v9 + 0.0027*v11 + 0.0027*v12 
23 0.0307*v1 + 0.0259*v2 + 0.0129*v4 + 0.0043*v5 + 0.0026*v6 - 0.0276*v8 + 0.0025*v11 + 0.0033*v12 + 0.0021*v16 - 0.0022*v29 
 
Table 3-42 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Large-scale Simulation Dataset #22 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
11 0.0325*v1 + 0.0109*v2 + 0.0024*v3 + 0.0047*v4 + 0.0029*v5 + 0.0052*v6 + 0.0036*v7 + 0.0024*v9 + 0.0048*v14 - 0.0197*v28 
15 0.003*v5 + 0.002*v8 + 0.0177*v15 + 0.0013*v17 - 0.0041*v19 - 3e-04*v20 - 0.0027*v21 - 9e-04*v24 - 0.0058*v25 - 1e-04*v27 
23 0.0313*v1 + 0.0112*v2 + 0.0028*v3 + 0.0056*v4 + 0.003*v5 + 0.0055*v6 + 0.0027*v7 - 0.0115*v11 + 0.018*v15 - 0.0181*v28 
24  -0.0001*v23 
25  -0.0002*v22 
 
Table 3-43 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Large-scale Simulation Dataset #25 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
4 -0.0422*v1 + 0.0359*v2 + 0.0096*v3 - 0.0208*v4 - 0.0136*v5 + 0.0044*v8 - 0.0223*v12 + 0.0052*v13 + 0.0069*v15 + 6e-04*v21 
5 -0.0024*v17 + 4e-04*v26 + 3e-04*v27 
9 -0.0425*v1 + 0.0334*v2 + 0.0088*v3 - 0.0213*v4 - 0.0137*v5 + 0.004*v8 - 0.0185*v12 + 0.0052*v13 - 0.0129*v14 + 0.0082*v15 
18 -0.0386*v1 + 0.0378*v2 + 0.0098*v3 - 0.0206*v4 - 0.013*v5 + 0.0047*v8 - 0.012*v10 - 0.023*v12 - 0.0118*v14 + 0.008*v15 





Figure 3-43 Clinical Risk Index Value Distribution in the Optimization Set for 
Large-scale Dataset #9, Bootstrap Sample #5 
 
Figure 3-44 Clinical Risk Index Value Distribution in the Optimization Set for 




Figure 3-45 Clinical Risk Index Value Distribution in the Optimization Set for 
Large-scale Dataset #25, Bootstrap Sample #4 
 
 
Figure 3-46 Clinical Risk Index Value Distribution in the Independent Testing Set 




Figure 3-47 Clinical Risk Index Value Distribution in the Independent Testing Set 
for Large-scale Dataset #22, Bootstrap Sample #11 
 
 
Figure 3-48 Clinical Risk Index Value Distribution in the Independent Testing Set 




Table 3-44 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Large-scale Simulation Dataset #9 
   Bootstrap Sample #5 Bootstrap Sample #12 Bootstrap Sample #14 Bootstrap Sample #20 Bootstrap Sample #23 

















1 1 1.006 1 0.451 0 0.841 1 0.683 1 0.497 1 
2 0 0.859 0 0.384 0 0.607 0 0.497 0 0.406 0 
3 1 0.985 1 0.489 1 0.817 1 0.665 1 0.515 1 
4 1 1.177 1 0.651 1 0.947 1 0.829 1 0.685 1 
5 0 0.721 0 0.254 0 0.405 0 0.330 0 0.269 0 
6 0 0.870 0 0.390 0 0.716 1 0.626 0 0.426 0 
7 0 0.726 0 0.244 0 0.440 0 0.452 0 0.265 0 
8 0 0.824 0 0.290 0 0.586 0 0.499 0 0.336 0 
9 1 0.993 1 0.485 1 0.790 1 0.615 0 0.532 1 
10 1 0.871 0 0.429 0 0.651 0 0.485 0 0.440 0 
11 0 0.731 0 0.189 0 0.482 0 0.418 0 0.229 0 
12 1 1.082 1 0.538 1 0.769 1 0.658 1 0.572 1 
13 0 0.889 0 0.310 0 0.569 0 0.539 0 0.357 0 
14 0 0.899 0 0.350 0 0.583 0 0.566 0 0.401 0 
15 0 0.872 0 0.316 0 0.588 0 0.426 0 0.362 0 
16 0 0.986 1 0.501 1 0.656 0 0.590 0 0.541 1 
17 1 1.005 1 0.474 0 0.780 1 0.709 1 0.522 1 
18 1 1.200 1 0.706 1 0.974 1 0.847 1 0.730 1 
19 1 1.165 1 0.658 1 0.898 1 0.708 1 0.697 1 
20 0 0.906 0 0.364 0 0.714 1 0.572 0 0.415 0 
21 0 0.872 0 0.335 0 0.685 0 0.468 0 0.383 0 
22 0 0.876 0 0.353 0 0.732 1 0.560 0 0.383 0 
23 0 0.934 0 0.377 0 0.551 0 0.551 0 0.418 0 
24 1 0.979 1 0.493 1 0.800 1 0.610 0 0.516 1 




Table 3-45 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Large-scale Simulation Dataset #22 
   Bootstrap Sample #11 Bootstrap Sample #15 Bootstrap Sample #23 Bootstrap Sample #23 Bootstrap Sample #25 

















1 1 0.950 1 0.171 0 1.053 1 -0.004 1 -0.014 0 
2 0 0.583 0 0.308 0 0.619 0 0.000 1 -0.010 1 
3 0 0.435 0 0.329 1 0.523 0 -0.012 0 -0.019 0 
4 0 0.591 0 0.217 0 0.716 0 -0.041 0 -0.011 1 
5 1 0.743 1 0.428 1 0.828 1 -0.020 0 -0.018 0 
6 0 0.529 0 0.303 0 0.627 0 0.009 1 -0.016 0 
7 0 0.668 0 0.319 1 0.820 1 -0.024 0 -0.019 0 
8 1 0.523 0 0.430 1 0.665 0 0.000 1 -0.014 0 
9 0 0.367 0 0.325 1 0.472 0 -0.024 0 -0.016 0 
10 0 0.650 0 0.168 0 0.776 1 -0.031 0 -0.021 0 
11 0 0.301 0 0.210 0 0.435 0 -0.012 0 -0.021 0 
12 0 0.416 0 0.159 0 0.429 0 -0.006 0 -0.013 1 
13 1 0.613 0 0.327 1 0.826 1 -0.012 0 -0.015 0 
14 1 0.413 0 0.341 1 0.485 0 -0.026 0 -0.019 0 
15 0 0.270 0 0.298 0 0.392 0 -0.010 0 -0.013 1 
16 0 0.466 0 0.297 0 0.608 0 -0.025 0 -0.013 1 
17 0 0.353 0 0.262 0 0.603 0 -0.010 0 -0.014 1 
18 1 0.498 0 0.314 1 0.639 0 -0.016 0 -0.008 1 
19 0 0.562 0 0.338 1 0.636 0 -0.028 0 -0.018 0 
20 0 0.616 0 0.211 0 0.664 0 -0.012 0 -0.019 0 
21 0 0.387 0 0.276 0 0.494 0 0.005 1 -0.012 1 
22 0 0.393 0 0.122 0 0.573 0 -0.022 0 -0.014 1 
23 1 0.826 1 0.257 0 0.916 1 -0.015 0 -0.011 1 
24 0 0.397 0 0.319 1 0.636 0 -0.009 0 -0.019 0 




Table 3-46 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Large-scale Simulation Dataset #25 
   Bootstrap Sample #4 Bootstrap Sample #5 Bootstrap Sample #9 Bootstrap Sample #18 Bootstrap Sample #21 

















1 0 -0.503 0 -0.087 0 -0.734 0 -0.747 0 0.139 0 
2 1 -0.460 0 0.004 1 -0.720 0 -0.843 0 0.118 0 
3 1 -0.382 1 0.019 1 -0.616 0 -0.629 0 0.161 0 
4 0 -0.453 0 -0.021 1 -0.609 0 -0.669 0 0.073 0 
5 1 -0.269 1 0.014 1 -0.399 1 -0.503 1 0.206 0 
6 1 -0.251 1 -0.069 0 -0.387 1 -0.446 1 0.346 1 
7 0 -0.438 0 0.017 1 -0.597 1 -0.644 0 0.032 0 
8 0 -0.253 1 -0.053 0 -0.498 1 -0.485 1 0.305 1 
9 0 -0.396 0 -0.050 0 -0.593 1 -0.735 0 0.021 0 
10 0 -0.836 0 -0.077 0 -0.990 0 -1.030 0 -0.026 0 
11 1 -0.529 0 -0.060 0 -0.675 0 -0.742 0 0.049 0 
12 0 -0.524 0 -0.058 0 -0.633 0 -0.705 0 0.017 0 
13 0 -0.333 1 -0.070 0 -0.497 1 -0.623 0 0.239 1 
14 0 -0.587 0 -0.041 0 -0.853 0 -0.987 0 -0.207 0 
15 0 -0.339 1 -0.067 0 -0.529 1 -0.702 0 0.205 0 
16 1 -0.306 1 -0.052 0 -0.427 1 -0.537 1 0.244 1 
17 1 -0.272 1 -0.029 0 -0.454 1 -0.538 1 0.343 1 
18 0 -0.343 1 -0.026 0 -0.496 1 -0.588 1 0.157 0 
19 0 -0.480 0 -0.046 0 -0.720 0 -0.764 0 0.016 0 
20 0 -0.615 0 -0.011 1 -0.831 0 -0.839 0 -0.034 0 
21 1 -0.234 1 -0.053 0 -0.456 1 -0.583 1 0.218 1 
22 1 -0.235 1 -0.020 1 -0.378 1 -0.480 1 0.206 0 
23 0 -0.583 0 -0.027 0 -0.777 0 -0.798 0 -0.133 0 
24 0 -0.459 0 -0.020 1 -0.657 0 -0.678 0 0.242 1 




Tables 3-46, 3-47, and 3-48 each show five trimmed Clinical + Genotype risk index 
models corresponding to the Clinical risk index models shown in Table 3-40, 3-41, and 3-
42. Tables 3-49, 3-50, and 3-51 show the risk index values and predictions from the same 
set of five Clinical + Genotype risk index models from the same three small-scale 
simulation datasets for a set of 25 individuals randomly selected from the optimization 
set. Figures 3-49, 3-50, and 3-51 show the full distribution of risk index values in the 
optimization set for a randomly selected trimmed Clinical + Genotype risk index model 
from each of the three small-scale simulation datasets. Figures 3-52, 3-53, and 3-54 show 
the full distribution of risk index values in the independent testing set for a randomly 
selected trimmed Clinical + Genotype risk index model from each of the three small-
scale simulation datasets. As in the previous set of figures, in all six of these figures a red 
line indicates the cut-off point. All individuals with a risk index value greater than or 
equal to this cut-off point are predicted as “high risk” and all individuals with a value less 




Table 3-47 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Large-scale Simulation Dataset #9 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
5 
0.0285*v1 + 0.0289*v2 + 0.0133*v4 + 0.0042*v5 + 0.0025*v6 - 0.03*v8 + 0.0029*v12 + 
0.0025*v16 + 0.0347*v26 + 0.001*v27 + 0.0738*rs859390 + 0.0644*rs12081663 + 
0.5065*rs753209 + 0.0725*rs6692452 + 0.0828*rs4652591 - 0.0617*rs4908596 + 
0.1819*rs10911598 - 0.1144*rs10783127 - 0.0401*rs184853 - 0.1772*rs17131544 + 
0.0034*rs2154367 - 0.0781*rs7528766 - 0.1336*rs1881029 - 0.1489*rs12403147 + 
0.003*rs215814 - 0.0421*rs1323126 - 0.056*rs2768761 
12 
0.0299*v1 + 0.0254*v2 + 0.0122*v4 + 0.0045*v5 + 0.0026*v6 - 0.0313*v8 + 0.0035*v11 
+ 0.0027*v12 + 0.0021*v16 + 0.0011*v27 + 0.687*rs7520551 - 0.1465*rs7554934 - 
0.162*rs12139740 + 0.1052*rs2996655 - 0.0581*rs12058254 - 0.0672*rs6658349 + 
0.0114*rs7556384 
14 
0.0291*v1 + 0.0279*v2 + 0.023*v3 + 0.0129*v4 + 0.0041*v5 + 0.0025*v6 - 0.0265*v8 + 
0.0058*v9 + 0.0029*v11 + 0.0032*v12 + 0.1488*rs12060150 + 0.1475*rs2861277 - 
0.0839*rs10489322 + 0.1374*rs859390 - 0.1091*rs443386 + 0.0525*rs6694817 + 
0.0906*rs2157381 - 0.1301*rs6689228 + 0.0587*rs1339876 
20 
0.0292*v1 + 0.0294*v2 + 0.0136*v4 + 0.0038*v5 + 0.0024*v6 + 0.0038*v7 - 0.0292*v8 + 
0.0056*v9 + 0.0027*v11 + 0.0027*v12 - 0.1466*rs443386 + 0.0317*rs10908327 - 
0.1028*rs6675190 + 0.1414*rs7519717 - 0.0702*rs12565849 - 0.1187*rs4908596 + 
0.024*rs10495276 + 0.031*rs12124394 + 0.0533*rs10914678 - 0.09*rs11102735 - 
0.0076*rs2494884 + 0.0479*rs445633 - 0.0817*rs1980445 + 0.0853*rs2039942 
23 
0.0307*v1 + 0.0259*v2 + 0.0129*v4 + 0.0043*v5 + 0.0026*v6 - 0.0276*v8 + 0.0025*v11 
+ 0.0033*v12 + 0.0021*v16 - 0.0022*v29 + 0.8946*rs7520551 + 0.0923*rs7515728 + 
0.0912*rs859452 + 0.009*rs4949516 - 0.121*rs10157799 - 0.1499*rs11209805 + 
0.5144*rs6659228 + 0.0968*rs12124394 + 0.1581*rs10911598 + 0.1247*rs16840450 - 





Table 3-48 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Large-scale Simulation Dataset #22 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
11 
0.0325*v1 + 0.0109*v2 + 0.0024*v3 + 0.0047*v4 + 0.0029*v5 + 0.0052*v6 + 0.0036*v7 
+ 0.0024*v9 + 0.0048*v14 - 0.0197*v28 + 0.1786*rs3892225 + 0.223*rs16828534 - 
0.1237*rs4950371 + 0.0777*rs11210675 + 0.0319*rs16849075 - 0.1109*rs4845222 + 
0.033*rs10801446 - 0.0799*rs12406369 + 0.2671*rs10912988 + 0.1421*rs1475766 + 
0.0496*rs2039942 - 0.0686*rs4434872 
15 
0.003*v5 + 0.002*v8 + 0.0177*v15 + 0.0013*v17 - 0.0041*v19 - 3e-04*v20 - 0.0027*v21 
- 9e-04*v24 - 0.0058*v25 - 1e-04*v27 + 0.078*rs828505 + 1.0241*rs7520551 + 
0.0061*rs6425826 + 0.1881*rs10863400 - 0.5156*rs16860461 + 0.0518*rs2800686 - 
0.0202*rs11205175 - 0.0427*rs647924 + 0.0233*rs10493414 + 0.0213*rs1389559 + 
0.0275*rs4987299 + 0.0118*rs170261 + 0.0245*rs17032950 - 0.7694*rs11576886 + 
0.0033*rs12145484 + 0.0453*rs7542386 + 0.0468*rs474189 + 0.0049*rs1016815 
23 
0.0313*v1 + 0.0112*v2 + 0.0028*v3 + 0.0056*v4 + 0.003*v5 + 0.0055*v6 + 0.0027*v7 - 
0.0115*v11 + 0.018*v15 - 0.0181*v28 + 0.1453*rs16829834 + 0.1044*rs12141159 + 
0.2619*rs873525 + 0.0586*rs7554714 + 0.1723*rs2786608 - 0.0127*rs645142 + 
0.3927*rs4660345 + 0.0894*rs12089508 + 0.0115*rs10776742 + 0.0712*rs12732088 + 
0.0304*rs9657961 + 0.0026*rs11210904 + 0.5356*rs1258022 - 0.0687*rs649352 - 
0.024*rs1881029 + 0.03*rs4908817 - 0.7821*rs11576886 - 0.1193*rs652052 - 
0.0161*rs1793319 
24 
 -0.0001*v23 - 0.0195*rs12048137 + 0.4799*rs1411400 - 0.3852*rs17131544 + 
0.1638*rs894216 - 0.2086*rs647924 - 0.3855*rs284175 - 0.0386*rs4253963 - 
0.0223*rs16823912 + 0.0133*rs1475766 - 0.0075*rs6661048 + 0.0222*rs12028179 + 
0.003*rs4839312 
25 
 -0.0002*v22 + 0.2237*rs2861311 - 0.1155*rs2050674 - 0.1018*rs12032522 - 






Table 3-49 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Large-scale Simulation Dataset #25 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
4 
-0.0422*v1 + 0.0359*v2 + 0.0096*v3 - 0.0208*v4 - 0.0136*v5 + 0.0044*v8 - 0.0223*v12 
+ 0.0052*v13 + 0.0069*v15 + 6e-04*v21 + 0.111*rs834996 - 0.1008*rs10754164 + 
0.1212*rs10890378 - 0.0802*rs16824455 
5 
-0.0024*v17 + 4e-04*v26 + 3e-04*v27 + 0.0502*rs10914739 + 0.0815*rs873525 + 
0.122*rs1411400 + 0.056*rs170261 - 0.5574*rs16860461 - 0.5574*rs563026 + 
0.0169*rs696722 - 0.1308*rs1176534 + 0.0135*rs11207408 - 0.0295*rs7553155 + 
0.0358*rs10874427 - 0.0342*rs4839312 + 0.6177*rs10890378 
9 
-0.0425*v1 + 0.0334*v2 + 0.0088*v3 - 0.0213*v4 - 0.0137*v5 + 0.004*v8 - 0.0185*v12 + 
0.0052*v13 - 0.0129*v14 + 0.0082*v15 + 0.094*rs16848600 + 0.0591*rs945179 + 
0.0418*rs7515728 + 0.065*rs10916131 + 0.0643*rs10914678 + 0.0256*rs12084264 - 
0.0874*rs6700777 - 0.8294*rs17131544 + 0.7284*rs1411400 - 0.343*rs3813639 + 
0.0165*rs619193 + 0.1626*rs1475766 + 0.0178*rs6657754 - 0.1221*rs10518299 + 
0.0597*rs10911065 + 0.2562*rs4311892 - 0.1235*rs12028179 - 0.1014*rs6682150 - 
0.0578*rs16830020 
18 
-0.0386*v1 + 0.0378*v2 + 0.0098*v3 - 0.0206*v4 - 0.013*v5 + 0.0047*v8 - 0.012*v10 - 
0.023*v12 - 0.0118*v14 + 0.008*v15 - 0.1935*rs4040617 - 0.0965*rs16848734 + 
0.164*rs952023 + 0.0775*rs16864515 + 0.0197*rs16826049 - 0.0388*rs9659765 + 
0.0397*rs11121007 + 0.1452*rs11121472 + 0.0481*rs10926660 + 0.1024*rs4474198 + 
0.0052*rs4532864 - 0.2001*rs1176534 - 0.2026*rs11589986 + 0.0071*rs16823983 - 
0.0796*rs12076197 + 0.0513*rs2386548 - 0.0048*rs4653279 
21 
-0.0417*v1 + 0.0336*v2 + 0.0091*v3 + 0.0043*v6 + 0.0026*v7 + 0.0378*v9 - 0.0207*v12 
+ 0.0056*v13 - 0.0016*v19 + 0.0064*v23 - 0.0378*rs1469919 + 0.0896*rs16864515 + 
0.0154*rs11264034 + 0.0612*rs542405 - 0.3383*rs17131544 + 0.0461*rs378557 + 
0.2682*rs6679643 - 0.0537*rs6699417 + 0.0827*rs2280635 - 0.4996*rs16860461 - 
0.1979*rs6667451 + 0.0037*rs6427261 + 0.0222*rs2811620 - 0.1377*rs11589986 - 





Figure 3-49 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Large-scale Dataset #9, Bootstrap Sample #5 
 
Figure 3-50 Clinical + Genotype Risk Index Value Distribution in the Optimization 





Figure 3-51 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Large-scale Dataset #25, Bootstrap Sample #4 
 
 
Figure 3-52 Clinical + Genotype Risk Index Value Distribution in the Independent 




Figure 3-53 Clinical + Genotype Risk Index Value Distribution in the Independent 
Testing Set for Large-scale Dataset #22, Bootstrap Sample #11 
 
Figure 3-54 Clinical + Genotype Risk Index Value Distribution in the Independent 




Table 3-50 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Large-scale Simulation Dataset #9 
   Bootstrap Sample #5 Bootstrap Sample #12 Bootstrap Sample #14 Bootstrap Sample #20 Bootstrap Sample #23 

















1 1 0.990 1 0.463 0 0.838 1 0.683 1 0.546 1 
2 0 0.845 0 0.372 0 0.599 0 0.473 0 0.417 0 
3 1 0.976 1 0.496 1 0.771 1 0.647 0 0.516 1 
4 1 1.162 1 0.641 1 0.987 1 0.820 1 0.731 1 
5 0 0.693 0 0.223 0 0.398 0 0.335 0 0.261 0 
6 0 0.852 0 0.353 0 0.767 1 0.618 0 0.480 0 
7 0 0.704 0 0.252 0 0.428 0 0.471 0 0.317 0 
8 0 0.812 0 0.289 0 0.595 0 0.481 0 0.368 0 
9 1 0.991 1 0.501 1 0.806 1 0.628 0 0.545 1 
10 1 0.842 0 0.417 0 0.626 0 0.466 0 0.452 0 
11 0 0.715 0 0.168 0 0.438 0 0.419 0 0.247 0 
12 1 1.097 1 0.535 1 0.784 1 0.670 1 0.606 1 
13 0 0.873 0 0.270 0 0.575 0 0.532 0 0.373 0 
14 0 0.876 0 0.320 0 0.630 0 0.582 0 0.429 0 
15 0 0.852 0 0.300 0 0.630 0 0.439 0 0.401 0 
16 0 0.976 1 0.502 1 0.706 1 0.575 0 0.569 1 
17 1 0.993 1 0.423 0 0.811 1 0.680 1 0.555 1 
18 1 1.192 1 0.692 1 0.998 1 0.855 1 0.749 1 
19 1 1.147 1 0.645 1 0.939 1 0.702 1 0.702 1 
20 0 0.898 0 0.363 0 0.675 0 0.579 0 0.425 0 
21 0 0.865 0 0.330 0 0.694 0 0.456 0 0.382 0 
22 0 0.854 0 0.327 0 0.771 1 0.569 0 0.422 0 
23 0 0.931 1 0.311 0 0.498 0 0.551 0 0.461 0 
24 1 0.973 1 0.481 1 0.784 1 0.591 0 0.529 1 




Table 3-51 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Large-scale Simulation Dataset #22 
   Bootstrap Sample #11 Bootstrap Sample #15 Bootstrap Sample #23 Bootstrap Sample #23 Bootstrap Sample #25 

















1 1 0.956 1 0.192 0 1.052 1 0.026 1 -0.025 0 
2 0 0.580 0 0.326 0 0.641 0 0.031 1 -0.020 1 
3 0 0.443 0 0.350 1 0.530 0 0.016 0 -0.024 1 
4 0 0.645 0 0.242 0 0.763 1 0.028 1 -0.009 1 
5 1 0.751 1 0.447 1 0.852 1 -0.007 0 -0.028 0 
6 0 0.520 0 0.318 0 0.641 0 0.035 1 -0.021 1 
7 0 0.640 0 0.342 1 0.820 1 0.005 0 -0.029 0 
8 1 0.568 0 0.444 1 0.700 0 0.027 1 -0.024 1 
9 0 0.352 0 0.330 0 0.476 0 -0.013 0 0.001 1 
10 0 0.660 0 0.181 0 0.775 1 -0.003 0 -0.031 0 
11 0 0.320 0 0.239 0 0.459 0 0.003 0 -0.031 0 
12 0 0.400 0 0.178 0 0.447 0 0.004 0 -0.007 1 
13 1 0.595 0 0.336 1 0.855 1 0.001 0 -0.025 0 
14 1 0.470 0 0.362 1 0.506 0 0.005 0 -0.030 0 
15 0 0.290 0 0.317 0 0.438 0 0.006 0 -0.050 0 
16 0 0.474 0 0.310 0 0.630 0 0.006 0 -0.050 0 
17 0 0.356 0 0.280 0 0.614 0 0.020 0 -0.024 1 
18 1 0.499 0 0.338 1 0.643 0 0.009 0 -0.046 0 
19 0 0.592 0 0.352 1 0.632 0 -0.013 0 -0.029 0 
20 0 0.596 0 0.231 0 0.672 0 0.018 0 -0.029 0 
21 0 0.400 0 0.288 0 0.499 0 0.030 1 -0.022 1 
22 0 0.447 0 0.116 0 0.592 0 0.004 0 -0.024 1 
23 1 0.865 1 0.289 0 0.941 1 0.001 0 -0.016 1 
24 0 0.427 0 0.335 1 0.646 0 0.003 0 -0.042 0 




Table 3-52 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Large-scale Simulation Dataset #25 
   Bootstrap Sample #4 Bootstrap Sample #5 Bootstrap Sample #9 Bootstrap Sample #18 Bootstrap Sample #21 

















1 0 -0.568 0 -0.090 0 -0.756 0 -0.766 0 0.115 0 
2 1 -0.449 0 0.012 1 -0.719 0 -0.861 0 0.118 0 
3 1 -0.354 1 0.030 1 -0.629 0 -0.637 0 0.157 0 
4 0 -0.478 0 -0.006 1 -0.629 0 -0.655 0 0.057 0 
5 1 -0.315 1 0.019 1 -0.433 1 -0.512 1 0.184 0 
6 1 -0.322 1 -0.062 0 -0.442 1 -0.440 1 0.311 1 
7 0 -0.488 0 0.013 1 -0.598 1 -0.650 0 0.015 0 
8 0 -0.271 1 -0.048 0 -0.508 1 -0.488 1 0.311 1 
9 0 -0.441 0 -0.043 0 -0.594 1 -0.727 0 0.021 0 
10 0 -0.876 0 -0.066 0 -1.004 0 -0.994 0 -0.018 0 
11 1 -0.567 0 -0.042 0 -0.664 0 -0.729 0 0.035 0 
12 0 -0.544 0 -0.044 0 -0.633 0 -0.720 0 0.001 0 
13 0 -0.424 1 -0.049 0 -0.518 1 -0.617 0 0.225 1 
14 0 -0.652 0 -0.033 0 -0.862 0 -0.961 0 -0.207 0 
15 0 -0.384 1 -0.064 0 -0.552 1 -0.704 0 0.201 0 
16 1 -0.376 1 -0.040 0 -0.442 1 -0.522 1 0.240 1 
17 1 -0.272 1 -0.017 0 -0.458 1 -0.529 1 0.333 1 
18 0 -0.413 1 -0.016 0 -0.516 1 -0.577 1 0.126 0 
19 0 -0.526 0 -0.039 0 -0.701 0 -0.749 0 0.003 0 
20 0 -0.660 0 -0.006 1 -0.840 0 -0.853 0 -0.024 0 
21 1 -0.254 1 -0.029 0 -0.459 1 -0.581 1 0.231 1 
22 1 -0.255 1 -0.025 0 -0.386 1 -0.492 1 0.198 0 
23 0 -0.653 0 -0.019 0 -0.783 0 -0.784 0 -0.139 0 
24 0 -0.530 0 -0.006 1 -0.661 0 -0.673 0 0.222 1 




3.5.3 Predictive Performance 
After the variable selection procedure is completed and the models are applied to each 
individual in the independent testing set then the sensitivity, specificity, misclassification, 
and positive predictive value are measured for both the Clinical and Clinical + Genotype 
risk index models for each of the 25 large-scale simulation datasets. Table 3-52 shows the 
means and standard deviations of these measurements. To provide a 95% confidence for 
these measurements of sensitivity, specificity, misclassification, and positive predictive 
value, for each independent testing set 1000 bootstrap samples were generated. By 
making predictions about each individual in these bootstrap samples and calculating the 
sensitivity, specificity, misclassification, and positive predictive value for each bootstrap 
sample, 95% confidence intervals were estimated for these measurements in each of the 
25 large-scale simulation datasets. The mean and standard deviation of the spread (i.e., 
range) of these confidence intervals for both the Clinical and Clinical + Genotype risk 
index model is shown in Table 3-53. Table 3-54 shows the predictive performance and 
confidence intervals for the three large-scale simulation datasets discussed in Section 
3.5.2. 
 
Table 3-53 Means and Standard Deviations of Predictive Performance Estimates for 





































Table 3-54 Means and Standard Deviations of Predictive Performance 95% 
Confidence Intervals for the 25 Large-scale Simulation Datasets 
 Mean Range of 95% Confidence Interval (SD) 
Model Sensitivity  Specificity  Misclassification  PPV  
Clinical 0.062 (0.003) 0.024 (0.003) 0.026 (0.002) 0.056 (0.005) 
Clinical + Genotype 0.061 (0.003) 0.022 (0.002) 0.026 (0.001) 0.054 (0.004) 
 
Table 3-55 Predictive Performance Estimates for Three Large-scale Simulation 
Datasets 


















































Using the number of models predicting an individual in the independent testing set as 
“high risk”, receiver operator characteristic (ROC) curves were generated for the Clinical 
and Clinical + Genotype risk index model for each of the 25 large-scale simulation 
datasets, and the AUC for the ROC curve was estimated. The average AUC for the 
Clinical risk index models was 0.926 (SD = 0.015), and the average AUC for the Clinical 
+ Genotype risk index models was 0.939 (SD = 0.012). Figure 3-53, 3-54, and 3-55 show 
the ROC curves for the Clinical risk index model the three large-scale simulation datasets 
discussed in sections 3.5.2, and Figure 3-56, 3-57, and 3-58 show the ROC curve for the 





Figure 3-55 ROC Curve of the Clinical Risk Index Model for Large-scale 
Simulation Dataset #9 
 
Figure 3-56 ROC Curve of the Clinical Risk Index Model for Large-scale 




Figure 3-57 ROC Curve of the Clinical Risk Index Model for Large-scale 
Simulation Dataset #25 
 
Figure 3-58 ROC Curve of the Clinical + Genotype Risk Index Model for Large-




Figure 3-59 ROC Curve of the Clinical + Genotype Risk Index Model for Large-
scale Simulation Dataset #22 
 
Figure 3-60 ROC Curve of the Clinical + Genotype Risk Index Model for Large-




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual as high risk, then, represents the predicted 
probability of an individual developing the outcome. For each individual a 95% 
confidence interval can be constructed as described in Section 3.2.3 
 
3.5.4 Random Forest Comparison 
For each of the 25 large-scale simulation datasets a random forest was generated using 
the optimization set created by the risk index procedure. The forests were generated using 
the methodology given in Section 3.2.4. For each of the random forests an ROC curve 
was generated and the AUC was estimated. The mean AUC for the random forest models 
was 0.915 (SD = 0.013). Figures 3-61, 3-62, and 3-63 show the ROC curve for the 
random forest generated from the three small-scale simulation datasets described in 
Section 3.5.2. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set using a range of proportions. 
First, an individual was assigned a prediction of “high risk” if 5% or more of the trees in 
the forest predicted the individual to be “high risk”. This was then repeated in increments 
of 5% until individuals were assigned a prediction of “high risk” only if 95% or more of 
the trees in the forest predicted the individual to be “high risk”. Table 3-55 shows the 
mean and standard deviation of the sensitivity, specificity, misclassification, and PPV for 




Figure 3-61 ROC Curve of the Random Forest Generated for Large-scale 
Simulation Dataset #9 
 
Figure 3-62 ROC Curve of the Random Forest Generated for Large-scale 





Figure 3-63 ROC Curve of the Random Forest Generated for Large-scale 




Table 3-56 Means and Standard Deviations of Performance Estimates of the 
Random Forest Models Generated from the 25 Large-scale Simulation Datasets 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 1 (0.001) 0.044 (0.019) 0.657 (0.017) 0.323 (0.012) 
0.1 0.996 (0.004) 0.121 (0.028) 0.605 (0.022) 0.341 (0.014) 
0.15 0.983 (0.011) 0.199 (0.028) 0.556 (0.02) 0.359 (0.015) 
0.2 0.956 (0.021) 0.264 (0.024) 0.519 (0.016) 0.372 (0.014) 
0.25 0.914 (0.028) 0.321 (0.018) 0.494 (0.012) 0.38 (0.014) 
0.3 0.854 (0.031) 0.369 (0.012) 0.479 (0.01) 0.381 (0.015) 
0.35 0.777 (0.032) 0.411 (0.007) 0.475 (0.011) 0.375 (0.016) 
0.4 0.694 (0.027) 0.442 (0.006) 0.479 (0.01) 0.361 (0.015) 
0.45 0.6 (0.017) 0.471 (0.004) 0.489 (0.006) 0.341 (0.014) 
0.5 0.502 (0.001) 0.499 (0) 0.5 (0) 0.314 (0.011) 
0.55 0.404 (0.017) 0.527 (0.004) 0.511 (0.006) 0.28 (0.013) 
0.6 0.306 (0.027) 0.558 (0.006) 0.521 (0.01) 0.24 (0.019) 
0.65 0.22 (0.032) 0.591 (0.007) 0.525 (0.011) 0.196 (0.023) 
0.7 0.146 (0.031) 0.631 (0.012) 0.521 (0.01) 0.152 (0.025) 
0.75 0.086 (0.028) 0.679 (0.018) 0.506 (0.012) 0.108 (0.027) 
0.8 0.046 (0.021) 0.734 (0.024) 0.482 (0.016) 0.07 (0.024) 
0.85 0.016 (0.01) 0.805 (0.028) 0.442 (0.02) 0.035 (0.016) 
0.9 0.004 (0.004) 0.879 (0.028) 0.395 (0.022) 0.013 (0.009) 
0.95 0 (0.001) 0.953 (0.019) 0.345 (0.018) 0.002 (0.005) 
 
3.5.5 Conclusion 
The results of the large-scale simulation study using the 500 most highly associated SNPs 
are extremely promising, and demonstrate robust predictive performance. Both the 
predictive performance estimates and the AUC for the ROC curves for the 25 large-scale 
simulation datasets are noticeably higher than the small-scale simulation studies. The 
average misclassification and PPV are higher than any average misclassification or PPV 
yielded by the random forest model. As with both small-scale simulation studies the 
average AUC is significantly higher for the Clinical + Genotype risk index model than 
for the Clinical risk index model (p=0.001), and the average AUC for the Clinical + 
Genotype risk index model is also significantly greater than the average AUC of the 
random forest model (p=1.5e-8). A risk index model built using only the five most highly 
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associated covariates and the six associated SNPs had performance characteristics that 
were comparable to, but somewhat lower than, the best Clinical and Clinical  + Genotype 
risk index models built using the standard variable selection procedure (Table 3-57) 
 
Table 3-57 Performance Characteristics of a Risk Index Model Built Using the Five 
Most Highly Associated Covariates and the Six Associated SNPs 
Model Sensitivity (SD) Specificity (SD) Misclassification (SD) PPV (SD) 
















3.6 Large-scale Simulation Study Top Principal Components Results 
3.6.1 Variable Selection 
Using the same procedure as in Section 3.2.1, Clinical and Clinical + Genotype risk index 
models were constructed for each of the 25 large-scale simulation datasets. In place of the 
500 SNPs most highly associated with the outcome, a principal components analysis was 
performed on the full set of 38,835 SNPs using SMARTPCA (Patterson, et al, 2006), and 
the top 500 principal components were used to build the risk index models.  
 
Table 3-56 shows the summary of the variable selection procedure from the Clinical risk 
index model averaged across the 25 simulation datasets. Variables v1 through v5 are the 
most frequently selected; on average, they each appear in more 14 of the 25 trimmed 
Clinical risk index models. Variable v14, v13, and v6 are also frequently selected, 
appearing in 12, 11.8, and 11.7 out of 25 trimmed Clinical risk index models, on average. 
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Table 3-57 shows the summary of the variable selection procedure from the Clinical + 
Genotype risk index model averaged across the 25 simulation datasets. No principal 
component was in more than 1.32 out of 25 trimmed Clinical + Genotype risk index 




Table 3-58 Summary of the Number of Times Each Variable is Selected into a 
Specific Model Position for the Large-scale Simulation Clinical Risk Index Models 
  Variable Position 
Variable 1 2 3 4 5 6 7 8 
Total # of Times 
in Trimmed 
Model 
v1 14.4 0.92 0.32 0.12 0.12 0.04 0 0 16.64 
v2 0.76 2.08 2.32 2.04 0.92 1.08 0.72 0.6 14.2 
v3 0.4 4 2.56 1.6 0.96 0.84 0.92 0.52 14.64 
v4 0.48 3.64 2.24 1.76 1.12 0.72 0.76 0.6 14.08 
v5 0.28 3 3.04 1.56 1.4 1 0.8 0.84 14.56 
v6 0.08 0.56 0.48 0.6 0.96 0.72 0.64 1.04 11.68 
v7 0.24 0.24 0.28 0.6 0.72 0.88 1.08 0.8 10.32 
v8 0.04 0.24 0.76 1.16 0.72 0.8 0.92 0.84 11.32 
v9 0.12 0.16 0.4 0.76 0.64 0.68 1.04 1.08 11.6 
v10 0.12 0.44 0.6 0.56 0.8 1.08 1.08 0.88 11.44 
v11 0.16 0.56 0.64 1.16 0.8 1.16 0.68 0.88 11.16 
v12 0.04 0.36 0.72 0.64 1.16 0.6 0.96 1.12 11.64 
v13 0.04 0.24 0.44 0.52 1.32 1 0.8 1.24 11.8 
v14 0.04 0.28 0.76 0.56 1.16 0.64 0.8 0.84 12 
v15 0.04 0.36 0.64 0.64 0.92 1.08 1.08 0.56 10.96 
v16 0.08 0.08 0.4 0.64 0.68 1.12 0.64 1.04 11.16 
v17 0.64 0.52 0.68 0.88 0.64 0.88 1 1 10.8 
v18 0.56 0.6 0.48 1.12 0.64 0.92 0.84 1.04 11.08 
v19 0.48 0.56 0.52 0.92 0.76 0.8 1.16 0.76 9.68 
v20 0.52 0.72 0.72 0.8 0.84 1.04 0.68 1.12 10.16 
v21 0.48 0.68 0.68 1.04 1.4 0.84 1.08 0.8 10.48 
v22 0.36 0.72 0.64 0.84 0.76 0.8 0.84 0.76 10.4 
v23 0.8 0.6 0.88 0.72 0.76 0.72 0.6 1.08 11.08 
v24 0.6 0.6 0.8 0.52 0.72 0.84 1.16 0.68 10.56 
v25 0.84 0.52 0.52 0.8 0.8 0.96 0.96 1.08 10.16 
v26 0.72 0.72 0.84 0.52 0.64 0.68 1.08 0.64 11.16 
v27 0.68 0.64 0.48 0.6 0.84 0.88 0.76 0.96 10.48 
v28 0.32 0.52 0.52 0.52 0.84 1.12 0.8 1.24 8.92 
v29 0.68 0.44 0.64 0.8 0.96 1.08 1.12 0.96 11.36 




Table 3-59 Summary of the Number of Times Selected Principal Component Variables are Selected into a Specific Model 
Position for the Large-scale Simulation Clinical + Genotype Risk Index Models  
  Variable Position 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 








pc407 0.16 0.04 0.12 0.08 0.12 0.08 0.08 0.08 0.2 0.04 0 0.08 0.04 0 0.04 0.04 0.16 0.12 0.12 0.04 1.64 1.32 
pc329 0.12 0 0.08 0.12 0.12 0.04 0.12 0.04 0.08 0.12 0 0.08 0 0.04 0.12 0.04 0.08 0.2 0.12 0.04 1.56 1.28 
pc359 0 0.12 0.16 0.04 0.08 0.12 0.04 0.08 0 0.08 0.04 0.08 0.16 0.12 0.08 0.12 0.12 0.04 0.04 0.08 1.6 1.28 
pc125 0.08 0.08 0.12 0.16 0.08 0 0.08 0 0.04 0.08 0.04 0.04 0.12 0.2 0 0.08 0.08 0.04 0.08 0.16 1.56 1.2 
pc232 0 0.08 0.08 0 0.16 0.12 0.04 0.08 0.12 0.04 0.12 0.08 0.04 0.08 0.04 0 0 0.16 0.12 0.2 1.56 1.2 
pc277 0.08 0.08 0.04 0.08 0.12 0.16 0.08 0.04 0 0.16 0.04 0.16 0.04 0.04 0 0.04 0.04 0.04 0.16 0.08 1.48 1.2 
pc442 0.12 0.04 0.08 0.04 0.16 0.04 0.08 0.12 0 0 0.04 0 0.12 0.08 0.08 0 0.12 0.04 0.12 0.08 1.36 1.2 
pc53 0.28 0.08 0.08 0.12 0.04 0.04 0.08 0.12 0.04 0.08 0.08 0.04 0.2 0.04 0 0 0 0.04 0 0 1.36 1.16 
pc129 0.12 0 0.08 0.12 0 0.12 0.08 0.12 0.04 0.08 0.08 0.12 0.04 0 0 0.08 0 0 0.12 0.08 1.28 1.16 
pc239 0.04 0.12 0.04 0.12 0.08 0 0.04 0 0.24 0.08 0.24 0.12 0 0 0.16 0 0.04 0.12 0.04 0.04 1.52 1.16 
pc268 0.04 0.08 0.08 0.16 0.12 0 0.16 0.16 0.08 0.04 0 0 0.04 0.12 0.04 0.08 0.08 0.04 0.04 0.24 1.6 1.16 
pc315 0.08 0.28 0.04 0.04 0.04 0.08 0.08 0 0 0.08 0.16 0.04 0.04 0.04 0.04 0.12 0.04 0.04 0.08 0.04 1.36 1.16 
pc126 0.08 0.08 0.04 0.04 0.08 0.04 0.12 0.04 0.12 0.04 0.04 0.2 0.04 0.04 0.12 0.04 0 0 0.08 0.04 1.28 1.12 
pc141 0 0.08 0.08 0.04 0.04 0.08 0.12 0.12 0.04 0.12 0.12 0 0 0.04 0.12 0.08 0.04 0.12 0.08 0 1.32 1.12 
pc144 0.04 0 0.08 0.08 0.04 0.08 0.04 0.12 0.08 0.12 0.04 0.08 0.04 0.04 0.08 0.08 0.04 0.16 0.08 0.04 1.36 1.12 
pc172 0.08 0.08 0.08 0.16 0.08 0.08 0.04 0.08 0.16 0.12 0.12 0.04 0.04 0 0 0.12 0.04 0 0.12 0.04 1.48 1.08 
pc191 0.04 0.08 0.08 0.04 0.08 0.16 0.04 0.08 0.04 0.08 0.08 0 0.04 0.08 0.04 0.04 0.12 0.08 0.04 0.08 1.32 1.08 




Once the variable selection procedure is finished each of the 25 large-scale simulation 
datasets have 25 trimmed Clinical and Clinical + Genotype risk index models. Tables 3-
58, 3-59, and 3-60 each show five trimmed Clinical risk index models randomly selected 
from one of three randomly chosen large-scale simulation datasets (datasets #9, #22, and 
#25). Figures 3-64, 3-65, and 3-66 show the full distribution of risk index values in the 
optimization set for a randomly selected trimmed Clinical risk index models from each of 
the three small-scale simulation datasets. Figures 3-67, 3-68, and 3-69 show the full 
distribution of risk index values in the independent testing set for a randomly selected 
trimmed Clinical risk index model from each of the three large-scale simulation datasets. 
In all six of these figures a red line indicates the cut-off point. All individuals with a risk 
index value greater than or equal to this cut-off point are predicted as “high risk” and all 
individuals with a value less than this cut-off point are predicted as “low risk”. Tables 3-
61, 3-62, and 3-63 show the risk index values and predictions from the same set of five 
Clinical risk index models from the same three large-scale simulation datasets for a set of 
25 individuals randomly selected from the independent test set.  
 
Table 3-60 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Large-scale Simulation Dataset #9 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
5 
0.0304*v1 + 0.0253*v2 - 0.012*v3 + 0.005*v4 + 0.0096*v5 - 0.0029*v7 - 0.0059*v8 + 
0.0032*v13 + 0.005*v14 + 0.0029*v15 + 0.0039*v16 - 0.0028*v18 + 0.0043*v19 - 9e-
04*v20 + 0.0042*v23 + 0.0185*v25 + 0.0021*v26 + 0*v27 + 5e-04*v29 
12 0.0033*v19 - 2e-04*v27 
14 
0.0282*v1 + 0.0337*v2 - 0.0111*v3 + 0.0065*v4 + 0.0084*v5 + 0.004*v6 - 0.0027*v7 - 
0.0067*v8 - 0.0012*v12 + 0.0028*v13 + 0.0036*v14 + 0.0023*v15 + 0.007*v16 + 




20 1e-04*v17 - 7e-04*v28 
23 
0.0309*v1 + 0.0268*v2 - 0.0127*v3 + 0.009*v5 - 0.0022*v7 - 0.0068*v8 - 0.0022*v12 + 
0.0041*v15 + 0.0043*v16 + 3e-04*v17 - 0.0028*v18 + 0.0014*v19 + 9e-04*v20 + 
0.001*v21 + 0.0013*v22 + 0.0136*v24 + 0.0029*v26 - 2e-04*v27 + 0.0034*v28 
 
Table 3-61 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Large-scale Simulation Dataset #22 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
11 
-0.0816*v1 + 0.1228*v2 + 0.0031*v3 + 0.0047*v4 + 0.0048*v5 + 0.0337*v6 + 0.0023*v8 
+ 0.0129*v9 - 0.0017*v11 + 0.0036*v12 - 0.002*v14 - 0.0053*v15 + 0.0039*v17 + 
0.0019*v19 - 0.0016*v21 - 0.0026*v22 - 1.2314*v25 + 0.0026*v28 
15 
-0.0929*v1 + 0.0031*v3 + 0.0049*v4 + 0.0059*v5 + 0.0236*v6 + 0.0027*v8 + 0.0096*v9 
+ 0.0015*v10 - 0.0043*v11 + 0.0026*v12 - 8e-04*v13 - 0.0043*v15 + 0.0038*v17 - 
0.0013*v18 + 2e-04*v20 + 0.0022*v22 - 0.2143*v25 + 5e-04*v26 + 0.0013*v28 - 8e-
04*v29 
23 4e-04*v13 - 0.001*v18 + 1e-04*v26 
24 -1e-04*v13 - 1e-04*v21 + 1e-04*v23 - 0.0014*v29 
25 -1.9043*v7 + 0.001*v22 - 0.0023*v29 
 
Table 3-62 Clinical Risk Index Models for Five Randomly Selected Bootstrap 
Samples from Large-scale Simulation Dataset #25 
Bootstrap 
Sample Trimmed Clinical Risk Index Model 
4 
0.009*v1 + 0.0101*v2 + 0.0341*v3 + 0.0134*v4 + 0.0024*v5 - 0.0086*v7 + 0.005*v8 + 
0.0178*v9 + 0.0067*v11 - 0.0011*v12 + 0.0058*v13 - 0.0034*v14 + 5e-04*v18 + 5e-
04*v20 + 6e-04*v22 
5 0.0106*v1 + 0.0099*v2 + 0.0116*v4 + 0.0024*v5 + 0.0128*v6 + 0.0052*v8 + 0.001*v10 + 0.0061*v11 + 1e-04*v20 + 4e-04*v23 - 0.0031*v27 + 7e-04*v29 
9 
0.0093*v1 + 0.01*v2 + 0.0336*v3 + 0.0127*v4 + 0.0022*v5 + 0.0137*v6 - 0.0075*v7 + 
0.0054*v8 + 0.0265*v9 + 0.0069*v11 + 0.0059*v13 + 0.0086*v16 + 5e-04*v18 + 3e-
04*v20 + 0.0013*v23 - 2e-04*v24 + 4e-04*v26 + 3e-04*v29 
18 
0.0098*v1 + 0.01*v2 + 0.034*v3 + 0.0138*v4 + 0.0023*v5 + 0.0136*v6 - 0.0052*v7 + 
0.0035*v8 + 0.0121*v9 + 0.0054*v11 - 0.0012*v12 + 0.0052*v13 - 0.0035*v14 + 
0.0016*v17 + 7e-04*v18 + 6e-04*v19 + 0.0016*v23 + 0.0013*v26 





Figure 3-64 Clinical Risk Index Value Distribution in the Optimization Set for 
Large-scale Dataset #9, Bootstrap Sample #5 
 
Figure 3-65 Clinical Risk Index Value Distribution in the Optimization Set for 




Figure 3-66 Clinical Risk Index Value Distribution in the Optimization Set for 
Large-scale Dataset #25, Bootstrap Sample #4 
 
 
Figure 3-67 Clinical Risk Index Value Distribution in the Independent Testing Set 




Figure 3-68 Clinical Risk Index Value Distribution in the Independent Testing Set 
for Large-scale Dataset #22, Bootstrap Sample #11 
 
 
Figure 3-69 Clinical Risk Index Value Distribution in the Independent Testing Set 




Table 3-63 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Large-scale Simulation Dataset #9 
   Bootstrap Sample #5 Bootstrap Sample #12 Bootstrap Sample #14 Bootstrap Sample #20 Bootstrap Sample #23 

















1 1 1.006 1 0.451 0 0.841 1 0.683 1 0.497 1 
2 0 0.859 0 0.384 0 0.607 0 0.497 0 0.406 0 
3 1 0.985 1 0.489 1 0.817 1 0.665 1 0.515 1 
4 1 1.177 1 0.651 1 0.947 1 0.829 1 0.685 1 
5 0 0.721 0 0.254 0 0.405 0 0.330 0 0.269 0 
6 0 0.870 0 0.390 0 0.716 1 0.626 0 0.426 0 
7 0 0.726 0 0.244 0 0.440 0 0.452 0 0.265 0 
8 0 0.824 0 0.290 0 0.586 0 0.499 0 0.336 0 
9 1 0.993 1 0.485 1 0.790 1 0.615 0 0.532 1 
10 0 0.871 0 0.429 0 0.651 0 0.485 0 0.440 0 
11 0 0.731 0 0.189 0 0.482 0 0.418 0 0.229 0 
12 1 1.082 1 0.538 1 0.769 1 0.658 1 0.572 1 
13 0 0.889 0 0.310 0 0.569 0 0.539 0 0.357 0 
14 0 0.899 0 0.350 0 0.583 0 0.566 0 0.401 0 
15 0 0.872 0 0.316 0 0.588 0 0.426 0 0.362 0 
16 1 0.986 1 0.501 1 0.656 0 0.590 0 0.541 1 
17 1 1.005 1 0.474 0 0.780 1 0.709 1 0.522 1 
18 1 1.200 1 0.706 1 0.974 1 0.847 1 0.730 1 
19 1 1.165 1 0.658 1 0.898 1 0.708 1 0.697 1 
20 0 0.906 0 0.364 0 0.714 1 0.572 0 0.415 0 
21 0 0.872 0 0.335 0 0.685 0 0.468 0 0.383 0 
22 0 0.876 0 0.353 0 0.732 1 0.560 0 0.383 0 
23 0 0.934 0 0.377 0 0.551 0 0.551 0 0.418 0 
24 1 0.979 1 0.493 1 0.800 1 0.610 0 0.516 1 




Table 3-64 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Large-scale Simulation Dataset #22 
   Bootstrap Sample #11 Bootstrap Sample #15 Bootstrap Sample #23 Bootstrap Sample #23 Bootstrap Sample #25 

















1 1 0.950 1 0.171 0 1.053 1 -0.004 1 -0.014 0 
2 0 0.583 0 0.308 0 0.619 0 0.000 1 -0.010 1 
3 0 0.435 0 0.329 1 0.523 0 -0.012 0 -0.019 0 
4 0 0.591 0 0.217 0 0.716 0 -0.041 0 -0.011 1 
5 1 0.743 1 0.428 1 0.828 1 -0.020 0 -0.018 0 
6 0 0.529 0 0.303 0 0.627 0 0.009 1 -0.016 0 
7 1 0.668 0 0.319 1 0.820 1 -0.024 0 -0.019 0 
8 0 0.523 0 0.430 1 0.665 0 0.000 1 -0.014 0 
9 0 0.367 0 0.325 1 0.472 0 -0.024 0 -0.016 0 
10 0 0.650 0 0.168 0 0.776 1 -0.031 0 -0.021 0 
11 0 0.301 0 0.210 0 0.435 0 -0.012 0 -0.021 0 
12 0 0.416 0 0.159 0 0.429 0 -0.006 0 -0.013 1 
13 1 0.613 0 0.327 1 0.826 1 -0.012 0 -0.015 0 
14 0 0.413 0 0.341 1 0.485 0 -0.026 0 -0.019 0 
15 0 0.270 0 0.298 0 0.392 0 -0.010 0 -0.013 1 
16 0 0.466 0 0.297 0 0.608 0 -0.025 0 -0.013 1 
17 1 0.353 0 0.262 0 0.603 0 -0.010 0 -0.014 1 
18 0 0.498 0 0.314 1 0.639 0 -0.016 0 -0.008 1 
19 1 0.562 0 0.338 1 0.636 0 -0.028 0 -0.018 0 
20 0 0.616 0 0.211 0 0.664 0 -0.012 0 -0.019 0 
21 0 0.387 0 0.276 0 0.494 0 0.005 1 -0.012 1 
22 0 0.393 0 0.122 0 0.573 0 -0.022 0 -0.014 1 
23 1 0.826 1 0.257 0 0.916 1 -0.015 0 -0.011 1 
24 1 0.397 0 0.319 1 0.636 0 -0.009 0 -0.019 0 




Table 3-65 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical Risk Index 
Models from Large-scale Simulation Dataset #25 
   Bootstrap Sample #4 Bootstrap Sample #5 Bootstrap Sample #9 Bootstrap Sample #18 Bootstrap Sample #21 

















1 0 -0.503 0 -0.087 0 -0.734 0 -0.747 0 0.139 0 
2 0 -0.460 0 0.004 1 -0.720 0 -0.843 0 0.118 0 
3 1 -0.382 1 0.019 1 -0.616 0 -0.629 0 0.161 0 
4 0 -0.453 0 -0.021 1 -0.609 0 -0.669 0 0.073 0 
5 1 -0.269 1 0.014 1 -0.399 1 -0.503 1 0.206 0 
6 1 -0.251 1 -0.069 0 -0.387 1 -0.446 1 0.346 1 
7 0 -0.438 0 0.017 1 -0.597 1 -0.644 0 0.032 0 
8 0 -0.253 1 -0.053 0 -0.498 1 -0.485 1 0.305 1 
9 0 -0.396 0 -0.050 0 -0.593 1 -0.735 0 0.021 0 
10 0 -0.836 0 -0.077 0 -0.990 0 -1.030 0 -0.026 0 
11 0 -0.529 0 -0.060 0 -0.675 0 -0.742 0 0.049 0 
12 0 -0.524 0 -0.058 0 -0.633 0 -0.705 0 0.017 0 
13 1 -0.333 1 -0.070 0 -0.497 1 -0.623 0 0.239 1 
14 0 -0.587 0 -0.041 0 -0.853 0 -0.987 0 -0.207 0 
15 1 -0.339 1 -0.067 0 -0.529 1 -0.702 0 0.205 0 
16 1 -0.306 1 -0.052 0 -0.427 1 -0.537 1 0.244 1 
17 1 -0.272 1 -0.029 0 -0.454 1 -0.538 1 0.343 1 
18 1 -0.343 1 -0.026 0 -0.496 1 -0.588 1 0.157 0 
19 0 -0.480 0 -0.046 0 -0.720 0 -0.764 0 0.016 0 
20 0 -0.615 0 -0.011 1 -0.831 0 -0.839 0 -0.034 0 
21 1 -0.234 1 -0.053 0 -0.456 1 -0.583 1 0.218 1 
22 1 -0.235 1 -0.020 1 -0.378 1 -0.480 1 0.206 0 
23 0 -0.583 0 -0.027 0 -0.777 0 -0.798 0 -0.133 0 
24 1 -0.459 0 -0.020 1 -0.657 0 -0.678 0 0.242 1 




Tables 3-64, 3-65, and 3-66 each show five trimmed Clinical + Genotype risk index 
models corresponding to the Clinical risk index models shown in Table 3-58, 3-59, and 3-
60. Tables 3-67, 3-68, and 3-69 show the risk index values and predictions from the same 
set of five Clinical + Genotype risk index models from the same three small-scale 
simulation datasets for a set of 25 individuals randomly selected from the optimization 
set. Figures 3-70, 3-71, and 3-72 show the full distribution of risk index values in the 
optimization set for a randomly selected trimmed Clinical + Genotype risk index model 
from each of the three small-scale simulation datasets. Figures 3-73, 3-74, and 3-74 show 
the full distribution of risk index values in the independent testing set for a randomly 
selected trimmed Clinical + Genotype risk index model from each of the three small-
scale simulation datasets. As in the previous set of figures, in all six of these figures a red 
line indicates the cut-off point. All individuals with a risk index value greater than or 
equal to this cut-off point are predicted as “high risk” and all individuals with a value less 




Table 3-66 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Large-scale Simulation Dataset #9 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
5 
0.0304*v1 + 0.0253*v2 - 0.012*v3 + 0.005*v4 + 0.0096*v5 - 0.0029*v7 - 0.0059*v8 + 
0.0032*v13 + 0.005*v14 + 0.0029*v15 + 0.0039*v16 - 0.0028*v18 + 0.0043*v19 - 9e-
04*v20 + 0.0042*v23 + 0.0185*v25 + 0.0021*v26 + 0*v27 + 5e-04*v29 + 10.4268*pc15 
+ 1.5052*pc17 - 2.5219*pc47 + 1.723*pc48 + 1.2779*pc50 - 4.9046*pc55 + 6.5569*pc91 
+ 16.9002*pc96 - 1.208*pc119 + 1.549*pc137 + 2.9244*pc188 - 1.4788*pc214 + 
2.7539*pc277 - 5.6822*pc342 - 0.9887*pc415 - 4.7684*pc425 + 5.6079*pc475 - 
3.1944*pc488 
12 
0.0033*v19 - 2e-04*v27 + 2.1123*pc54 + 0.504*pc58 - 0.2667*pc69 - 2.4151*pc82 - 
0.9506*pc83 + 0.0606*pc136 + 2.0214*pc147 + 0.2685*pc191 - 1.6497*pc194 - 
1.1582*pc214 - 0.8613*pc264 + 3.5242*pc283 - 0.0481*pc302 + 1.3812*pc312 - 
2.1866*pc331 - 3.633*pc347 + 0.4781*pc394 + 2.0683*pc424 + 1.2825*pc436 - 
0.7198*pc454 
14 
0.0282*v1 + 0.0337*v2 - 0.0111*v3 + 0.0065*v4 + 0.0084*v5 + 0.004*v6 - 0.0027*v7 - 
0.0067*v8 - 0.0012*v12 + 0.0028*v13 + 0.0036*v14 + 0.0023*v15 + 0.007*v16 + 
0.0018*v22 + 0.0044*v23 + 0.0198*v24 + 0.0401*v25 - 0.001*v27 + 0.0012*v28 - 1e-
04*v29 - 4.6747*pc110 + 1.8926*pc175 - 3.5362*pc294 - 1.5334*pc363 + 3.8903*pc487 
20 
1e-04*v17 - 7e-04*v28 - 1.0924*pc21 - 1.852*pc61 + 0.9555*pc66 - 0.3569*pc70 - 
0.6179*pc80 + 0.6884*pc105 - 0.0886*pc114 + 1.3183*pc149 - 1.1099*pc158 - 
1.1446*pc197 + 0.1409*pc284 - 1.345*pc291 - 0.5679*pc306 + 2.6538*pc319 - 
0.1269*pc325 - 0.3187*pc338 + 1.4281*pc362 - 1.4539*pc439 - 0.8631*pc451 + 
0.6004*pc454 
23 
0.0309*v1 + 0.0268*v2 - 0.0127*v3 + 0.009*v5 - 0.0022*v7 - 0.0068*v8 - 0.0022*v12 + 
0.0041*v15 + 0.0043*v16 + 3e-04*v17 - 0.0028*v18 + 0.0014*v19 + 9e-04*v20 + 
0.001*v21 + 0.0013*v22 + 0.0136*v24 + 0.0029*v26 - 2e-04*v27 + 0.0034*v28 + 
1.9072*pc35 + 4.8736*pc57 - 7.2265*pc64 + 5.0892*pc81 - 1.3005*pc108 - 2.942*pc124 
+ 4.2528*pc142 - 1.0769*pc182 - 2.057*pc186 + 8.186*pc213 - 0.0804*pc275 + 
1.4593*pc279 + 3.5455*pc364 + 10.5203*pc372 + 0.6332*pc391 + 0.3351*pc415 + 





Table 3-67 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Large-scale Simulation Dataset #22 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
11 
0.0816*v1 + 0.1228*v2 + 0.0031*v3 + 0.0047*v4 + 0.0048*v5 + 0.0337*v6 + 0.0023*v8 
+ 0.0129*v9 - 0.0017*v11 + 0.0036*v12 - 0.002*v14 - 0.0053*v15 + 0.0039*v17 + 
0.0019*v19 - 0.0016*v21 - 0.0026*v22 - 1.2314*v25 + 0.0026*v28 - 2.9607*pc9 + 
10.6006*pc54 - 1.5149*pc80 + 1.5525*pc111 + 5.052*pc159 + 0.2661*pc166 - 
1.2869*pc176 + 2.1985*pc217 + 7.781*pc232 - 3.4101*pc248 + 2.994*pc300 - 
3.4148*pc314 + 1.1547*pc315 - 4.3981*pc381 + 0.7789*pc404 - 1.8525*pc433 + 
9.1892*pc438 - 0.028*pc448 + 1.1909*pc452 
15 
0.0929*v1 + 0.0031*v3 + 0.0049*v4 + 0.0059*v5 + 0.0236*v6 + 0.0027*v8 + 0.0096*v9 
+ 0.0015*v10 - 0.0043*v11 + 0.0026*v12 - 8e-04*v13 - 0.0043*v15 + 0.0038*v17 - 
0.0013*v18 + 2e-04*v20 + 0.0022*v22 - 0.2143*v25 + 5e-04*v26 + 0.0013*v28 - 8e-
04*v29 - 9.3102*pc20 + 2.253*pc54 - 0.1406*pc74 - 0.3688*pc105 - 2.0127*pc237 - 
3.3434*pc289 + 2.3869*pc290 - 9.4705*pc329 - 1.7357*pc341 + 4.1052*pc351 + 
1.5242*pc357 - 0.4548*pc392 + 5.4061*pc405 + 4.1047*pc458 - 1.8367*pc473 
23 
4e-04*v13 - 0.001*v18 + 1e-04*v26 + 0.0157*pc21 + 0.6324*pc35 - 0.6543*pc51 + 
1.4247*pc54 - 0.6302*pc64 + 0.0406*pc68 + 1.1264*pc74 - 0.2137*pc82 - 0.1152*pc99 - 
0.2328*pc192 - 2.6897*pc203 - 1.3432*pc209 + 1.2853*pc240 + 0.4899*pc260 + 
0.8595*pc313 + 0.484*pc338 - 0.2808*pc373 - 1.3172*pc429 - 0.2584*pc453 + 
1.046*pc485 
24 
1e-04*v13 - 1e-04*v21 + 1e-04*v23 - 0.0014*v29 + 0.7593*pc26 - 1.0653*pc46 - 
2.1887*pc54 - 1.3976*pc128 - 0.2316*pc207 + 1.4773*pc221 - 0.25*pc228 + 
0.1307*pc230 - 2.6488*pc231 + 0.7317*pc279 - 1.2732*pc290 + 3.5582*pc316 - 
0.1958*pc373 + 0.8422*pc386 + 0.0368*pc404 - 2.4583*pc418 + 0.9927*pc420 - 
0.6906*pc427 + 3.5142*pc494 + 0.159*pc498 
25 
1.9043*v7 + 0.001*v22 - 0.0023*v29 + 0.6937*pc22 - 0.7539*pc47 - 0.4838*pc53 - 
1.8419*pc136 + 0.6845*pc178 + 2.5352*pc179 + 0.7473*pc219 - 0.6718*pc223 - 
0.2302*pc228 - 2.613*pc234 - 1.1156*pc265 - 1.4993*pc272 - 4.4805*pc279 + 
0.1639*pc331 + 1.9301*pc336 - 1.4362*pc365 + 1.1986*pc400 + 1.1249*pc465 + 




Table 3-68 Clinical + Genotype Risk Index Models for Five Randomly Selected 
Bootstrap Samples from Large-scale Simulation Dataset #25 
Bootstrap 
Sample Trimmed Clinical + Genotype Risk Index Model 
4 
0.009*v1 + 0.0101*v2 + 0.0341*v3 + 0.0134*v4 + 0.0024*v5 - 0.0086*v7 + 0.005*v8 + 
0.0178*v9 + 0.0067*v11 - 0.0011*v12 + 0.0058*v13 - 0.0034*v14 + 5e-04*v18 + 5e-
04*v20 + 6e-04*v22 - 2.1793*pc46 + 2.4691*pc136 - 3.8813*pc217 + 2.5162*pc259 + 
3.6647*pc268 + 0.6671*pc351 + 3.5406*pc356 - 6.6699*pc361 - 1.5907*pc467 + 
2.8208*pc476 
5 
0.0106*v1 + 0.0099*v2 + 0.0116*v4 + 0.0024*v5 + 0.0128*v6 + 0.0052*v8 + 0.001*v10 
+ 0.0061*v11 + 1e-04*v20 + 4e-04*v23 - 0.0031*v27 + 7e-04*v29 - 4.3389*pc37 + 
3.4038*pc38 - 3.4022*pc43 - 2.4419*pc47 - 3.8996*pc58 + 0.9099*pc87 + 2.1992*pc89 + 
4.4688*pc173 - 1.5497*pc184 - 0.4699*pc219 + 3.6666*pc254 + 0.1264*pc326 - 
2.4101*pc328 - 6.1056*pc330 - 0.4309*pc335 - 2.0316*pc339 - 0.731*pc499 
9 
0.0093*v1 + 0.01*v2 + 0.0336*v3 + 0.0127*v4 + 0.0022*v5 + 0.0137*v6 - 0.0075*v7 + 
0.0054*v8 + 0.0265*v9 + 0.0069*v11 + 0.0059*v13 + 0.0086*v16 + 5e-04*v18 + 3e-
04*v20 + 0.0013*v23 - 2e-04*v24 + 4e-04*v26 + 3e-04*v29 - 0.7968*pc69 - 0.6128*pc91 
- 13.0616*pc106 - 0.286*pc116 - 1.2397*pc135 + 2.1316*pc136 - 1.8439*pc148 - 
6.0649*pc186 - 3.7377*pc205 - 2.3404*pc221 - 7.2134*pc273 - 5.5888*pc301 - 
5.2375*pc324 + 1.1473*pc365 + 2.3426*pc404 + 1.6862*pc415 - 12.9176*pc492 
18 
0.0098*v1 + 0.01*v2 + 0.034*v3 + 0.0138*v4 + 0.0023*v5 + 0.0136*v6 - 0.0052*v7 + 
0.0035*v8 + 0.0121*v9 + 0.0054*v11 - 0.0012*v12 + 0.0052*v13 - 0.0035*v14 + 
0.0016*v17 + 7e-04*v18 + 6e-04*v19 + 0.0016*v23 + 0.0013*v26 - 1.3138*pc360 + 
0.7202*pc388 - 2.0318*pc493 
21 
0.0104*v1 + 0.0094*v2 + 0.0288*v3 + 0.0117*v4 + 0.0021*v5 + 0.0144*v6 - 0.0065*v7 + 
0.0047*v8 + 0.0122*v9 + 0.0085*v11 - 0.0113*v15 + 3e-04*v20 + 8e-04*v21 - 5e-04*v24 





Figure 3-70 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Large-scale Dataset #9, Bootstrap Sample #5 
 
Figure 3-71 Clinical + Genotype Risk Index Value Distribution in the Optimization 




Figure 3-72 Clinical + Genotype Risk Index Value Distribution in the Optimization 
Set for Large-scale Dataset #25, Bootstrap Sample #4 
 
 
Figure 3-73 Clinical + Genotype Risk Index Value Distribution in the Independent 




Figure 3-74 Clinical + Genotype Risk Index Value Distribution in the Independent 
Testing Set for Large-scale Dataset #22, Bootstrap Sample #11 
 
Figure 3-75 Clinical + Genotype Risk Index Value Distribution in the Independent 




Table 3-69 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Large-scale Simulation Dataset #9 
   Bootstrap Sample #5 Bootstrap Sample #12 Bootstrap Sample #14 Bootstrap Sample #20 Bootstrap Sample #23 

















1 1 0.990 1 0.463 0 0.838 1 0.683 1 0.546 1 
2 0 0.845 0 0.372 0 0.599 0 0.473 0 0.417 0 
3 1 0.976 1 0.496 1 0.771 1 0.647 0 0.516 1 
4 1 1.162 1 0.641 1 0.987 1 0.820 1 0.731 1 
5 0 0.693 0 0.223 0 0.398 0 0.335 0 0.261 0 
6 0 0.852 0 0.353 0 0.767 1 0.618 0 0.480 0 
7 0 0.704 0 0.252 0 0.428 0 0.471 0 0.317 0 
8 0 0.812 0 0.289 0 0.595 0 0.481 0 0.368 0 
9 1 0.991 1 0.501 1 0.806 1 0.628 0 0.545 1 
10 0 0.842 0 0.417 0 0.626 0 0.466 0 0.452 0 
11 0 0.715 0 0.168 0 0.438 0 0.419 0 0.247 0 
12 1 1.097 1 0.535 1 0.784 1 0.670 1 0.606 1 
13 0 0.873 0 0.270 0 0.575 0 0.532 0 0.373 0 
14 0 0.876 0 0.320 0 0.630 0 0.582 0 0.429 0 
15 0 0.852 0 0.300 0 0.630 0 0.439 0 0.401 0 
16 1 0.976 1 0.502 1 0.706 1 0.575 0 0.569 1 
17 1 0.993 1 0.423 0 0.811 1 0.680 1 0.555 1 
18 1 1.192 1 0.692 1 0.998 1 0.855 1 0.749 1 
19 1 1.147 1 0.645 1 0.939 1 0.702 1 0.702 1 
20 0 0.898 0 0.363 0 0.675 0 0.579 0 0.425 0 
21 0 0.865 0 0.330 0 0.694 0 0.456 0 0.382 0 
22 0 0.854 0 0.327 0 0.771 1 0.569 0 0.422 0 
23 0 0.931 1 0.311 0 0.498 0 0.551 0 0.461 0 
24 1 0.973 1 0.481 1 0.784 1 0.591 0 0.529 1 




Table 3-70 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Large-scale Simulation Dataset #22 
   Bootstrap Sample #11 Bootstrap Sample #15 Bootstrap Sample #23 Bootstrap Sample #23 Bootstrap Sample #25 

















1 1 0.956 1 0.192 0 1.052 1 0.026 1 -0.025 0 
2 0 0.580 0 0.326 0 0.641 0 0.031 1 -0.020 1 
3 0 0.443 0 0.350 1 0.530 0 0.016 0 -0.024 1 
4 0 0.645 0 0.242 0 0.763 1 0.028 1 -0.009 1 
5 1 0.751 1 0.447 1 0.852 1 -0.007 0 -0.028 0 
6 0 0.520 0 0.318 0 0.641 0 0.035 1 -0.021 1 
7 1 0.640 0 0.342 1 0.820 1 0.005 0 -0.029 0 
8 0 0.568 0 0.444 1 0.700 0 0.027 1 -0.024 1 
9 0 0.352 0 0.330 0 0.476 0 -0.013 0 0.001 1 
10 0 0.660 0 0.181 0 0.775 1 -0.003 0 -0.031 0 
11 0 0.320 0 0.239 0 0.459 0 0.003 0 -0.031 0 
12 0 0.400 0 0.178 0 0.447 0 0.004 0 -0.007 1 
13 1 0.595 0 0.336 1 0.855 1 0.001 0 -0.025 0 
14 0 0.470 0 0.362 1 0.506 0 0.005 0 -0.030 0 
15 0 0.290 0 0.317 0 0.438 0 0.006 0 -0.050 0 
16 0 0.474 0 0.310 0 0.630 0 0.006 0 -0.050 0 
17 1 0.356 0 0.280 0 0.614 0 0.020 0 -0.024 1 
18 0 0.499 0 0.338 1 0.643 0 0.009 0 -0.046 0 
19 1 0.592 0 0.352 1 0.632 0 -0.013 0 -0.029 0 
20 0 0.596 0 0.231 0 0.672 0 0.018 0 -0.029 0 
21 0 0.400 0 0.288 0 0.499 0 0.030 1 -0.022 1 
22 0 0.447 0 0.116 0 0.592 0 0.004 0 -0.024 1 
23 1 0.865 1 0.289 0 0.941 1 0.001 0 -0.016 1 
24 1 0.427 0 0.335 1 0.646 0 0.003 0 -0.042 0 




Table 3-71 Risk Index Values for 25 Randomly Selected Individuals from the Optimization Set of Five Clinical + Genotype 
Risk Index Models from Large-scale Simulation Dataset #25 
   Bootstrap Sample #4 Bootstrap Sample #5 Bootstrap Sample #9 Bootstrap Sample #18 Bootstrap Sample #21 

















1 0 -0.568 0 -0.090 0 -0.756 0 -0.766 0 0.115 0 
2 0 -0.449 0 0.012 1 -0.719 0 -0.861 0 0.118 0 
3 1 -0.354 1 0.030 1 -0.629 0 -0.637 0 0.157 0 
4 0 -0.478 0 -0.006 1 -0.629 0 -0.655 0 0.057 0 
5 1 -0.315 1 0.019 1 -0.433 1 -0.512 1 0.184 0 
6 1 -0.322 1 -0.062 0 -0.442 1 -0.440 1 0.311 1 
7 0 -0.488 0 0.013 1 -0.598 1 -0.650 0 0.015 0 
8 0 -0.271 1 -0.048 0 -0.508 1 -0.488 1 0.311 1 
9 0 -0.441 0 -0.043 0 -0.594 1 -0.727 0 0.021 0 
10 0 -0.876 0 -0.066 0 -1.004 0 -0.994 0 -0.018 0 
11 0 -0.567 0 -0.042 0 -0.664 0 -0.729 0 0.035 0 
12 0 -0.544 0 -0.044 0 -0.633 0 -0.720 0 0.001 0 
13 1 -0.424 1 -0.049 0 -0.518 1 -0.617 0 0.225 1 
14 0 -0.652 0 -0.033 0 -0.862 0 -0.961 0 -0.207 0 
15 1 -0.384 1 -0.064 0 -0.552 1 -0.704 0 0.201 0 
16 1 -0.376 1 -0.040 0 -0.442 1 -0.522 1 0.240 1 
17 1 -0.272 1 -0.017 0 -0.458 1 -0.529 1 0.333 1 
18 1 -0.413 1 -0.016 0 -0.516 1 -0.577 1 0.126 0 
19 0 -0.526 0 -0.039 0 -0.701 0 -0.749 0 0.003 0 
20 0 -0.660 0 -0.006 1 -0.840 0 -0.853 0 -0.024 0 
21 1 -0.254 1 -0.029 0 -0.459 1 -0.581 1 0.231 1 
22 1 -0.255 1 -0.025 0 -0.386 1 -0.492 1 0.198 0 
23 0 -0.653 0 -0.019 0 -0.783 0 -0.784 0 -0.139 0 
24 1 -0.530 0 -0.006 1 -0.661 0 -0.673 0 0.222 1 
25 1 -0.035 1 -0.057 0 -0.247 1 -0.441 1 0.496 1 
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3.6.3 Predictive Performance 
After the variable selection procedure is completed and the models are applied to each 
individual in the independent testing set then the sensitivity, specificity, misclassification, 
and positive predictive value are measured for both the Clinical and Clinical + Genotype 
risk index models for each of the 25 large-scale simulation datasets. Table 3-70 shows the 
means and standard deviations of these measurements. To provide a 95% confidence for 
these measurements of sensitivity, specificity, misclassification, and positive predictive 
value, for each independent testing set 1000 bootstrap samples were generated. By 
making predictions about each individual in these bootstrap samples and calculating the 
sensitivity, specificity, misclassification, and positive predictive value for each bootstrap 
sample, 95% confidence intervals were estimated for these measurements in each of the 
25 large-scale simulation datasets. The mean and standard deviation of the spread (i.e., 
range) of these confidence intervals for both the Clinical and Clinical + Genotype risk 
index model is shown in Table 3-71. Table 3-72 shows the predictive performance and 
confidence intervals for the three small-scale simulation datasets discussed in Section 
3.5.2. 
 
Table 3-72 Means and Standard Deviations of Predictive Performance Estimates for 







































Table 3-73 Means and Standard Deviations of Predictive Performance 95% 
Confidence Intervals for the 25 Large-scale Simulation Datasets 
 Mean Range of the 95% Confidence Interval (SD) 
Model Sensitivity  Specificity  Misclassification  PPV  
Clinical 0.108 (0.009) 0.044 (0.007) 0.047 (0.004) 0.101 (0.008) 
Clinical + Genotype 0.110 (0.009) 0.043 (0.008) 0.046 (0.004) 0.100 (0.010) 
 
Table 3-74 Predictive Performance Estimates for Three Large-scale Simulation 
Datasets 


















































Using the number of models predicting an individual in the independent testing set as 
“high risk”, receiver operator characteristic (ROC) curves were generated for the Clinical 
and Clinical + Genotype risk index model for each of the 25 large-scale simulation 
datasets, and the AUC for the ROC curve was estimated. The average AUC for the 
Clinical risk index models was 0.931 (SD = 0.021), and the average AUC for the Clinical 
+ Genotype risk index models was 0.931 (SD = 0.022). Figure 3-76, 3-77, and 3-78 show 
the ROC curves for the Clinical risk index model the three small-scale simulation 
datasets discussed in sections 3.5.2, and Figure 3-79, 3-80, and 3-81 show the ROC curve 





Figure 3-76 ROC Curve of the Clinical Risk Index Model for Large-scale 
Simulation Dataset #9 
 
Figure 3-77 ROC Curve of the Clinical Risk Index Model for Large-scale 




Figure 3-78 ROC Curve of the Clinical Risk Index Model for Large-scale 
Simulation Dataset #25 
 
Figure 3-79 ROC Curve of the Clinical + Genotype Risk Index Model for Large-




Figure 3-80 ROC Curve of the Clinical + Genotype Risk Index Model for Large-
scale Simulation Dataset #22 
 
Figure 3-81 ROC Curve of the Clinical + Genotype Risk Index Model for Large-




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual as high risk, then, represents the predicted 
probability of an individual developing the outcome. For each individual a 95% 
confidence interval can be constructed as described in Section 3.2.3 
 
3.6.4 Random Forest Comparison 
For each of the 25 large-scale simulation datasets a random forest was generated using 
the optimization set created by the risk index procedure. The forests were generated using 
the methodology given in Section 3.2.4. For each of the random forests an ROC curve 
was generated and the AUC was estimated. The mean AUC for the random forest models 
was 0.856 (SD = 0.022). Figures 3-82, 3-83, and 3-84 show the ROC curve for the 
random forest generated from the three small-scale simulation datasets described in 
Section 3.5.2. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set using a range of proportions. 
First, an individual was assigned a prediction of “high risk” if 5% or more of the trees in 
the forest predicted the individual to be “high risk”. This was then repeated in increments 
of 5% until individuals were assigned a prediction of “high risk” only if 95% or more of 
the trees in the forest predicted the individual to be “high risk”. Table 3-73 shows the 
mean and standard deviation of the sensitivity, specificity, misclassification, and PPV for 




Figure 3-82 ROC Curve of the Random Forest Generated for Large-scale 
Simulation Dataset #9 
 
Figure 3-83 ROC Curve of the Random Forest Generated for Large-scale 





Figure 3-84 ROC Curve of the Random Forest Generated for Large-scale 
Simulation Dataset #25 
 
Table 3-75 Means and Standard Deviations of Performance Estimates of the 
Random Forest Models Generated from the 25 Large-scale Simulation Datasets 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 1 (0.001) 0.009 (0.012) 0.684 (0.017) 0.312 (0.016) 
0.1 0.999 (0.003) 0.077 (0.052) 0.637 (0.036) 0.327 (0.019) 
0.15 0.99 (0.012) 0.228 (0.087) 0.536 (0.056) 0.367 (0.027) 
0.2 0.964 (0.025) 0.395 (0.094) 0.428 (0.059) 0.42 (0.034) 
0.25 0.912 (0.034) 0.556 (0.077) 0.333 (0.046) 0.483 (0.038) 
0.3 0.841 (0.034) 0.685 (0.052) 0.266 (0.032) 0.548 (0.039) 
0.35 0.747 (0.04) 0.785 (0.035) 0.227 (0.025) 0.612 (0.04) 
0.4 0.653 (0.069) 0.854 (0.026) 0.208 (0.022) 0.67 (0.042) 
0.45 0.546 (0.093) 0.909 (0.022) 0.204 (0.023) 0.732 (0.046) 
0.5 0.439 (0.103) 0.95 (0.015) 0.209 (0.028) 0.8 (0.04) 
0.55 0.326 (0.096) 0.977 (0.011) 0.225 (0.029) 0.865 (0.043) 
0.6 0.198 (0.076) 0.992 (0.008) 0.255 (0.025) 0.923 (0.056) 
0.65 0.104 (0.06) 0.997 (0.004) 0.28 (0.023) 0.96 (0.05) 
0.7 0.042 (0.041) 0.999 (0.001) 0.298 (0.02) 0.978 (0.04) 





The results of the large-scale simulation study using the top 500 principal components are 
extremely promising, and demonstrate robust predictive performance. As with the large-
scale simulation study using the 500 most highly associated SNPs, both the predictive 
performance estimates and the AUC for the ROC curves for the 25 large-scale simulation 
datasets are noticeably higher than the small-scale simulation studies. The average 
misclassification and PPV are higher than any average misclassification or PPV yielded 
by the random forest model, and the random forests models were not able to provide the 
same levels of high sensitivity and high specificity simultaneously. Unlike the previous 
results, however, the Clinical + Genotype risk index model does not have a significantly 
higher average AUC than the Clinical risk index model (p=0.98), however the average 
AUC for the Clinical + Genotype risk index model is significantly greater than the 
average AUC of the random forest model (p=4.4e-16). 
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Chapter 4  
The Application of the Risk Index Methodology to the Framingham Heart Study 
4.1 The Framingham Heart Study 
The Framingham Heart Study (FHS) is a large, multi-generational study that has 
collected health data from residents of Framingham, MA for nearly sixty years. The study 
was originally developed to allow the study of the epidemiology of cardiovascular 
disease (Dawber, et al, 1951). The investigators’ initial assumption was that 
cardiovascular disease, unlike infectious diseases, which had received the bulk of 
epidemiological attention up to that time, has multiple causes and develops over a fairly 
long span of time. Working from this perspective, the investigators developed a study 
design calling for approximately 6,000 people who, for practical purposes, would be 
drawn from a single town of between 25,000 and 50,000 residents. The National 
Institutes of Health, working with the Massachusetts Health Commission, chose 
Framingham, MA as the site for this study. 
 
In 1949 the initial cohort of 5,209 subjects were recruited, and by 1952 the initial 
examination, consisting of a detailed medical history, a comprehensive physical exam 
including anthropometric measurements, x-rays, electrocardiography, and blood analysis 
was completed (Dawber, et al, 1951). The ages of the subjects in the initial cohort was 
28-62 years, with a mean age of 44.14 years, and 54.7% of the subjects were female 
(Dawber, et al, 1957). In 1971, 5,124 offspring of the original FHS cohort, along with the 
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offspring’s spouses, were recruited (Feinleib, et al, 1975). The ages of these participants 
at enrollment ranged from 12-60 years, with a mean of 39.16 years, and 51.5% of the 
offspring cohort were female. In 2002, 4,095 grandchildren of members of the original 
cohort were recruited into the third generation cohort (Splansky, et al, 2007). These 
subjects ranged in age from 19-71 years, with a mean age of 40.16 years, and 53.3% of 
the subjects were female.  
 
The 14,158 subjects of this study have had biennial exams that assess clinical measures 
of health, such as blood pressure and biochemical assays, as well as medical history, 
demographic factors, and psychological, social, and economic measures. Recently, 
genome-wide genotyping was performed on 6,575 subjects using the Affymetrix 
Genome-wide Human SNP Array 5.0, which genotypes ~500K SNPs. Other genotyping 
data, including a 100K SNP array and a 50K SNP array, both from Affymetrix, have also 
been collected.  
 
4.1.1 Sample  Selection for Risk Index Evaluation 
This analysis of the FHS data examines the ability of the risk index procedure to combine 
clinical and genotypic data to make prognostic predictions about an individual’s risk of 
developing a disease. It requires that subjects have both sufficient follow-up time for 
assessment of disease onset and available DNA samples for genotyping. This analysis 
focuses on the FHS offspring cohort, which has sufficient follow-up time, but excludes 
the third-generation cohort, whose follow-up time is insufficient, and the original cohort, 
which has a small number of subjects who have had DNA collected for genotyping. Of 
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the 5,214 subjects in the FHS offspring cohort, 2,817 individuals have had DNA 
collected and been genotyped. These 2,817 subjects were used as the sample for all of the 
analyses that have been performed on the FHS data.. 
 
4.2 Definition of Outcomes 
This portion of the dissertation will focus on three outcomes: ten-year incident 
hypertension, ten-year incident type 2 diabetes (referred to after this as simply “ten-year 
incident diabetes”), and prevalent hypertension. These diseases represent a range of 
prevalence (approximately 10% to approximately 35%) representative of common 
chronic diseases and are known to be strongly influenced by genetic factors. For both 
incident hypertension and incident diabetes the risk index procedure will be used to 
identify individuals at high risk of developing the outcome within ten years. Clinical, 
biochemical, and other predictive variables obtained at the beginning of a ten-year 
interval will be used to predict the outcome, which is assessed at the end of that ten-year 
interval. For the offspring cohort the available follow-up time covers only 12 years, and 
the data available from their first exam is significantly less than what is available from 
their second exam. Therefore, the ten-year window spanning offspring exam two and 
offspring exam seven will be used as the source data for both outcomes. For prevalent 
hypertension the risk index procedure will be used to identify individuals that are 




4.2.1 Ten-Year Incident Hypertension 
Using the American Heart Association’s diagnostic criteria for hypertension, a subject 
will be considered to have hypertension in exam two if their average systolic blood 
pressure is greater than 140 mm Hg, their average diastolic blood pressure is greater than 
90 mm Hg, or they are currently taking anti-hypertensive medication (Chobanian, et al, 
2003). The 2,283 subjects who began exam two without hypertension will be used for 
this analysis. Using the same criteria, a subject will be considered to have hypertension in 
exam seven if their average systolic blood pressure is greater than 140 mm Hg, their 
average diastolic blood pressure is greater than 90 mm Hg, or they are currently taking 
anti-hypertensive medication (Chobanian, et al, 2003). Of the 2,283 subjects who did not 
have hypertension in exam two, 777 (34.0%) developed hypertension by exam seven. 
 
4.2.2 Ten-Year Incident Diabetes 
Neither exam two nor exam seven contains a pre-defined variable indicating whether a 
subject has diabetes. For both exams, however, information on both fasting blood glucose 
levels and anti-diabetic medications is available. Using the National Diabetes Data Group 
criteria, a subject will be considered to have diabetes if their fasting blood glucose level is 
greater than 126 mg/dL or they are taking anti-diabetic medication (National Diabetes 
Data Group, 1979). At exam two, 2,746 individuals do not have diabetes, and 253 (9.2%) 




4.2.3 Prevalent Hypertension 
Using the American Heart Association’s diagnostic criteria for hypertension, a subject 
will be considered to have hypertension in exam two if their average systolic blood 
pressure is greater than 140 mm Hg, their average diastolic blood pressure is greater than 
90 mm Hg, or they are currently taking anti-hypertensive medication (Chobanian, et al, 
2003). Of the 2,817 individuals for whom genotypes are available, 534 (19.0%) are 
hypertensive at exam two. While hypertension is a straight-forward disease to diagnose, 
requiring only blood pressure measurements, it is also an excellent model of a complex, 
multi-factorial disease. For this reason it makes an excellent test of the risk index 
procedure’s ability to identify individuals that have a complex disease, a potentially 
important application, especially for diseases which are harder to diagnose than 
hypertension and diabetes, such as auto-immune disorders. Identifying individuals who 
are at high risk of currently having these diseases could allow physicians to target 
potentially invasive diagnostic procedures to those most likely to require them. 
 
4.3 Predictor Variable Selection 
The FHS data is rich with variables, with each biennial exam comprised of several 
hundred questions, measurements, and laboratory assessments. This analysis will focus 
on a fairly small number of clinical variables that are relatively easy to obtain and would 
be routinely collected in a patient care setting. These variables are age (yrs), sex, weight 
(lbs), height (in), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg), 
total cholesterol (mg/dL), high-density lipoprotein level (mg/dL), low-density lipoprotein 
level (mg/dL), triglycerides (mg/dL), ever smoked, current smoking status, weekly 
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alcohol consumption, marital status, left ventricular mass (g), left ventricular ejection 
fraction (%), blood glucose (mg/dL), blood urea nitrogen (mg/dL), total serum protein 
level (mg/dL), serum albumin level (mg/dL), serum bilirubin level (mg/dL), serum 
alkaline phosphatase level (mg/dL), and serum creatine level (mg/dL). Descriptive 
statistics for these variables in the 2,817 individuals for which genotypes are available are 
given in Table 4-1. 
 
Table 4-1 Descriptive Statistics of Predictor Variables 
Variable Mean SD Range 
Age (yrs) 43.2 9.68 17-70 
Weight (in) 160.3 34.1 79-326 
Height (lbs) 66 3.8 56-79 
Cholesterol (mg/dl) 201.6 38.07 52-511 
High Density Lipoprotein Cholesterol (mg/dl) 48.98 13.31 14-111 
Low Density Lipoprotein Cholesterol (mg/dl) 129.2 34.21 7-311 
Triglycerides (mg/dl) 345 287.44 37-6,539 
Weekly Alcohol Consumption 3.5 4.88 0-57 
Left Ventricular Mass (g) 186.1 55.67 65-476 
Left Ventricular Ejection Fraction (%) 74.6 4.36 44-90 
Blood Glucose (mg/dl) 97.5 16.1 50-339 
Blood Urea Nitrogen (mg/dl) 15.6 4.09 4-49 
Serum Protein (mg/dl) 72.2 4.28 54-92 
Albumin (mg/dl) 44.5 3.01 34-56 
Bilirubin (mg/dl) 72.8 34.48 10-340 
Alkaline Phosphotase (mg/dl) 26.6 9.74 4-106 
Creatine (mg/dl) 11.5 2.39 4-26 
Bilirubin/Creatine Ratio 139.9 42.78 44-467 
White Blood Cell Count  63.3 17.57 29-243 
Red Blood Cell Count 477.6 42.49 335-685 
Hemoglobin 145.3 13.37 79-186 
Average Sytolic Blood Pressure (mm Hg) 120.7 15.69 82-203 




4.4 Genotype Variable Selection 
As described above, the FHS has extensively genotyped subjects, using Affymetrix  
platforms measuring 50K, 100K, and 500K genome-wide genotypes. For these analyses, 
because of constraints of scale and computing resources, the 50K genome-wide 
genotypes will be used. Focusing solely on autosomal polymorphisms, genotypes were 
available for 48,071 SNPs. Figure 4-1 shows the calling rates for the 48,071 SNPs in the 
2,817 individuals being examined in this project. This graph shows that the majority of 
SNPs have calling rates of >99% (i.e., fewer than 1% of individuals could not be 
assigned a genotype for that SNP). To improve the quality of the genotypes and reduce 
the number of missing genotypes, the HelixTree SNP Variation Suite (Golden Helix) was 
used to perform SNP genotype imputation. Imputed genotypes with a probability of 75% 
or greater were retained, and those with a probability lower than 75% were left as missing 
data. 1,935,361 missing genotypes out of 3,394,984 missing genotypes (57.0%) were 
imputed with this approach. One observation that potentially accounts for the relatively 
low proportion of missing genotypes recovered by imputation is that while many subjects 
were missing a very small number of genotypes, a small subset of individuals were 
missing the majority of genotypes. Figure 4-1 shows that after imputation the distribution 
of minor allele frequencies for this collection of SNPs. 4,788 SNPs had a minor allele 
frequency of less than 5%, and 2,244 SNPs were monomorphic. Monomorphic SNPs 





Figure 4-1 Histogram of SNP Call Rates 
 
Figure 4-2 Histogram of SNP Minor Allele Frequencies 
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4.4.1 SNP Selection  
To reduce the potential search space and to identify SNPs most likely to be predictive of 
the outcome being examined, a simple SNP selection procedure was used. The 
association between each SNP and each of the outcomes was assessed using logistic 
regression, and the 500 SNPs with the smallest p-values for a particular outcome were 
selected. Each SNP was encoded using a genotypic model, with the major homozygous 
genotype being marked as the reference group, and individual coefficients estimated for 
the heterozygous genotype and the minor homozygous genotype. These SNPs were then 
used as the genotype predictors for the risk index procedure for that outcome. 
 
4.4.2 Principal Components Analysis 
Principal Components Analysis (PCA) will be used as a second procedure to reduce the 
number of genotype variables being considered (See Chapter 2 for a discussion of PCA). 
The SMARTPCA program (a part of EIGENSTRAT (Patterson, et al, 2006)) that was 
used to generate the principal components for this analysis requires a dataset with no 
missing values. To ensure that only the smallest number of polymorphisms and 
individuals were excluded, a staged removal procedure was used. First, polymorphisms 
with a genotyping success rate of less than 99.5%were removed from the data. Next, 
individuals who were missing more than 0.5% of potential genotypes are removed. 
Finally, SNPs with less than complete genotyping success were removed. After this data 
cleaning, 17,268 SNPs in 2,652 people were available for PCA. Using the smartpca 
program, 500 principal components were estimated. Eigenvectors were computed for 
each individual for each of the 500 components. The percentage of variance explained by 
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each component is shown in Figure 4-3. The first 500 components (indicated in red in 
Figure 4-3) account for 44.6% of the total variance.  
 
 
Figure 4-3 Percentage of Variance Explained by Each Principal Component 
 
4.5 Ten-Year Incident Hypertension Results Using 500 Most Highly Associated 
SNPs 
4.5.1 Variable Selection 
The risk index procedure was applied to the FHS Offspring cohort data described above. 
A logistic regression analysis was performed to estimate the association between each of 
the 48,127 SNPs and the development of hypertension by exam seven. The 500 SNPs 
with the smallest association p-values were selected for this analysis. Of the 2,283 
subjects who did not have hypertension at exam 2, 777, or 34.0%, developed 
hypertension by exam seven. The data was divided into an independent testing set, 
consisting of 571 individuals, and an optimization set, consisting of 1712 individuals. 
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One hundred bootstrap samples of the optimization set were generated, and the risk index 
procedure was used to generate Clinical and Clinical + Genotype risk index models for 
each of the bootstrap samples. Each of these models was then used to make a prediction 
(high risk or low risk for developing hypertension) about each of the 571 individuals in 
the independent testing set. For both the Clinical risk index model and the Clinical + 
Genotype risk index model the predictions from each of the 100 bootstrap samples were 
used as votes, and the prediction most frequently assigned was designated as the 
consensus prediction.  
 
Table 4-2 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the optimization set used to build the Clinical risk index model for 
incident hypertension. The relatively small number of clinical variables leads to each of 
the variables being selected into at least 72 of the 100 untrimmed Clinical risk index 
models, with height, current smoking status, and marital status selected into all 100 
untrimmed Clinical risk index models and weekly alcohol consumption, serum albumin 
level, serum bilirubin level, and serum creatine level selected into 99 of the 100 
untrimmed Clinical risk index models. Fifty out of the 100 trimmed Clinical risk index 
models contained Marital Status as a variable. Weekly alcohol consumption was included 
in 47 out of the 100 trimmed Clinical risk index models. Height, systolic blood pressure, 
and current smoking status, were also frequently included in the set of 100 trimmed 





Table 4-3 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the Optimization Set used to build the Clinical + Genotype risk 
index model. Because of the much larger number of available genotype variables, no 
single polymorphism was selected as the first variable in the Clinical + Genotype risk 
index model by more than 3 of the 100 bootstrap samples. Likewise, no individual 
polymorphisms was selected as either the second or third variable in the Clinical + 
Genotype risk index model by more than 4 out of 100 bootstrap samples. Table 4-3 
shows a summary of variable selection process for the 15 SNPs that were selected into 20 
or more untrimmed Clinical + Genotype risk index models. All of these variables also 




Table 4-2 Summary of Number of Times Each Variable is Selected into a Specific Model Position for the Clinical Risk Index 
Models for Incident Hypertension 
  Variable Position 








Age (yrs) 3 4 4 0 2 3 4 0 2 5 2 3 4 3 6 5 0 4 10 8 72 14 
Sex 0 6 5 3 3 3 4 3 6 1 4 7 8 4 9 4 3 3 6 4 86 14 
Weight (lbs) 0 1 0 0 1 2 1 3 1 6 5 8 5 4 3 4 10 6 4 12 76 7 
Height (in) 4 12 13 10 12 12 9 7 6 2 1 3 3 1 1 1 0 1 0 2 100 46 
Systolic Blood Pressure 
(mm Hg) 27 2 1 0 1 2 0 4 4 2 3 4 2 4 7 2 3 3 5 7 83 36 
Diastolic Blood Pressure 
(mm Hg) 15 4 2 3 1 0 4 3 3 0 2 1 1 8 4 3 7 2 7 5 75 23 
Total Cholesterol  (mg/dL) 2 0 3 1 0 0 1 1 4 2 5 3 5 4 3 7 11 9 11 6 78 7 
High-density Lipoprotein Level 
(mg/dL) 1 3 2 1 4 4 0 5 4 5 7 6 3 8 5 5 9 8 2 8 90 15 
Low-density Lipoprotein Level 
(mg/dL) 1 2 0 2 3 1 1 4 2 6 2 5 6 6 4 12 8 5 2 13 85 10 
Triglycerides (mg/dL) 3 1 1 3 2 1 3 4 3 3 7 2 7 5 10 4 4 5 7 4 79 11 
Ever Smoked 0 10 8 7 10 4 12 9 4 6 7 4 6 3 2 3 1 0 0 0 96 29 
Currently Smokes 0 11 11 11 4 10 12 8 6 4 1 5 6 3 0 4 1 3 0 0 100 31 
Weekly Alcohol Consumption 18 9 6 5 14 9 10 4 6 5 5 1 1 2 1 1 0 1 0 1 99 47 
Marital Status 6 16 22 19 12 3 5 2 2 3 3 0 2 0 2 1 0 1 1 0 100 50 
Left Ventricular Mass (g) 1 0 2 3 0 2 2 2 5 4 2 4 1 6 5 5 8 4 4 3 63 7 
Left Ventricular Ejection 
Fraction (%) 4 6 6 3 5 3 2 8 6 7 4 7 5 2 2 2 1 3 2 3 81 18 
Blood Glucose (mg/dL) 2 0 1 2 3 2 2 4 3 4 4 4 7 4 4 6 8 8 10 7 85 9 
Blood Urea Nitrogen (mg/dL) 0 2 1 1 2 6 1 1 6 4 3 3 8 8 7 6 5 6 9 4 83 10 
Total Serum Protein Level 




Serum Albumin Level (mg/dL) 1 3 1 2 4 12 9 9 10 6 10 8 3 5 5 4 1 3 2 1 99 18 
Serum Bilirubin Level (mg/dL) 3 0 2 11 4 7 5 11 5 6 9 6 7 3 5 4 0 4 6 1 99 19 
Serum Alkaline Phosphatase 
Level (mg/dL) 1 1 2 2 0 1 1 2 3 1 4 1 4 5 9 12 10 9 6 5 79 6 
Serum Creatine Level (mg/dL) 3 2 7 5 8 11 5 3 6 9 5 7 2 5 3 1 5 6 3 3 99 18 
 
Table 4-3 Summary of Number of Times Selected Genotype Variables are Selected into a Specific Model Position for Clinical 
+ Genotype Risk Index Models for Incident Hypertension 
 Variable Position 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Total # of 
Models 




rs16995309 1 0 4 0 0 3 0 3 2 3 2 2 1 1 0 0 1 2 3 0 28 23 
rs10082778 0 3 0 0 2 1 5 2 0 2 2 2 3 1 3 3 5 4 2 1 41 29 
rs241419 0 0 1 1 1 3 2 0 1 3 1 0 0 1 1 1 0 0 1 3 20 18 
rs3733920 0 0 1 0 0 1 4 1 0 2 4 3 0 3 1 2 1 1 3 1 28 24 
rs6137081 0 0 2 0 2 0 0 2 3 1 3 0 2 0 2 3 4 2 4 0 30 21 
rs33965313 0 4 0 1 2 1 3 0 1 0 2 0 1 3 0 3 1 0 0 0 22 16 
rs12812222 1 1 1 2 2 1 0 0 1 2 1 1 3 0 0 1 1 0 0 3 21 15 
rs6878329 1 1 3 2 3 3 1 6 0 3 2 1 5 1 1 1 2 0 1 2 39 34 
rs11693983 2 0 1 1 1 4 1 1 1 1 2 1 1 3 2 1 1 1 0 1 26 21 
rs6059153 2 2 1 4 2 6 6 7 3 3 4 6 2 2 2 0 1 0 3 1 57 49 
rs17047347 0 0 3 0 1 3 3 1 3 2 1 1 2 2 2 1 3 3 3 1 35 25 
rs6004901 2 3 2 1 1 1 2 0 0 1 0 1 2 2 1 0 1 0 0 0 20 18 
rs10492357 1 0 0 5 2 0 1 1 1 1 3 0 1 1 2 1 3 6 1 0 30 23 
rs1555498 2 2 1 1 0 1 0 3 0 1 3 1 2 4 3 1 3 1 1 1 31 23 




Table 4-4 shows the trimmed Clinical risk index models for a selection of five random 
bootstrap samples. Figure 4-4 shows the distribution of risk index values in the 
optimization set for the Clinical risk index model from one randomly selected bootstrap 
sample (Bootstrap Sample #9), and Figure 4-5 shows the distribution of risk index values 
in the independent testing set for the Clinical risk index model from the same randomly 
selected bootstrap sample (Bootstrap Sample #9). The red line on each graph marks the 
cutoff point for the model. All individuals with a risk index value greater than this are 
predicted as “high risk of developing hypertension” and those with a risk index value 
lower are predicted as “low risk of developing hypertension”. Table 4-5 shows the risk 
index values for 25 randomly chosen individuals from the Independent Testing Set from 
these five Clinical risk index models along with that risk index model’s prediction about 
each individual, where 0 indicates low risk of developing hypertension and 1 indicates 
high risk of developing hypertension. 
 
Table 4-4 Five Randomly Selected Trimmed Clinical Risk Index Models for 
Incident Hypertension 
Bootstrap Trimmed Clinical Risk Index Model 
9 0.0697*Systolic Blood Pressure + 0.1913*Marital Status  
51 
-0.0212*Height + 0.0019*Triglycerides + 0.1182*Current Smoking Status + 0.0207*Weekly 
Alcohol Consumption + 0.2024*Marital Status + 0.0039*Left Ventricular Mass + 
0.0326*Blood Urea Nitrogen + 0.0413*Total Serum Protein - 0.036*Albumin - 
0.0076*Bilirubin  
59 -0.0017*Height + 0.0747*Current Smoking Status + 0.0109*Weekly Alcohol Consumption + 0.0962*Marital Status - 0.0051*Albumin  
72 0.1116*Diastolic Blood Pressure + 0.01*Total Cholesterol + 0.0924*Ever Smoked + 0.0119*Weekly Alcohol Consumption  
84 
0.0553*Age - 0.1312*Sex + 0.0085*Weight - 0.0152*HDL + 0.3433*Ever Smoked + 
0.1008*Current Smoking Status + 0.0066*Weekly Alcohol Consumption + 0.1688*Marital 




Figure 4-4 Clinical Risk Index Model Risk Index Values Distribution in the 
Optimization Set, Bootstrap Sample #9 
 
Figure 4-5 Clinical Risk Index Model Risk Index Values Distribution in the 





Table 4-5 Risk Index Values for 25 Individuals in the Optimization Set for the Clinical Risk Index Models for Incident 
Hypertension from Five Randomly Selected Bootstrap Samples 
  Bootstrap Sample #9 Bootstrap Sample #51 Bootstrap Sample #59 Bootstrap Sample #72 Bootstrap Sample #84 
  Cutoff Value = 4.224 Cutoff Value = 0.168 Cutoff Value = -0.015 Cutoff Value = 2.796 Cutoff Value = 0.394 









1 1 5.375 1 0.187 1 0.008 1 2.909 1 0.482 1 
2 0 4.025 0 0.127 0 -0.015 0 2.291 0 0.308 0 
3 1 5.140 1 0.201 1 -0.006 1 2.982 1 0.453 1 
4 0 4.513 1 0.113 0 -0.008 1 2.751 0 0.417 1 
5 0 3.511 0 0.050 0 -0.052 0 2.274 0 0.202 0 
6 0 3.441 0 0.207 1 0.002 1 2.788 0 0.341 0 
7 1 4.425 1 0.225 1 0.006 1 2.970 1 0.407 1 
8 1 6.116 1 0.167 0 -0.018 0 3.688 1 0.420 1 
9 1 4.513 1 0.182 1 -0.032 0 2.885 1 0.471 1 
10 0 4.164 0 0.118 0 -0.031 0 2.669 0 0.365 0 
11 1 3.955 0 0.107 0 -0.001 1 2.454 0 0.338 0 
12 0 4.381 1 0.217 1 0.068 1 2.688 0 0.415 1 
13 1 3.816 0 0.189 1 0.001 1 2.444 0 0.310 0 
14 0 4.234 0 0.210 1 -0.022 0 2.575 0 0.410 1 
15 1 3.441 0 0.178 1 -0.024 0 2.142 0 0.335 0 
16 0 4.792 1 0.112 0 -0.025 0 2.529 0 0.436 1 
17 1 4.774 1 0.227 1 0.023 1 2.959 1 0.499 1 
18 0 4.025 0 -0.070 0 0.020 1 2.635 0 0.518 1 
19 0 3.720 0 0.137 0 -0.025 0 2.458 0 0.325 0 
20 1 4.582 1 0.091 0 -0.026 0 2.647 0 0.279 0 
21 0 3.816 0 0.094 0 -0.013 1 2.560 0 0.503 1 
22 1 5.698 1 0.213 1 -0.011 1 2.828 1 0.439 1 
23 0 3.607 0 0.155 0 -0.030 0 2.161 0 0.290 0 
24 1 4.286 1 0.142 0 0.114 1 2.697 0 0.588 1 
25 1 4.373 1 0.168 0 -0.020 0 2.876 1 0.342 0 
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Table 4-6 shows the trimmed Clinical + Genotype risk index models for the same set of 
five bootstraps shown in Table 4-4, and Table 4-7 shows the risk index values and 
predictions of the same 25 randomly chosen individuals for the 5 bootstrap samples 
shown in Table 4-5. Figure 4-6 shows the distribution of risk index values in the 
optimization set for the Clinical + Genotype risk index model from one randomly 
selected bootstrap sample (Bootstrap Sample #9). Figure 4-7 shows the distribution of 
risk index values in the independent testing set for the Clinical + Genotype risk index 
model from the same randomly selected bootstrap sample (Bootstrap Sample #9). The red 
line on each graph marks the cutoff point for the model. All individuals with a risk index 
value greater than this are predicted as “high risk of developing hypertension” and those 




Table 4-6 Five Randomly Selected Clinical + Genotype Risk Index Models for 
Incident Hypertension 
Bootstrap Trimmed Clinical + Genetics Risk Index Model 
9 0.0697*Systolic Blood Pressure + 0.1913*Marital Status + SNP_M-583177(C_G=0.3172, G_G=0.3868) + SNP_M-310902(C_G=0.4776, G_G=0.7179) 
51 
-0.0212*Height + 0.0019*Triglycerides + 0.1182*Current Smoking Status + 0.0207*Weekly 
Alcohol Consumption + 0.2024*Marital Status + 0.0039*Left Ventricular Mass + 
0.0326*Blood Urea Nitrogen + 0.0413*Total Serum Protein - 0.036*Albumin - 
0.0076*Bilirubin + SNP_M-600701(C_T=1.3306, T_T=1.3627) + SNP_M-
594285(A_C=0.1237, C_C=15.1625) + SNP_M-319308(C_G=-0.1289, G_G=-13.5691) + 
SNP_M-180302(C_T=-0.3018, T_T=-0.2546) + SNP_M-592316(C_T=-1.0852, NA) + 
SNP_M-317848(T_T=1.3633, NA) + SNP_M-324013(A_G=-0.9846, G_G=-1.0584) + 
SNP_M-179284(C_T=0.0504, T_T=-0.0504) + SNP_M-319058(A_G=-0.3462, 
G_G=16.2787) 
59 
-0.0017*Height + 0.0747*Current Smoking Status + 0.0109*Weekly Alcohol Consumption + 
0.0962*Marital Status - 0.0051*Albumin + SNP_M-607627(C_T=0.2081, T_T=1.7121) + 
SNP_M-599757(C_T=-0.6624, T_T=-0.9666) + SNP_M-180069(C_T=0.1609, T_T=0.3887) 
+ SNP_M-306806(C_T=-1.5941, NA) + SNP_M-589310(C_T=0.6218, T_T=0.8646) + 
SNP_M-185374(A_T=1.0779, NA) + SNP_M-591588(G_T=0.2153, T_T=1.0864) + 
SNP_M-580964(A_G=0.665, G_G=0.8924) + SNP_M-597220(G_T=0.2554, T_T=0.8698) + 
SNP_M-603278(C_T=0.0995, T_T=0.9101) + SNP_M-599155(G_T=-1.1167, T_T=-0.4468) 
+ SNP_M-590943(A_C=0.5146, C_C=0.6543) + SNP_M-611577(A_T=-15.0476, T_T=-
16.2242) + SNP_M-612475(C_T=-0.424, T_T=-2.0049) + SNP_M-582008(C_T=0.0845, 
T_T=2.1746) + SNP_M-317848(T_T=2.1421, NA) + SNP_M-597857(A_G=-0.5716, G_G=-
0.8797) + SNP_M-594033(C_G=0.2302, G_G=0.4309) + SNP_M-603817(A_G=0.1525, 
G_G=0.279) + SNP_M-587757(C_T=-17.8997, T_T=-18.0137) 
72 
0.1116*Diastolic Blood Pressure + 0.01*Total Cholesterol + 0.0924*Ever Smoked + 
0.0119*Weekly Alcohol Consumption + SNP_M-580646(C_T=0.2179 ,T_T=0.4832) + 
SNP_M-177199(C_G=0.3118 ,G_G=0.4673) + SNP_M-597655(A_G=-0.1203 ,G_G=-
0.0561) + SNP_M-598920(A_G=-0.2478 ,G_G=-0.6533) + SNP_M-592316(C_T=-0.9288 
,NA) + SNP_M-600051(A_G=-0.2553 ,G_G=-1.0712) + SNP_M-611577(A_T=0.2607 
,T_T=-0.2607) + SNP_M-610223(A_T=0.0567 ,T_T=0.5653) + SNP_M-
598811(A_G=0.6177 ,G_G=0.6401) + SNP_M-602035(A_G=-0.129 ,G_G=-0.1316) + 
SNP_M-327317(C_T=-0.4836 ,T_T=-0.3172) + SNP_M-310902(C_G=14.3295 
,G_G=14.3208) + SNP_M-588824(A_G=0.2089 ,G_G=0.2652) + SNP_M-182866(C_T=-
0.1895 ,T_T=0.1413) + SNP_M-594503(A_G=-0.046 ,G_G=0.0596) 
84 
0.0553*Age - 0.1312*Sex + 0.0085*Weight - 0.0152*HDL + 0.3433*Ever Smoked + 
0.1008*Current Smoking Status + 0.0066*Weekly Alcohol Consumption + 0.1688*Marital 
Status + 0.0473*Blood Urea Nitrogen - 0.0013*Bilirubin + 0.0293*Creatine + SNP_M-
580646(C_T=0.5211, T_T=0.3669) + SNP_M-609794(A_T=-0.1066, T_T=-0.617) + 
SNP_M-589026(A_T=-0.0312, T_T=0.0312) + SNP_M-608322(C_G=0.1269, G_G=0.4254) 
+ SNP_M-580415(A_C=0.0215, C_C=-0.0642) + SNP_M-599120(G_T=0.1178, 
T_T=0.1993) + SNP_M-185297(C_G=-9.385, G_G=-10.7958) + SNP_M-603138(C_T=-
0.1022, T_T=-0.258) + SNP_M-602581(A_T=17.0589, T_T=16.9035) + SNP_M-
181501(C_G=-0.1468, G_G=0.9559) + SNP_M-323893(A_G=-0.2881, G_G=-0.4792) + 
SNP_M-322333(C_T=-0.9651, T_T=-1.2191) + SNP_M-609320(A_G=-0.0513, 
G_G=0.7844) + SNP_M-319195(C_T=-0.4342, NA) + SNP_M-324013(A_G=0.0311, 






Figure 4-6 Clinical + Genotype Risk Index Model Risk Index Values Distribution in 
the Optimization Set, Bootstrap Sample #9 
 
 
Figure 4-7 Clinical + Genotype Risk Index Model Risk Index Values Distribution in 





Table 4-7 Risk Index Values for 25 Individuals in the Optimization Set for the Clinical + Genotype Risk Index Models for 
Incident Hypertension from Five Randomly Selected Bootstrap Samples 
  Bootstrap Sample #9 Bootstrap Sample #51 Bootstrap Sample #59 Bootstrap Sample #72 Bootstrap Sample #84 












1 1 5.734 1 0.381 1 -1.530 1 3.947 1 1.897 1 
2 0 4.457 0 0.438 1 -1.453 1 3.277 0 1.717 0 
3 1 5.499 1 0.344 0 -1.506 1 4.024 1 1.847 1 
4 0 5.030 1 0.306 0 -1.617 0 3.794 1 1.858 1 
5 0 3.870 0 0.229 0 -1.586 0 3.234 0 1.660 0 
6 0 3.959 0 0.387 1 -1.517 1 3.755 0 1.760 0 
7 1 4.943 1 -1.103 0 -1.548 0 3.944 1 1.838 1 
8 1 6.475 1 0.347 1 -1.505 1 4.673 1 1.850 1 
9 1 5.030 1 2.046 1 -1.549 0 3.866 1 1.901 1 
10 0 4.523 0 0.264 0 -1.487 1 3.670 0 1.801 0 
11 1 4.473 0 0.287 0 -1.550 0 3.450 0 1.780 0 
12 0 4.740 1 0.396 1 -1.391 1 3.616 0 1.824 1 
13 1 4.213 0 0.349 1 -1.471 1 3.429 0 1.764 0 
14 0 4.751 1 0.390 1 -1.674 0 3.539 0 1.840 1 
15 1 3.959 0 0.358 1 -1.586 0 3.119 0 1.771 0 
16 0 5.150 1 0.259 0 -1.495 1 3.607 0 1.849 1 
17 1 5.291 1 0.406 1 -1.496 1 3.907 1 1.926 1 
18 0 4.384 0 0.110 0 -1.437 1 3.678 0 1.935 1 
19 0 4.079 0 0.317 0 -1.546 0 3.411 0 1.732 0 
20 1 4.941 1 0.270 0 -1.414 1 3.635 0 1.727 0 
21 0 4.175 0 0.273 0 -1.476 1 3.527 0 1.939 1 
22 1 6.215 1 0.360 1 -1.556 0 3.834 1 1.874 1 
23 0 4.124 0 0.297 0 -1.542 0 3.109 0 1.698 0 
24 1 4.645 0 0.330 0 -1.441 1 3.682 0 2.012 1 
25 1 4.732 1 0.348 1 -1.565 0 3.872 1 1.736 0 
 
 207 
4.5.3 Predictive Performance 
Once predictions were made for each individual in the independent testing set the 
sensitivity, specificity, misclassification, and positive predictive value were calculated for 
the Clinical risk index model and the Clinical + Genotype risk index model. One 
thousand bootstrap samples of the independent testing set were generated, and the 100 
trimmed Clinical risk index models and the 100 trimmed Clinical + Genotype risk index 
models were applied to each individual in each of the 1000 bootstrap samples. The 
sensitivity, specificity, misclassification, and positive predictive value of the risk index 
models were calculated for each of the 1000 bootstrap samples, and 95% confidence 
intervals for each of these measurements were estimated from this data. The estimates 
and confidence intervals for sensitivity, specificity, misclassification, and positive 
predictive value are given in Table 4-2. Lastly, using the individual predictions from each 
of the 100 trimmed Clinical risk index models and 100 trimmed Clinical + Genotype risk 
index models for the individuals in the independent testing set, receiver operating 
characteristic (ROC) curves were generated, and the area under the ROC curve (AUC) 
was estimated for both the Clinical and Clinical + Genotype risk index models (Figure 4-
8, Figure 4-9). For the Clinical risk index model the AUC for the ROC curve was 0.567, 








Table 4-8 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for Ten-year Incident Hypertension 







Clinical 0.667  (0.594 - 0.736) 
0.486  
(0.444 - 0.53) 
0.468  
(0.433 - 0.504) 
0.308  
(0.26 - 0.352) 
Clinical + Genotype 0.539  (0.464 - 0.609) 
0.457  
(0.413 - 0.497) 
0.522  
(0.487 - 0.559) 
0.254  
(0.21 - 0.298) 
 
 





Figure 4-9 ROC Curve and AUC for the Incident Hypertension Clinical + Genotype 
Risk Index Model 
 
The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual is at high risk of developing hypertension, then, 
represents the predicted probability of an individual developing hypertension. Using the 
binomial distribution a 95% confidence interval can be constructed for this estimated 
probability with the Wilson score interval (Wilson, 1927). This interval, given by 
! 
95% CI =












, can then be used by physicians to gauge 
the prediction. As an example, one individual in the independent testing set had a 
predicted probability of developing hypertension from the Clinical risk index model of 
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 or 0.883. 
 
Figure 4-10 shows the distribution of the predicted probability of developing 
hypertension for the Clinical risk index model in the independent testing set, and Figure 
4-11 shows the distribution of the predicted probability of developing hypertension for 
the Clinical + Genotype risk index model in the independent testing set. In both Figures, 
a density line is shown on the graph to indicate the density of a normal distribution with 




Figure 4-10 Histogram of the Predicted Probability of Developing Hypertension for 
the Clinical Risk Index Model 
 
 
Figure 4-11 Histogram of the Predicted Probability of Developing Hypertension for 




4.5.4 Random Forests Comparison 
A random forest was generated using the optimization set created by the risk index 
procedure. The forest had 500 individual trees, and a tuning procedure was used to find 
the number of variables k considered at each split that provided the lowest out-of-bag 
error estimate. Beginning with , where v is the total number of predictor variables, 
the forest was grown and out-of-bag error was measured. Then, the number of variables 
considered at each split was progressively increased by a factor of two (i.e., 
) until the out-of-bag error decreased by less than 5% from the 
out-of-bag error for the previous value of k. Next, returning to , the number of 
variables considered at each split was progressively decreased by a factor of two (i.e., 
) until the out-of-bag error decreased by less than 5% from the 
out-of-bag error for the previous value of k. The optimized k chosen was 78, which gave 
an out-of-bag error estimate of 24.9%. 
 
When working with a dataset that has two possible classes, the standard procedure for a 
random forest is to assign a prediction to an individual based on a simple majority of 
votes, when the prevalence of the outcome is less than 50% changing the proportion of 
votes needed to classify an individual can significantly impact the estimates of 
performance. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set on a range of proportions. First, 
an individual was assigned a prediction of “high risk” if 5% or more of the trees in the 
forest predicted the individual to be “high risk”. This was then repeated in increments of 
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5% until individuals were assigned a prediction of “high risk” only if 95% or more of the 
trees in the forest predicted the individual to be “high risk”. Table 4-9 shows the results 
of this investigation. 
 
Predictions were then made about each individual in the independent testing set created 
by the risk index procedure, and the sensitivity, specificity, misclassification, and positive 
predictive value of the predictions was assessed. One thousand bootstrap samples of the 
independent testing set were generated, and predictions were made about each individual 
in each of the bootstrap samples. This data was used to create 95% confidence intervals 
for the sensitivity, specificity, misclassification, and positive predictive value estimates. 
Table 4-10 shows the sensitivity, specificity, misclassification, and positive predictive 
value estimates for the random forest as well as the 95% confidence interval for each 
estimate. Lastly, using the class votes for the individuals in the independent testing set, an 




Table 4-9 Performance Estimates of the Random Forest 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 1.000 0.000 0.659 0.341 
0.1 1.000 0.038 0.634 0.349 
0.15 0.978 0.166 0.557 0.377 
0.2 0.956 0.340 0.450 0.428 
0.25 0.898 0.498 0.366 0.480 
0.3 0.839 0.615 0.308 0.530 
0.35 0.737 0.728 0.269 0.584 
0.4 0.657 0.815 0.239 0.647 
0.45 0.526 0.887 0.236 0.706 
0.5 0.380 0.940 0.251 0.765 
0.55 0.219 0.985 0.276 0.882 
0.6 0.051 0.992 0.328 0.778 
0.65 0.007 1.000 0.338 1.000 
0.7 0.000 1.000 0.341 - 
0.75 0.000 1.000 0.341 - 
0.8 0.000 1.000 0.341 - 
0.85 0.000 1.000 0.341 - 
0.9 0.000 1.000 0.341 - 
0.95 0.000 1.000 0.341 - 
 
Table 4-10 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for the Random Forest Model 
Proportion of Votes for  









0.25 0.898  (0.841 - 0.944) 
0.498  
(0.435 - 0.556) 
0.366  
(0.318 - 0.413) 
0.480  
(0.423 - 0.543) 
0.3 0.839  (0.775 - 0.901) 
0.615  
(0.552 - 0.674) 
0.308  
(0.264 - 0.358) 
0.530  
(0.462 - 0.596) 
0.35 0.737  (0.664 - 0.811) 
0.728  
(0.673 - 0.781) 
0.269  
(0.226 - 0.313) 
0.584  
(0.510 - 0.660) 
0.4 0.657  (0.583 - 0.736) 
0.815  
(0.769 - 0.859) 
0.239 (0.199 - 
0.279) 
0.647  
(0.567 - 0.719) 
0.45 0.526  (0.448 - 0.607) 
0.887  
(0.845 - 0.923) 
0.236  
(0.197 - 0.279) 
0.706  
(0.615 - 0.793) 
0.5 0.380  (0.297 - 0.466) 
0.940  
(0.908 - 0.967) 
0.251  
(0.206 - 0.296) 
0.765  









The performance of the risk index procedure in predicting the development of 
hypertension with a ten-year period is fairly poor, despite a large number of Clinical 
variables and 500 polymorphisms selected because of their association in logistic 
regression models with the development of hypertension. The random forest, however, 
performed much better than the risk index model in overall classification accuracy, 
prediction specificity, and positive predictive value. However, the Clinical risk index 
model produced a sensitivity that was significantly higher than the random forest (the 
95% confidence interval of the risk index model does not overlap with the 95% 
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confidence interval for the sensitivity estimate of the random forest) if a simple majority 
of trees in the random forest is used to assign the predictions. Likewise, the sensitivity 
estimate for the Clinical + Genotype risk index model has a 95% confidence interval that 
is higher than the random forest, and it only just overlaps with the 95% confidence 
interval of the sensitivity estimate of the random forest. However, by lowering the 
proportion of trees necessary to assign an individual a “high risk” classification, the 
random forest can yield performance that is noticeably better than the Clinical or Clinical 
+ Genotype risk index models. As Table 4-10 shows, by setting the proportion of trees 
voting for a classification of “high risk” to 0.35 a nearly balanced sensitivity and 
specificity, with a misclassification much lower than that of the risk index models. The 
relatively linear AUC curves for the Clinical and Clinical + Genotype risk index models 
indicates that varying the proportion of votes need to make a prediction of “high risk” 
will not yield a marked improvement in sensitivity without a corresponding drop in 
specificity. 
 
4.6 Ten-Year Incident Hypertension Results Using Top 500 Principal Components 
4.6.1 Variable Selection 
Using the procedure described in Section 4.5.1, the risk index procedure was repeated, 
replacing the 500 SNPs most highly associated with 10-year incident hypertension with 





Table 4-11 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the optimization set used to build the Clinical risk index model. 
Fifty-three out of the 100 trimmed Clinical risk index models contained height as a 
variable, and 51 contained marital status. Diastolic blood pressure was included in 43 out 
of the 100 trimmed Clinical risk index models. Weekly alcohol consumption, current 
smoking status, and age were also frequently included in the set of 100 trimmed Clinical 
risk index models, appearing in 41, 37, and 33 trimmed Clinical risk index models, 
respectively. 
 
Table 4-12 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the Optimization Set used to build the Clinical + Genotype risk 
index model. Table 4-12 shows a summary of variable selection process for the 19 PCs 
that were selected into 8 or more untrimmed Clinical + Genotype risk index models. All 




Table 4-11 Summary of Number of Times Each Variable is Selected into a Specific Model Position for the Clinical Risk Index 
Model for Incident Hypertension 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 









Age (yrs) 4 13 6 0 5 1 2 3 4 4 3 2 3 3 4 3 6 6 1 7 80 33 
Sex 0 8 2 7 3 3 7 4 2 7 5 7 3 6 4 6 2 5 1 5 87 22 
Weight (lbs) 0 1 0 2 1 0 1 3 1 5 2 2 0 4 4 7 5 8 8 4 58 7 
Height (in) 6 8 10 8 10 11 20 5 9 2 3 1 1 0 1 0 2 2 1 0 100 53 
Systolic Blood Pressure 
(mm Hg) 17 1 4 3 0 3 3 0 1 1 7 3 5 4 6 6 4 6 4 5 83 29 
Diastolic Blood Pressure 
(mm Hg) 26 4 4 1 3 3 1 2 1 1 1 1 1 1 2 2 3 1 3 6 67 43 
Total Cholesterol  (mg/dL) 1 3 0 1 2 2 1 1 3 4 4 2 7 8 5 4 5 7 8 10 78 14 
High-density Lipoprotein 
Level (mg/dL) 4 3 1 3 5 4 1 2 4 4 2 5 5 5 5 3 9 5 9 7 86 21 
Low-density Lipoprotein 
Level (mg/dL) 0 4 5 5 2 2 3 3 3 6 4 3 3 6 4 3 13 5 7 3 84 19 
Triglycerides (mg/dL) 2 2 2 3 2 6 2 5 1 1 1 7 5 2 7 9 2 2 9 9 79 19 
Ever Smoked 3 4 5 14 4 0 5 5 8 6 4 7 9 4 6 6 3 3 0 2 98 31 
Currently Smokes 0 11 16 14 6 7 7 7 2 6 3 4 5 4 3 2 1 0 0 1 99 37 
Weekly Alcohol 
Consumption 13 3 6 3 11 3 7 7 6 5 7 7 3 3 7 2 3 1 0 1 98 41 
Marital Status 9 18 10 11 6 12 5 4 5 5 4 1 0 3 2 0 0 2 2 1 100 51 
Left Ventricular Mass (g) 3 1 1 1 2 3 1 3 6 2 3 8 4 5 3 5 6 7 8 9 81 14 
Left Ventricular Ejection 
Fraction (%) 0 6 9 4 12 5 3 7 6 3 1 4 5 5 3 3 4 4 3 1 88 28 
Blood Glucose (mg/dL) 0 3 0 3 1 4 1 6 3 3 8 4 7 2 4 4 14 12 7 1 87 13 
Blood Urea Nitrogen 




Total Serum Protein Level 
(mg/dL) 4 2 1 6 3 3 3 7 7 6 3 6 5 7 7 7 0 4 7 5 93 18 
Serum Albumin Level 
(mg/dL) 1 0 8 1 6 8 6 4 6 8 9 7 3 9 4 7 3 2 2 2 96 27 
Serum Bilirubin Level 




0 0 2 2 3 3 2 1 5 1 7 3 4 3 3 8 6 7 6 6 72 13 
Serum Creatine Level 






Table 4-12 Summary of Number of Times Selected Principal Component Variables are Selected into a Specific Model Position 
for the Clinical + Genotype Risk Index Model for Incident Hypertension 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Total # of Times 
in Untrimmed 
Model 
Total # of Times 
in Trimmed 
Model 
PC23 0 0 0 1 1 0 1 1 0 0 1 2 1 0 0 0 0 1 3 1 13 10 
PC53 1 1 0 0 2 1 0 2 1 0 0 0 0 0 0 2 0 0 0 0 10 10 
PC88 1 1 0 1 0 1 0 1 1 1 0 0 0 0 1 0 0 1 2 0 11 10 
PC57 1 1 1 0 0 1 0 1 1 0 0 0 0 1 1 1 0 0 1 1 11 9 
PC254 0 0 2 0 0 1 0 0 0 1 2 0 0 3 0 0 0 0 0 0 9 9 
PC348 1 0 0 0 0 1 0 0 1 0 0 1 1 0 0 2 1 1 0 0 9 9 
PC500 1 0 0 0 1 1 0 0 1 1 3 0 0 0 0 0 0 1 0 1 10 9 
PC13 1 0 1 0 1 1 1 1 0 1 0 0 0 0 1 0 1 0 0 0 9 8 
PC14 0 0 0 0 1 0 2 0 0 1 0 0 0 2 0 1 0 1 2 1 11 8 
PC29 0 0 0 1 0 0 0 0 3 0 0 1 0 1 1 0 1 0 0 0 8 8 
PC36 1 0 0 0 1 1 0 0 0 1 0 0 0 1 0 2 0 0 1 0 8 8 
PC125 1 1 0 0 0 2 0 0 0 0 0 0 1 0 1 1 1 1 0 0 9 8 
PC225 2 0 0 0 0 0 0 1 0 0 1 0 0 1 1 0 1 0 0 2 9 8 
PC227 0 1 2 0 0 1 1 0 0 0 1 0 0 0 0 0 1 1 0 0 8 8 
PC347 2 0 0 0 1 2 0 0 0 1 0 0 0 0 1 0 1 0 0 0 8 8 
PC357 1 1 1 0 1 0 0 1 0 0 0 0 0 1 0 0 0 1 0 1 8 8 




Table 4-13 shows the trimmed Clinical risk index models for a selection of five random 
bootstrap samples. Figure 4-13 shows the distribution of risk index values in the 
optimization set for the Clinical risk index model from one randomly selected bootstrap 
sample (Bootstrap Sample #2), and Figure 4-14 shows the distribution of risk index 
values in the independent testing set for the Clinical risk index model from the same 
randomly selected bootstrap sample (Bootstrap Sample #2). The red line on each graph 
marks the cutoff point for the model. All individuals with a risk index value greater than 
this are predicted as “high risk of developing hypertension” and those with a risk index 
value lower are predicted as “low risk of developing hypertension”. Table 4-14 shows the 
risk index values for 25 randomly chosen individuals from the Independent Testing Set 
from these five Clinical risk index models along with that risk index model’s prediction 
about each individual, where 0 indicates low risk of developing hypertension and 1 
indicates high risk of developing hypertension. 
 
Table 4-13 Five Randomly Selected Trimmed Clinical Risk Index Models for 
Incident Hypertension 
Bootstrap Sample Model 
2 - 0.2706*Sex - 0.016*Height + 0.0649*Marital Status + 0.0133*lvef + 0.015*Blood Glucose + 0.0569*Blood Urea Nitrogen 
16 
0.0577*Age - 0.0407*Height + 0.0702*Systolic Blood Pressure - 0.0225*HDL 
+ 0.0067*LDL + 0.0018*Triglycerides - 0.0038*Weekly Alcohol Consumption 
+ 0.0602*Marital Status 
39 0.1052*Diastolic Blood Pressure + 0.259*Marital Status 
44 0.2289*Marital Status 
99 
0.0666*Age - 0.0215*Height + 0.0019*Triglycerides + 0.2416*Ever Smoked - 
0.106*Current Smoking Status + 0.0262*Weekly Alcohol Consumption + 
0.1361*Marital Status + 0.0037*Left Ventricular Mass + 0.0293*Left 
Ventricular Ejection Fractions + 0.068*Blood Urea Nitrogen - 0.045*Serum 




Table 4-14 Risk Index Values for 25 Individuals from the Independent Testing Set from Five Randomly Selected Clinical Risk 
Index Models 
   Bootstrap Sample #2 Bootstrap Sample #16 Bootstrap Sample #39 Bootstrap Sample #44 Bootstrap Sample #99 

















1 0 0.324 1 1.545 1 3.836 0 0.458 0 0.338 0 
2 1 0.276 0 1.185 1 3.941 0 0.458 0 0.383 1 
3 1 0.378 1 1.010 0 4.677 1 0.458 0 0.347 0 
4 0 -0.095 0 0.912 0 4.257 0 0.458 0 0.589 1 
5 1 0.345 1 1.186 1 4.677 1 0.458 0 0.364 0 
6 0 0.322 1 0.911 0 4.046 0 0.458 0 0.332 0 
7 0 0.304 0 1.028 0 3.941 0 0.458 0 0.296 0 
8 0 0.287 0 0.736 0 3.310 0 0.458 0 0.168 0 
9 0 0.216 0 1.042 0 3.941 0 0.458 0 0.236 0 
10 1 0.321 1 1.111 1 3.941 0 0.458 0 0.418 1 
11 1 0.270 0 1.050 0 4.677 1 0.458 0 0.283 0 
12 0 0.324 1 1.311 1 4.467 1 0.458 0 0.343 0 
13 0 0.235 0 1.028 0 3.941 0 0.458 0 0.270 0 
14 1 -0.144 0 1.130 1 3.812 0 0.229 0 0.389 1 
15 0 0.282 0 0.919 0 3.941 0 0.458 0 0.251 0 
16 1 0.305 0 1.300 1 5.624 1 0.458 0 0.389 1 
17 1 0.313 0 1.194 1 4.572 1 0.458 0 0.316 0 
18 0 0.271 0 0.925 0 3.836 0 0.458 0 0.304 0 
19 1 0.258 0 1.205 1 3.941 0 0.458 0 0.424 1 
20 1 0.351 1 0.786 0 4.362 1 0.458 0 0.277 0 
21 1 0.333 1 1.107 1 4.257 0 0.458 0 0.434 1 
22 0 0.335 1 1.283 1 4.467 1 0.458 0 0.463 1 
23 1 0.425 1 1.433 1 5.098 1 0.458 0 0.501 1 
24 1 0.368 1 0.870 0 3.601 0 0.229 0 0.227 0 




Figure 4-13 Distribution of Risk Index Values in the Optimization Set from the 
Clinical Risk Index Model for Bootstrap Sample #2 
 
 
Figure 4-14 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical Risk Index Model for Bootstrap Sample #2 
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Table 4-15 shows the trimmed Clinical + Genotype risk index models for the same set of 
five bootstraps shown in Table 4-13, and Table 4-16 shows the risk index values and 
predictions of the same 25 randomly chosen individuals for the 5 bootstrap samples 
shown in Table 4-14. Figure 4-15 shows the distribution of risk index values in the 
optimization set for the Clinical + Genotype risk index model from one randomly 
selected bootstrap sample (Bootstrap Sample #2). Figure 4-16 shows the distribution of 
risk index values in the independent testing set for the Clinical + Genotype risk index 
model from the same randomly selected bootstrap sample (Bootstrap Sample #2). The red 
line on each graph marks the cutoff point for the model. All individuals with a risk index 
value greater than this are predicted as “high risk of developing hypertension” and those 




Table 4-15 Five Randomly Selected Clinical + Genotype Risk Index Models For 
Incident Hypertension 
Bootstrap Sample Model 
2 
- 0.2706*Sex - 0.016*Height + 0.0649*Marital Status + 0.0133*lvef + 
0.015*Blood Glucose + 0.0569*Blood Urea Nitrogen - 0.8055*PC7 + 
0.726*PC18 - 0.8886*PC28 + 0.5323*PC29 + 0.7198*PC43 + 0.334*PC52 - 
1.8591*PC65 + 0.1256*PC73 - 4.362*PC95 - 1.1804*PC108 - 1.3473*PC115 - 
0.6482*PC120 - 1.4195*PC130 + 4.2483*PC227 - 0.8451*PC263 - 
0.3596*PC314 - 2.0389*PC348 - 0.4656*PC433 - 0.1687*PC464 
16 
0.0577*Age - 0.0407*Height + 0.0702*Systolic Blood Pressure - 0.0225*HDL 
+ 0.0067*LDL + 0.0018*Triglycerides - 0.0038*Weekly Alcohol Consumption 
+ 0.0602*Marital Status + 4.4639*PC18 + 0.8152*PC30 + 0.4643*PC107 + 
0.1066*PC111 - 1.9152*PC130 + 4.2281*PC163 - 1.1749*PC167 - 
1.345*PC196 - 0.9547*PC208 + 1.0625*PC211 - 2.6757*PC241 - 
0.8091*PC245 + 1.9528*PC269 + 0.3945*PC306 - 0.8056*PC344 - 
3.9691*PC393 + 5.869*PC435 + 7.5732*PC444 + 1.3192*PC448 + 
0.8623*PC465 
39 
0.1052*Diastolic Blood Pressure + 0.259*Marital Status + 0.655*PC14 - 
4.5884*PC28 - 5.0108*PC36 + 2.1823*PC146 - 4.5874*PC171 + 
0.1737*PC205 + 0.5732*PC211 + 0.4999*PC230 + 0.6401*PC256 - 
0.8464*PC282 + 0.2285*PC294 + 5.1635*PC334 + 1.4181*PC336 + 
0.2759*PC342 + 0.6679*PC379 - 1.6134*PC397 + 2.7397*PC416 + 
7.2186*PC427 + 0.5282*PC457 
44 
0.2289*Marital Status - 0.1024*PC23 + 0.1156*PC39 + 0.3855*PC60 + 
0.4568*PC86 - 0.811*PC88 - 0.1054*PC94 + 0.7108*PC98 + 1.066*PC107 - 
0.8398*PC156 + 0.5521*PC178 - 2.4885*PC179 + 0.4583*PC190 + 
0.0081*PC195 - 0.166*PC197 + 0.4936*PC225 - 0.2339*PC243 - 
0.0632*PC254 + 0.0569*PC358 - 0.6113*PC415 - 0.9741*PC455 
99 
0.0666*Age - 0.0215*Height + 0.0019*Triglycerides + 0.2416*Ever Smoked - 
0.106*Current Smoking Status + 0.0262*Weekly Alcohol Consumption + 
0.1361*Marital Status + 0.0037*Left Ventricular Mass + 0.0293*Left 
Ventricular Ejection Fractions + 0.068*Blood Urea Nitrogen - 0.045*Serum 
Albumin - 0.0038*Serum Bilirubin + 1.8893*PC24 - 1.1636*PC33 + 
0.1657*PC93 - 2.3146*PC98 + 2.8609*PC186 + 1.1718*PC301 + 
2.1745*PC332 - 1.6836*PC348 - 1.1166*PC356 + 1.5775*PC389 + 




Table 4-16 Risk Index Values for 25 Individuals in the Independent Testing Set for the Clinical + Genotype Risk Index Models 
from Five Randomly Selected Bootstrap Samples 
   Bootstrap Sample #2 Bootstrap Sample #16 Bootstrap Sample #39 Bootstrap Sample #44 Bootstrap Sample #99 

















1 0 0.334 1 1.573 1 3.824 0 0.457 0 0.341 0 
2 1 0.274 0 1.194 1 3.938 0 0.455 0 0.383 1 
3 1 0.383 1 1.023 0 4.690 1 0.459 1 0.341 0 
4 0 -0.086 0 0.914 0 4.258 0 0.460 1 0.596 1 
5 1 0.353 1 1.214 1 4.705 1 0.456 0 0.349 0 
6 0 0.333 1 0.908 0 4.044 0 0.460 1 0.319 0 
7 0 0.308 0 1.039 0 3.946 0 0.457 0 0.293 0 
8 0 0.281 0 0.723 0 3.320 0 0.457 0 0.169 0 
9 0 0.216 0 1.043 0 3.941 0 0.453 0 0.227 0 
10 1 0.320 1 1.113 1 3.933 0 0.459 0 0.405 1 
11 1 0.272 0 1.050 0 4.689 1 0.455 0 0.286 0 
12 0 0.308 0 1.323 1 4.468 1 0.455 0 0.355 0 
13 0 0.238 0 1.037 0 3.947 0 0.458 0 0.277 0 
14 1 -0.147 0 1.130 1 3.826 0 0.232 0 0.380 1 
15 0 0.283 0 0.908 0 3.929 0 0.456 0 0.248 0 
16 1 0.305 0 1.297 1 5.613 1 0.448 0 0.384 1 
17 1 0.306 0 1.192 1 4.570 1 0.460 1 0.315 0 
18 0 0.273 0 0.920 0 3.847 0 0.460 1 0.293 0 
19 1 0.261 0 1.225 1 3.931 0 0.460 1 0.428 1 
20 1 0.351 1 0.777 0 4.381 0 0.455 0 0.272 0 
21 1 0.326 1 1.123 1 4.272 0 0.456 0 0.437 1 
22 0 0.335 1 1.276 1 4.472 1 0.458 0 0.452 1 
23 1 0.427 1 1.422 1 5.101 1 0.456 0 0.517 1 
24 1 0.376 1 0.871 0 3.578 0 0.228 0 0.224 0 




Figure 4-15 Distribution of Risk Index Values in the Optimization Set from the 
Clinical + Genotype Risk Index Model for Bootstrap Sample #2 
 
 
Figure 4-16 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical + Genotype Risk Index Model for Bootstrap Sample #2 
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4.6.3 Predictive Performance 
Once predictions were made for each individual in the independent testing set the 
sensitivity, specificity, misclassification, and positive predictive value were calculated for 
the Clinical risk index model and the Clinical + Genotype risk index model as described 
in Section 4.5.3. The estimates and confidence intervals for sensitivity, specificity, 
misclassification, and positive predictive value are given in Table 4-17. Lastly, using the 
individual predictions from each of the 100 trimmed Clinical risk index models and 100 
trimmed Clinical + Genotype risk index models for the individuals in the independent 
testing set, ROC curves were generated, and the AUC for the ROC curve was estimated 
for both the Clinical and Clinical + Genotype risk index models (Figure 4-17, Figure 4-
18). For the Clinical risk index model the AUC for the ROC curve was 0.566, and for the 
Clinical + Genotype risk index model the AUC for the ROC curve was 0.563. 
 
Table 4-17 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for Ten-year Incident Hypertension 

























Figure 4-17 ROC Curve and AUC for the Incident Hypertension PCA Clinical Risk 
Index Model 
 
Figure 4-18 ROC Curve and AUC for the Incident Hypertension PCA Clinical + 




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual is at high risk of developing hypertension, then, 
represents the predicted probability of an individual developing hypertension. Section 
4.5.3 describes the calculation of a confidence interval for this predicted probability. 
 
Figure 4-20 shows the distribution of the predicted probability of developing 
hypertension for the Clinical risk index model in the independent testing set, and Figure 
4-11 shows the distribution of the predicted probability of developing hypertension for 
the Clinical + Genotype risk index model in the independent testing set. In both Figures, 
a density line is shown on the graph to indicate the density of a normal distribution with 
the mean and standard deviation matching that of the confidence score distribution. 
 
Figure 4-19 Histogram of the Predicted Probability of Developing Hypertension for 





Figure 4-20 Histogram of the Predicted Probability of Developing Hypertension for 
the Clinical + Genotype Risk Index Model 
 
4.6.4 Random Forests Comparison 
A random forest was generated using the optimization set created by the risk index 
procedure. The forest had 500 individual trees, and the tuning procedure described in 
detail in Section 4.6.4 was used to find the number of variables k considered at each split 
that provided the lowest out-of-bag error estimate. The optimized k chosen was 45, which 
gave an out-of-bag error estimate of 31.4%. 
 
When working with a dataset that has two possible classes, the standard procedure for a 
random forest is to assign a prediction to an individual based on a simple majority of 
votes, when the prevalence of the outcome is less than 50% changing the proportion of 
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votes needed to classify an individual can significantly impact the estimates of 
performance. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set on a range of proportions. First, 
an individual was assigned a prediction of “high risk” if 5% or more of the trees in the 
forest predicted the individual to be “high risk”. This was then repeated in increments of 
5% until individuals were assigned a prediction of “high risk” only if 95% or more of the 
trees in the forest predicted the individual to be “high risk”. Table 4-18 shows the results 
of this investigation. 
 
Predictions were then made about each individual in the independent testing set created 
by the risk index procedure, and the sensitivity, specificity, misclassification, and positive 
predictive value of the predictions was assessed. One thousand bootstrap samples of the 
independent testing set were generated, and predictions were made about each individual 
in each of the bootstrap samples. This data was used to create 95% confidence intervals 
for the sensitivity, specificity, misclassification, and positive predictive value estimates. 
Table 4-19 shows the sensitivity, specificity, misclassification, and positive predictive 
value estimates for the random forest as well as the 95% confidence interval for each 
estimate. Lastly, using the class votes for the individuals in the independent testing set, an 




Table 4-18 Performance Estimates of the Random Forest 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 1.000 0.000 0.686 0.314 
0.1 1.000 0.003 0.684 0.315 
0.15 1.000 0.031 0.665 0.321 
0.2 0.979 0.116 0.613 0.336 
0.25 0.952 0.310 0.488 0.387 
0.3 0.836 0.480 0.409 0.424 
0.35 0.712 0.646 0.333 0.479 
0.4 0.534 0.762 0.310 0.506 
0.45 0.329 0.843 0.318 0.490 
0.5 0.123 0.950 0.310 0.529 
0.55 0.027 0.994 0.310 0.667 
0.6 0.000 0.997 0.316 0.000 
0.65 0.000 1.000 0.314 - 
0.7 0.000 1.000 0.314 - 
0.75 0.000 1.000 0.314 - 
0.8 0.000 1.000 0.314 - 
0.85 0.000 1.000 0.314 - 
0.9 0.000 1.000 0.314 - 
0.95 0.000 1.000 0.314 - 
 
Table 4-19 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for the Random Forest Model 
Proportion of Votes for  









































































As expected, the performance of the Clinical risk index model for this dataset is 
comparable to the performance of the Clinical risk index model built for the Incident 
Hypertension dataset with the 500 most highly associated SNPs. The inclusion of the top 
500 principal components, however, increases the AUC of the Clinical + Genotype risk 
index model from 0.475 to 0.563. The random forest, however, did not perform as well 
when built using the top 500 principal components. The AUC for the random forest built 
using the principal components was 0.719, as opposed to 0.811 for the random forest 
built using the 500 most highly associated SNPs. Tables 4-18 and 4-19 show that there is 
not a proportion cutoff to assign a prediction of “high risk” for the random forest that 
achieves the same level of fairly high, balanced predictive performance as was available 
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when the random forest was built using the top 500 most highly associated SNPs. Even 
still, for the cutpoint that yields the most balanced predictive performance, the random 
forest performed better than either risk index model in overall classification accuracy, 
prediction specificity, and positive predictive value. However, the both the Clinical and 
Clinical + Genotype risk index model produced a sensitivity that was equal to that of the 
random forest.  
 
4.7 Ten-Year Incident Diabetes Results Using 500 Most Highly Associated SNPs 
4.7.1 Variable Selection 
Using the procedure described in Section 4.5.1, the risk index procedure was performed 
to predict risk of developing diabetes within a ten-year time frame. The 500 SNPs most 
highly associated with this outcome (i.e., which had the lowest p-values from a logistic 
regression analysis of this outcome) were identified and used to build the risk index. 
 
Table 4-20 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the optimization set used to build the Clinical risk index model. 
Forty-seven out of the 100 trimmed Clinical risk index models contained marital status as 
a variable, and 46 contained weight. Blood glucose was included in 42 out of 100 of the 
100 trimmed Clinical risk index models. Having ever smoked, current smoking status, 
and age were also frequently included in the set of 100 trimmed Clinical risk index 




Table 4-21 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the Optimization Set used to build the Clinical + Genotype risk 
index model. Several SNPs were selected into the first five positions 15 or more times. 
Table 4-21 shows a summary of variable selection process for the 11 SNPs that were 
selected into 50 or more untrimmed Clinical + Genotype risk index models. All of these 




Table 4-20 Summary of Number of Times Each Variable is Selected into a Specific Model Position for the Clinical Risk Index 
Model for Incident Diabetes 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 









Age (yrs) 2 10 11 4 9 1 7 8 4 4 2 5 3 6 4 3 3 2 3 4 95 29 
Sex 5 6 12 5 4 6 4 5 4 5 5 2 5 1 1 7 4 2 6 7 96 24 
Weight (lbs) 21 15 3 8 2 4 3 3 3 3 2 3 1 3 2 1 5 5 3 5 95 46 
Height (in) 1 1 7 2 10 12 9 10 8 2 8 2 6 5 4 2 4 2 2 1 98 21 
Systolic Blood Pressure 
(mm Hg) 4 2 5 2 4 5 6 4 2 6 9 8 3 5 3 3 4 1 6 5 87 15 
Diastolic Blood Pressure 
(mm Hg) 1 0 5 0 0 5 6 2 7 8 9 6 6 6 3 3 7 3 2 6 85 17 
Total Cholesterol  (mg/dL) 3 0 1 2 7 2 10 3 8 6 9 6 5 9 7 4 4 6 3 3 98 16 
High-density Lipoprotein 
Level (mg/dL) 3 10 2 8 5 4 2 3 0 5 1 11 7 4 6 5 2 5 6 7 96 28 
Low-density Lipoprotein 
Level (mg/dL) 0 0 2 0 2 4 1 6 7 5 8 4 14 9 9 6 4 6 6 5 98 8 
Triglycerides (mg/dL) 6 4 1 2 1 3 1 1 1 3 5 3 2 9 8 10 3 9 11 6 89 20 
Ever Smoked 1 5 11 10 7 6 4 6 6 11 9 5 7 4 1 2 2 1 0 2 100 34 
Currently Smokes 2 12 8 9 12 9 6 8 7 3 3 8 4 1 1 3 0 2 1 0 99 31 
Weekly Alcohol 
Consumption 3 4 5 4 10 5 9 5 7 3 4 7 5 5 6 5 4 2 4 1 98 24 
Marital Status 7 17 10 22 7 8 4 7 7 1 2 2 0 4 0 0 1 0 1 0 100 47 
Left Ventricular Mass (g) 1 1 0 1 0 1 2 1 0 0 1 1 0 2 12 3 1 1 2 8 38 2 
Left Ventricular Ejection 
Fraction (%) 1 1 1 1 0 0 2 1 0 1 2 1 2 0 3 13 2 4 2 3 40 5 
Blood Glucose (mg/dL) 32 3 2 1 2 0 0 2 3 3 0 3 1 2 0 1 17 4 3 3 82 42 
Blood Urea Nitrogen 




Total Serum Protein Level 
(mg/dL) 0 1 2 2 2 1 5 1 4 6 3 3 5 5 7 5 4 7 24 3 90 13 
Serum Albumin Level 
(mg/dL) 3 4 1 4 6 6 5 4 7 2 5 3 6 5 6 4 2 4 1 18 96 23 
Serum Bilirubin Level 




0 1 4 1 1 1 4 3 1 3 0 2 0 6 3 2 11 6 10 7 66 9 
Serum Creatine Level 
(mg/dL) 1 0 2 4 3 8 3 3 3 5 6 3 5 4 8 9 7 1 2 0 77 16 
 
Table 4-21 Summary of Number of Times Selected Genotype Variables are Selected into a Specific Model Position for the 
Clinical + Genotype Risk Index Model for Incident Diabetes 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Total # of Times 
in Untrimmed 
Model 
Total # of Times 
in Trimmed 
Model 
rs6891442 0 4 5 4 7 5 5 5 8 4 3 4 5 3 4 0 1 1 1 1 70 54 
rs2021319 4 7 4 7 3 9 7 4 6 4 1 2 3 2 3 3 2 1 2 1 75 54 
rs4986893 2 3 4 6 4 3 6 3 3 1 2 5 6 1 3 4 4 4 1 0 65 50 
rs11975965 1 4 4 7 4 9 4 0 2 3 5 4 1 3 2 2 0 3 4 2 64 46 
rs2720533 2 3 4 6 1 4 2 4 5 6 1 4 3 0 4 0 3 1 0 3 56 39 
rs7114437 0 0 5 1 3 2 2 1 8 1 3 3 8 3 1 1 1 0 2 3 48 38 
rs12610412 1 0 3 2 3 4 2 0 5 2 3 4 8 3 3 2 5 5 3 2 60 37 
rs2069168 0 4 3 1 6 7 6 5 1 2 2 2 2 2 1 3 0 2 0 1 50 36 
rs3821406 3 0 4 2 2 1 1 6 3 1 3 4 3 4 2 4 2 3 2 3 53 36 
rs1804254 0 4 0 2 3 3 0 3 2 4 1 3 1 4 6 2 3 1 2 0 44 32 




Table 4-22 shows the trimmed Clinical risk index models for a selection of five random 
bootstrap samples. Figure 4-22 shows the distribution of risk index values in the 
optimization set for the Clinical risk index model from one randomly selected bootstrap 
sample (Bootstrap Sample #2), and Figure 4-23 shows the distribution of risk index 
values in the independent testing set for the Clinical risk index model from the same 
randomly selected bootstrap sample (Bootstrap Sample #2). The red line on each graph 
marks the cutoff point for the model. All individuals with a risk index value greater than 
this are predicted as “high risk of developing diabetes” and those with a risk index value 
lower are predicted as “low risk of developing diabetes”. Although Figures 4-22 and 4-23 
appear discontinuous in their distribution, this is simply due to the presence of only one 
categorical variable, marital status, which takes only a small number of values, in the 
Clinical risk index model for bootstrap sample #2. Table 4-23 shows the risk index values 
for 25 randomly chosen individuals from the Independent Testing Set from these five 
Clinical risk index models along with that risk index model’s prediction about each 





Table 4-22 Five Randomly Selected Trimmed Clinical Risk Index Models for 
Incident Diabetes 
Bootstrap Sample Model 
2 -0.2017*Marital Status 
45 
0.0396*Age + 0.0605*Height + 0.0096*Total Cholesterol - 0.0655*HDL + 
0.0092*LDL + 0.2239*Ever Smoked + 0.1754*Current Smoking Status + 
0.0213*Weekly Alcohol Consumption + 0.0531*Marital Status + 
0.1124*Blood Glucose + 0.0491*bun + 0.03*Serum Albumin + 
0.0021*Serum Bilirubin + 0.0451*Serum Alkaline Phophatase + 
0.0375*Serum Creatine 
54 
0.0208*Weight + 1e-04*Height + 0.0583*diastolicBP + 
0.0018*Triglycerides + 0.2566*Ever Smoked + 0.0709*Current Smoking 
Status + 0.121*Marital Status + 0.1016*Blood Glucose + 0.0369*Total 
Serum Protein - 0.0446*Serum Albumin - 0.0031*Serum Bilirubin + 
0.0349*Serum Creatine 
59 0.0255*Weight + 0.0735*Height + 0.0062*Total Cholesterol - 0.0738*HDL + 0.0294*Weekly Alcohol Consumption 




Table 4-23 Risk Index Values for 25 Individuals from the Independent Testing Set for Clinical Risk Index Models for Incident 
Diabetes from Five Randomly Selected Bootstrap Samples 
   Bootstrap Sample #2 Bootstrap Sample #45 Bootstrap Sample #54 Bootstrap Sample #59 Bootstrap Sample #76 

















1 0 -0.403 0 1.146 0 1.602 0 0.681 0 0.029 0 
2 0 -0.403 0 1.423 0 1.756 0 1.886 0 0.871 0 
3 0 -0.403 0 1.430 0 1.701 0 1.434 0 0.549 0 
4 0 -0.403 0 1.220 0 1.699 0 1.607 0 0.712 0 
5 1 -0.403 0 1.533 0 1.910 1 1.803 0 0.964 1 
6 0 -0.403 0 1.416 0 1.568 0 0.711 0 0.080 0 
7 0 -0.202 1 1.350 0 1.214 0 3.037 1 0.985 1 
8 0 -0.807 0 1.316 0 1.571 0 1.156 0 0.431 0 
9 0 -0.403 0 1.507 0 1.704 0 1.263 0 0.594 0 
10 0 -0.403 0 1.509 0 1.879 1 1.380 0 0.599 0 
11 1 -0.202 1 1.399 0 1.587 0 1.517 0 0.660 0 
12 0 -1.009 0 1.296 0 1.734 0 1.502 0 0.699 0 
13 0 -0.403 0 1.417 0 1.829 1 1.580 0 0.646 0 
14 0 -0.403 0 1.495 0 1.525 0 1.076 0 0.352 0 
15 0 -0.403 0 1.451 0 1.945 1 1.396 0 0.601 0 
16 1 -0.403 0 1.724 1 1.603 0 1.174 0 0.382 0 
17 0 -0.403 0 1.166 0 1.713 0 1.120 0 0.357 0 
18 0 -0.403 0 1.166 0 1.830 1 3.653 1 1.538 1 
19 0 -0.605 0 1.369 0 1.345 0 0.454 0 0.010 0 
20 0 -0.403 0 1.386 0 1.712 0 1.925 1 0.968 1 
21 0 -0.403 0 1.610 1 1.592 0 1.633 0 0.766 0 
22 0 -0.403 0 1.351 0 1.474 0 1.071 0 0.323 0 
23 0 -0.403 0 0.794 0 1.654 0 1.546 0 0.703 0 
24 0 -0.403 0 1.346 0 1.527 0 1.031 0 0.393 0 





Figure 4-22 Distribution of Risk Index Values in the Optimization Set from the 
Clinical Risk Index Model for Bootstrap Sample #2 
 
 
Figure 4-23 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical Risk Index Model for Bootstrap Sample #2 
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Table 4-24 shows the trimmed Clinical + Genotype risk index models for the same set of 
five bootstraps shown in Table 4-22, and Table 4-25 shows the risk index values and 
predictions of the same 25 randomly chosen individuals for the 5 bootstrap samples 
shown in Table 4-23. Figure 4-24 shows the distribution of risk index values in the 
optimization set for the Clinical + Genotype risk index model from one randomly 
selected bootstrap sample (Bootstrap Sample #2). Figure 4-25 shows the distribution of 
risk index values in the independent testing set for the Clinical + Genotype risk index 
model from the same randomly selected bootstrap sample (Bootstrap Sample #2). The red 
line on each graph marks the cutoff point for the model. All individuals with a risk index 
value greater than this are predicted as “high risk of developing diabetes” and those with 




Table 4-24 Five Randomly Selected Clinical + Genotype Risk Index Models for 
Incident Diabetes 
Bootstrap Sample Model 
2 
 -0.2017*Marital Status + rs12610412(C_G=0.4812) + rs2239811(A_C=0.3766, 
C_C=-0.9967) + rs2021319(G_G=-9.8516) + rs2720533(A_G=15.0516) + 
rs3821406(A_C=-0.8067) + rs2908780(G_G=-0.4694) + rs3918021(G_G=0.4714) 
45 
0.0396*Age + 0.0605*Height + 0.0096*Total Cholesterol - 0.0655*HDL + 
0.0092*LDL + 0.2239*Ever Smoked + 0.1754*Current Smoking Status + 
0.0213*Weekly Alcohol Consumption + 0.0531*Marital Status + 0.1124*Blood 
Glucose + 0.0491*bun + 0.03*Serum Albumin + 0.0021*Serum Bilirubin + 
0.0451*Serum Alkaline Phophatase + 0.0375*Serum Creatine + 
rs2069168(G_G=96.6672) + rs3736352(A_C=-0.1512, C_C=-712.1793) + 
rs3745489(C_T=-0.752) + rs12072734(A_G=1.5317, G_G=1.645) + 
rs3745581(C_G=27.0546, G_G=27.7574) + rs16939879(A_G=-0.546, G_G=-
0.5386) + rs1017842(C_G=98.7711, G_G=39.6089) + rs6891442(T_T=3.2488) + 
rs2021319(G_G=3.0098) + rs2720533(A_G=-2.3309) + rs1804254(C_C=1.2153) 
+ rs10514767(C_G=0.6335, G_G=0.71) + rs4711000(C_T=-0.2313, T_T=-
0.5737) + rs17010210(G_G=0.4383) + rs3918021(G_G=-0.092) 
54 
0.0208*Weight + 1e-04*Height + 0.0583*diastolicBP + 0.0018*Triglycerides + 
0.2566*Ever Smoked + 0.0709*Current Smoking Status + 0.121*Marital Status + 
0.1016*Blood Glucose + 0.0369*Total Serum Protein - 0.0446*Serum Albumin - 
0.0031*Serum Bilirubin + 0.0349*Serum Creatine + rs2289622(G_G=0.9044) + 
rs1800361(G_G=0.6614) + rs3111222(A_G=-0.0578, G_G=-0.0525) + 
rs9635334(A_T=0.2905, T_T=-0.8468) + rs3764633(A_G=-0.7265, G_G=-0.676) 
+ rs17787561(C_T=-0.4008) + rs4986893(G_G=1.8691) + 
rs9724933(A_G=0.5904, G_G=0.6278) + rs6891442(T_T=3.9009) + 
rs2021319(G_G=2.2705) + rs2720533(A_G=-2.2751) + rs1804254(C_C=1.2692) 
+ rs12818539(A_C=0.2794, C_C=0.3856) + rs12136578(C_T=0.2783, 
T_T=0.276) + rs17010210(G_G=0.8918) + rs3918021(G_G=0.1882) + 
rs11975965(C_T=-1.6993) 
59 
0.0255*Weight + 0.0735*Height + 0.0062*Total Cholesterol - 0.0738*HDL + 
0.0294*Weekly Alcohol Consumption + rs4084639(G_G=0.6644) + 
rs2290427(A_C=1.5041, C_C=2.2818) + rs2289622(G_G=0.3645) + 
rs3745489(C_T=-0.5684) + rs17179966(A_G=-0.324, G_G=0.324) + 
rs9257940(A_G=-0.0026, G_G=-1.5549) + rs12464093(G_T=0.1202, 
T_T=0.3303) + rs2288663(A_G=1.2017, G_G=0.9963) + 
rs7373862(A_G=0.0795, G_G=-0.2653) + rs751191(G_T=0.1059, T_T=-0.3885) 
+ rs12528104(C_T=0.5498, T_T=0.549) + rs6891442(T_T=1.8469) + 
rs2021319(G_G=0.6368) + rs3821406(A_C=-0.1651) + rs3918021(G_G=0.4557) 
+ rs11975965(C_T=-2.142) 
81 
0.0317*Age - 0.5642*Sex + 0.0229*Weight + 0.0258*Height - 0.0571*HDL + 
0.1177*Marital Status + rs2289622(G_G=1.1543) + rs7114437(A_T=-0.4356) + 
rs12610412(C_G=-0.018) + rs6086342(A_C=0.415, C_C=0.4348) + 
rs555990(C_G=1.0379, G_G=1.1079) + rs4986893(G_G=1.818) + 
rs11220285(A_G=-0.0185, G_G=0.4039) + rs6924468(A_G=0.8622, 
G_G=0.9034) + rs3745581(C_G=-0.1301, G_G=0.1301) + rs11889528(A_G=-
15.5226, G_G=-15.4986) + rs6891442(T_T=2.2284) + rs4910163(A_G=0.1847, 
G_G=-0.0056) + rs3821406(A_C=-1.8263) + rs1804254(C_C=2.2329) + 





Table 4-25 Risk Index Values for 25 Individuals in the Independent Testing Set for the Clinical + Genotype Risk Index Models 
for Incident Diabetes from Five Randomly Selected Bootstrap Samples 
   Bootstrap Sample #2 Bootstrap Sample #45 Bootstrap Sample #54 Bootstrap Sample #59 Bootstrap Sample #76 

















1 0 -1.810 0 12.723 0 2.298 0 1.208 0 -0.231 0 
2 0 -1.878 0 13.022 0 2.482 0 2.330 0 1.578 1 
3 0 -1.810 0 13.006 0 2.431 0 1.881 0 0.294 0 
4 0 -1.810 0 12.748 0 2.436 0 2.092 0 0.452 0 
5 1 -1.757 1 13.126 1 2.644 1 2.282 0 0.701 1 
6 0 -1.810 0 13.007 0 2.392 0 1.219 0 -0.197 0 
7 0 -1.555 1 12.949 0 1.950 0 3.551 1 0.723 1 
8 0 -2.214 0 13.669 1 2.322 0 1.683 0 0.158 0 
9 0 -1.810 0 13.083 0 2.404 0 1.740 0 0.326 0 
10 0 -1.757 1 13.123 0 2.615 1 1.907 0 0.265 0 
11 1 -1.609 1 12.948 0 2.320 0 2.000 0 0.399 0 
12 0 -2.416 0 12.867 0 2.470 0 1.990 0 0.371 0 
13 0 -1.810 0 12.979 0 2.557 1 1.960 0 0.371 0 
14 0 -1.757 1 13.093 0 2.269 0 1.603 0 0.062 0 
15 0 -1.810 0 12.936 0 2.682 1 1.908 0 0.308 0 
16 1 -1.810 0 13.328 1 2.336 0 1.678 0 0.123 0 
17 0 -1.810 0 12.742 0 2.447 0 1.605 0 0.098 0 
18 0 -1.810 0 12.734 0 2.558 1 4.179 1 1.265 1 
19 0 -2.012 0 12.944 0 1.845 0 0.871 0 -0.393 0 
20 0 -1.810 0 12.984 0 2.445 0 2.358 0 0.633 0 
21 0 -1.757 1 13.167 1 2.369 0 2.133 0 0.505 0 
22 0 -1.810 0 12.949 0 2.216 0 1.585 0 0.062 0 
23 0 -1.810 0 12.408 0 2.390 0 2.019 0 0.373 0 
24 0 -1.810 0 12.960 0 2.257 0 1.549 0 0.124 0 




Figure 4-24 Distribution of Risk Index Values in the Optimization Set from the 
Clinical + Genotype Risk Index Model for Bootstrap Sample #2 
 
 
Figure 4-25 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical + Genotype Risk Index Model for Bootstrap Sample #2 
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4.7.3 Predictive Performance 
Once predictions were made for each individual in the independent testing set the 
sensitivity, specificity, misclassification, and positive predictive value were calculated for 
the Clinical risk index model and the Clinical + Genotype risk index model as described 
in Section 4.5.3. The estimates and confidence intervals for sensitivity, specificity, 
misclassification, and positive predictive value are given in Table 4-26. Lastly, using the 
individual predictions from each of the 100 trimmed Clinical risk index models and 100 
trimmed Clinical + Genotype risk index models for the individuals in the independent 
testing set, ROC curves were generated, and the AUC for the ROC curve was estimated 
for both the Clinical and Clinical + Genotype risk index models (Figure 4-26, Figure 4-
27). For the Clinical risk index model the AUC for the ROC curve was 0.722, and for the 
Clinical + Genotype risk index model the AUC for the ROC curve was 0.683. 
 
Table 4-26 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for Ten-year Incident Diabetes 

























Figure 4-26 ROC Curve and AUC for the Incident Diabetes Clinical Risk Index 
Model 
 
Figure 4-27 ROC Curve and AUC for the Incident Diabetes Clinical + Genotype 




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual is at high risk of developing diabetes, then, 
represents the predicted probability of an individual developing diabetes. Section 4.5.3 
describes the calculation of a confidence interval for this predicted probability. 
 
Figure 4-28 shows the distribution of the predicted probability of developing diabetes for 
the Clinical risk index model in the independent testing set, and Figure 4-29 shows the 
distribution of the predicted probability of developing diabetes for the Clinical + 
Genotype risk index model in the independent testing set. In both Figures, a density line 
is shown on the graph to indicate the density of a normal distribution with the mean and 
standard deviation matching that of the predicted probability distribution. 
 
Figure 4-28 Histogram of the Predicted Probability of Developing Diabetes for the 





Figure 4-29 Histogram of the Predicted Probability of Developing Diabetes for the 
Clinical + Genotype Risk Index Model 
 
4.7.4 Random Forests Comparison 
A random forest was generated using the optimization set created by the risk index 
procedure. The forest had 500 individual trees, and the tuning procedure described in 
detail in Section 4.6.4 was used to find the number of variables k considered at each split 
that provided the lowest out-of-bag error estimate. The optimized k chosen was 10, which 
gave an out-of-bag error estimate of 8.84%. 
 
When working with a dataset that has two possible classes, the standard procedure for a 
random forest is to assign a prediction to an individual based on a simple majority of 
votes, when the prevalence of the outcome is less than 50% changing the proportion of 
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votes needed to classify an individual can significantly impact the estimates of 
performance. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set on a range of proportions. First, 
an individual was assigned a prediction of “high risk” if 5% or more of the trees in the 
forest predicted the individual to be “high risk”. This was then repeated in increments of 
5% until individuals were assigned a prediction of “high risk” only if 95% or more of the 
trees in the forest predicted the individual to be “high risk”. Table 4-27 shows the results 
of this investigation. 
 
Predictions were then made about each individual in the independent testing set created 
by the risk index procedure, and the sensitivity, specificity, misclassification, and positive 
predictive value of the predictions was assessed. One thousand bootstrap samples of the 
independent testing set were generated, and predictions were made about each individual 
in each of the bootstrap samples. This data was used to create 95% confidence intervals 
for the sensitivity, specificity, misclassification, and positive predictive value estimates. 
Table 4-28 shows the sensitivity, specificity, misclassification, and positive predictive 
value estimates for the random forest as well as the 95% confidence interval for each 
estimate. Lastly, using the class votes for the individuals in the independent testing set, an 




Table 4-27 Performance Estimates of the Random Forest 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 1.000 0.065 0.850 0.097 
0.1 0.956 0.635 0.335 0.209 
0.15 0.556 0.946 0.089 0.510 
0.2 0.089 0.996 0.087 0.667 
0.25 0.000 1.000 0.091 - 
0.3 0.000 1.000 0.091 - 
0.35 0.000 1.000 0.091 - 
0.4 0.000 1.000 0.091 - 
0.45 0.000 1.000 0.091 - 
0.5 0.000 1.000 0.091 - 
0.55 0.000 1.000 0.091 - 
0.6 0.000 1.000 0.091 - 
0.65 0.000 1.000 0.091 - 
0.7 0.000 1.000 0.091 - 
0.75 0.000 1.000 0.091 - 
0.8 0.000 1.000 0.091 - 
0.85 0.000 1.000 0.091 - 
0.9 0.000 1.000 0.091 - 
0.95 0.000 1.000 0.091 - 
 
Table 4-28 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for the Random Forest Model 
Proportion of Votes for  






































Both the Clinical and Clinical + Genotype risk index models had very high specificities 
but very low sensitivities. However, the AUC for both is higher than the AUCs achieved 
by the Clinical and Clinical + Genotype risk index models in the Incident Hypertension 
analysis. Choosing the proportion cutoff that gives the random forest model the most 
balanced performance (0.15), the sensitivity, misclassification, and positive predictive 
value of the random forest model is greater than either the Clinical or the Clinical + 
Genotype risk index model. However, the specificity of the random forest is in the same 
range as the Clinical and Clinical + Genotype risk index models. The ROC curves for 
each of the risk index models also exhibit a greater curve than that seen in the Incident 
Hypertension analysis. This suggests that modifying the proportion of votes required to 
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give a prediction of “high risk” might be able to increase the predictive performance of 
the models. 
 
4.8 Ten-Year Incident Diabetes Results Using Top 500 Principal Components 
4.8.1 Variable Selection 
Using the procedure described in Section 4.5.1, the risk index procedure was performed 
to predict risk of developing diabetes within a ten-year time frame. In place of the 500 
SNPs most highly associated with ten-year incident diabetes, the top 500 principal 
components from a principal components analysis of all available SNPs were used. 
 
Table 4-29 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the optimization set used to build the Clinical risk index model. 
Forty-seven out of the 100 trimmed Clinical risk index models contained marital status as 
a variable, and 46 contained weight. Marital status was included in 56 out of 100 of the 
100 trimmed Clinical risk index models. Weight, weekly alcohol consumption, and 
current smoking status, were also frequently included in the set of 100 trimmed Clinical 
risk index models, appearing in 51, 36, and 31 trimmed Clinical risk index models, 
respectively. Table 4-30 gives a summary of the order in which the most commonly 
chosen principal components were selected into the 100 Clinical + Genotype risk index 
models. Each principal component in Table 4-30 appears in at least 10 trimmed Clinical 




Table 4-29 Summary of Number of Times Each Variable is Selected into a Specific Model Position for the Clinical Risk Index 
Model for Incident Diabetes 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 









Age (yrs) 1 8 8 7 6 6 5 11 3 2 7 6 4 6 3 3 4 2 2 2 96 26 
Sex 3 6 4 11 7 14 7 4 5 2 1 6 2 2 6 4 2 1 3 6 96 26 
Weight (lbs) 32 6 5 3 6 3 4 6 3 3 0 4 5 2 0 2 2 3 3 1 93 51 
Height (in) 2 4 7 6 14 13 7 9 8 5 4 2 6 5 1 2 2 0 0 3 100 27 
Systolic Blood Pressure 
(mm Hg) 2 5 6 3 2 3 5 3 13 13 3 3 3 7 6 4 4 4 2 3 94 19 
Diastolic Blood Pressure 
(mm Hg) 6 5 1 1 3 2 4 7 8 10 8 4 4 2 5 1 3 10 3 3 90 22 
Total Cholesterol  (mg/dL) 2 2 1 2 0 4 4 3 2 5 8 14 7 7 4 9 8 4 5 7 98 10 
High-density Lipoprotein 
Level (mg/dL) 5 2 5 5 2 3 1 5 5 1 12 10 10 6 2 5 6 1 6 3 95 21 
Low-density Lipoprotein 
Level (mg/dL) 1 1 3 2 3 2 1 2 6 8 3 7 14 7 5 5 8 8 4 4 94 14 
Triglycerides (mg/dL) 6 4 0 2 2 0 1 5 1 6 8 2 7 13 5 4 2 7 11 6 92 16 
Ever Smoked 0 8 10 14 8 10 11 9 6 1 2 3 2 4 4 4 2 0 1 1 100 28 
Currently Smokes 1 12 15 6 6 5 11 7 4 8 5 3 4 3 2 3 0 0 2 2 99 31 
Weekly Alcohol 
Consumption 5 6 9 11 6 10 10 6 5 4 4 5 4 3 3 3 3 0 2 0 99 36 
Marital Status 7 17 18 13 12 8 8 2 6 3 1 2 0 2 0 0 1 0 0 0 100 56 
Left Ventricular Mass (g) 0 0 0 0 1 0 0 0 0 2 1 0 0 0 18 2 2 6 1 9 42 1 
Left Ventricular Ejection 
Fraction (%) 1 2 0 2 0 0 1 0 4 1 2 2 0 0 0 15 2 4 4 3 43 6 
Blood Glucose (mg/dL) 18 5 1 2 0 2 3 1 1 4 0 3 2 2 1 2 16 6 5 5 79 28 
Blood Urea Nitrogen 




Total Serum Protein Level 
(mg/dL) 1 0 1 0 2 1 2 1 2 2 8 2 2 4 8 5 5 9 21 10 86 9 
Serum Albumin Level 
(mg/dL) 1 2 1 3 7 3 4 5 2 8 8 5 8 6 4 4 6 3 0 17 97 20 
Serum Bilirubin Level 




2 1 1 0 0 2 2 0 1 2 2 3 3 4 5 4 7 5 9 7 60 9 
Serum Creatine Level 
(mg/dL) 0 1 1 0 1 2 2 2 5 2 6 7 4 3 4 8 6 3 7 6 70 11 
 
Table 4-30 Summary of Number of Times Selected Principal Components Variables are Selected into a Specific Model 
Position for the Clinical + Genotype Risk Index Model for Incident Diabetes 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Total # of Times 
in Untrimmed 
Model 
Total # of Times 
in Trimmed 
Model 
PC3 1 1 3 0 1 6 6 2 2 2 1 4 0 0 0 2 2 1 1 1 36 29 
PC10 0 0 1 1 1 1 0 2 2 1 3 0 0 1 0 1 0 0 1 0 15 13 
PC11 0 1 1 0 1 3 0 1 1 1 2 1 0 0 1 1 0 0 2 0 16 12 
PC148 2 0 1 1 1 1 0 0 1 1 2 0 0 0 0 1 0 1 0 0 12 11 
PC198 0 0 2 0 1 1 0 2 0 0 1 2 0 0 0 0 0 1 1 1 12 11 
PC4 0 0 0 1 0 1 0 0 0 2 2 0 0 2 0 1 1 0 0 1 11 10 
PC57 0 0 0 1 0 0 0 1 2 1 0 1 1 2 0 0 0 1 0 0 10 10 
PC104 0 2 0 1 0 1 1 2 0 0 0 0 1 0 0 0 0 0 1 1 10 10 
PC152 0 1 0 0 1 0 1 1 0 1 2 1 0 1 1 1 0 1 2 1 15 10 




Table 4-31 shows the trimmed Clinical risk index models for a selection of five random 
bootstrap samples. Figure 4-31 shows the distribution of risk index values in the 
optimization set for the Clinical risk index model from one randomly selected bootstrap 
sample (Bootstrap Sample #32), and Figure 4-32 shows the distribution of risk index 
values in the independent testing set for the Clinical risk index model from the same 
randomly selected bootstrap sample (Bootstrap Sample #32). The red line on each graph 
marks the cutoff point for the model. All individuals with a risk index value greater than 
this are predicted as “high risk of developing diabetes” and those with a risk index value 
lower are predicted as “low risk of developing diabetes”. Table 4-32 shows the risk index 
values for 25 randomly chosen individuals from the Independent Testing Set from these 
five Clinical risk index models along with that risk index model’s prediction about each 
individual, where 0 indicates low risk of developing diabetes and 1 indicates high risk of 
developing diabetes. 
 
Table 4-31 Five Randomly Selected Trimmed Clinical Risk Index Models for 
Incident Diabetes 
Bootstrap Sample Model 
32 
0.0304*Height + 0.0348*Systolic Blood Pressure + 0.0515*Diastolic Blood 
Pressure + 0.0093*Total Cholesterol - 0.0546*HDL + 0.0123*LDL + 
0.0019*Triglycerides - 0.0663*Ever Smoked - 0.1709*Current Smoking 
Status - 0.0277*Weekly Alcohol Consumption + 0.0507*Marital Status 
36 0.0763*Diastolic Blood Pressure - 0.0908*Marital Status 
41 
0.0326*Systolic Blood Pressure - 0.0574*HDL + 0.0017*Triglycerides + 
0.2083*Ever Smoked + 0.2976*Current Smoking Status + 0.0343*Weekly 
Alcohol Consumption + 0.0125*Marital Status + 0.0941*Blood Glucose - 
0.0238*Blood Urea Nitrogen + 0.0243*Serum Albumin - 4e-04*Serum 
Bilirubin + 0.0409*Serum Alkaline Phosphotase 





Table 4-32 Risk Index Values for 25 Individuals from the Independent Testing Set from Five Randomly Selected Clinical Risk 
Index Models for Incident Diabetes 
   Bootstrap Sample #32 Bootstrap Sample #36 Bootstrap Sample #41 Bootstrap Sample #90 Bootstrap Sample #96 

















1 0 1.152 0 3.038 0 1.182 0 0.405 0 4.557 0 
2 0 1.063 0 3.038 0 1.118 0 0.405 0 4.352 0 
3 1 1.398 1 3.953 1 1.344 1 0.405 0 4.813 0 
4 0 1.013 0 3.495 0 0.977 0 0.405 0 3.098 0 
5 0 1.288 1 3.572 0 1.274 1 0.405 0 4.454 0 
6 0 1.350 1 3.190 0 1.234 1 0.405 0 5.018 0 
7 1 1.312 1 3.343 0 1.304 1 0.405 0 5.478 0 
8 0 0.741 0 2.122 0 0.864 0 0.405 0 3.277 0 
9 0 0.799 0 2.732 0 0.857 0 0.405 0 3.558 0 
10 0 1.162 0 2.809 0 1.179 0 0.405 0 4.582 0 
11 0 1.066 0 3.266 0 1.263 1 0.405 0 4.275 0 
12 1 1.271 1 3.266 0 1.217 1 0.405 0 3.789 0 
13 0 1.252 1 3.114 0 1.713 1 0.405 0 4.275 0 
14 0 1.116 0 3.572 0 0.971 0 0.405 0 4.019 0 
15 0 0.987 0 2.198 0 0.921 0 0.405 0 3.251 0 
16 0 1.003 0 2.809 0 0.952 0 0.405 0 3.507 0 
17 0 0.632 0 2.031 0 0.722 0 0.810 1 2.918 0 
18 0 0.612 0 2.549 0 0.765 0 0.203 0 3.533 0 
19 0 0.860 0 2.732 0 0.981 0 0.405 0 3.558 0 
20 0 1.121 0 3.266 0 1.125 0 0.405 0 4.710 0 
21 0 1.404 1 3.495 0 1.269 1 0.405 0 5.990 1 
22 0 1.267 1 3.038 0 1.107 0 0.405 0 6.323 1 
23 0 0.856 0 2.885 0 0.782 0 0.405 0 3.226 0 
24 1 1.010 0 3.023 0 1.224 1 0.810 1 4.659 0 





Figure 4-31 Distribution of Risk Index Values in the Optimization Set from the 
Clinical Risk Index Model for Bootstrap Sample #32 
 
 
Figure 4-32 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical Risk Index Model for Bootstrap Sample #32 
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Table 4-33 shows the trimmed Clinical + Genotype risk index models for the same set of 
five bootstraps shown in Table 4-31, and Table 4-34 shows the risk index values and 
predictions of the same 25 randomly chosen individuals for the 5 bootstrap samples 
shown in Table 4-32. Figure 4-33 shows the distribution of risk index values in the 
optimization set for the Clinical + Genotype risk index model from one randomly 
selected bootstrap sample (Bootstrap Sample #32). Figure 4-34 shows the distribution of 
risk index values in the independent testing set for the Clinical + Genotype risk index 
model from the same randomly selected bootstrap sample (Bootstrap Sample #32). The 
red line on each graph marks the cutoff point for the model. All individuals with a risk 
index value greater than this are predicted as “high risk of developing diabetes” and those 




Table 4-33 Five Randomly Selected Clinical + Genotype Risk Index Models for 
Incident Diabetes 
Bootstrap Sample Model 
32 
0.0304*Height + 0.0348*Systolic Blood Pressure + 0.0515*Diastolic Blood 
Pressure + 0.0093*Total Cholesterol - 0.0546*HDL + 0.0123*LDL + 
0.0019*Triglycerides - 0.0663*Ever Smoked - 0.1709*Current Smoking Status - 
0.0277*Weekly Alcohol Consumption + 0.0507*Marital Status + 3.9359*PC3 + 
9.9229*PC29 + 0.5186*PC71 + 2.3951*PC87 - 0.8883*PC95 + 1.7747*PC100 + 
0.2637*PC160 - 1.0093*PC225 - 2.0324*PC250 + 10.1536*PC423 + 
0.4997*PC490 - 6.6034*PC491 
36 
0.0763*Diastolic Blood Pressure - 0.0908*Marital Status + 8.3048*PC58 + 
4.5072*PC75 - 1.3113*PC91 - 2.5058*PC276 - 0.2329*PC336 + 3.5587*PC382 - 
1.4082*PC406 + 12.8929*PC487 - 0.1383*PC490 
41 
0.0326*Systolic Blood Pressure - 0.0574*HDL + 0.0017*Triglycerides + 
0.2083*Ever Smoked + 0.2976*Current Smoking Status + 0.0343*Weekly 
Alcohol Consumption + 0.0125*Marital Status + 0.0941*Blood Glucose - 
0.0238*Blood Urea Nitrogen + 0.0243*Serum Albumin - 4e-04*Serum Bilirubin 
+ 0.0409*Serum Alkaline Phosphatase + 1.4758*PC11 - 6.9019*PC12 - 
5.9903*PC199 + 2.8352*PC215 + 2.5872*PC237 + 13.172*PC248 - 
0.2214*PC376 - 0.8552*PC388 - 2.2939*PC476 + 15.5728*PC480 + 
3.9395*PC484 
90 
0.2025*Marital Status + 1.2357*PC10 + 2.4205*PC20 - 0.3959*PC24 - 
0.0429*PC32 + 2.2258*PC51 - 0.4129*PC54 + 0.2607*PC95 - 7.282*PC130 + 
1.5002*PC136 - 0.0582*PC146 - 2.134*PC148 - 0.533*PC152 - 2.2258*PC156 - 
0.2734*PC160 + 2.0539*PC162 - 0.1559*PC184 + 1.5615*PC233 + 
0.6637*PC316 + 1.6871*PC318 + 2.0245*PC382 
96 
0.0256*Weight + 3.3456*PC50 + 0.14*PC57 + 0.8653*PC59 + 2.0555*PC98 + 
1.3727*PC127 + 0.1076*PC128 + 13.5397*PC140 - 0.6265*PC148 + 
1.7555*PC178 + 5.8116*PC245 - 0.319*PC338 + 14.536*PC343 + 1.674*PC417 




Table 4-34 Risk Index Values for 25 Individuals in the Independent Testing Set for the Clinical + Genotype Risk Index Models 
from Five Randomly Selected Bootstrap Samples for Incident Diabetes 
   Bootstrap Sample #32 Bootstrap Sample #36 Bootstrap Sample #41 Bootstrap Sample #90 Bootstrap Sample #96 

















1 0 1.150 0 3.070 0 1.160 0 0.405 0 4.584 0 
2 0 1.061 0 3.043 0 1.205 0 0.404 0 4.346 0 
3 1 1.336 1 3.927 1 1.379 1 0.394 0 4.810 0 
4 0 1.004 0 3.470 0 1.009 0 0.413 0 3.128 0 
5 0 1.260 1 3.569 0 1.237 1 0.384 0 4.483 0 
6 0 1.309 1 3.207 0 1.289 1 0.404 0 4.980 0 
7 1 1.348 1 3.337 0 1.269 1 0.404 0 5.474 0 
8 0 0.755 0 2.108 0 0.936 0 0.414 0 3.249 0 
9 0 0.819 0 2.730 0 0.903 0 0.400 0 3.578 0 
10 0 1.162 0 2.789 0 1.192 0 0.400 0 4.575 0 
11 0 1.060 0 3.268 0 1.224 1 0.406 0 4.275 0 
12 1 1.296 1 3.293 0 1.226 1 0.397 0 3.803 0 
13 0 1.282 1 3.066 0 1.713 1 0.416 0 4.268 0 
14 0 1.116 0 3.528 0 0.953 0 0.415 0 4.017 0 
15 0 1.013 0 2.220 0 0.920 0 0.406 0 3.295 0 
16 0 1.012 0 2.807 0 0.940 0 0.400 0 3.505 0 
17 0 0.721 0 2.016 0 0.730 0 0.818 1 2.856 0 
18 0 0.599 0 2.519 0 0.693 0 0.188 0 3.522 0 
19 0 0.854 0 2.676 0 0.947 0 0.396 0 3.615 0 
20 0 1.148 0 3.259 0 1.126 0 0.407 0 4.687 0 
21 0 1.410 1 3.413 0 1.277 1 0.414 0 5.945 1 
22 0 1.261 1 3.025 0 1.063 0 0.399 0 6.350 1 
23 0 0.851 0 2.925 0 0.774 0 0.399 0 3.193 0 
24 1 0.988 0 3.070 0 1.242 1 0.814 1 4.676 0 




Figure 4-33 Distribution of Risk Index Values in the Optimization Set from the 
Clinical + Genotype Risk Index Model for Bootstrap Sample #32 
 
 
Figure 4-34 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical + Genotype Risk Index Model for Bootstrap Sample #32 
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4.8.3 Predictive Performance 
Once predictions were made for each individual in the independent testing set the 
sensitivity, specificity, misclassification, and positive predictive value were calculated for 
the Clinical risk index model and the Clinical + Genotype risk index model as described 
in Section 4.5.3. The estimates and confidence intervals for sensitivity, specificity, 
misclassification, and positive predictive value are given in Table 4-35. Lastly, using the 
individual predictions from each of the 100 trimmed Clinical risk index models and 100 
trimmed Clinical + Genotype risk index models for the individuals in the independent 
testing set, ROC curves were generated, and the AUC for the ROC curve was estimated 
for both the Clinical and Clinical + Genotype risk index models (Figure 4-35, Figure 4-
36). For the Clinical risk index model the AUC for the ROC curve was 0.768, and for the 
Clinical + Genotype risk index model the AUC for the ROC curve was 0.782. 
 
Table 4-35 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for Ten-year Incident Diabetes 

























Figure 4-35 ROC Curve and AUC for the Incident Diabetes Clinical Risk Index 
Model 
 
Figure 4-36 ROC Curve and AUC for the Incident Diabetes Clinical + Genotype 




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models which predict that an individual is at high risk of developing diabetes, then, 
represents the predicted probability of an individual developing diabetes. Section 4.5.3 
describes the calculation of a confidence interval for this predicted probability. 
 
Figure 4-37 shows the distribution of the predicted probability of developing diabetes for 
the Clinical risk index model in the independent testing set, and Figure 4-38 shows the 
distribution of the predicted probability of developing diabetes for the Clinical + 
Genotype risk index model in the independent testing set. In both Figures, a density line 
is shown on the graph to indicate the density of a normal distribution with the mean and 
standard deviation matching that of the predicted probability distribution. 
 
Figure 4-37 Histogram of the Predicted Probability of Developing Diabetes for the 





Figure 4-38 Histogram of the Predicted Probability of Developing Diabetes for the 
Clinical + Genotype Risk Index Model 
 
4.8.4 Random Forests Comparison 
A random forest was generated using the optimization set created by the risk index 
procedure. The forest had 500 individual trees, and the tuning procedure described in 
detail in Section 4.6.4 was used to find the number of variables k considered at each split 
that provided the lowest out-of-bag error estimate. The optimized k chosen was 45, which 
gave an out-of-bag error estimate of 8.36%. 
 
When working with a dataset that has two possible classes, the standard procedure for a 
random forest is to assign a prediction to an individual based on a simple majority of 
votes, when the prevalence of the outcome is less than 50% changing the proportion of 
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votes needed to classify an individual can significantly impact the estimates of 
performance. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set on a range of proportions. First, 
an individual was assigned a prediction of “high risk” if 5% or more of the trees in the 
forest predicted the individual to be “high risk”. This was then repeated in increments of 
5% until individuals were assigned a prediction of “high risk” only if 95% or more of the 
trees in the forest predicted the individual to be “high risk”. Table 4-36 shows the results 
of this investigation. 
 
Predictions were then made about each individual in the independent testing set created 
by the risk index procedure, and the sensitivity, specificity, misclassification, and positive 
predictive value of the predictions was assessed. One thousand bootstrap samples of the 
independent testing set were generated, and predictions were made about each individual 
in each of the bootstrap samples. This data was used to create 95% confidence intervals 
for the sensitivity, specificity, misclassification, and positive predictive value estimates. 
Table 4-37 shows the sensitivity, specificity, misclassification, and positive predictive 
value estimates for the random forest as well as the 95% confidence interval for each 
estimate. Lastly, using the class votes for the individuals in the independent testing set, an 




Table 4-36 Performance Estimates of the Random Forest 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 0.941 0.337 0.611 0.119 
0.1 0.765 0.624 0.364 0.162 
0.15 0.510 0.810 0.216 0.203 
0.2 0.294 0.918 0.136 0.254 
0.25 0.176 0.963 0.105 0.310 
0.3 0.098 0.983 0.094 0.357 
0.35 0.039 0.991 0.092 0.286 
0.4 0.000 0.993 0.094 0.000 
0.45 0.000 0.998 0.088 0.000 
0.5 0.000 0.998 0.088 0.000 
0.55 0.000 1.000 0.087 - 
0.6 0.000 1.000 0.087 - 
0.65 0.000 1.000 0.087 - 
0.7 0.000 1.000 0.087 - 
0.75 0.000 1.000 0.087 - 
0.8 0.000 1.000 0.087 - 
0.85 0.000 1.000 0.087 - 
0.9 0.000 1.000 0.087 - 
0.95 0.000 1.000 0.087 - 
 
Table 4-37 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for the Random Forest Model 
Proportion of Votes for  



























































As with the risk index models for ten-year incident diabetes built using the 500 most 
highly associated SNPs, both the Clinical and Clinical + Genotype risk index models had 
very high specificities but very low sensitivities. However, as was observed for the 10-
year incident hypertension analyses, the AUC for both is higher than the AUCs achieved 
by the Clinical and Clinical + Genotype risk index models in the ten-year incident 
diabetes analysis using the 500 most highly associated SNPs. Additionally, the AUC for 
the Clinical + Genotype model is basically equivalent to the AUC for the random forests 
model. The ROC curves for each of the risk index models also exhibit a greater curve 
than that seen in the incident hypertension analysis. This suggests that modifying the 
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proportion of votes required to give a prediction of “high risk” might be able to increase 
the predictive performance of the models. 
 
4.9 Prevalent Hypertension Using 500 Most Highly Associated SNPs 
4.9.1 Variable Selection 
Using the procedure described in Section 4.5.1, the risk index procedure was performed 
to predict risk of developing diabetes within a ten-year time frame. The 500 SNPs most 
highly associated with this outcome (i.e., which had the lowest p-values from a logistic 
regression analysis of this outcome) were identified and used to build the risk index. 
 
Table 4-38 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the optimization set used to build the Clinical risk index model. 
Sixt-two out of the 100 trimmed Clinical risk index models contained age as a variable, 
and 46 contained weight. Marital status was included in 46 out of the 100 trimmed 
Clinical risk index models. Serum albumin levels, height, and blood glucose levels, were 
also frequently included in the set of 100 trimmed Clinical risk index models, appearing 
in 38, 35, and 33 trimmed Clinical risk index models, respectively. Table 4-39 gives a 
summary of the order in which the most commonly chosen principal components were 
selected into the 100 Clinical + Genotype risk index models. Each SNP in Table 4-39 




Table 4-38 Summary of Number of Times Each Variable is Selected into a Specific Model Position for the Clinical Risk Index 
Model for Prevalent Hypertension 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 









Age (yrs) 46 8 5 4 7 3 3 4 3 0 8 2 1 0 3 0 1 1 1 0 100 62 
Sex 1 7 3 7 9 10 5 6 7 6 1 3 5 2 4 4 3 4 6 3 96 18 
Weight (lbs) 3 14 5 1 2 7 14 9 5 6 2 3 1 3 4 4 3 6 6 1 99 24 
Height (in) 2 12 11 11 10 5 14 9 8 6 7 2 0 1 0 0 1 0 1 0 100 35 
Systolic Blood Pressure 
(mm Hg) 0 0 1 2 1 2 3 4 9 7 5 2 3 4 3 10 10 9 9 8 92 6 
Diastolic Blood Pressure 
(mm Hg) 0 0 0 1 0 2 2 5 6 14 10 6 8 6 8 5 7 13 4 1 98 4 
Total Cholesterol  (mg/dL) 0 0 0 0 0 0 2 1 1 8 7 8 6 7 6 5 9 12 11 6 89 0 
High-density Lipoprotein 
Level (mg/dL) 5 1 1 2 1 0 0 2 3 6 7 13 9 4 7 9 9 9 5 4 97 10 
Low-density Lipoprotein 
Level (mg/dL) 0 15 12 12 7 9 7 9 4 3 4 5 5 1 0 6 1 0 0 0 100 31 
Triglycerides (mg/dL) 4 5 12 12 6 10 5 3 2 3 4 4 6 11 4 0 0 4 1 2 98 24 
Ever Smoked 0 3 5 9 9 9 3 6 0 7 6 4 9 15 5 5 1 0 1 2 99 23 
Currently Smokes 5 13 15 11 16 9 9 9 1 1 2 1 0 4 2 0 1 1 0 0 100 46 
Weekly Alcohol 
Consumption 2 3 3 4 5 6 2 5 2 2 2 0 2 2 5 4 5 8 6 18 86 8 
Marital Status 1 3 3 1 1 2 4 2 6 2 3 4 4 2 11 6 3 1 10 18 87 9 
Left Ventricular Mass (g) 8 9 7 3 5 2 2 4 4 0 3 4 3 5 7 13 8 2 5 2 96 33 
Left Ventricular Ejection 
Fraction (%) 0 0 1 4 2 0 3 2 4 4 8 8 6 7 7 11 13 8 4 4 96 8 
Blood Glucose (mg/dL) 0 2 8 4 2 2 8 8 6 3 2 5 8 3 4 3 7 12 8 3 98 22 
Blood Urea Nitrogen 




Total Serum Protein Level 
(mg/dL) 4 3 2 6 5 6 2 4 11 11 4 5 7 3 6 2 1 0 10 6 98 16 
Serum Albumin Level 
(mg/dL) 1 0 2 2 3 5 4 1 4 1 4 4 5 8 8 5 7 4 3 18 89 8 
Serum Bilirubin Level 
(mg/dL) 0 0 1 3 3 6 1 3 3 6 3 8 8 10 4 6 7 2 4 4 82 13 
Serum Alkaline 
Phosphatase Level 
(mg/dL) 46 8 5 4 7 3 3 4 3 0 8 2 1 0 3 0 1 1 1 0 100 62 
Serum Creatine Level 
(mg/dL) 1 7 3 7 9 10 5 6 7 6 1 3 5 2 4 4 3 4 6 3 96 18 
 
Table 4-39 Summary of Number of Times Selected Genotype Variables are Selected into a Specific Model Position for the 
Clinical + Genotype Risk Index Model for Prevalent Hypertension 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Total # of Times 
in Untrimmed 
Model 
Total # of Times 
in Trimmed 
Model 
rs3087481 0 7 10 10 8 6 12 2 1 0 8 4 1 2 1 1 0 1 1 0 75 58 
rs12024717 3 4 4 3 3 3 3 2 2 3 6 3 1 3 2 1 2 3 3 2 56 36 
rs11880330 1 2 4 4 2 6 6 2 3 1 2 5 5 2 0 1 4 0 1 4 55 32 
rs4302331 0 2 1 2 3 5 5 0 5 6 5 2 4 0 3 4 2 2 2 1 54 31 
rs16858033 0 2 4 4 2 4 2 1 1 3 3 2 2 3 5 5 4 3 0 2 52 31 
rs6844109 0 2 2 2 5 1 1 2 2 6 1 6 1 1 2 1 3 1 2 1 42 29 
rs6475322 1 1 4 7 7 5 4 4 1 4 2 1 3 3 0 5 0 1 1 2 56 29 
rs4768264 0 2 2 1 4 4 5 6 5 1 2 4 2 2 2 5 2 2 1 1 53 28 
rs12039283 1 1 0 3 5 3 3 2 3 3 5 4 2 2 2 2 1 2 2 2 48 27 
rs3006870 0 1 2 2 2 2 4 3 3 2 7 1 1 2 3 1 1 2 3 1 43 25 




Table 4-40 shows the trimmed Clinical risk index models for a selection of five random 
bootstrap samples. Figure 4-40 shows the distribution of risk index values in the 
optimization set for the Clinical risk index model from one randomly selected bootstrap 
sample (Bootstrap Sample #27), and Figure 4-41 shows the distribution of risk index 
values in the independent testing set for the Clinical risk index model from the same 
randomly selected bootstrap sample (Bootstrap Sample #27). The red line on each graph 
marks the cutoff point for the model. All individuals with a risk index value greater than 
this are predicted as “high risk of having hypertension” and those with a risk index value 
lower are predicted as “low risk of having hypertension”. Table 4-41 shows the risk index 
values for 25 randomly chosen individuals from the Independent Testing Set from these 
five Clinical risk index models along with that risk index model’s prediction about each 
individual, where 0 indicates low risk of having hypertension and 1 indicates high risk of 
having hypertension. 
 
Table 4-40 Five Randomly Selected Trimmed Clinical Risk Index Models for 
Prevalent Hypertension 
Bootstrap Sample Model 
27 0.0995*Age - 0.0519*Ever Smoked + 0.0365*Marital Status 
38 0.0043*Height - 0.0226*Ever Smoked + 0.0517*Serum Albumin 
44 0.1061*Age + 0.1173*Marital Status 
63 0.1131*Age - 0.3159*Sex + 0.0455*Marital Status + 0.0458*Blood Glucose + 0.0494*Serum Alkaline Phosphatase + 0.0197*Serum Creatine 




Table 4-41 Risk Index Values for 25 Individuals from the Independent Testing Set from Five Randomly Selected Clinical Risk 
Index Models for Prevalent Hypertension 
   Bootstrap Sample #27 Bootstrap Sample #38 Bootstrap Sample #44 Bootstrap Sample #63 Bootstrap Sample #82 

















1 0 1.756 0 0.822 0 2.993 1 1.788 0 0.083 1 
2 1 1.931 1 0.881 0 3.194 1 1.941 0 0.076 0 
3 0 1.665 0 0.910 1 2.770 0 1.767 0 0.072 0 
4 0 1.557 0 0.828 0 2.675 0 1.738 0 0.087 1 
5 0 1.650 0 0.850 0 2.717 0 1.971 0 0.073 0 
6 0 1.500 0 0.848 0 2.505 0 1.828 0 0.077 0 
7 1 1.815 1 0.874 0 2.982 1 1.935 0 0.066 0 
8 0 1.201 0 0.841 0 2.027 0 1.448 0 0.072 0 
9 0 1.433 0 0.804 0 2.398 0 1.594 0 0.070 0 
10 0 1.325 0 0.756 0 2.304 0 1.602 0 0.085 1 
11 0 0.990 0 0.792 0 1.650 0 1.293 0 0.068 0 
12 1 1.732 0 0.791 0 2.876 1 1.802 0 0.073 0 
13 0 1.997 1 0.840 0 3.300 1 2.026 1 0.071 0 
14 1 1.201 0 0.914 1 2.027 0 1.675 0 0.075 0 
15 0 1.384 0 0.793 0 2.292 0 1.637 0 0.069 0 
16 0 1.400 0 0.851 0 2.345 0 1.601 0 0.079 0 
17 0 1.367 0 0.809 0 2.292 0 1.597 0 0.074 0 
18 1 1.138 0 0.878 0 2.044 0 1.372 0 0.092 1 
19 0 1.152 0 0.910 1 1.921 0 1.679 0 0.079 0 
20 0 1.318 0 0.810 0 2.186 0 1.424 0 0.069 0 
21 0 1.716 0 0.817 0 2.823 0 2.344 1 0.074 0 
22 0 0.941 0 0.896 0 1.544 0 1.505 0 0.074 0 
23 0 1.002 0 0.811 0 1.709 0 1.374 0 0.075 0 
24 0 1.500 0 0.916 1 2.505 0 1.980 0 0.076 0 





Figure 4-40 Distribution of Risk Index Values in the Optimization Set from the 
Clinical Risk Index Model for Bootstrap Sample #27 
 
 
Figure 4-41 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical Risk Index Model for Bootstrap Sample #27 
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Table 4-42 shows the trimmed Clinical + Genotype risk index models for the same set of 
five bootstraps shown in Table 4-40, and Table 4-43 shows the risk index values and 
predictions of the same 25 randomly chosen individuals for the 5 bootstrap samples 
shown in Table 4-41. Figure 4-42 shows the distribution of risk index values in the 
optimization set for the Clinical + Genotype risk index model from one randomly 
selected bootstrap sample (Bootstrap Sample #27). Figure 4-43 shows the distribution of 
risk index values in the independent testing set for the Clinical + Genotype risk index 
model from the same randomly selected bootstrap sample (Bootstrap Sample #27). The 
red line on each graph marks the cutoff point for the model. All individuals with a risk 
index value greater than this are predicted as “high risk of having hypertension” and 




Table 4-42 Five Randomly Selected Clinical + Genotype Risk Index Models for 
Prevalent Hypertension 
Bootstrap Sample Model 
27 0.0995*Age - 0.0519*Ever Smoked + 0.0365*Marital Status + rs9994289(C_T=-0.2157, T_T=-0.6068) + rs17031297(C_C=1.4318) 
38 
0.0043*Height - 0.0226*Ever Smoked + 0.0517*Serum Albumin + 
rs13256239(A_C=0.6367, C_C=1.0273) + rs13242(C_T=1.049, T_T=18.9896) + 
rs940224(A_G=-0.9546, G_G=-1.2444) + rs4302331(G_G=2.181) + 
rs5491(A_T=-2.6136) + rs16858033(A_G=-3.4422) + rs4507748(A_G=-0.8966, 
NA) + rs3087481(G_G=3.8066, NA) + rs289059(C_T=-0.2222, T_T=-0.3453) + 
rs12024717(C_T=-1.9, T_T=-32.1701) + rs17439459(C_T=0.8757, T_T=1.0827) 
+ rs7945609(C_T=-0.1973, T_T=-1.4705) + rs2291256(C_T=0.3162, T_T=-
1.1085) + rs9976886(A_C=0.4639, C_C=0.6816) + rs1510955(A_G=-0.4285, 
G_G=-0.6372) + rs17867624(G_T=-0.3673, T_T=0.3673) + 
rs3802384(G_G=0.0639) + rs2269714(C_T=-0.044, T_T=8942.447) + 
rs11703393(A_G=-0.0554, G_G=0.0624) + rs2915400(C_T=0.2492, T_T=-
0.0072) 
44 
0.1061*Age + 0.1173*Marital Status + rs2292664(G_G=0.3336) + 
rs7729495(T_T=-0.5198) + rs3087481(G_G=2.5349) + rs45497698(A_G=-
642.1136, G_G=-641.8706) + rs11705259(A_G=10.7366, G_G=11.028) + 
rs17867624(G_T=-0.0562, T_T=0.0562) + rs2269714(C_T=-0.0916, T_T=-
0.0537) 
63 
0.1131*Age - 0.3159*Sex + 0.0455*Marital Status + 0.0458*Blood Glucose + 
0.0494*Serum Alkaline Phosphatase + 0.0197*Serum Creatine + 
rs2961944(A_G=0.2217, G_G=0.3388) + rs16858033(A_G=-0.7358) + 
rs12510552(C_G=0.0464, G_G=0.0584) + rs6475322(A_C=0.3663) 
82 
0.0019*Height + 0.012*Marital Status + rs2292664(G_G=2.1354) + 
rs9497762(C_T=-0.5166, T_T=-19.6005) + rs11003001(C_G=0.653, 
G_G=0.7901) + rs13395300(A_G=-0.3285, G_G=-0.4343) + rs2171497(C_G=-
0.2303, G_G=-0.5966) + rs6512087(C_T=-1.7552, T_T=-1.8575) + 
rs17354559(C_G=1.5243, G_G=26.314) + rs12039283(G_G=1.664) + 
rs3006870(A_G=-2.009) + rs4768264(G_G=1.5142) + rs1867435(C_C=1.5142) + 
rs4768268(C_C=1.5142) + rs2493151(A_G=0.4256, G_G=0.6677) + 
rs17031297(C_C=0.4971) + rs9976886(A_C=0.3079, C_C=0.4395) + 
rs6869755(C_T=0.4382, T_T=0.2873) + rs11880330(A_G=-1.6592) + 





Table 4-43 Risk Index Values for 25 Individuals in the Independent Testing Set for the Clinical + Genotype Risk Index Models 
from Five Randomly Selected Bootstrap Samples for Prevalent Hypertension 
   Bootstrap Sample #27 Bootstrap Sample #38 Bootstrap Sample #44 Bootstrap Sample #63 Bootstrap Sample #82 

















1 0 2.472 1 1.026 0 -86.784 1 1.843 0 0.507 0 
2 1 2.539 1 1.237 0 -86.583 1 2.008 0 0.536 0 
3 0 2.273 0 1.252 1 -87.007 0 1.852 0 0.476 0 
4 0 2.273 0 1.096 0 -87.102 0 1.822 0 0.563 0 
5 0 2.365 0 1.127 0 -87.060 0 2.026 0 0.544 0 
6 0 2.215 0 1.181 0 -87.272 0 1.828 0 0.565 0 
7 1 2.531 1 1.179 0 -86.808 1 1.991 0 0.497 0 
8 0 1.809 0 1.226 0 -87.750 0 1.515 0 0.654 1 
9 0 2.041 0 1.141 0 -87.391 0 1.649 0 0.563 0 
10 0 1.933 0 0.953 0 -87.473 0 1.658 0 0.497 0 
11 0 1.706 0 1.160 0 -88.127 0 1.360 0 0.504 0 
12 1 2.340 0 1.097 0 -86.901 1 1.857 0 0.514 0 
13 0 2.410 0 1.258 1 -86.477 1 2.093 0 0.534 0 
14 1 1.917 0 1.314 1 -87.750 0 1.675 0 0.630 1 
15 0 2.100 0 1.111 0 -87.484 0 1.722 0 0.535 0 
16 0 2.008 0 1.151 0 -87.431 0 1.686 0 0.569 0 
17 0 1.975 0 1.155 0 -87.484 0 1.694 0 0.516 0 
18 1 1.854 0 1.255 1 -87.733 0 1.428 0 0.568 0 
19 0 1.868 0 1.254 1 -87.869 0 1.776 0 0.592 1 
20 0 1.926 0 1.164 0 -87.591 0 1.523 0 0.539 0 
21 0 2.324 0 1.190 0 -86.954 0 2.400 1 0.591 1 
22 0 1.657 0 1.289 1 -88.233 0 1.505 0 0.552 0 
23 0 1.718 0 1.196 0 -88.103 0 1.470 0 0.552 0 
24 0 1.912 0 1.264 1 -87.314 0 2.064 0 0.534 0 




Figure 4-42 Distribution of Risk Index Values in the Optimization Set from the 
Clinical + Genotype Risk Index Model for Bootstrap Sample #27 
 
 
Figure 4-43 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical + Genotype Risk Index Model for Bootstrap Sample # 
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4.9.3 Predictive Performance 
Once predictions were made for each individual in the independent testing set the 
sensitivity, specificity, misclassification, and positive predictive value were calculated for 
the Clinical risk index model and the Clinical + Genotype risk index model as described 
in Section 4.5.3. The estimates and confidence intervals for sensitivity, specificity, 
misclassification, and positive predictive value are given in Table 4-44. Lastly, using the 
individual predictions from each of the 100 trimmed Clinical risk index models and 100 
trimmed Clinical + Genotype risk index models for the individuals in the independent 
testing set, ROC curves were generated, and the AUC for the ROC curve was estimated 
for both the Clinical and Clinical + Genotype risk index models (Figure 4-44, Figure 4-
45). For the Clinical risk index model the AUC for the ROC curve was 0.733, and for the 
Clinical + Genotype risk index model the AUC for the ROC curve was 0.692. 
 
Table 4-44 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for Prevalent Hypertension 

























Figure 4-44 ROC Curve and AUC for the Incident Diabetes Clinical Risk Index 
Model 
 
Figure 4-45 ROC Curve and AUC for the Incident Diabetes Clinical + Genotype 




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual is at high risk of having hypertension, then, 
represents the predicted probability of an individual having hypertension. Section 4.5.3 
describes the calculation of a confidence interval for this predicted probability. 
 
Figure 4-46 shows the distribution of the predicted probability of having hypertension for 
the Clinical risk index model in the independent testing set, and Figure 4-47 shows the 
distribution of the predicted probability of having hypertension for the Clinical + 
Genotype risk index model in the independent testing set. In both Figures, a density line 
is shown on the graph to indicate the density of a normal distribution with the mean and 
standard deviation matching that of the predicted probability distribution. 
 
Figure 4-46 Histogram of the Predicted Probability of Developing Diabetes for the 





Figure 4-47 Histogram of the Predicted Probability of Developing Diabetes for the 
Clinical + Genotype Risk Index Model 
 
4.9.4 Random Forests Comparison 
A random forest was generated using the optimization set created by the risk index 
procedure. The forest had 500 individual trees, and the tuning procedure described in 
detail in Section 4.6.4 was used to find the number of variables k considered at each split 
that provided the lowest out-of-bag error estimate. The optimized k chosen was 44, which 
gave an out-of-bag error estimate of 18.32%. 
 
When working with a dataset that has two possible classes, the standard procedure for a 
random forest is to assign a prediction to an individual based on a simple majority of 
votes, when the prevalence of the outcome is less than 50% changing the proportion of 
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votes needed to classify an individual can significantly impact the estimates of 
performance. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set on a range of proportions. First, 
an individual was assigned a prediction of “high risk” if 5% or more of the trees in the 
forest predicted the individual to be “high risk”. This was then repeated in increments of 
5% until individuals were assigned a prediction of “high risk” only if 95% or more of the 
trees in the forest predicted the individual to be “high risk”. Table 4-45 shows the results 
of this investigation. 
 
Predictions were then made about each individual in the independent testing set created 
by the risk index procedure, and the sensitivity, specificity, misclassification, and positive 
predictive value of the predictions was assessed. One thousand bootstrap samples of the 
independent testing set were generated, and predictions were made about each individual 
in each of the bootstrap samples. This data was used to create 95% confidence intervals 
for the sensitivity, specificity, misclassification, and positive predictive value estimates. 
Table 4-46 shows the sensitivity, specificity, misclassification, and positive predictive 
value estimates for the random forest as well as the 95% confidence interval for each 
estimate. Lastly, using the class votes for the individuals in the independent testing set, an 




Table 4-45 Performance Estimates of the Random Forest 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 1.000 0.034 0.806 0.170 
0.1 1.000 0.172 0.691 0.193 
0.15 0.913 0.345 0.561 0.216 
0.2 0.739 0.586 0.388 0.262 
0.25 0.565 0.793 0.245 0.351 
0.3 0.435 0.905 0.173 0.476 
0.35 0.348 0.948 0.151 0.571 
0.4 0.087 0.974 0.173 0.400 
0.45 0.087 0.991 0.158 0.667 
0.5 0.087 1.000 0.151 1.000 
0.55 0.043 1.000 0.158 1.000 
0.6 0.000 1.000 0.165 - 
0.65 0.000 1.000 0.165 - 
0.7 0.000 1.000 0.165 - 
0.75 0.000 1.000 0.165 - 
0.8 0.000 1.000 0.165 - 
0.85 0.000 1.000 0.165 - 
0.9 0.000 1.000 0.165 - 
0.95 0.000 1.000 0.165 - 
 
Table 4-46 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for the Random Forest Model 
Proportion of Votes for  


































































Prevalent hypertension occurs in 19% of subjects, making it intermediate in commonness 
to incident hypertension (30%) and incident diabetes (10%). As might be expected, then, 
the predictive performance for prevalent hypertension falls between these outcomes as 
well, with a sensitivity less than that for incident hypertension but greater than that for 
incident diabetes, with a similar pattern observed for specificity, misclassification, and 
PPV. As for the risk index for incident hypertension and incident diabetes built with the 
500 most highly associated SNPs the AUC for both the Clinical and Clinical + Genotype 
risk index model is less than that form the random forest model, and modifying the voting 
procedure for the random forest yields predictive performance exceeding that of either 
risk index model. However, no single set of predictions from the random forest provides 
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predictive performance where the 95% confidence intervals do not overlap with the 
performance estimates from the risk index models. 
 
4.10 Prevalent Hypertension Results Using Top 500 Principal Components 
4.10.1 Variable Selection 
Using the procedure described in Section 4.5.1, the risk index procedure was performed 
to predict risk of developing diabetes within a ten-year time frame. In place of the 500 
SNPs most highly associated with prevalent hypertension, the top 500 principal 
components from a principal components analysis of all available SNPs were used. 
 
Table 4-47 gives a summary of the order in which variables were selected for the 100 
bootstrap samples of the optimization set used to build the Clinical risk index model. 
Sixty-seven out of the 100 trimmed Clinical risk index models contained age as a 
variable, and 46 contained weight. Marital status was included in 58 out of the 100 
trimmed Clinical risk index models. Weight, height, and having ever smoked, were also 
frequently included in the set of 100 trimmed Clinical risk index models, appearing in 39, 
39, and 28 trimmed Clinical risk index models, respectively. Table 4-48 gives a summary 
of the order in which the most commonly chosen principal components were selected into 
the 100 Clinical + Genotype risk index models. Each principal component in Table 4-48 




Table 4-47 Summary of Number of Times Each Variable is Selected into a Specific Model Position for the Clinical Risk Index 
Model for Prevalent Hypertension 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 









Age (yrs) 54 8 4 2 1 1 3 2 1 3 1 0 3 3 1 1 2 4 2 0 96 67 
Sex 1 7 4 6 8 9 8 11 7 5 2 0 4 2 1 4 4 6 3 6 98 16 
Weight (lbs) 1 26 6 5 2 1 5 1 6 4 7 2 1 7 7 1 4 5 3 1 95 39 
Height (in) 5 2 14 14 14 8 6 10 5 8 3 1 5 2 0 0 1 1 0 0 99 39 
Systolic Blood Pressure 
(mm Hg) 0 0 0 0 1 1 2 0 4 7 7 7 2 5 6 8 11 11 7 11 90 2 
Diastolic Blood Pressure 
(mm Hg) 0 0 2 1 5 7 4 5 11 10 9 13 8 3 9 1 5 3 2 2 100 13 
Total Cholesterol  (mg/dL) 1 0 0 0 1 2 3 4 0 3 9 7 6 11 2 7 11 5 12 9 93 5 
High-density Lipoprotein 
Level (mg/dL) 3 2 1 2 1 2 2 1 3 3 11 5 8 6 6 11 7 3 11 7 95 9 
Low-density Lipoprotein 
Level (mg/dL) 0 4 17 16 15 15 8 5 5 5 0 2 5 2 1 0 0 0 0 0 100 28 
Triglycerides (mg/dL) 2 4 11 5 7 9 13 12 3 4 3 1 8 3 3 2 4 1 2 1 98 25 
Ever Smoked 3 2 9 7 7 12 6 3 7 6 3 3 3 4 4 5 4 4 2 2 96 27 
Currently Smokes 10 16 12 18 14 10 2 4 4 1 1 3 1 1 1 1 0 1 0 0 100 58 
Weekly Alcohol 
Consumption 2 8 1 4 1 5 1 6 11 3 1 5 2 2 3 4 6 3 8 13 89 10 
Marital Status 1 0 2 1 4 4 9 6 4 10 3 4 4 0 5 3 5 4 9 12 90 8 
Left Ventricular Mass (g) 3 4 2 6 2 3 2 1 1 5 1 5 7 5 7 7 5 13 6 8 93 17 
Left Ventricular Ejection 
Fraction (%) 0 2 1 0 0 0 6 3 3 3 12 6 6 5 11 11 9 11 4 3 96 9 
Blood Glucose (mg/dL) 1 2 6 4 1 0 2 3 3 3 8 7 3 7 11 7 4 7 6 11 96 16 
Blood Urea Nitrogen 




Total Serum Protein Level 
(mg/dL) 11 3 1 4 2 4 7 5 6 2 5 6 7 8 9 7 4 3 2 3 99 24 
Serum Albumin Level 
(mg/dL) 0 0 0 0 0 2 1 4 3 6 3 10 8 7 2 9 5 6 9 6 81 5 
Serum Bilirubin Level 




54 8 4 2 1 1 3 2 1 3 1 0 3 3 1 1 2 4 2 0 96 67 
Serum Creatine Level 
(mg/dL) 1 7 4 6 8 9 8 11 7 5 2 0 4 2 1 4 4 6 3 6 98 16 
 
Table 4-48 Summary of Number of Times Selected Principal Component Variables are Selected into a Specific Model Position 
for the Clinical + Genotype Risk Index Model for Prevalent Hypertension 
Variable Position 
Variable 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Total # of Times 
in Untrimmed 
Model 
Total # of Times 
in Trimmed 
Model 
PC55 1 0 0 1 0 0 1 1 1 0 0 0 1 1 1 1 0 0 1 1 11 10 
PC160 1 0 1 1 0 1 0 1 2 0 1 0 0 0 0 0 2 0 1 0 11 10 
PC3 0 0 0 2 1 0 1 2 0 0 1 1 1 0 0 0 1 1 0 0 11 9 
PC36 0 0 0 0 1 1 0 1 0 1 0 0 1 0 2 1 0 1 1 1 11 9 
PC104 1 1 1 0 0 1 1 1 0 1 0 0 0 0 0 0 0 1 1 0 9 9 
PC116 0 1 0 0 0 1 2 0 1 0 1 0 1 0 0 1 0 0 1 1 10 9 




Table 4-49 shows the trimmed Clinical risk index models for a selection of five random 
bootstrap samples. Figure 4-49 shows the distribution of risk index values in the 
optimization set for the Clinical risk index model from one randomly selected bootstrap 
sample (Bootstrap Sample #14), and Figure 4-50 shows the distribution of risk index 
values in the independent testing set for the Clinical risk index model from the same 
randomly selected bootstrap sample (Bootstrap Sample #14). The red line on each graph 
marks the cutoff point for the model. All individuals with a risk index value greater than 
this are predicted as “high risk of having hypertension” and those with a risk index value 
lower are predicted as “low risk of having hypertension”. Table 4-50 shows the risk index 
values for 25 randomly chosen individuals from the Independent Testing Set from these 
five Clinical risk index models along with that risk index model’s prediction about each 
individual, where 0 indicates low risk of having hypertension and 1 indicates high risk of 
having hypertension. 
 
Table 4-49 Five Randomly Selected Trimmed Clinical Risk Index Models for 
Prevalent Hypertension 
Bootstrap Sample Model 
14 
0.0207*Height - 0.0167*HDL + 0.0114*LDL + 0.028*Blood Urea Nitrogen 
+ 0.0569*Serum Albumin + 0.0029*Serum Bilirubin + 0.0404*Serum 
Creatine 
49 0.1028*Age - 0.2738*Sex + 0.0181*Weight + 0.0062*Height + 0.0603*Weekly Alcohol Consumption - 0.0429*Marital Status 
58 
0.0963*Age - 0.0231*HDL + 0.002*Triglycerides - 0.6903*Current 
Smoking Status + 0.1074*Marital Status + 0.0405*Blood Glucose + 
0.0798*Serum Creatine 
61 0.1074*Marital Status 




Table 4-50 Risk Index Values for 25 Individuals from the Independent Testing Set from Five Randomly Selected Clinical Risk 
Index Models for Prevalent Hypertension 
   Bootstrap Sample #14 Bootstrap Sample #49 Bootstrap Sample #58 Bootstrap Sample #61 Bootstrap Sample #97 

















1 0 0.875 0 1.470 0 1.615 1 0.215 0 2.065 1 
2 1 0.754 0 0.921 0 0.977 0 0.215 0 1.446 0 
3 0 0.785 0 1.494 0 1.345 1 0.215 0 2.209 1 
4 0 0.651 0 1.377 0 1.342 1 0.322 0 2.134 1 
5 0 0.858 0 1.273 0 1.280 0 0.215 0 1.941 0 
6 0 0.747 0 1.024 0 1.000 0 0.215 0 1.498 0 
7 1 0.795 0 1.429 0 1.610 1 0.215 0 2.081 1 
8 0 0.781 0 0.908 0 0.792 0 0.107 0 1.176 0 
9 1 0.754 0 1.353 0 1.388 1 0.107 0 2.034 1 
10 1 0.948 1 1.736 1 1.970 1 0.215 0 2.523 1 
11 0 0.783 0 1.651 1 1.584 1 0.215 0 2.488 1 
12 0 0.708 0 1.156 0 1.258 0 0.430 1 1.799 0 
13 0 0.878 0 1.406 0 1.163 0 0.215 0 1.993 0 
14 0 0.723 0 0.983 0 1.138 0 0.215 0 1.492 0 
15 0 0.906 0 1.194 0 1.420 1 0.215 0 1.846 0 
16 0 0.792 0 0.959 0 1.180 0 0.215 0 1.502 0 
17 0 0.709 0 1.210 0 1.115 0 0.215 0 1.520 0 
18 1 0.779 0 1.411 0 1.357 1 0.215 0 2.066 1 
19 0 0.811 0 1.437 0 1.487 1 0.430 1 2.107 1 
20 0 0.802 0 1.095 0 1.107 0 0.215 0 1.462 0 
21 0 0.903 0 1.332 0 1.278 0 0.430 1 1.996 0 
22 0 0.771 0 1.288 0 1.159 0 0.215 0 1.681 0 
23 0 0.876 0 1.338 0 1.330 0 0.215 0 2.050 1 
24 0 0.713 0 1.282 0 1.277 0 0.322 0 1.982 0 





Figure 4-49 Distribution of Risk Index Values in the Optimization Set from the 
Clinical Risk Index Model for Bootstrap Sample #14 
 
 
Figure 4-50 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical Risk Index Model for Bootstrap Sample #14 
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Table 4-51 shows the trimmed Clinical + Genotype risk index models for the same set of 
five bootstraps shown in Table 4-49, and Table 4-52 shows the risk index values and 
predictions of the same 25 randomly chosen individuals for the 5 bootstrap samples 
shown in Table 4-50. Figure 4-51 shows the distribution of risk index values in the 
optimization set for the Clinical + Genotype risk index model from one randomly 
selected bootstrap sample (Bootstrap Sample #14). Figure 4-52 shows the distribution of 
risk index values in the independent testing set for the Clinical + Genotype risk index 
model from the same randomly selected bootstrap sample (Bootstrap Sample #14). The 
red line on each graph marks the cutoff point for the model. All individuals with a risk 
index value greater than this are predicted as “high risk of having hypertension” and 




Table 4-51 Five Randomly Selected Clinical + Genotype Risk Index Models for 
Prevalent Hypertension 
Bootstrap Sample Model 
14 
0.0207*Height - 0.0167*HDL + 0.0114*LDL + 0.028*Blood Urea Nitrogen + 
0.0569*Serum Albumin + 0.0029*Serum Bilirubin + 0.0404*Serum Creatine + 
1.1469*PC30 - 2.7755*PC41 - 0.2129*PC81 + 0.6202*PC104 - 0.446*PC106 - 
1.164*PC109 + 0.3898*PC135 - 0.2404*PC153 - 0.393*PC172 - 1.6513*PC223 
+ 0.1298*PC260 - 0.2362*PC316 - 0.0653*PC337 - 1.0113*PC343 - 
0.747*PC363 - 0.1273*PC371 + 0.9937*PC436 + 4.0547*PC454 
49 
0.1028*Age - 0.2738*Sex + 0.0181*Weight + 0.0062*Height + 0.0603*Weekly 
Alcohol Consumption - 0.0429*Marital Status + 0.4226*PC36 - 0.5782*PC68 + 
0.2086*PC116 - 6.1775*PC131 - 1.2208*PC248 + 1.3316*PC282 + 
0.5426*PC394 + 0.6511*PC470 
58 
0.0963*Age - 0.0231*HDL + 0.002*Triglycerides - 0.6903*Current Smoking 
Status + 0.1074*Marital Status + 0.0405*Blood Glucose + 0.0798*Serum 
Creatine + 3.6541*PC6 - 1.9015*PC50 + 0.3906*PC70 + 0.3068*PC128 - 
0.9822*PC171 + 13.5045*PC213 + 1.6875*PC241 + 3.6425*PC329 + 
1.8774*PC363 - 3.5805*PC395 - 0.7359*PC403 + 4.4064*PC427 - 
1.2497*PC478 + 1.2648*PC481 
61 
0.1074*Marital Status - 0.5996*PC7 - 3.7335*PC16 + 0.0024*PC110 + 
0.9075*PC134 + 1.1272*PC141 - 0.3245*PC171 - 0.643*PC173 - 1.6777*PC212 
- 0.1376*PC233 + 5.5252*PC273 + 1.2982*PC336 - 1.7907*PC364 - 
0.3527*PC371 + 1.6016*PC388 + 2.5273*PC397 + 0.0266*PC405 - 
1.4463*PC418 + 0.9719*PC430 + 1.0295*PC465 
97 
0.1019*Age + 0.0172*Weight - 0.7112*Current Smoking Status + 0.068*Marital 
Status - 0.9318*PC22 - 0.7419*PC54 + 2.3027*PC55 - 0.538*PC58 - 
0.2581*PC86 - 0.675*PC88 - 0.3091*PC100 - 2.0593*PC101 - 1.1611*PC107 - 
3.3506*PC170 + 0.3638*PC175 - 1.7034*PC182 - 2.6485*PC215 - 1.455*PC225 
+ 0.1955*PC276 + 2.887*PC355 + 0.8472*PC363 + 0.808*PC394 - 




Table 4-52 Risk Index Values for 25 Individuals in the Independent Testing Set for the Clinical + Genotype Risk Index Models 
from Five Randomly Selected Bootstrap Samples for Prevalent Hypertension 
   Bootstrap Sample #14 Bootstrap Sample #49 Bootstrap Sample #58 Bootstrap Sample #61 Bootstrap Sample #97 

















1 0 0.874 0 1.475 0 1.653 1 0.217 0 2.051 1 
2 1 0.765 0 0.920 0 0.977 0 0.215 0 1.436 0 
3 0 0.781 0 1.511 0 1.351 1 0.202 0 2.202 1 
4 0 0.657 0 1.359 0 1.304 0 0.317 1 2.131 1 
5 0 0.851 0 1.284 0 1.293 0 0.213 0 1.935 0 
6 0 0.747 0 1.031 0 1.001 0 0.215 0 1.511 0 
7 1 0.792 0 1.422 0 1.585 1 0.210 0 2.066 1 
8 0 0.783 0 0.901 0 0.774 0 0.112 0 1.168 0 
9 1 0.770 0 1.373 0 1.408 1 0.100 0 2.032 1 
10 1 0.949 1 1.760 1 1.969 1 0.205 0 2.516 1 
11 0 0.783 0 1.677 1 1.608 1 0.234 0 2.484 1 
12 0 0.709 0 1.162 0 1.271 0 0.434 1 1.796 0 
13 0 0.874 0 1.413 0 1.160 0 0.214 0 1.987 0 
14 0 0.719 0 0.991 0 1.147 0 0.220 0 1.491 0 
15 0 0.907 0 1.172 0 1.414 1 0.205 0 1.842 0 
16 0 0.792 0 0.955 0 1.192 0 0.210 0 1.512 0 
17 0 0.703 0 1.214 0 1.091 0 0.224 0 1.514 0 
18 1 0.773 0 1.407 0 1.357 1 0.211 0 2.066 1 
19 0 0.806 0 1.443 0 1.506 1 0.397 1 2.109 1 
20 0 0.797 0 1.100 0 1.074 0 0.246 0 1.460 0 
21 0 0.890 0 1.328 0 1.280 0 0.427 1 1.987 0 
22 0 0.769 0 1.284 0 1.182 0 0.211 0 1.683 0 
23 0 0.871 0 1.359 0 1.327 0 0.223 0 2.054 1 
24 0 0.703 0 1.290 0 1.257 0 0.328 1 1.976 0 




Figure 4-51 Distribution of Risk Index Values in the Optimization Set from the 
Clinical + Genotype Risk Index Model for Bootstrap Sample #14 
 
 
Figure 4-52 Distribution of Risk Index Values in the Independent Testing Set from 
the Clinical + Genotype Risk Index Model for Bootstrap Sample #14 
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4.10.3 Predictive Performance 
Once predictions were made for each individual in the independent testing set the 
sensitivity, specificity, misclassification, and positive predictive value were calculated for 
the Clinical risk index model and the Clinical + Genotype risk index model as described 
in Section 4.5.3. The estimates and confidence intervals for sensitivity, specificity, 
misclassification, and positive predictive value are given in Table 4-53. Lastly, using the 
individual predictions from each of the 100 trimmed Clinical risk index models and 100 
trimmed Clinical + Genotype risk index models for the individuals in the independent 
testing set, ROC curves were generated, and the AUC for the ROC curve was estimated 
for both the Clinical and Clinical + Genotype risk index models (Figure 4-53, Figure 4-
54). For the Clinical risk index model the AUC for the ROC curve was 0.722, and for the 
Clinical + Genotype risk index model the AUC for the ROC curve was 0.712. 
 
Table 4-53 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for Prevalent Hypertension 

























Figure 4-53 ROC Curve and AUC for the Incident Diabetes Clinical Risk Index 
Model 
 
Figure 4-54 ROC Curve and AUC for the Incident Diabetes Clinical + Genotype 




The ensemble nature of the final risk index prediction means that there is a consensus 
prediction based on votes from the individual bootstrap samples. The proportion of 
models that predict that an individual is at high risk of having hypertension, then, 
represents the predicted probability of an individual having hypertension. Section 4.5.3 
describes the calculation of a confidence interval for this predicted probability. 
 
Figure 4-55 shows the distribution of the predicted probability of having hypertension for 
the Clinical risk index model in the independent testing set, and Figure 4-56 shows the 
distribution of the predicted probability of having hypertension for the Clinical + 
Genotype risk index model in the independent testing set. In both Figures, a density line 
is shown on the graph to indicate the density of a normal distribution with the mean and 
standard deviation matching that of the predicted probability distribution. 
 
Figure 4-55 Histogram of the Predicted Probability of Developing Diabetes for the 





Figure 4-56 Histogram of the Predicted Probability of Developing Diabetes for the 
Clinical + Genotype Risk Index Model 
 
4.10.4 Random Forests Comparison 
A random forest was generated using the optimization set created by the risk index 
procedure. The forest had 500 individual trees, and the tuning procedure described in 
detail in Section 4.6.4 was used to find the number of variables k considered at each split 
that provided the lowest out-of-bag error estimate. The optimized k chosen was 45, which 
gave an out-of-bag error estimate of 18.86%. 
 
When working with a dataset that has two possible classes, the standard procedure for a 
random forest is to assign a prediction to an individual based on a simple majority of 
votes, when the prevalence of the outcome is less than 50% changing the proportion of 
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votes needed to classify an individual can significantly impact the estimates of 
performance. To fully examine the performance of the random forest, predictions were 
made about each individual in the independent testing set on a range of proportions. First, 
an individual was assigned a prediction of “high risk” if 5% or more of the trees in the 
forest predicted the individual to be “high risk”. This was then repeated in increments of 
5% until individuals were assigned a prediction of “high risk” only if 95% or more of the 
trees in the forest predicted the individual to be “high risk”. Table 4-54 shows the results 
of this investigation. 
 
Predictions were then made about each individual in the independent testing set created 
by the risk index procedure, and the sensitivity, specificity, misclassification, and positive 
predictive value of the predictions was assessed. One thousand bootstrap samples of the 
independent testing set were generated, and predictions were made about each individual 
in each of the bootstrap samples. This data was used to create 95% confidence intervals 
for the sensitivity, specificity, misclassification, and positive predictive value estimates. 
Table 4-55 shows the sensitivity, specificity, misclassification, and positive predictive 
value estimates for the random forest as well as the 95% confidence interval for each 
estimate. Lastly, using the class votes for the individuals in the independent testing set, an 




Table 4-54 Performance Estimates of the Random Forest 
Proportion of Votes for  
"High Risk" Class Sensitivity Specificity Misclassification PPV 
0.05 0.990 0.043 0.803 0.167 
0.1 0.929 0.170 0.707 0.178 
0.15 0.909 0.391 0.525 0.224 
0.2 0.818 0.577 0.384 0.273 
0.25 0.576 0.740 0.287 0.300 
0.3 0.424 0.849 0.220 0.353 
0.35 0.303 0.939 0.164 0.492 
0.4 0.162 0.969 0.162 0.500 
0.45 0.051 0.992 0.161 0.556 
0.5 0.000 0.998 0.164 0.000 
0.55 0.000 1.000 0.162 - 
0.6 0.000 1.000 0.162 - 
0.65 0.000 1.000 0.162 - 
0.7 0.000 1.000 0.162 - 
0.75 0.000 1.000 0.162 - 
0.8 0.000 1.000 0.162 - 
0.85 0.000 1.000 0.162 - 
0.9 0.000 1.000 0.162 - 
0.95 0.000 1.000 0.162 - 
 
Table 4-55 Estimates and 95% Confidence Intervals of Sensitivity, Specificity, 
Misclassification, and Positive Predictive Value for the Ranomd Forest Model 
Proportion of Votes for  









































































Although the predictive performance estimates for the Clinical and Clinical + Genotype 
risk index models for prevalent hypertension built with the top 500 principal components 
is somewhat lower than those for the Clinical and Clinical + Genotype risk index models 
for prevalent hypertension built with the 500 most highly associated SNPs, the AUC of 
the Clinical + Genotype model is higher for the top 500 principal components than for the 
500 most highly associated SNPs. This trend was also observed for the incident 
hypertension and incident diabetes outcomes. This suggests that the risk index is able to 
take advantage of this additional information to improve prediction. The random forests 
model built with the top 500 principal components, however, has a lower AUC than the 
random forest model built using the 500 most highly associated SNPs, and this was also 
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observed for the incident hypertension and incident diabetes outcomes. Because the 
random forest methodology classifies individuals based on finding context-dependent 
relationships in variables, the uncorrelated nature of the principal components, even 
though it captures a larger amount of genetic information, is not as well-suited to 
prediction with random forests as a smaller number of polymorphisms that are somewhat 
correlated and may be involved in the context-dependent effects that the tree-structure of 
the random forest method is designed to exploit. 
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Chapter 5  
Conclusion 
5.1 Development of the Risk Index 
The risk index procedure created and tested in this dissertation is intended as an 
expansion of genetic risk score methods used in a number of studies as a means to 
harness genetic information to make predictions about disease risk. Sequence variations, 
especially single nucleotide polymorphisms (SNPs), which can now be easily and 
inexpensively genotyped in large numbers, provide a solid starting place for disease risk 
prediction. An individual’s genetic polymorphisms are, in large part, static, and so they 
can be queried long before a disease process has even begun (Plomin, et al, 2007a). In 
contrast, transcriptomic and proteomic markers that indicate disease are unlikely to be 
detected until an individual has already begun to develop that disease, even if they are 
outwardly asymptomatic (Plomin, et al, 2007b). When SNPs that can be used to identify 
a pool of individuals at increased risk of a disease are identified, doctors can then monitor 
these individuals more closely and track the development and progression of the disease 
(Ziogas, et al, 2009). 
 
By creating a robust framework in which risk models can be constructed and tested, the 
risk index procedure is intended to develop the genetic risk score methods proposed and 
used in other contexts into a machine learning algorithm that can combine clinical data 
with genotype data to classify an individual at high or low risk for a particular disease. 
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The risk index procedure developed in this dissertation can thus move genetic risk scores 
from an ad-hoc strategy that is feasible only on a small scale with a limited number of 
polymorphisms to a large-scale process that incorporates statistical techniques in order to 
provide high quality predictions. Using a forward-selection procedure, prediction models 
that contain clinical variables were created for bootstrap samples of a dataset. With the 
addition of each variable the model is assessed using the Brier score, a metric developed 
to assess a model’s predictive accuracy. Once the forward selection is complete, the 
model is pared back (ie. “trimmed”) so that the best performing model remains. Using 
this model made up of clinical variables as a base the procedure is then repeated for the 
genotype variables. Once Clinical + Genotype models are created for each of the 
bootstrap samples of the dataset, they are used to make predictions about a fully 
independent testing set, with the prediction from each of the models acting as a vote. 
Each individual in the independent testing set is assigned a prediction of either high risk 
or low risk based on the majority vote of these models. Figure 5-1 shows a graphical 
overview of the risk index procedure. The models created by the risk index procedure can 
be easily applied to patients in a clinic, giving doctors a prediction about the individual’s 
risk of developing the disease, a predicted probability of the individual developing the 
disease, and a 95% confidence interval around that predicted probability.  
 
Chapter 2 describes in detail the risk index procedure, as well as the use of random 
forests (Breiman, 1996) as a standard metric against which to compare the performance 
of the risk index procedure. Chapter 3 discusses two simulation studies undertaken to 
characterize the performance of the risk index procedure. The first uses a small dataset of 
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1000 individuals, each with a binary outcome variable (with a 30% prevalence for the 
disease),  
 
Figure 5-1 Graphic Overview of the Risk Index Procedure 
 
eight clinical covariates (four associated with the outcome and four noise variables), and 
500 SNPs (four associated with the outcome and the remainder noise variables). The 
second simulation is of a larger dataset of 10,000 individuals, again with a binary 
outcome that has 30% prevalence. Each individual has 29 clinical covariates (one very 
strongly associated with the outcome, three highly associated with the outcome, 11 
moderately associated with the outcome, and the remainder weakly associated with the 
outcome) and 38,835 SNPs, simulating the SNPs on chromosome one from the 
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Affymetrix Genome-wide Human SNP Array 5.0 (Affymetrix, 2007), six of which were 
simulated to be associated with the outcome. Chapter 4 describes the application of the 
risk index procedure to Framingham Heart Study (FHS), and examines its ability to 
predict ten-year incident hypertension, ten-year incident diabetes, and prevalent 
hypertension. 
 
5.2 Small-scale Simulation 
5.2.1 Complete SNP Set 
Table 5-1 shows a summary of the results from the small-scale suimulation. The first 
analysis in the small-scale simulation study was to determine the performance of the risk 
index procedure on a small set of clinical variables and 500 SNPs. On average across the 
100 small-scale simulation datasets the Clinical risk index model produced a sensitivity 
of 60.6% and a specificity of 88.6%, and the Clinical + Genotype risk index model 
produced a sensitivity of 58.9% and a specificity of 89.6%. The average area under the 
receiver operating characteristic (ROC) curve (AUC) of the Clinical risk index model 
was 0.832 (SD = 0.027), and the average AUC of the Clinical + Genotype risk index 
model was 0.846 (SD = 0.024). The Clinical + Genotype risk index model does have a 
significantly higher mean AUC than the Clinical risk index model, however the 
difference is fairly small, and its effect on prediction in a real-world situation is unclear. 
The performance of the risk index here is fairly good, however the random forest excels 
at predicting these datasets, with a mean AUC of 0.987 (SD=0.006), suggesting that, 
particularly for these fairly simplistic datasets, random forests are better positioned to 
provide accurate classification. 
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5.2.2 Principal Components of the Complete SNP Set 
The second analysis in the small-scale simulation study was to determine the 
performance of the risk index procedure on a small set of clinical variables and the 
principal components that explain 90% of the variance in the set of 500 SNPs simulated 
for the dataset. On average across the 100 small-scale simulation datasets the Clinical risk 
index model produced a sensitivity of 60.7% and a specificity of 88.3%, and the Clinical 
+ Genotype risk index model produced a sensitivity of 59.0% and a specificity of 89.1%. 
The average AUC of the ROC curve for the Clinical risk index model was 0.826 (SD = 
0.033), and the average AUC of the Clinical + Genotype risk index models was 0.839 
(SD = 0.032). The random forest models that were created for each of the 100 small-scale 
simulation datasets had, on average, an AUC of 0.821 (SD = 0.031). Tuning the class 
voting procedure for these random forests models did not produce the same level of 
predictive performance that was achieved for the random forests models created using the 
full set of 500 SNPs; while some cut-off values could lead to higher sensitivities or 
specificities than what was observed for the Clinical + Genotype risk index model, no 
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cut-off demonstrated predictive performance that exceeded the Clinical + Genotype risk 
index model for all four predictive performance metrics. 
 
The Clinical + Genotype risk index model built using the principal components of the 
SNPs has a significantly higher mean AUC than the Clinical risk index model (p=0.008) 
and the Clinical + Genotype model built using the SNPs. Again, however, these increases 
are relatively small. The Clinical + Genotype risk index model built using the principal 
components of the SNPs also has a significantly higher mean AUC than the random 
forest built using the clinical variables and the principal components of the SNPs 
(p=8.4E-5), however both of these means are much lower than the mean AUC for the 
random forest built with clinical covariates and SNP genotypes. This suggests that while 
the inclusion of the principal components improves the predictive ability of the risk 
index, it hampers the predictive ability of the random forest, likely because the 
orthoganalization of the genotype data breaks up the context-dependent effects the 
random forest leverages to make predictions. 
 
5.3 Large-scale Simulation 
5.3.1 500 Most Highly Associated SNPs 
Table 5-2 shows a summary of the results from the large-scale simulation study. The first 
analysis in the large-scale simulation study was to determine the performance of the risk 
index procedure on a set of 29 clinical variables and 500 SNPs that were identified as 
highly associated with the outcome after a logistic regression analysis of the full set of 
38,835 SNPs. On average across the 25 large-scale simulation datasets the Clinical risk 
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index model produced a sensitivity of 73.5% and a specificity of 93.3%, and the Clinical 
+ Genotype risk index model produced a sensitivity of 73.4% and a specificity of 94.0%. 
The average AUC of the ROC curves for the Clinical risk index model was 0.926 (SD = 
0.015), and the average AUC for the Clinical + Genotype risk index models was 0.932 
(SD = 0.012). The random forest models that were created for each of the 25 large-scale 
simulation datasets on average had an AUC of 0.915 (SD = 0.013). Tuning the class 
voting procedure for these random forests models did not produce predictive performance 
that equaled either the Clinical or the Clinical + Genotype risk index models. 
 
As with the small-scale simulation results, the Clinical + Genotype risk index model has 
a mean AUC significantly higher than the mean AUC for the Clinical risk index model 
(p=0.001), but again the difference in mean AUCs is small and it’s impact on predictive 
performance is unclear. The random forest built using the clinical covariates and SNP 
genotypes, however, had a mean AUC that was significantly lower than the Clinical + 
Genotype model built using the most highly associated SNPs (p=1.5E-8), and the 
difference between the AUCs here is considerably more sizeable. One explanation for 
this is that the larger number of clinical covariates and fairly low correlation among the 
clinical covariates means that the data is too complex for fairly simple trees to be 





































































5.3.2 Principal Components of Complete SNP Set 
The second analysis in the large-scale simulation study was to determine the performance 
of the risk index procedure on a set of 29 clinical variables and 500 most highly ranked 
principal components after a principal components analysis of the full set of 38,835 
SNPs. On average across the 25 large-scale simulation datasets the Clinical risk index 
model produced a sensitivity of 73.8% and a specificity of 92.7%, and the Clinical + 
Genotype risk index model produced a sensitivity of 74.9% and a specificity of 93.0%. 
The average AUC of the ROC curves for the Clinical risk index model was 0.931 (SD = 
0.021), and the average AUC for the Clinical + Genotype risk index models was 0.931 
(SD = 0.022). The random forest models that were created for each of the 25 large-scale 
simulation datasets on average had an AUC of 0.856 (SD = 0.022). Tuning the class 
voting procedure for these random forest models did not produce predictive performance 
that equaled either the Clinical or the Clinical + Genotype risk index model. 
 
The mean AUCs for the Clinical and Clinical + Genotype risk index model here are 
effectively identical, with neither model providing significantly higher values (p=0.98). 
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The Clinical + Genotype risk index model built with the principal components of the 
SNPs does have a significantly higher mean AUC than the random forests model built 
with principal components (p=4.4E-16). This provides further evidence that the 
uncorrelated nature of the principal components makes them a better choice for the risk 
index than for the random forest. As observed for the small-scale simulation, the 
principal components do not perform as well in the random forest as do the most highly 
associated SNPs (p=6.5E-14). 
 
5.4 Simulation Study Conclusions 
The results from the simulation study offer some important insights into the functioning 
and performance of the risk index. First of all, the results from the Clinical + Genotype 
risk models for the small-scale simulation study using a set of 500 SNPs and the large-
scale simulation using the set of 500 SNPs most highly associated with the outcome show 
that while the predictive performance of the these models is quite good, the genotype 
variables selected into the models do not reflect the known, true positive genotype 
variables. This suggests that while the risk index may be useful for predictive 
applications, the resulting models are not interpretable and are probably not useful as 
starting points for investigation into the role of implicated polymorphisms in the disease 
process being investigated. 
 
Second, the Clinical + Genotype risk index models outperformed the Clinical risk index 
models in all but one case. T-tests show that the mean AUC for the Clinical + Genotype 
risk index model was statistically significantly higher than the mean AUC for the Clinical 
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risk index model for the small-scale simulation using the full set of 500 SNPs (p=0.006), 
the small-scale simulation using the principal components that accounted for 90% of the 
variance in the genotype variables (p=0.008), and the large-scale simulation using the top 
500 most highly associated SNPs (p=0.001). For the large-scale simulation using the top 
500 principal components of the 38,835 SNPs, however, the Clinical and Clinical + 
Genotype risk index models do not have statistically significantly different performance 
(p=0.98). 
 
Lastly, the difference in performance between the risk index models constructed using a 
set of SNPs and the risk index models constructed using sets of principal components 
suggests that the risk index procedure performs best with the uncorrelated data provided 
by principal components. Given the statistical procedures used to build the risk index, 
this is an understandable result, but it is important to note that the fact that the principal 
components data is uncorrelated is not the sole reason that the risk index performance is 
improved. The fact that the top 500 principal components also encode more information 
than the 500 most highly associated SNPs also likely plays a role in the performance 
improvement (Raychaudhuri, et al, 2000). 
 
5.5 Framingham Heart Study 
The analysis of the FHS data focused on three outcomes: ten-year incident hypertension, 
ten-year incident diabetes, and prevalent hypertension. Table 5-3 shows an overview of 




Table 5-3 A Summary of the Risk Index's Predictive Performance on the 
Framingham Heart Study Data 






(95% CI) AUC 
Clinical 0.667  (0.594 - 0.736) 
0.486  
(0.444 - 0.53) 
0.468  
(0.433 - 0.504) 
0.308  








(0.464 - 0.609) 
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(0.487 - 0.559) 
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(0.286-0.489) 0.722 Prevalent Hypertension 












5.5.1 Ten-Year Incident Hypertension Using 500 Most Highly Associated SNPs 
Using the 500 SNPs most highly associated with ten-year incident hypertension, the risk 
index methodology was able to build a Clinical risk index model with a sensitivity of 
66.7% and a specificity of 46.8% and a Clinical + Genotype risk index model with a 
sensitivity of 53.9% and a specificity of 45.7%. The Clinical risk index model had an 
AUC of 0.567, while the Clinical + Genotype risk index model had an AUC of 0.475. 
The random forest model constructed with this data had an AUC of 0.811, and tuning the 
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class voting procedure produced predictive performance greater than either of the risk 
index models. 
 
5.5.2 Ten-year Incident Hypertension Using Principal Components of Complete SNP Set 
Using the top 500 principal components of the full set of SNPs from the Affymetrix 50K 
SNP genotyping platform, the risk index methodology was able to build a Clinical risk 
index model with a sensitivity of 60.8% and a specificity of 50.5% and a Clinical + 
Genotype risk index model with a sensitivity of 59.1% and a specificity of 54.4%. The 
Clinical risk index model had an AUC of 0.566, while the Clinical + Genotype risk index 
model had an AUC of 0.563. The random forest model constructed with this data had an 
AUC of 0.719, and tuning the class voting procedure produced predictive performance 
greater than either of the risk index models. 
 
5.5.3 Ten-Year Incident Diabetes Using 500 Most Highly Associated SNPs 
Using the 500 SNPs most highly associated with ten-year incident diabetes, the risk index 
methodology was able to build a Clinical risk index model with a sensitivity of 22.4% 
and a specificity of 90.1% and a Clinical + Genotype risk index model with a sensitivity 
of 10.4% and a specificity of 92.3%. The Clinical risk index model had an AUC of 0.722, 
while the Clinical + Genotype risk index model had an AUC of 0.683. The random forest 
model constructed with this data had an AUC of 0.905, and tuning the class voting 




5.5.4 Ten-Year Incident Diabetes Using Principal Components of Complete SNP Set 
Using the top 500 principal components of the full set of SNPs from the Affymetrix 50K 
SNP genotyping platform, the risk index methodology was able to build a Clinical risk 
index model with a sensitivity of 20.5% and a specificity of 95.9% and a Clinical + 
Genotype risk index model with a sensitivity of 13.0% and a specificity of 97.4%. The 
Clinical risk index model had an AUC of 0.769, while the Clinical + Genotype risk index 
model had an AUC of 0.782. The random forest model constructed with this data had an 
AUC of 0.78. While tuning the class voting procedure could produce sensitivities and 
specificities better than either risk index model, however, in order to match the risk index 
models’ misclassification rates (10.2% and 9.5% for the Clinical and the Clinical + 
Genotype risk index models, respectively) and PPV (30.6% and 30.4% respectively) the 
random forests model had a sensitivity and specificity comparable to that of the two risk 
index models. 
 
5.5.5 Prevalent Hypertension Using 500 Most Highly Associated SNPs 
Using the 500 SNPs most highly associated with prevalent hypertension, the risk index 
methodology was able to build a Clinical risk index model with a sensitivity of 45.9% 
and a specificity of 84.4% and a Clinical + Genotype risk index model with a sensitivity 
of 32.3% and a specificity of 84.6%. The Clinical risk index model had an AUC of 0.733, 
while the Clinical + Genotype risk index model had an AUC of 0.692. The random forest 
model constructed with this data had an AUC of 0.857, and tuning the class voting 




5.5.6 Prevalent Hypertension Using Principal Components of Complete SNP Set 
Using the top 500 principal components of the full set of SNPs from the Affymetrix 50K 
SNP genotyping platform, the risk index methodology was able to build a Clinical risk 
index model with a sensitivity of 26.3% and a specificity of 89.5% and a Clinical + 
Genotype risk index model with a sensitivity of 20.3% and a specificity of 93.2%. The 
Clinical risk index model had an AUC of 0.722, while the Clinical + Genotype risk index 
model had an AUC of 0.712. The random forest model constructed with this data had an 
AUC of 0.74, and tuning the class voting procedure produced predictive performance 
greater than either of the risk index models. 
 
5.5.7 Framingham Heart Study Conclusions 
The real-world application of the risk index to the FHS provided performance that is 
noticeably worse than the results of the simulation study. In all but one case (diabetes 
using the top 500 principal components) the Clinical risk index model had an AUC 
greater than that of the Clinical + Genotype risk index model. Likewise, in all but that 
same case the random forest model produced an AUC greater than either of the risk index 
models. However, for ten-year incident diabetes and prevalent hypertension, the risk 
index methodology’s performance, while less than that of random forests, is still fairly 
comparable, and does not have nearly the performance gap observed between the risk 
index models created for ten-year incident hypertension and the random forests created to 




One unexplained occurrence is the extremely poor performance that the risk index 
demonstrated in predicting ten-year incident hypertension. The poor performance seems 
to be isolated to this outcome, as the predictive performance for ten-year incident 
diabetes and prevalent hypertension were noticeably better. It seems unlikely that 
developing hypertension is an inherently more complex trait than developing diabetes, 
but this result could be explained by a combination of several factors. First, it may be that 
the variables included in this analysis are simply not the optimal predictors. The set of 
variables, however, did include the most commonly used predictors of hypertension risk: 
age, weight, and current blood pressure. Secondly, it may be that in this particular sample 
the individuals who develop hypertension do so through a number of heterogeneous 
pathways, while the individuals who develop diabetes do so in a relatively homogenous 
way. Lastly, the apparent increase in predictive performance may simply stem from the 
lower relative frequencies of incident diabetes and prevalent hypertension as compared to 
incident hypertension. The less frequent outcomes mean that a lower misclassification 
can be achieved by simply marking every individual as “low risk” and misclassifying 
every high risk individual. The much lower sensitivities and high specificities for incident 
diabetes and prevalent hypertension support the idea that the lower relative frequencies 
are playing a role in the apparent increase in performance. 
 
One notable consistency between the FHS study and the simulation study is the relative 
improvement in predictive performance that occurs when the risk index methodology is 
presented with principal components data compared to when it is presented with SNP 
genotype data. Conversely, random forest performance decreases when using principal 
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components data compared to using SNP genotypes. This is discussed in further detail 
Section 5.7 below. 
 
5.6 Methodological Limitations 
Although the risk index offers reasonably good predictive performance in certain cases, 
there are some limitations to its use that mist be addresses. First, because of the way the 
data is divided first between the optimization set and independent testing set and then into 
cross-validation sets, the risk index is poorly suited to predicting risk for very uncommon 
outcomes. 
 
Also, although the individual models created by the risk index from each bootstrap 
sample of the optimization set are much simpler to interpret than the decision trees 
making up a random forest, the method still relies on ensemble prediction, and so the end 
result is not one single model but rather a set of models, making interpretation much 
more difficult. Additionally, the fact that this method provides set of models that are 
difficult to interpret and the fact that the modeling was done with the intention of 
prediction and not biological interpretability means that it is not a strong starting point for 
further biological investigation. Although the most commonly selected variables may 
play some biological role in the disease process this is not necessarily the case. 
 
5.7 Methodological Expansions and Future Directions 
In several cases the overall predictive performance of the risk index procedure is 
noticeably poorer than that of random forests. However, examining the best aspects of the 
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risk index procedure and the difference between the approach of the risk index procedure 
and random forests offers some insights into how to improve the risk index procedure in 
the future. First and foremost, the primary difference between random forests and the risk 
index procedure is the presence of interactions. The decision tree structures that compose 
a random forest account for interactions at each level. Each new split finds the variable 
that best divides a subset of the data given the context of the previous splits. The risk 
index procedure, however, does not account for interactions, but rather composes a set of 
individual linear models that are applied equally to each individual. Although this is a 
shortcoming of the risk index procedure, some information about interactions would still 
be expected to be captured by this approach. Cheverud suggests that SNPs involved in 
interactions, when modeled univariately, typically show some marginal univariate effect 
(Cheverud, et al, 1995). 
 
It would be possible, however, to include interaction terms directly in the risk index. In 
addition to the univariate logistic regression models currently used to estimate 
coefficients, it would be straightforward to include interaction terms. This must be done 
with caution, though, because with even a moderate number of variables the available 
number of interaction terms increases tremendously. Taking a cue from Cheverud, the 
variables considered could be limited to those that demonstrate a marginally significant 
effect, for example, those variables with a p-value from logistic regression modeling of 
0.2 or lower. By reducing the search space in this way the effect of interactions on the 
risk index’s predictive performance could be investigated manageably while still focusing 




As currently implemented the risk index methodology allows the user to specify the 
maximum number of variables to grow a risk index model to. For variables types (e.g., 
clinical covariates) that include only a small number of variables (e.g., 10 or 15) it would 
make sense to have these models grown to include all possible variables. For variables 
types (e.g., genotypes) that include a much larger number of variables (e.g., 500), 
growing the risk index model to include all possible variables is prohibitive. Instead, 
some reasonable maximum size should be used. In this dissertation, that maximum was 
20 variables, a number chosen because it is sufficiently large but not prohibitively so. A 
better approach might be to develop a stopping rule of some type that followed the 
performance of the risk index model as it was built and stop the model building process 
when the performance gains drop below a certain threshold. Implementing this, however, 
would require a thorough investigation of the Brier score in real-world prediction, 
because if the score rate of change varies widely as more variables are added then a 
programmatically defined stopping rule may not be feasible. 
 
Another possible enhancement to the risk index methodology would be the addition of a 
sequential prediction procedure, in which individuals with very high or very low 
predicted probabilities of developing disease are assigned a prediction while those with 
more intermediate values are not. The remaining, unclassified individuals could then be 
used to perform the risk index procedure a second time, hopefully producing more 
accurate predictions for these individuals. The underlying rationale for this approach is 
that while only one coefficient is estimated for each variable, if the sample of individuals 
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used to create the risk index is composed of individuals at varying stages of disease, the 
relationship between their outcome and a particular variable may not be constant across 
the entire sample. Taking a sequential approach might allow for these differing 
relationships to be explicitly considered leading to better predictive performance. 
 
A further possible enhancement to the risk index methodology concerns the assignment 
of final predictions to new individuals. As it is currently implemented, a prediction is 
made for a new individual for each of the n Clinical or Clinical + Genotype risk index 
models created using the bootstrap samples of the optimization set. The final prediction 
(i.e., “high risk” or “low risk”) is chosen based on a majority vote of these n predictions. 
This may not provide the best possible predictive performance, however, and could be 
addressed by a simple optimization step. Once all n Clinical or Clinical + Genotype risk 
index models have been built, they could be applied to the full optimization set. The 
proportion p* of votes required to assign an individual a prediction of “high” risk could 
be examined over a range of values, for example from 0.05 to 0.95 in steps of 0.05. The 
Brier score, described in detail in Chapter 2, Section 2, could be calculated for each 
examined value of p*, and the value which minimizes the Brier score could then be 
chosen and used to make predictions about any new individuals the risk index is applied 
to. For example, if p*=0.35 gives the lowest Brier score, then for any new individual to 
whom the risk index the risk index is applied if 35% or more of the n Clinical or Clinical 
+ Genotype risk index models predict the individual is at high risk then they would be 
assigned a prediction of “high risk”. However, if 34% or fewer of the n Clinical or 
 
 325 
Clinical + Genotype risk index models predict the individual is at high risk then they 
would be assigned a prediction of “low risk”. 
 
Alternatively, a weighted voting procedure could be implemented in which the 
predictions from each of the n Clinical or Clinical + Genotype risk index models could be 
weighted by the inverse of their Brier score (because the optimal Brier score value is the 
lowest, this would give greatest weight to those models with the lowest Brier score). The 
predictions could then be summed, and the prediction (i.e., “high risk” or “low risk”) with 
the highest value would be the prediction assigned to a new individual. 
 
5.8 Conclusion 
Considering the results from the risk index procedure, a few trends become evident. First, 
and most importantly, the risk index methodology performs better when provided with a 
set of principal components from a large set of SNPs compared to when it is provided 
with a set of SNPs that have been selected because of high association with the outcome 
being examined. Considering the way in which the risk index methodology builds 
predictive models makes the reason behind this clear. The risk index methodology creates 
a linear combination, and so implicitly makes the assumption that each variable that is 
added to the model has the same effect for all individuals. However, it is well known that 
the effect of polymorphisms on a particular phenotype is influenced both by 
environmental factors as well as by the individual’s other polymorphisms. Random 
forests, with its tree-based structure, accounts for this differential impact by selecting the 
variable with the best predictive power in the context of all of the variables that have 
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been previously selected. By using principal components, however, the risk index 
methodology is supplied with a set of variables that are completely uncorrelated and 
therefore are not subject to the interactive effects observed between SNPs. Conversely, 
random forests tend to perform more poorly when presented with principal components 
as compared to a set of highly associated SNPs. This is likely because the uncorrelated 
nature of these variables makes it difficult for random forests to identify the context-
dependent effects it uses for classification. 
 
Second, while the simulation studies showed that the Clinical + Genotype risk index 
models had significantly better average AUC than the Clinical risk index models in all 
but one case, the application of the risk index methodology to the FHS data showed an 
improvement in the AUC of the Clinical + Genotype risk index model over the AUC of 
the Clinical risk index model in only one case. It is not immediately apparent why this 
would be the case, but one possible explanation is the use of the 50K Affymetrix 
genotypes. Perhaps the 500K Affymetrix will offer better performance because of the 
improved genome coverage of this technology. 
 
Overall, the goal of this dissertation was to develop the risk index described by Beer, at 
al. (Beer, et al, 2002) into a flexible risk prediction system capable of predicting an 
individual’s risk of developing a particular chronic disease. The simulation study 
performed in Chapter 3 suggests that for very large datasets in certain circumstances the 
risk index methodology may perform quite well and may even outperform random 
forests. The application of the risk index methodology to the FHS data in Chapter 4 did 
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not provide strong support for the potential of the risk index methodology to have greater 
predictive performance than random forests in real-world datasets, but for both ten-year 
incident diabetes and prevalent hypertension the performance of the risk index 
methodology was comparable to that of random forests. Additionally, these results add 
support to the observation in the large-scale simulation data that using the top available 
principal components for the risk index procedure led to improved performance over the 
use of a set of highly associated SNPs.  
 
Taken as a whole, this dissertation demonstrates the potential of genetic risk score 
methodologies for large-scale prediction. By including important statistical 
enhancements, such as forward selection to improve the model and the use of cross-
validation and an independent testing set to reduce misclassification, the concept of a 
genetic risk score has been modified from a typically ad-hoc, small-scale procedure 
focusing on a small number of polymorphisms to a more robust, statistically focused 
method that is more in line with the requirements of a clinical risk prediction method. 
Although this method was not designed for and would likely be poor at identifying the 
biological underpinnings of chronic disease risk, as a pure risk prediction method it has 
the potential to improve public health through the identification of individuals most in 
need of interventions. Additionally, by incorporating both clinical covariates and 
genotypes, it represents an attempt to integrate information that is typically treated 
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